0001144204-14-051396.txt : 20140819 0001144204-14-051396.hdr.sgml : 20140819 20140819163931 ACCESSION NUMBER: 0001144204-14-051396 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140819 DATE AS OF CHANGE: 20140819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cell Source, Inc. CENTRAL INDEX KEY: 0001569340 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS AMUSEMENT & RECREATION [7990] IRS NUMBER: 320379665 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-187049 FILM NUMBER: 141052502 BUSINESS ADDRESS: STREET 1: 2620 REGATTA DR. STREET 2: STE 102 CITY: LAS VEGAS STATE: NV ZIP: 89128 BUSINESS PHONE: 18889709463 MAIL ADDRESS: STREET 1: 2620 REGATTA DR. STREET 2: STE 102 CITY: LAS VEGAS STATE: NV ZIP: 89128 FORMER COMPANY: FORMER CONFORMED NAME: TICKET TO SEE, INC. DATE OF NAME CHANGE: 20130211 10-Q 1 v387117_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 333-187049

CELL SOURCE, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction

of incorporation or organization)

65 Yigal Alon Street

Tel Aviv, Israel

(Address of principal executive offices)

32-0379665

(I.R.S. Employer Identification No.)

67433

(Zip Code)

Registrant’s telephone number, including area code 011 972 3 562-1755

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨	Accelerated filer ¨

Non-accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of August 15, 2014, the registrant had 23,345,923 shares of $0.001 par value common stock outstanding.

CELL SOURCE, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2014

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

Condensed Consolidated Balance Sheets as of
June 30, 2014 (Unaudited) and December 31, 2013		1

Unaudited Condensed Consolidated Statements of Operations for the
Three and Six Months Ended June 30, 2014 and 2013		2

Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Deficiency for the
Six Months Ended June 30, 2014		3

Unaudited Condensed Consolidated Statements of Cash Flows for the
Six Months Ended June 30, 2014 and 2013		4

Notes to Unaudited Condensed Consolidated Financial Statements		5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.		14

Item 3. Quantitative and Qualitative Disclosures About Market Risk.		19

Item 4. Controls and Procedures.		19

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.		21

Item 1A. Risk Factors.		21

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.		21

Item 3. Defaults Upon Senior Securities.		21

Item 4. Mine Safety Disclosures.		21

Item 5. Other Information.		21

Item 6. Exhibits.		22

SIGNATURES		23

CELL SOURCE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30,			December 31,
	2014			2013
	(Unaudited)
Assets

Current Assets:
Cash	$	889,332		$	28,878
Prepaid expenses		135,000			-
Other current assets		59,564			63,337

Total Current Assets		1,083,896			92,215
Property and equipment, net		2,557			-

Total Assets	$	1,086,453		$	92,215

Liabilities and Stockholders’ Deficiency

Current Liabilities:
Accounts payable and accrued expenses	$	70,626		$	116,649
Accounts payable and accrued expenses - related party		216,035			441,700
Derivative liabilities		2,476,800			231,200

Total Current Liabilities		2,763,461			789,549

Commitments and contingencies (Note 8)		-			-

Stockholders’ Deficiency:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2014 and December 31, 2013		-			-
Common stock, $0.001 par value; 200,000,000 shares authorized; 23,245,923 and 14,155,262 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively		23,246			14,155
Additional paid-in capital		4,047,077			3,229,522
Accumulated deficit		(5,747,331	)		(3,941,011	)

Total Stockholders’ Deficiency		(1,677,008	)		(697,334	)

Total Liabilities and Stockholders’ Deficiency	$	1,086,453		$	92,215

See Notes to these Condensed Consolidated Financial Statements

CELL SOURCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For The						For The
	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2014			2013			2014			2013

Revenues	$	-		$	-		$	-		$	-

Operating Expenses
Research and development		220,995			87,436			545,412			193,806
Research and development - related party		398,845			329,753			611,203			402,629
Selling, general and administrative		397,338			79,100			633,305			127,853

Total Operating Expenses		1,017,178			496,289			1,789,920			724,288

Loss From Operations		(1,017,178	)		(496,289	)		(1,789,920	)		(724,288	)

Other (Expense) Income
Interest expense		-			(362,001	)		-			(396,534	)
Change in fair value of derivative liabilities		31,100			54,300			(16,400	)		64,500

Total Other Income (Expense)		31,100			(307,701	)		(16,400	)		(332,034	)

Net Loss	$	(986,078	)	$	(803,990	)	$	(1,806,320	)	$	(1,056,322	)

Net Loss Per Share
- Basic and Diluted	$	(0.05	)	$	(0.06	)	$	(0.10	)	$	(0.08	)

Weighted Average Number of
Common Shares Outstanding
- Basic and Diluted		20,228,764			12,763,818			18,774,759			12,763,818

See Notes to these Condensed Consolidated Financial Statements

CELL SOURCE, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIENCY

FOR THE SIX MONTHS ENDED JUNE 30, 2014

(Unaudited)

					Additional
	Common Stock				Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total

Balance - December 31, 2013		14,155,262	$	14,155	$	3,229,522		$	(3,941,011	)	$	(697,334	)

Issuance of common stock and warrants for cash, net [1]		4,090,661		4,091		3,008,755			-			3,012,846

Reclassification of detachable warrants to derivative liabilities		-		-		(1,499,000	)		-			(1,499,000	)

Shares retained by public company stockholders in Share Exchange		5,000,000		5,000		(735,200	)		-			(730,200	)

Stock-based compensation		-		-		43,000			-			43,000

Net loss		-		-		-			(1,806,320	)		(1,806,320	)

Balance - June 30, 2014		23,245,923	$	23,246	$	4,047,077		$	(5,747,331	)	$	(1,677,008	)

[1] Net of $55,150 of issuance costs.

See Notes to these Condensed Consolidated Financial Statements

CELL SOURCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For The Six Months Ended
	June 30,
	2014			2013
Cash Flows From Operating Activities
Net loss	$	(1,806,320	)	$	(1,056,322	)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of debt discount		-			384,034
Interest expense		-			12,500
Change in fair value of derivative liabilities		16,400			(64,500	)
Depreciation		25			-
Stock-based compensation		43,000			-
Contribution of services by officers		-			76,990
Changes in operating assets and liabilities:
Prepaid expenses		(135,000	)		-
Other assets		3,773			26,418
Accounts payable and accrued expenses		(271,688	)		280,790

Net Cash Used in Operating Activities		(2,149,810	)		(340,090	)

Cash Flows From Investing Activities
Purchase of propery and equipment		(2,582	)		-

Net Cash Used in Investing Activities		(2,582	)		-

Cash Flows From Financing Activities
Proceeds from issuance of convertible note		-			210,000
Proceeds from issuance of common stock and warrants, net [1]		3,012,846			-

Net Cash Provided by Financing Activities		3,012,846			210,000

Net Increase (Decrease) In Cash		860,454			(130,090	)

Cash - Beginning		28,878			161,323

Cash - Ending	$	889,332		$	31,233

Supplemental Disclosures of Cash Flow Information:
Non-cash investing and financing transactions:
Reclassification of warrants to derivative liabilities	$	1,499,000		$	-
Reclassification of embedded conversion options to derivative liabilities	$	-		$	315,200

[1] Net of $55,150 of issuance costs.

See Notes to these Condensed Consolidated Financial Statements

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 – Organization, Operations and Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial position of Cell Source, Inc. (“CSI” or the “Company”), formerly known as Ticket To See, Inc. (“TTSI”), as of June 30, 2014 and the condensed consolidated results of its operations and cash flows for the three and six months ended June 30, 2014 and 2013. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the operating results for the full year. It is recommended that these condensed consolidated financial statements be read in conjunction with the financial statements and related disclosures of Cell Source Limited for the year ended December 31, 2013 which were included in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on July 1, 2014.

Organization and Operations

The Company is a Nevada corporation formed on June 6, 2012 under the name TTSI. Prior to the Share Exchange (as defined below), the Company did not have any significant assets or operations.

The Company is the parent company of Cell Source Limited, which was founded in Israel in 2011 in order to commercialize a suite of inventions relating to certain cancer treatments. Cell Source Limited’s target indications include treatment of lymphoma, multiple myeloma and BCLL (which is a common form of leukemia), facilitating transplantation acceptance (initially bone marrow transplantation and subsequently organ transplantation) and ultimately treating a variety of non-malignant diseases. Cell Source Limited’s lead prospective product is its patented Veto-Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Cell Source Limited’s Veto-Cell immune system management technology is based on technologies patented, owned, and licensed to Cell Source Limited by Yeda Research and Development Company Limited, an Israeli corporation (“Yeda”).

Share Exchange and Reorganization

On May 7, 2014, the Board of Directors and the majority stockholder of TTSI adopted resolutions approving an amendment (the “Amendment”) of the Company’s Articles of Incorporation to increase the number of authorized shares. Prior to the Amendment, the authorized shares of the Company consisted of 75,000,000 shares of common stock, $0.001 par value. The Amendment was filed with the Secretary of State of the State of Nevada on May 20, 2014, which increased the number of shares of common stock that the Company is authorized to issue from 75,000,000 shares to 200,000,000 shares. The Company also authorized 10,000,000 shares of preferred stock, par value $0.001, for designation in one or more series, with such designations, preferences and relative, participating, optional, or other special rights and qualifications, limitations, or restrictions thereof, as may, from time to time, be adopted by the Company’s Board of Directors.

On June 23, 2014, the majority stockholder of TTSI adopted resolutions approving an amendment of the Company’s Articles of Incorporation to change the name of the corporation from Ticket to See, Inc. to Cell Source, Inc. The Amendment was filed with the Secretary of State of the State of Nevada on June 23, 2014, which changed the name of the corporation from Ticket to See, Inc. to Cell Source, Inc., effective June 26, 2014. In connection with the name change, the trading symbol of the Company’s common stock was changed from TTSE to CLCS.

On June 27, 2014, CSI issued five-year warrants to purchase an aggregate of 2,000,000 shares of common stock at a price of $0.75 per share to consultants in exchange for consulting services previously provided to the Company.

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 – Organization, Operations and Basis of Presentation – Continued

Share Exchange and Reorganization – Continued

On June 30, 2014 (the “Closing Date”), CSI entered into and closed a Share Exchange Agreement (the “Share Exchange Agreement”) with Cell Source Limited and 100% of the shareholders of Cell Source Limited (the “CSL Shareholders”) whereby Cell Source Limited became the wholly-owned subsidiary of CSI (the “Share Exchange”), and whereby the CSL Shareholders, transferred to the Company all 18,245,923 outstanding shares of Cell Source Limited’s ordinary shares (“CSL Ordinary Shares”) in exchange for an aggregate of 18,245,923 newly issued shares of the Company’s Common Stock, par value $0.001 per share (the “Company Common Stock” or the “Common Stock”). The aggregate of 18,245,923 shares of newly issued Company Common Stock represents 78.5% of the 23,245,923 outstanding shares of Company Common Stock following the Closing Date. In addition, outstanding five (5) year warrants to acquire 4,859,324 CSL Ordinary Shares at an exercise price of $0.75 per share (the “CSL Warrants”) were exchanged for newly issued warrants to purchase shares of Company Common Stock at $0.75 per share (the “Company Warrants”), which Company Warrants contain substantially similar terms as the CSL Warrants. In addition, outstanding seven-year warrants to acquire 2,043,835 CSL Ordinary Shares at $0.001 per share were exchanged for warrants to purchase shares of Company Common Stock at $0.001 per share (the “Researcher Company Warrants”), which Researcher Company Warrants contain substantially similar terms as their warrants to acquire CSL Ordinary Shares. The aggregate of 6,903,159 Company Warrants and Researcher Company Warrants represents 77.5% of the outstanding warrants to purchase Common Stock of the Company following the Closing Date.

For accounting purposes, the Share Exchange will be treated as a recapitalization of the Company, the accounting acquirer, because the Company shareholders own the majority of CSI’s outstanding common stock following the transaction and exercise significant influence over the operating and financial policies of the consolidated entity. CSI was a non-operating company prior to the share exchange. Pursuant to Securities and Exchange Commission rules, the merger or acquisition of a private operating company into a non-operating public company with nominal net assets is considered a capital transaction in substance, rather than a business combination.

Note 2 – Going Concern

The Company has not generated any revenues, has recurring net losses, a working capital deficiency as of June 30, 2014 and December 31, 2013 of approximately $1,680,000 and $697,000, respectively, and used cash in operations of approximately $2,150,000 and $340,000 for the six months ended June 30, 2014 and 2013, respectively. In addition, as of June 30, 2014, the Company had an accumulated deficit of approximately $5,747,000. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

These unaudited condensed consolidated financial statements have been prepared on the going concern basis, which assumes the realization of assets and liquidation of liabilities in the normal course of operations. The ability of the Company to continue its operations is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to incur additional liabilities with certain related parties to sustain the Company’s existence. If the Company were not to continue as a going concern, it would likely not be able to realize its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the preparation of the unaudited condensed consolidated financial statements.

There can be no assurances that the Company will be successful in generating additional cash from equity or other sources to be used for operations. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary. Based on the Company’s current funding levels, the Company expects to be able to fund its operations through November 2014. Should the Company not be successful in obtaining the necessary financing to fund its operations, the Company would need to curtail certain or all operational activities and/or contemplate the sale of its assets if necessary.

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 3 – Significant Accounting Policies

Principles of Consolidation

For June 30, 2014 and forward, the Company’s financial statements are consolidated and include the accounts of CSI and Cell Source Limited. All significant intercompany transactions have been eliminated in the consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates, among other things, are used in accounting for allowances for deferred income taxes, contingencies, as well as the recording and presentation of its common stock and related warrant issuances. Estimates and assumptions are periodically reviewed and the effects of any material revisions are reflected in the financial statements in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions.

Research and Development Costs

Research and development costs are expensed as they are incurred and consist of salaries, benefits and other personnel related costs, fees paid to consultants, clinical trials and related clinical manufacturing costs, license and milestone fees, and facilities and overhead costs.

Loss Per Share

The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. For the three and six months ended June 30, 2014, warrants to purchase 2,043,835 shares of common stock were included in the loss per share denominator because their exercise price was determined to be nominal.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	June 30,
	2014		2013

Warrants		6,859,324		-
Convertible notes		-		2,297,487
Total		6,859,324		2,297,487

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For non-employees, the fair value of the award is generally re-measured on financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period the services are required to be provided in exchange for the award, usually the vesting period. Because the Company’s common stock historically was not actively traded on a public market, the fair value of the Company’s restricted equity instruments are estimated based on the historical observations of cash prices paid for the Company’s common stock.

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 3 – Significant Accounting Policies - Continued

Derivative Financial Instruments

The fair value of an embedded conversion option that is convertible into a variable amount of shares and warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815 “Derivatives and Hedging”, since “down-round protection” is not an input into the calculation of the fair value of the conversion option and warrants and cannot be considered “indexed to the Company’s own stock” which is a requirement for the scope exception as outlined under ASC 815.

The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option and warrants at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification.

The Black-Scholes option valuation model was used to estimate the fair value of the warrants and conversion options. The model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or conversion options.

Conversion options are recorded as debt discount and are amortized as interest expense over the life of the underlying debt instrument.

Reclassifications

Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.

Recent Accounting Standards

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.” This ASU removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company elected to adopt this ASU effective with its Current Report on Form 8-K filed with SEC on July 1, 2014 and the adoption resulted in the removal of previously required development stage disclosures.

In June 2014, the FASB issued ASU No. 2014-12, “Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation - Stock Compensation” as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its condensed consolidated financial statements.

The Company has implemented all new accounting standards that are in effect and may impact its financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations.

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 4 - Fair Value

The Company determines the estimated fair value of amounts presented in these condensed consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of June 30, 2014 and 2013, plus December 31, 2013 and 2012, and, as of those dates, the carrying value of all amounts approximates fair value.

The Company has categorized its assets and liabilities at fair value based upon the following fair value hierarchy:

Level 1 - Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

Level 2 - Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 - Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability.

In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair measurements requires judgment and considers factors specific to each asset or liability.

Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category presented in the tables below may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs.

The following table summarizes the valuation of the Company’s derivatives by the above fair value hierarchy levels as of June 30, 2014 and December 31, 2013 using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):

			Quoted Prices
			In Active		Significant
			Markets for		Other		Significant
			Identical		Observable		Unobservable
			Liabilities		Inputs		Inputs
	Total		(Level 1)		(Level 2)		(Level 3)

Warrant liability	$	2,476,800	$	-	$	-	$	2,476,800

Balance - June 30, 2014	$	2,476,800	$	-	$	-	$	2,476,800

Warrant liability	$	231,200	$	-	$	-	$	231,200

Balance - December 31, 2013	$	231,200	$	-	$	-	$	231,200

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The Company’s Level 3 liabilities shown in the above table consist of warrants with “down-round protection”, as the Company is unable to determine if it will have sufficient authorized common stock to settle such arrangements. Earlier in 2013, the Company’s Level 3 liabilities consisted of conversion options with “down-round protection”.

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 4 - Fair Value – Continued

Assumptions utilized in the valuation of Level 3 liabilities are described as follows:

	For the Three Months Ended				For the Six Months Ended
	June 30,				June 30,
	2014		2013		2014			2013

Risk-free interest rate	1.62% - 1.65%		0.05% - 0.08%		1.46% - 1.73		%	0.02% - 0.08%
Expected term (years)		4.33 - 5.00		0.00 - 0.24		4.33 - 5.00			0.00 - 0.50
Expected volatility		164% - 166%		65%		164% - 168	%		65% - 99%
Expected dividends		0.00%		0.00%		0.00	%		0.00%

The expected term used is the contractual life of the instrument being valued. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the six months ended June 30, 2014 and 2013:

	2014		2013

Balance - January 1,	$	231,200	$	38,300

Change in fair value of derivative liability		16,400		(64,500	)

Issuance of derivative liability		2,229,200		434,200

Balance - June 30,	$	2,476,800	$	408,000

The Company’s significant financial instruments such as cash, accounts payable and accrued expenses were deemed to approximate fair value due to their short term nature.

Note 5 – Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	June 30,		December 31,
	2014		2013
	(unaudited)

Accrued fees and expenses	$	29,332	$	103,705
Accrued payroll		41,294		12,944
Total	$	70,626	$	116,649

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 6 – Consulting Agreements – Related Party

On October 3, 2011, the Company entered into a definitive license agreement for Veto Cell technology and also an exclusive option agreement to negotiate an additional license for organ regeneration technology with Yeda Research and Development Company Limited (“Yeda”), a founder and shareholder of the Company. Yeda is the technology transfer and commercial arm of the Weizmann Institute of Science, for research conducted at the Weizmann Institute of Science for an invention comprising methods of bone marrow transplantation and cell therapy utilizing Veto-Cells. The evaluation period with respect to the option to license the organ regeneration technology originally expired on October 3, 2012 and has since been extended to September 1, 2014. See Note 9 – Subsequent Events for information regarding an additional extension of the expiration date.

Under the terms of the agreement, Yeda granted the Company an exclusive worldwide license for the licensed information and the patents for the development, manufacture and sale of the products derived therefrom. In consideration for the grant of the license, the Company has paid and will pay Yeda: (1) $210,000 on October 3, 2011; (2) an annual Research budget commitment for 3 years in the amount of $800,000 for the period until October 3, 2014; (3) a non-refundable and non-creditable license fee of $50,000 per year during the terms of the agreement, commencing on the first day after the date of termination or expiry of the research period (which period has not expired and will be extended), (4) a royalty of 4% of net future sales by or on behalf of the Company or any sub licensees.

If the Company fails to achieve any of the milestones by the dates set forth in the agreement, Yeda is entitled to terminate the license upon written notice to the Company. To date, the Company has met all of the milestones and the next milestone in the agreement is October 3, 2016. Either Yeda or the Company may terminate the agreement and the license after the commitment of a material breach by the other party and in certain other instances as detailed in the agreement.

For the three and six months ended June 30, 2014, the Company recorded a charge to operations of approximately $399,000 and $611,000, respectively, for this consulting arrangement. For the three and six months ended June 30, 2013, the Company recorded a charge to operations of approximately $330,000 and $403,000, respectively, for this consulting arrangement. As of June 30, 2014 and December 31, 2013, approximately $216,000 and $442,000 has been accrued and is payable, respectively.

Note 7 – Stockholders’ Deficiency

Common Stock and Warrant Offerings

During the six months ended June 30, 2014, the Company entered into an investment agreement with a group of investors. Pursuant to the agreement, the investors contributed to the Company aggregate net proceeds of $3,012,846 (gross proceeds of $3,067,996 less issuance costs of $55,150) in exchange for 4,090,661 units. Each unit was sold for $0.75 per unit and consisted of one share of common stock and an immediately vested five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share. The warrants carried provisions that were deemed to be “down round” price protection features. As a result, during the six months ended June 30, 2014, the Company reclassified $1,499,000 for the fair value of the warrants to derivative liabilities and will be marked to market for each reporting period.

Stock-Based Compensation

On July 7, 2014, the Board of Directors resolved to issue 100,000 shares of common stock to a service provider in connection with the June 30, 2014 completion of the Share Exchange. The Company recognized the $43,000 value of the award as stock-based compensation expense during the three months ended June 30, 2014, which was the service period. See Note 9 – Subsequent Events for additional information regarding the common stock award.

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 7 – Stockholders’ Deficiency – Continued

Stock Warrants

A summary of the warrant activity during the six months ended June 30, 2014 is presented below:

					Weighted
			Weighted		Average
			Average		Remaining
	Number of		Exercise		Life		Intrinsic
	Warrants		Price		In Years		Value

Outstanding, December 31, 2013		2,812,498	$	0.21
Granted		6,090,661		0.75
Exercised		-		-
Forfeited		-		-
Outstanding, June 30, 2014		8,903,159	$	0.58		5.1	$	815,490

Exercisable, June 30, 2014		6,859,324	$	0.75		4.7	$	-

The following table presents information related to stock warrants at June 30, 2014:

Warrants Outstanding				Warrants Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Warrants		In Years		Warrants

$	0.001		2,043,835		-		-
$	0.750		6,859,324		4.7		6,859,324
			8,903,159		4.7		6,859,324

Note 8 – Commitments and Contingencies

Litigation

Certain conditions may exist as of the date the condensed consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company, or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed, unless they involve guarantees, in which case the guarantees would be disclosed. There can be no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. As of June 30, 2014 and December 31, 2013, the Company has not accrued any amounts for contingencies.

CELL SOURCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 9 – Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would require adjustment or disclosure in the condensed consolidated financial statements, other than as disclosed below.

Issuance of Common Stock

On July 29, 2014, the Company issued 100,000 shares of common stock to a service provider in order to satisfy a stock-based compensation award. See Note 7 - Stockholders’ Deficiency – Stock-Based Compensation for additional details.

Extension of Evaluation Period of Yeda’s Organ Regeneration Technology

On August 15, 2014, the Company and Yeda executed an amendment to the exclusive option agreement to negotiate a license for organ regeneration technology which extends the evaluation period through December 31, 2015. The Company has been informed that Yeda is currently investigating the scope of its rights and title to the patents and inventions that comprise the organ regeneration technology (see Note 6 – Consulting Agreements – Related Party).

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The information set forth below should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, as well as with the financial statements and related disclosures of Cell Source Limited for the years ended December 31, 2013 and 2012, which were included in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on July 1, 2014. Unless stated otherwise, references in this Quarterly Report on Form 10-Q to the “Company,” “us,” “we,” “our,” and similar terms refer to Cell Source, Inc., a Nevada corporation, and its subsidiaries.

Forward-Looking Statements

This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur. Generally these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words “may,” “will,” “expect,” “believe,” “anticipate,” “project,” “plan,” “intend,” “estimate,” and “continue,” and their opposites and similar expressions are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, that may influence the accuracy of the statements and the projections upon which the statements are based. Factors which may affect our results include, but are not limited to, the risks factors and uncertainties set forth in Part I, Item 1A of our Current Report on Form 8-K which was filed with the SEC on July 1, 2014.

Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

Overview

Cell Source, Inc. is a Nevada corporation formed on June 6, 2012 under the name Ticket to See, Inc. (“TTSI”). On June 30, 2014, TTSI, Cell Source Limited and 100% of the shareholders of Cell Source Limited entered into and closed a Share Exchange Agreement pursuant to which Cell Source Limited became the wholly-owned subsidiary of TTSI (the “Share Exchange”). In connection with the Share Exchange, on June 26, 2014, TTSI changed its name to “Cell Source, Inc.”

Our wholly-owned subsidiary, Cell Source Limited was founded in 2011 as a privately held company located in Tel Aviv, Israel. Our business is based on over ten (10) years of prominent research at the Weizmann Institute, whose commercial arm is Yeda, from whom we license patented technology. Our exclusive, world-wide license provides us with access to certain discoveries, inventions and other intellectual property generated by Dr. Yair Reisner, Head of the Immunology Department at the Weizmann Institute, together with others. Dr. Reisner leads a team at the Weizmann Institute to continue the development of these technologies in order to facilitate the transition of those technologies from the laboratory to clinical trials. We also collaborate with Dr. Herman Einsele and Dr. Franco Aversa, leading figures in bone marrow transplantation for cancer treatment and research, both of whom plan to serve on our Scientific Advisory Board and will oversee our initial clinical trials which, when started, will focus on addressing cancer through cell therapy accompanied by bone marrow transplants.

Our lead prospective product is our patented Veto-Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The Company’s target indications include lymphoma, multiple myeloma and BCLL, a form of leukemia. The treatment involves facilitating safe and successful transplantation engraftment (initially bone -marrow transplantation and subsequently organ transplantation) and ultimately effective treatment of a variety of non-malignant diseases.

Results of Operations

Three Months Ended June 30, 2014 Compared to Three Months Ended June 30, 2013

The following table presents selected items in our unaudited condensed consolidated statements of operations for the three months ended June 30, 2014 and 2013, respectively:

	For The
	Three Months Ended
	June 30,
	2014			2013

Revenues	$	-		$	-

Operating Expenses
Research and development		220,995			87,436
Research and development - related party		398,845			329,753
Selling, general and administrative		397,338			79,100

Total Operating Expenses		1,017,178			496,289

Loss From Operations		(1,017,178	)		(496,289	)

Other (Expense) Income
Interest expense		-			(362,001	)
Change in fair value of derivative liability		31,100			54,300

Total Other Income (Expense)		31,100			(307,701	)

Net Loss	$	(986,078	)	$	(803,990	)

Research and Development

Research and development expense was $619,840 and $417,189 for the three months ended June 30, 2014 and 2013, respectively, an increase of $202,651, or 49%, primarily because the proceeds from our recent equity financing permitted us to expand our research and development expenses, including expenses associated with key patents entering the National Phase in a number of countries around the world.

Selling, General and Administrative

Selling, general and administrative expense was $397,338 and $79,100 for the three months ended June 30, 2014 and 2013, respectively, an increase of $318,238, or 402%, primarily as a result of legal and professional fees associated with our Share Exchange transaction which was prepared for and closed in the current period.

Interest Expense

Interest expense for the three months ended June 30, 2014 and 2013, was $0 and $362,001, respectively. Interest expense during the three months ended June 30, 2013 was primarily related to the amortization of debt discount associated with our convertible notes.

Change in Fair Value of Derivative Liability

The change in fair value of derivative liability for the three months ended June 30, 2014 and 2013 was $31,100 and $54,300, respectively, which represents the change in fair value of the warrants and embedded conversion options associated with our convertible notes that were deemed to be derivative liabilities.

Six Months Ended June 30, 2014 Compared to Six Months Ended June 30, 2013

The following table presents selected items in our unaudited condensed consolidated statements of operations for the six months ended June 30, 2014 and 2013, respectively:

	For The
	Six Months Ended
	June 30,
	2014			2013

Revenues	$	-		$	-

Operating Expenses
Research and development		545,412			193,806
Research and development - related party		611,203			402,629
Selling, general and administrative		633,305			127,853

Total Operating Expenses		1,789,920			724,288

Loss From Operations		(1,789,920	)		(724,288	)

Other (Expense) Income
Interest expense		-			(396,534	)
Change in fair value of derivative liability		(16,400	)		64,500

Total Other Income (Expense)		(16,400	)		(332,034	)

Net Loss	$	(1,806,320	)	$	(1,056,322	)

Research and Development

Research and development expense was $1,156,615 and $596,435 for the six months ended June 30, 2014 and 2013, respectively, an increase of $560,180, or 94%, primarily because the proceeds from our recent equity financing permitted us to expand our research and development expenses, including expenses associated with key patents entering the National Phase in a number of countries around the world.

Selling, General and Administrative

Selling, general and administrative expense was $633,305 and $127,853 for the six months ended June 30, 2014 and 2013, respectively, an increase of $505,452, or 395%, primarily as a result of legal and professional fees associated with our Share Exchange transaction, which was prepared for and closed in the current period.

Interest Expense

Interest expense for the six months ended June 30, 2014, and 2013 was $0 and $396,534, respectively. Interest expense during the six months ended June 30, 2013 was primarily related to the amortization of debt discount associated with our convertible notes.

Change in Fair Value of Derivative Liability

The change in fair value of derivative liability for the six months ended June 30, 2014 and 2013 was $(16,400) and $64,500, respectively, which represents the change in fair value of the warrants and embedded conversion options associated with our convertible notes that were deemed to be derivative liabilities.

Liquidity and Capital Resources

We measure our liquidity in a number of ways, including the following:

	June 30,			December 31,
	2014			2013
	(unaudited)

Cash	$	889,332		$	28,878
Working capital deficiency	$	(1,679,565	)	$	(697,334	)

We have not generated any revenues since our inception, we have recurring net losses, we have a working capital deficiency as of June 30, 2014 and December 31, 2013 of $1,679,565 and $697,334, respectively, and we have used cash in operations of $2,149,810 and $340,090 during the six months ended June 30, 2014 and 2013, respectively. These conditions raise substantial doubt about our ability to continue as a going concern. Based upon our working capital deficiency and forecast for continued operating losses, we expect that the cash we currently have available will fund our operations through November 2014.

Our ability to continue our operations is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. We may need to incur additional liabilities with certain related parties to sustain our existence. If we were not to continue as a going concern, we would likely not be able to realize our assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the preparation of our financial statements.

There can be no assurances that the Company will be successful in generating additional cash from equity or debt financings or other sources to be used for operations. Should the Company not be successful in obtaining the necessary financing to fund its operations, the Company would need to curtail certain or all operational activities and/or contemplate the sale of its assets if necessary.

During the six months ended June 30, 2014 and 2013, our sources and uses of cash were as follows:

Net Cash Used in Operating Activities

We experienced negative cash flows from operating activities for the six months ended June 30, 2014 and 2013 in the amounts of $2,149,810 and $340,090, respectively. The net cash used in operating activities for the six months ended June 30, 2014 was primarily due to cash used to fund a net loss of $1,806,320, adjusted for net non-cash expenses in the aggregate amount of $59,425, and $402,915 of net cash used to fund changes in the levels of operating assets and liabilities, primarily as a result of payments to vendors due to improved cash availability. The net cash used in operating activities for the six months ended June 30, 2013 was primarily due to cash used to fund a net loss of $1,056,322, adjusted for non-cash expenses in the aggregate amount of $409,024 partially offset by $307,208 of net cash provided due to changes in the levels of operating assets and liabilities, primarily as a result of increases in accounts payable and accrued expenses, due to cash constraints during the period.

Net Cash Used in Investing Activities

Net cash used in investing activities was $2,582 for the six months ended June 30, 2014, which was related to purchases of property and equipment.

Net Cash Provided by Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2014 and 2013 was $3,012,846 and $210,000, respectively. The net cash provided by financing activities during the six months ended June 30, 2014 was attributable to $3,012,846 of net proceeds from our IPO (gross proceeds of $3,067,996 less $55,150 of issuance costs). The net cash provided by financing activities during the six months ended June 30, 2013 was attributable $210,000 of proceeds from the issuance of convertible notes.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies

There are no material changes from the critical accounting policies set forth in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Current Report on Form 8-K which was filed with the SEC on July 1, 2014. Please refer to that document for disclosures regarding the critical accounting policies related to our business.

Recent Accounting Standards

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation - Stock Compensation” as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We do not anticipate that the adoption of this standard will have a material impact on our condensed consolidated financial statements.

See the Notes to the Condensed Financial Statements within our Current Report on Form 8-K, which was filed with the SEC on July 1, 2014 for additional Recent Accounting Standards.

Significant Factors, Assumptions, and Methodologies Used in Estimating Fair Value of Common Stock

We performed valuations to estimate the fair value of our common stock during the first half of 2014 and during 2013. To determine the value of our common stock, we considered the following three possible valuation methods (1) the income approach, (2) the market approach and the (3) cost approach to estimate our enterprise value.

The income approach focuses on the income-producing capability of a business by estimating value based on the expectation of future cash flows that a company will generate – such as cash earnings, cost savings, tax deductions, and the proceeds from disposition. These cash flows are discounted to the present using a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation, and risks associated with the particular investment. The selected discount rate is generally based on rates of return available from alternative investments of similar type, quality, and risk.

The market approach valuation method measures the value of an asset or business through an analysis of recent sales or offerings of comparable investments or assets. When applied to the valuation of equity interests, consideration is given to the financial condition and operating performance of the entity being appraised relative to those of publicly traded entities operating in the same or similar lines of business, potentially subject to corresponding economic, environmental, and political factors and considered to be reasonable investment alternatives.

In addition to the income approach and market approach valuation methods, we also considered the cost approach as a valuation method. This approach measures the value of an asset by the cost to reconstruct or replace it with another of like utility.

We selected the Market Approach to estimate the fair value of the Common shares as the Company sold shares of Common Stock to third parties in 2014 and 2013.

During the year ended December 31, 2013, we entered into an agreement with a group of investors whereby, the investors purchased 735,327 units for cash proceeds of $551,497 at $0.75 per unit. Each unit consisted of 1 share of common stock and 1 five-year warrant, which entitles the holder to purchase 1 share of common stock at an exercise price of $0.75 per share.

During the six months ended June 30, 2014, we entered into an agreement with a group of investors whereby the investors purchased 4,090,661 units for cash proceeds of $3,067,996. Each unit was sold for $0.75 and consisted of 1 share of common stock and 1 five-year warrant, which entitles the holder to purchase 1 share of common stock at an exercise price of $0.75 per share.

Using an option pricing method and the relative fair values, we derived the implied equity value for the Common Stock based on the sale of the Units described above.

	Six months ended June 30, 2014							Year ended December 31, 2013
	Common Stock		Fair		Allocation			Common Stock		Fair		Allocation
	Equivalents		Value		%			Equivalents		Value		%

Common stock		4,090,661	$	3,067,996		57	%		735,327	$	551,497		54	%
Warrants		4,090,661	$	2,320,054		43	%		735,327	$	470,800		46	%

	Relative fair value of the common stock				$	0.43			Relative fair value of the common stock			$	0.40

There is inherent uncertainty in our forecasts and projections, and if we had made different assumptions and estimates than those described previously, the determined fair value of our common stock for either period could have been materially different.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), such as this Quarterly Report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Principal Executive and Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Internal controls are procedures which are designed with the objective of providing reasonable assurance that (1) our transactions are properly authorized, recorded and reported; and (2) our assets are safeguarded against unauthorized or improper use, to permit the preparation of our condensed consolidated financial statements in conformity with United States generally accepted accounting principles.

In connection with the preparation of this Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, management, with the participation of our Principal Executive and Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)). Based upon that evaluation, our Principal Executive and Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were not effective.

In preparing our financial statements as of and for the year ended December 31, 2013, we identified control deficiencies in the design and operation of our internal control over financial reporting that together constituted a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. The material weaknesses identified were that we did not have adequate accounting systems and our accounting staff was inadequate both in terms of the number of personnel and their expertise in U.S. GAAP and SEC rules and regulations. As such, our controls over financial reporting were not designed or operating effectively.

As of the date of this filing, we have taken steps to remediate this material weakness. We have engaged the services of additional personnel with knowledge of U.S. GAAP and public company financial reporting expertise to enhance our financial management and reporting infrastructure, and further develop and document our accounting policies and financial reporting procedures. As of the end of the period covered by our next Quarterly Report on Form 10-Q, we will test the effects of such remedies on the efficacy of our controls over financial reporting.

If we failed to remediate the material weakness or if in the future we fail to meet the demands that will be placed upon us as a public company, we may be unable to accurately report our financial results, or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities.

Changes in Internal Controls

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f)) during the quarter ended June 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations of the Effectiveness of Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations of any control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently a party to any material legal proceedings.

Item 1A. Risk Factors.

There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Current Report on Form 8-K which was filed with the SEC on July 1, 2014

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In July 2014, we issued 100,000 shares of common stock in lieu of cash payment for legal services. For the issuance of these securities, we relied on the exemption from securities registration provided by Section 4(a)(2) of the Securities Act for transactions not involving a public offering.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

On August 15, 2014, we executed an amendment to the exclusive option agreement to negotiate a license for organ regeneration technology from Yeda Research and Development Company Limited (“Yeda”), a founder and shareholder of the Company, which extends the evaluation period through December 31, 2015. We have been informed that Yeda is currently investigating the scope of its rights and title to the patents and inventions that comprise the organ regeneration technology. The foregoing description does not purport to be complete and is qualified in its entirety by reference to the complete text of the amendment agreement, which is filed as an exhibit hereto and is incorporated herein by reference.

Item 6. Exhibits.

Exhibit
Number		Description
2.1	[1]	Share Exchange Agreement, dated June 30, 2014, by and between Cell Source, Ltd., and Ticket to See, Inc.
3.1	[2]	Certificate of Amendment to Articles of Incorporation of Ticket to See, Inc., dated May 20, 2014
3.2	[3]	Certificate of Amendment to Articles of Incorporation of Ticket to See, Inc., dated June 23, 2014
10.1	[1]	Form of Subscription Agreement
10.2	[1]	Form of Registration Rights Agreement
10.3	[1]	Form of Investor Warrant
10.4	[1]	Form of Researcher Company Warrant
10.5	[1]	Form of Company Warrant
10.6	[1]	Form of Lockup Agreement (included in Exhibit 2.1)
10.7	[1]	Research and License Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited, dated October 3, 2011
10.8	[1]	Amendment to Research and License Agreement
10.9	[1]	Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited, dated Oct. 3, 2011 (included in Exhibit 10.7)
10.10	[1]	Second Amendment dated June 22, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited
10.11	*	Third Amendment dated August 15, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited
10.12	[1]	Consulting Agreement by and between Cell Source Limited and Professor Yair Reisner
10.13	[1]	Form of Amendment No. 1 to Registration Rights Agreement
10.14	[4]	Form of Consulting Agreement
10.15	[4]	Form of Consultant Warrant
31.1	*	Certificate of the Chief Executive Officer
31.2	*	Certificate of the Chief Financial Officer
32	**	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	***	XBRL Instance Document
101.SCH	***	XBRL Schema Document
101.CAL	***	XBRL Calculation Linkbase Document
101.DEF	***	XBRL Definition Linkbase Document
101.LAB	***	XBRL Label Linkbase Document
101.PRE	***	XBRL Presentation Linkbase Document

	[1]	Incorporated by reference to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on July 1, 2014
	[2]	Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 6, 2014.
	[3]	Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 26, 2014.
	[4]	Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 30, 2014.

	*	Filed herewith
	**	This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise be subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.
	***	Pursuant to Rule 406T of Regulation S-T, this XBRL related information shall not be deemed to be “filed” for purposes of
		Section 18 of the Exchange Act, or otherwise be subject to the liability of that section, and shall not be deemed part of a registration statement, prospectusor other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filings.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CELL SOURCE, INC.


Date: August 19, 2014	By:	/s/ Itamar Shimrat
		Itamar Shimrat
		Chief Executive Officer, Chief Financial Officer, President and Director
		(Principal Executive and Financial Officer)

EX-10.11 2 v387117_ex10-11.htm EXHIBIT 10.11

Exhibit 10.11

THIRD AMENDMENT TO EVALUATION AND EXCLUSIVE OPTION AGREEMENT

Made and entered in to this 15th day of August, 2014

By and between

YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED

a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel

(hereinafter, “Yeda”)

and

CELL SOURCE LIMITED

a company duly registered under the laws of Israel of 65 Yigal Alon St., Toyota Tower, 23^rd Floor, Tel Aviv 67443, Israel

(hereinafter, “Cell Source”)

WHEREAS

Yeda and Cell Source are parties to an evaluation and exclusive option agreement dated October 3, 2011 as amended on April 1, 2014 and further amended on June 22, 2014 ("the E&O Agreement”); and

WHEREAS

the parties are contemplating to enter into a Research and License Agreement, pursuant to which Yeda shall grant to Cell Source a worldwide exclusive license in respect of, inter alia, a certain invention, more fully described in PCT patent application no. PCT/IB2012/057042 entitled “MAMMALIAN FETAL PULMONARY CELLS AND THERAPEUTIC USE OF SAME” (Yeda ref. 2011-092), and any further development arrived at under the Research, as shall be outlined in the said Agreement, whether covered by this patent or another current or future patent application developed under the said Research; and

WHEREAS

Cell Source has also requested to preserve its option to obtain a licence to the Patents and the Inventions under the E&O Agreement (the “Option”) that may be relevant to Cell Source’s business, and has further requested to extend the Option until December 31, 2015; and

WHEREAS

the parties hereby agree that the said preservation and extension of the Option shall be subject to the acknowledgements and representations of Cell Source set out herein below,

NOW THEREFORE IT IS AGREED BY THE PARTIES HERETO AS FOLLOWS:

Terms and phrases used in this Amendment which are defined in the E&O Agreement shall have in this Amendment the same meaning as that attributed to them in the E&O Agreement, unless otherwise expressly defined in this Amendment. The above preamble forms an integral part of this Amendment.

Cell Source hereby acknowledges and represents that:

2.1

it has been informed by Yeda that certain of the scientists listed as inventors to the Inventions in the applicable Patents were, during part or all of the period in which they contributed to such Inventions at the Institute, physicians that may have been affiliated with various respective health care institutions in Israel other than the Institute (the “Other Institutions” and the “Employed Inventors”, respectively);

2.2

Yeda intends to investigate the above issue and, if necessary, to make commercially reasonable efforts to resolve it in a manner that will, de facto, provide Cell Source with the opportunity to license these Inventions on an exclusive worldwide basis in a manner that will be acceptable to the Other Institutions; and

2.3

in light of the above, Yeda may not have full right and title to the Patents and the Inventions that are the subject of the Option, and therefore, the Option is limited to the rights that Yeda shall in fact have in respect of the Patents and the Inventions (as the case may be) at the time of the exercise (if exercised) of the Option by Cell Source (the “Yeda Rights”) and Cell Source hereby waives any claim against Yeda in that respect.

Subject to the above, the E&O Agreement shall be modified, such that, the Option detailed in clause 7.1 thereto shall be limited to the Yeda Rights and the words “until September 1st, 2014” in the said clause shall be replaced by the words “until December 31^st, 2015”.

This Amendment and the E&O Agreement shall be read as one and shall represent the complete current understanding between the parties with respect to the subject matter hereof. Subject to the modifications contained herein, the provisions of the E&O Agreement shall remain unaltered and in full force and effect.

IN WITNESS WHEREOF the parties hereto have set their signatures as of the date set out above.

for	YEDA RESEARCH AND DEVELOPMENT CO., LTD.	for	CELL SOURCE LIMITED


Signature:		Signature:

Name:		Name:

Title:		Title:

EX-31.1 3 v387117_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, Itamar Shimrat, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Cell Source, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 19, 2014

/s/ Itamar Shimrat
Itamar Shimrat
Chief Executive Officer, Chief Financial Officer,
President and Director
(Principal Executive Officer)

EX-31.2 4 v387117_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, Itamar Shimrat, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Cell Source, Inc.;

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 19, 2014

/s/ Itamar Shimrat
Itamar Shimrat
Chief Executive Officer, Chief Financial Officer,
President and Director
(Principal Financial Officer)

EX-32 5 v387117_ex32.htm EXHIBIT 32

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Cell Source, Inc., a Nevada corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended June 30, 2014 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 19, 2014	By:	/s/ Itamar Shimrat
		Itamar Shimrat
		Chief Executive Officer, Chief Financial Officer,
		President and Director
		(Principal Executive and Financial Officer)

EX-101.INS 6 clcs-20140630.xml XBRL INSTANCE DOCUMENT 0001569340 2013-01-01 2013-06-30 0001569340 2013-01-01 2013-12-31 0001569340 2014-01-01 2014-06-30 0001569340 2013-04-01 2013-06-30 0001569340 2014-04-01 2014-06-30 0001569340 2014-05-07 0001569340 2014-06-30 0001569340 2014-08-15 0001569340 2013-12-31 0001569340 2012-12-31 0001569340 2013-06-30 0001569340 us-gaap:SubsequentEventMember 2014-07-29 0001569340 us-gaap:CommonStockMember 2013-12-31 0001569340 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001569340 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-12-31 0001569340 us-gaap:CommonStockMember 2014-01-01 2014-06-30 0001569340 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-06-30 0001569340 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2014-01-01 2014-06-30 0001569340 us-gaap:CommonStockMember 2014-06-30 0001569340 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0001569340 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2014-06-30 0001569340 us-gaap:FairValueInputsLevel1Member 2013-01-01 2013-12-31 0001569340 us-gaap:FairValueInputsLevel2Member 2013-01-01 2013-12-31 0001569340 us-gaap:FairValueInputsLevel3Member 2013-01-01 2013-12-31 0001569340 us-gaap:FairValueInputsLevel1Member 2014-01-01 2014-06-30 0001569340 us-gaap:FairValueInputsLevel2Member 2014-01-01 2014-06-30 0001569340 us-gaap:FairValueInputsLevel3Member 2014-01-01 2014-06-30 0001569340 clcs:ShareExchangeAgreementMember 2014-06-30 0001569340 clcs:ResearcherCompanyWarrantsMember 2014-06-30 0001569340 clcs:ConsultantsMember 2014-06-01 2014-06-27 0001569340 us-gaap:WarrantMember 2014-06-01 2014-06-30 0001569340 clcs:ResearcherCompanyWarrantsMember 2014-06-01 2014-06-30 0001569340 clcs:ConsultantsMember 2014-06-27 0001569340 us-gaap:WarrantMember 2014-06-30 0001569340 clcs:CompanyWarrantsMember 2014-06-30 0001569340 clcs:CslOrdinarySharesMember 2014-06-30 0001569340 clcs:ShareExchangeAgreementMember 2014-06-01 2014-06-30 0001569340 us-gaap:FairValueInputsLevel1Member 2014-06-30 0001569340 us-gaap:FairValueInputsLevel2Member 2014-06-30 0001569340 us-gaap:FairValueInputsLevel3Member 2014-06-30 0001569340 us-gaap:FairValueInputsLevel3Member 2013-12-31 0001569340 us-gaap:FairValueInputsLevel2Member 2013-12-31 0001569340 us-gaap:FairValueInputsLevel1Member 2013-12-31 0001569340 us-gaap:MinimumMember 2013-01-01 2013-06-30 0001569340 us-gaap:MaximumMember 2013-01-01 2013-06-30 0001569340 us-gaap:MinimumMember 2014-01-01 2014-06-30 0001569340 us-gaap:MaximumMember 2014-01-01 2014-06-30 0001569340 us-gaap:MinimumMember 2013-04-01 2013-06-30 0001569340 us-gaap:MaximumMember 2013-04-01 2013-06-30 0001569340 us-gaap:MinimumMember 2014-04-01 2014-06-30 0001569340 us-gaap:MaximumMember 2014-04-01 2014-06-30 0001569340 clcs:YedamemberMember 2011-10-01 2011-10-03 0001569340 clcs:ExercisePriceOneMember 2014-06-30 0001569340 clcs:ExercisePirceTwoMember 2014-06-30 0001569340 clcs:ExercisePriceOneMember 2014-01-01 2014-06-30 0001569340 clcs:ExercisePirceTwoMember 2014-01-01 2014-06-30 0001569340 clcs:ConsultingagreementmemberMember 2013-01-01 2013-06-30 0001569340 clcs:ConsultingagreementmemberMember 2014-01-01 2014-06-30 0001569340 clcs:ConsultingagreementmemberMember 2013-04-01 2013-06-30 0001569340 clcs:ConsultingagreementmemberMember 2014-04-01 2014-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

889332

28878

216035

441700

70626

116649

2763461

789549

23246

14155

4047077

3229522

-5747331

-3941011

-1677008

-697334

1086453

92215

0.001

200000000

23245923

14155262

23245923

14155262

724288

1789920

496289

1017178

-1056322

-1806320

-803990

-986078

-0.08

-0.10

-0.06

-0.05

12763818

18774759

12763818

20228764

280790

-271688

-340090

-2149810

-2582

-130090

860454

161323

28878

31233

889332

10-Q false 2014-06-30 2014 Q2 CELL SOURCE, INC. 0001569340 --12-31 Smaller Reporting Company CLCS 23345923

100000

135000

59564

63337

1083896

92215

2557

1086453

92215

2476800

231200

6859324

2297487

6859324

2043835

193806

545412

87436

220995

127853

633305

79100

397338

-724288

-1789920

-496289

-1017178

402629

611203

329753

398845

14155

3229522

-3941011

384034

14155262

3012846

4091

3008755

4090661

12500 0

-64500

16400

43000

396534

362001

76990

135000

43000

-1806320

-26418

-3773

23246

4047077

-5747331

23245923

2582

-1499000

5000000 -730200 5000 -735200 0

210000

3012846

-332034

-16400

-307701

31100

-54300

-31100

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 4 - Fair Value</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company determines the estimated fair value of amounts presented in these condensed consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of June 30, 2014 and 2013, plus December 31, 2013 and 2012, and, as of those dates, the carrying value of all amounts approximates fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company has categorized its assets and liabilities at fair value based upon the following fair value hierarchy:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 1 - Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 2 - Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 3 - Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair measurements requires judgment and considers factors specific to each asset or liability.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category presented in the tables below may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the valuation of the Company’s derivatives by the above fair value hierarchy levels as of June 30, 2014 and December 31, 2013 using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Quoted Prices</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>In Active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Markets for</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Identical</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Observable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Unobservable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Liabilities</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(Level 1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(Level 2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(Level 3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,476,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,476,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div>Balance - June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,476,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,476,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>231,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>231,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div>Balance - December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>231,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>231,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The Company’s Level 3 liabilities shown in the above table consist of warrants with “down-round protection”, as the Company is unable to determine if it will have sufficient authorized common stock to settle such arrangements. Earlier in 2013, the Company’s Level 3 liabilities consisted of conversion options with “down-round protection”.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <br/> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Assumptions utilized in the valuation of Level 3 liabilities are described as follows: </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"> <div>For the Three Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"> <div>For the Six Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.62% - 1.65%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.05% - 0.08%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.46% - 1.73%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.02% - 0.08%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.33 - 5.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00 - 0.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.33 - 5.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00 - 0.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>164% - 166%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>164% - 168%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65% - 99%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The expected term used is the contractual life of the instrument being valued. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the six months ended June 30, 2014 and 2013: </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>Balance - January 1,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>231,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Change in fair value of derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,400</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(64,500)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Issuance of derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,229,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>434,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>Balance - June 30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,476,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>408,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company’s significant financial instruments such as cash, accounts payable and accrued expenses were deemed to approximate fair value due to their short term nature. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.001

10000000

29332

103705

41294

12944

70626

116649

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 7  Stockholders’ Deficiency</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Common Stock and Warrant Offerings</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the six months ended June 30, 2014, the Company entered into an investment agreement with a group of investors. Pursuant to the agreement, the investors contributed to the Company aggregate net proceeds of $3,012,846 (gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,067,996</font> less issuance costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,150</font>) in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,090,661</font> units. Each unit was sold for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per unit and consisted of one share of common stock and an immediately vested five-year warrant to purchase one share of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share. The warrants carried provisions that were deemed to be “down round” price protection features. As a result, during the six months ended June 30, 2014, the Company reclassified $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,499,000</font> for the fair value of the warrants to derivative liabilities and will be marked to market for each reporting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Stock-Based Compensation</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On July 7, 2014, the Board of Directors resolved to issue <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of common stock to a service provider in connection with the June 30, 2014 completion of the Share Exchange. The Company recognized the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">43,000</font> value of the award as stock-based compensation expense during the three months ended June 30, 2014, which was the service period. See Note 9  Subsequent Events for additional information regarding the common stock award.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Stock Warrants</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the warrant activity during the six months ended June 30, 2014 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>In Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Outstanding, December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,812,498</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,090,661</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Outstanding, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,903,159</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>815,490</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Exercisable, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,859,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table presents information related to stock warrants at June 30, 2014:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 55%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Warrants Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%" colspan="5"> <div>Warrants Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Remaining Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>In Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,043,835</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,859,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>4.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,859,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,903,159</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>4.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,859,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

231200

2476800

75000000

0.001

200000000

10000000

0.001

0.75

18245923

23245923

0.785

18245923

0.775

0.001

6903159

340000

2150000

1680000 697000 2476800 0 0 2476800 231200 231200 0 0

0.0002

0.0008

0.0146

0.0173

0.0005

0.0008

0.0162

0.0165

P0Y

P6M

P4Y3M29D

P5Y

P0Y

P2M26D

P4Y3M29D

P5Y

0.65

0.99

1.64

1.68

0.65

1.64

1.66

210000

annual Research budget commitment for 3 years in the amount of $800,000 for the period until October 3, 2014;

50000 0.04 the option to license the organ regeneration technology originally expired on October 3, 2012 and has since been extended to September 1, 2014

38300

231200

-64500

16400

408000

2476800

434200 2229200

216000

442000

2812498

6090661

6859324

0.001

0.750

8903159

2043835

6859324

P4Y8M12D

P0Y

P4Y8M12D

0 6859324

0.21

0.75

815490

4090661

Each unit was sold for $0.75 per unit and consisted of one share of common stock and an immediately vested five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share. 1499000

0.75

0.58

P5Y1M6D

210000

0 3012846 0 315200 0

3067996

55150

100000

43000

403000

611000

330000

399000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">A summary of the warrant activity during the six months ended June 30, 2014 is presented below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>In Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Outstanding, December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,812,498</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,090,661</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Outstanding, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,903,159</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>815,490</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Exercisable, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,859,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table presents information related to stock warrants at June 30, 2014:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 55%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Warrants Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%" colspan="5"> <div>Warrants Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Remaining Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>In Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,043,835</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,859,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>4.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,859,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,903,159</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>4.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,859,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.00

Net of $55,150 of issuance costs. EX-101.SCH 7 clcs-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Organization, Operations and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Going concern link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Fair Value link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Consulting Agreements - Related Party link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stockholders' Deficiency link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stockholders' Deficiency (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Organization, Operations and Basis of Presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Going Concern (Details Textual) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Fair Value (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Fair Value (Details 1) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Fair value (Details 2) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Consulting Agreements - Related Party (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Stockholders' Deficiency (Details) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Stockholders' Deficiency (Details 1) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Stockholders' Deficiency (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 clcs-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 clcs-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 clcs-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Statement of Financial Position [Abstract] Statement [Table] Assets, Current [Abstract] Current Assets: Cash Cash Assets [Abstract] Assets Liabilities, Current [Abstract] Current Liabilities: Accrued Liabilities, Current Accounts payable and accrued expenses Notes Payable, Related Parties, Current Accounts payable and accrued expenses - related party NotesPayableRelatedPartiesClassifiedCurrent Derivative Liability, Current Derivative liabilities Commitments and Contingencies Commitments and contingencies (Note 8) Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2014 and December 31, 2013 Common Stock, Value, Issued Common stock, $0.001 par value; 200,000,000 shares authorized; 23,245,923 and 14,155,262 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Deficiency: Preferred Stock, Par or Stated Value Per Share Preferred stock, par value [in dollars per share] Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Income Statement [Abstract] Sales Revenue, Services, Net Revenues Research and Development Expense Research and development Related Party Transaction, Expenses from Transactions with Related Party Research and development - related party Selling, General and Administrative Expense Selling, general and administrative Operating Expenses [Abstract] Operating Expenses Interest Expense Interest expense Increase (Decrease) in Derivative Liabilities Change in fair value of derivative liabilities Change in fair value of derivative liabilities Statement of Cash Flows [Abstract] Net Income (Loss) Attributable to Parent Net loss Net Loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Accretion of Discount Accretion of debt discount Increase (Decrease) in Prepaid Expense Prepaid expenses Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Used in Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows From Operating Activities Payments to Acquire Property, Plant, and Equipment Purchase of propery and equipment Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows From Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows From Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Net Increase (Decrease) In Cash Cash and Cash Equivalents, at Carrying Value Cash - Beginning Cash - Ending Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing transactions: Subsequent Events [Abstract] Subsequent Events [Text Block] Document And Entity Information [Abstract] Document Information [Table] Legal Entity [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Common Stock, Shares, Issued Common stock, shares issued Subsequent Event [Member] Consolidation, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Earnings Per Share, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Reclassification, Policy [Policy Text Block] Prepaid Expense, Current Prepaid expenses Other Assets, Current Other current assets Assets, Current Total Current Assets Property, Plant and Equipment, Net Property and equipment, net Schedule of Weighted Average Number of Shares [Table Text Block] Assets Total Assets Schedule Of Significant Accounting Policies [Table] Schedule of significant accounting policies. Entity [Domain] Liabilities, Current Total Current Liabilities Liabilities and Equity Total Liabilities and Stockholders' Deficiency Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total Stockholders' Deficiency Begining Balance Ending Balance Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Warrants Incremental Common Shares Attributable to Dilutive Effect of Written Put Options Convertible notes Weighted Average Number Diluted Shares Outstanding Adjustment Total Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation Operating Expenses Total Operating Expenses Income (Loss) from Continuing Operations Attributable to Parent Loss From Operations Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Coupon Interest Expense Interest expense Amount of the cost of borrowed funds accounted for as coupon interest expense. Common Stock, Shares, Outstanding Begining Balance (in shares) Ending Balance (in shares) Common stock, shares outstanding Stock Issued During Period, Value, New Issues Issuance of common stock and warrants for cash, net Stock Issued During Period, Shares, New Issues Issuance of common stock and warrants for cash, net (in shares) Depreciation Depreciation Share-based Compensation Stock-based compensation Nonoperating Income (Expense) Total Other Income (Expense) Class of Stock [Axis] Class of Stock [Domain] Statement [Line Items] Officers' Compensation Contribution of services by officers Other Income and Expenses [Abstract] Other (Expense) Income Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Other Current Assets Other assets Adjustments to Additional Paid in Capital, Warrant Issued Reclassification of detachable warrants to derivative liabilities Shares Retained By Public Company Stockholders Value In Share Exchange Shares retained by public company stockholders in Share Exchange Represents this element stockholders value in share exchange by public company. Increase (Decrease) in Accrued Liabilities Accounts payable and accrued expenses Shares Retained By Public Company Stockholders Shares In Share Exchange Shares retained by public company stockholders in Share Exchange (in shares) Represents this element stockholders shares in share exchange by public company Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit during Development Stage [Member] Accumulated Deficit [Member] Net Cash Provided by (Used in) Investing Activities Net Cash Used in Investing Activities Liabilities and Equity [Abstract] Liabilities and Stockholders' Deficiency Preferred Stock, Shares Outstanding Supplemental Cash Flow Information [Abstract] Supplemental Disclosures of Cash Flow Information: Proceeds from Convertible Debt Proceeds from issuance of convertible note Earnings Per Share, Basic and Diluted Net Loss Per Share - Basic and Diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average common shares outstanding, basic and diluted (in shares) Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Common Stock, Par or Stated Value Per Share Common stock, par value [in dollars per share] Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Accounts Payable and Accrued Liabilities [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accounts Payable And Accrued Expenses [Table] Schedule of accounts payable and accrued expenses. Accrued Professional Fees Accrued fees and expenses Accrued Payroll Taxes Accrued payroll Accounts Payable and Accrued Liabilities Total Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Hierarchy [Axis] Fair Value Adjustment of Warrants Warrant liability Active Markets Foridentical Assets or Liabilities At Fairvalue Balance Represent the value of Active Markets For Identical Assetsor Liabilities At Fairvalue. Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Title of Individual [Axis] Excess Stock, Shares Authorized Going Concern [Abstract] Going Concern [Text Block] The entire disclosure for going concern. Warrants Exercisable Term Represents warrants exercisable term. Warrants To Purchase Common Stock Represents the number of warrants issued to purchase the common stock of the company during the period. Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Financial Instrument [Axis] Relationship to Entity [Domain] Consultants [Member] Shares, Outstanding Equity Method Investment, Ownership Percentage Conversion of Stock, Shares Issued Financial Instruments [Domain] Share Exchange Agreement [Member] Class Of Warrant Or Right To Purchase Common Stock Percentage Represents the percentage of outstanding warrants to purchase common stock of the company following the closing date. Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] CSL Ordinary Shares [Member] Researcher Company Warrants [Member] Share Price Share price (in dollars per share) Warrants and Rights Outstanding Warrant [Member] CSL Warrants [Member] Going Concern [Table] Represents the going concern policy. Net Cash Provided by (Used in) Operating Activities Working Capital The amount of total working capital as defined in the regulations. Schedule Of Significant Accounting Policies [Line Items] Represents the significant accounting policies fallowed. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Range [Axis] Fair Value Assumptions, Risk Free Interest Rate Fair Value Assumptions, Expected Term Fair Value Assumptions, Expected Volatility Rate Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Range [Domain] Maximum [Member] Minimum [Member] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Research and Development Arrangement, Contract to Perform for Others, Description and Terms ResearchAndDevelopmentArrangementContractToPerfromForOthersNonRefundableAmount The value represent research and development arrangement contract to perform for others non refundable amount. RoyaltyEffectivePercentage Disclosure of percentage of royalty on annual sales of the company. EX-101.PRE 11 clcs-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`=?[]DX`$``+H6```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-UNVC`8AL\G[1XBGT[$ MV-FZMB+T8#^'&]+8!;CQ!XE(;,MV.[C[.8&B"E$J5*2^)T00^WL?K.B1\D[N MUEV;/9(/C34E$_F8960JJQNS+-G?^<_1-VIC]6*>?MR2>VL"R;]N%?5;)E'-M4ZF82/FCT0:<:\\1](G]8'/AP$1<&Z?_?,/A,#@G"48!P M?`;A^`+"<07"\16$XQJ$XP:$0XQ10%",*E"4*E"<*E"D*E"L*E"T*E"\*E#$ M*E#,*E',*E',*E',*E',*E',*E',*E',*E',*E',*E',6J"8M4`Q:X%BU@+% MK`6*68OW,FM,S2#QX?/MC^DPYI5J*L1-2^'"KY/;H:\EU\J3_A-]ZE`O#O!\ M]BF.U##.O'4A=:V>SC^%IS*UWSUR:1#YV-"^3CU62^X34T][?N!!+TI]$ZQ) M'\GF0_,\_0\``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)? M]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBR MBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'% M#U1?````__\#`%!+`P04``8`"````"$`Z,')Y]\!``"K%0``&@`(`7AL+U]R M96QS+W=OZP*4BK!91/-)I(=U;FZ,[TGD^N;C\VZ>/,AKKJV-#29FL*W55>O MVF5IGI_N3BY,$9-K:[?N6E^:K8_F9GY\=/W@UR[E'\5FU<_;?&?1A8U+>1F6MG?5BUMZR]/IS(:?9YCYP9G%?5V:<%^3F.)I MV^='_W]XMUBL*G_;5:\;WZ9?GF'?N_`2&^]3/M2%I4^E&;:BW=TAF63-QOXA M)_NA*^<"R>&9LAR>03FD+8>0'#E5EB.G2,ZYLIIS)(9860TQE*-M#D%W^$S9 M'3Y#[HAV"`H,01DU!&/C@J\?4\C,B=GVKUP^V$;F:# MK='?2)N5$)6DK8:@'-8F-T-R\ZCD'D:G?;<,6U_3%,/Q148-O92G3K^7LEO: MW16&"VDSDB`C29N1!!DIVB006"QM$$`.:%<*%HJTK2'H#6LSDB$C>51&#BFW M3YMAZSOXX'PIVIDC,'-$&YH"H:D-*1XG6G*YZD M]N!FP2/V4C*R:)),:`QU;R+;BFBJQR'7+.S;/5C*-:O=4%ERE_$(GE[Y'=]V M!A7)9V6%;$&S2,^!WAX=]/*ZGG>>_S.7XH6S=7K8E"^MS2L7H5SG?P5IM]7* MAP+6Q:-7'NH5/.]T.M6]'XPO5WI_$^`=A%\H".<4OY8HZ.T5(4,1DK'07&_) MHRC5YQ):F*O^",Q2H8"X0S,5IU8`>%0RDMR)UV829JB45_&\1'C)-F"IC1"#M MY(XB%!^3NFK"?)29[JE;Q$K*,--E3&(#SJ["Z&M M!'1-C\+4@:&0USU<*@:C0>B4_,H'$@!AG%KN#)?.M`S>5S(*86R1$0-5.$SA M+0;`D7--?\HXYKH\/F_?O2S4!!`.`_O0DRZ.G&OXQ/!BS(^"/G@K?B MG+F&)]O;B8/6Q4ES#5>V`^&H=;$M7<.7!V.0>=[D&AGL39C,C4'8[H\:&6Q. MSS#G)XW]3T'8L)YAV/:HXH)ZV+&>X=@RK&"//*Q@-4UYE)(YV^B,PBNR"J^' MNPV+AD#M30*3'8!PMSW#N.U`>)3!>_80Q?*E6QRR>P.B;N]8X2)J[3:\:^XE M6%*OUF/#L,7NCWP`57IBEWJUSAHN;;<:!O)Q9V'1:`GTM&4683X]6%1#S3_: MLZ6L2%4?SR18-`KZS/LE#B[(QU,)%B&PO=V]R:W-H965T&ULE)C;;JLX M%(;O1YIW0-PGV)ACE&2K!#JSI3W2:#2':T*_FTLO[V7A;&&ZV;G%4;$R^1:=`J8X>\.FW,?_Y^7@2FT;1I=4@+5M&- M^4$;\]OVUU_65U:_-&=*6P,4JF9CGMOVLK*L)CO3,FV6[$(KJ#FRNDQ;^%J? MK.92T_30-2H+RT;(L\HTKTRAL*H?T6#'8Y[1F&6O):U:(5+3(FUA_,TYOS2# M6ID](E>F] MU:QAQW8)FUD?XW MFC.[_E;GAQ]Y16&V(4X\`GO&7CCZ_<"+H+$U:?W<1>#/VCC08_I:M'^QZ^\T M/YU;"+<+CKBQU>$CIDT&,PHR2]OE2ADK8`#P:90Y7QHP(^E[]_>:']KSQB3> MTO41P8`;>]JTSSF7-(WLM6E9^9^`<"\E1.Q>!%KT(AB*YAM;8B"=KSAMT^VZ M9E<#%@MTU5Q2OO3P"@0'0Z+[F\6?.01K7.2)JVQ,WS1@\`V$Y6WK^FOK#68R MZY'H#A*HR&Y`^+QQV7@H&&6QVB09"!XT<'2S!1,BV[H?GV'T'.:C'_J-1`%H MW^S8:K^[*>&&*A)/$4TDF1*2B&*'?,4.AS MJ4ONURDVG*_8X##L#]F&%OU((/!Y<^JJ1G>?$O&G1#)'*/9@_SR^Z#BL14E; M'Y%`O"Y*MHW"4'I8A$.K\># MQV'-FJ-9$\A@S2=$/^UDP`\QTO9A+-=[A!"DS4TB`]CV`VEN%&?\\2$=\?-! MX[#F3.LW$HAPAA'VL:];DPDG].Q@G'-QL,L`-`]#6W.?R(1O.W8P]J&8"[]B MCL.:N7'!=R.+!"+,+>Z[4Y"[]A3BOC\%F3.(89\]'KZ.UD[-R4W,%3?FW+'9 MR\P@\>=(,HLH4<3\'G]XC7:T%L=Q>8@X]HQS]XKK*_LH$P]>T=K5$L^U3[3V MH>>2HB@2(A*$V3[&*8+C`P81Z$R4:@UQ@ MQH>`&DC^()!L/KAV M1P(\#K1C8I4)?-_QI<2@8WB6._8UT1&&11HKTKV2UB>ZHT71&!E[Y2DJ@5#< M2F_I\Y/-TR"M/,(K2,ZFY3%/MWFY=6L`V>XE/=$_TOJ45XU1T"-TA98^3'`M M\F7QI667+OGP>V7DNW_````__\#`%!+ M`P04``8`"````"$`Q1\KBH@"``!W!@``&0```'AL+W=O';[*AOTPK41JBUP$L48\9:I4K2K`O_Z^7@S MQLA8VI:T42TO\!LW^';^^=-LJ_3:U)Q;!`RM*7!M;3:T]$FR(6D+`,-77<*BJ$HP_*+:1O+6!1/.&6M!O:M&9 M/9MDU]!)JM>;[H8IV0'%4C3"OGE2C"2;/JU:I>FR@;I?DP%E>VY_N*"7@FEE M5&4CH"-!Z&7-$S(AP#2?E0(J<+8CS:L"WR73Q1"3^0D&N MKFGY]L`-`T.!)DJ]#*8:$`"?2`IW,\`0^NK7K2AM7>`LCX:C.$L`CI;]-)=AY?',>3.!O%!^DGPJ"ZZX4Y\+FP[,RT M@,F]L$&23LXZOSB.N_`A?J(+GLWUNASX5-?H4&[H98`$OT9QGN:GLF&X.(H0 M3Y(\'TQZ0-`59D=X'1U=\6>J5Z(UJ.$5M"F.1L"@P^0(!ZLZ_PJ6RL*+]]L: M!CR')Q)'`*Z4LON#FTW]7\;\+P```/__`P!02P,$%``&``@````A`.32W[CG M`@``M`<``!D```!X;"]W;W)K&ULC)5=;YLP%(;O M)^T_6+XOWR$?"JD:JFZ5-FF:]G'M@`&K@)'M-.V_WS$.U)`UZDT2\.N7Y[S' MG&QO7YH:/5,A&6\3[#L>1K3->,[:,L&_?SWB=&4G*,G[34WM!IX7 MNPUA+38.&_$1#UX4+*/W/#LVM%7&1-":*."7%>ODX-9D'[%KB'@Z=C<9;SJP M.+":J=?>%*,FVSR6+1?D4$/=+WY$LL&[O[BP;U@FN.2%J$/T#1 M8HVBP]=L>W,#O$>V&5EZJ5BL1[0)"21DD^BTHG?;/Q#I3=!H"R",P]'?0!I- M9&D64T5Z33%A!!.;\7I:6IQ@".`MG,";/GEO-*N^K0&<5&\F2&U!N`JM]0D8 M!&6#Z?!">`.O`^I-<\#9N=D;3=P#^G%D/;\/-[77;^)H80DF@/$4\#J8%L_! M9@=K;S0&+`B"]65TMB(*(ULP08-7R\[N.IH6S]'F!\YHSDV-EO'*"L6D9BLB M#];?VF[0S)0TTZ2AHJ0IK6N),G[4$S"`=HQWQ^%\%^@7/$]!\0%YVJX MT&-E_+_=_0,``/__`P!02P,$%``&``@````A`'.[[2%Z!```-Q(``!D```!X M;"]W;W)K&ULI%C?;Z,X$'X_Z?X'Q'L!0TB:*,FJ M_.CN2G?2:K5[]TR(DZ`"CC!IVO_^9C`DV&1-L]>'$LPW'_/-C.TQRT]O16Z\ MTHIGK%R9Q'),@Y8IVV;E?F7^_/'\\&@:O$[*;9*SDJ[,=\K-3^L__UB>6?7" M#Y36!C"4?&4>ZOJXL&V>'FB1<(L=:0E/=JPJDAINJ[W-CQ5-MHU1D=NNXTSM M(LE*4S`LJH]PL-TN2VG$TE-!RUJ05#1/:O"?'[(C[]B*]"-T15*]G(X/*2N. M0+')\JQ^;TA-HT@77_UB\E@6N+0NYWY5)2P+7_^$*2&^B`M?. M%="FCX8M(MLD*DKJ9+VLV-F`ZH?8\6."_2AF$&4F>D&5E MSDP#LL&ASE[7GN\L[5>HC;3%!$.,_RA#P@Z"Z4/>J!NX\A+9).X06(8@Z:(+ M(M+7=;OB.O<1C.YW[PW$`'!?]+CR>\,API_+D&@(44CB(:)'(LF!LNO+P31- M(%UZ66@$4Z:GPO.5^`4"`P5Y4>K+,L)11#2*B'4(22QCI'L:_>"AIFLJ:]!E#L*IE(KL;"(PN8Z.(:!01ZQ"2/ECK MCX;?D_A!J9A(,B#6S)U+?X,WQ)*!_@U2C.:_$R,T4F,T56I>8/JUX+E*',,; M&'\F\T0W,"I/?`/3VY`EO026X/N+HK%2%2M)#EK0M2R4D(0MH!\3)2+1@$/I M*V(9X%CSZU8MZ\1NHE?\^D6,B-Y#WG>NS$T'$[0@C?OA."0:A\1:B*P2VXZ> MRH\U$T0T*["3]W99M9MH05JU@D<#B<998BU$5HN]AZ)V?$$CHF.1"\"9(J:GH)DAABF^"KDRR:FQG[J\(T03)%3%8S:1."38Y)9TA MGGXA=OVP*%45M9!K52D<>&)'CA8@=:I"ISB/BV->0:L]#6F>]#@ M7D8OWP&>7#S]*.,!6<"9;#@>X7<#'+`=8W5W@R\X=Y]\UO\!``#__P,` M4$L#!!0`!@`(````(0!7!4ZSG`,```(.```9````>&PO=V]R:W-H965T,Q62\3Q$>#1&'LTC'K/\$*(_ MOQ]OELB3BN0Q27E.0_1*);K=?OZT.7/Q)(^4*@\4 MT!Q&$BXRHN!6''Q9"$KB.YGA.7(**S%$`V>)"RB#SPZ93171D30 ME"CP+X^LD!>U+!HBEQ'Q="IN(IX5(+%G*5.OI2CRLFC][9!S0?8IK/L%!R2Z M:);,D!_ M&3W+QG=/'OGYBV#Q=Y93B#;D26=@S_F31K_%^B>8['=F/Y89^"F\F";DE*I? M_/R5LL-10;IGL"*]L'7\^D!E!!$%F=%DII4BGH(!^/0RIDL#(D)>RNN9Q>H8 MHNE\-%N,IQAP;T^E>F1:$GG122J>_3,0KJ2,R*02@6LE@F>C8#);+*]1F58J M<+VHS`>K^&9=99@>B"+;C>!G#VH/G,N"Z$K&:U#NCPL$1+-W&@[1`GFP9`G) M?-Y.@^G&?X8$1!5S;QCXK!EL$[LN,0V"FO'!6.T.(C;_-"T M,JD?4Q*['F)1(Y83B$W3B:ZCX-TZNL1+3X**:<1B&LQJ?6/2,$&#:1$[%V%Y M!)&F1WA(LYLOQV':_LPCX4S0`RQJ$:K@U#=O6 MIL'8.:Q;AL#:_QIJ&V];>*L9DU#`0F3JRK;CN7(05-OBK-<,VK.KT MI(^JSC`NCR["\JBWRL$=1,-V_'"GZ@P3E*EMUUO_F.5G=8T?#=M^NJ5FF'X_ M_6.6'PR;UO``E73;T;)5_!7D2I\3L?WI?MQ(X+`BPZ:+NWM;!3E]&IU^Q/:I MFW7#I[N]8=/:W?VM@OI3^\Z@[4GWYN&>3"=O>NI6&[ZT>[V]MLO_G4';$\3R M"D^:;M?;JEUO!NI/DME)L0NQ_;7V@H'U9MKY!_5F(*=/%V+[O&ICP-V=H=O9 M*LBU:]F(8]N"4_,U:3;M_(/2,Y!KOR^?&J(*Z;-GCN+FC)E1<:`[FJ;2B_A) M'[,Q=/7ZU_H5X&Y2'N+K`3B!%^1`?Q!Q8+GT4IK`U/%H`;D3Y@QO;A0ORA/L MGBLX>Y=?C_"N1>'P-QX!G'"N+C?Z+:%^>]O^!P``__\#`%!+`P04``8`"``` M`"$`V[OV]7P"``#J!0``&0```'AL+W=O]C+!FVY-D*U.8Z"$"/>,E6(MLKQKY^KNPE&QM*VH(UJ>8[? MN,$/\\^?9CNE7TW-N47`T)HI?MUT M=TS)#BC6HA'VK2?%2++I<]4J3=<-^-Y'*65'[GYQ12\%T\JHT@9`1[S0:\_W MY)X`TWQ6"'#@8D>:ESE^C*;+%)/YK,_GM^`[<_*.3*UV7[0HOHF60]A0)E>` MM5*O#OIHX"7=-/:'VGWEHJHM5#L#0\[7M'A[XH9!H$`3 MQ)EC8JH!`?!$4KC.@$#HOO_=B<+6.4Y&038.DPC@:,V-70E'B1';&*OD'P^* M#E2>)#Z0)*#^\#T+TC@;3S[`0KRBWN`3M70^TVJ'H&G@/TU'70M&4V`^.O,Z M!J_O606/CN31L>1XC!&X,%">[3Q)HQG90J;L@%EX##P'3#8YARRO(?]("`@> M5$,6IZK_7X>C.`=VXEQ=G-J%WSA5$E\(N84X$P*1G0IQ\2707K<%N4.`.TDB M2<-S!0N/24\PV3EB>0MQIA%(+C6F[S;O,31W*,>0PU"M)+U(:>$QH[[><9@F MD^12XRV$U^AGSK>DY+KB2]XT!C&UP.XSZ8]Q/Z_`!1JVC%7^ANA*M M00TOX6@8C,&D]L/J%U9U?<.OE84AZU]KN%,Y]$08`+A4RAX7[CH8;NGY7P`` M`/__`P!02P,$%``&``@````A`)12,"BW`@``"P<``!D```!X;"]W;W)K&ULE)5=;]L@%(;O)^T_(.[KS]AIHCA5DZI;I56:IGU< M$XQM5&,L($W[[W7IYS#CY>W;R(&CTSI;EL,AQZ`4:LH3+G M39GA7S_OKZXQTH8T.:EEPS+\RC2^67_^M#I(]:0KQ@P"AT9GN#*F7?J^IA43 M1'NR90VL%%()8F"H2E^WBI&\VR1J/PJ"U!>$-]@Y+-5'/&11<,KN)-T+UAAG MHEA-#/#KBK?ZY";H1^P$44_[]HI*T8+%CM? MOC)>5@:JG4!`-JYE_GK'-(6$@HT7)=:)RAH`X!<);F\&)(2\=/\'GILJPW'J M)?,@#D&.=DR;>VXM,:)[;:3XXT3AT3&.B/ZS!U>;/O0+JX[H@AZY62 M!P1W!8[2+;$W+UR"X2D@=WP?XK\BA-"LR:UUR?`<(X#74)7G=1PO5OXSI)(> M-9MS33A6;$\*6P'`ZQDANB'C^\D^H5BQ1;')MVP;-P'>/5LT.?=!:,$39.,QMHDK%B>TDQ8@23(>-E-BO.,"2@3TZ8 MS,8G;YPF[+.)HHMDXQZQ1OD8VHX'I_G,J*IU3IA,IIIF=V)=^Z-4<< M18OY['K>[QY1I?]#9<5CJOFD2!LGN92JH>)]--=\W$LJF"K9EM6U1E3N;6.) M(,G];-_S;B-[WR?S&^B%7>?P^P7H12TIV2-1)6\TJED!EH$WAX0IU\WU_XRM_P(``/__`P!02P,$%``&``@` M```A`.`B]7WW`@``(@@``!D```!X;"]W;W)K&UL ME%5;;YLP&'V?M/]@^;U<`R0HI&J"NDW:I&G:Y=D!$ZP"1K;3M/]^GW%"N71M ME@>"S?'AG//9'^O;I[I"CU1(QIL$NY:#$6TRGK/FD.!?/^]OEAA)19J<5+RA M"7ZF$M]N/GY8G[AXD"6E"@%#(Q-<*M7&MBVSDM9$6KRE#3PIN*B)@J$XV+(5 ME.3=HKJR/<<)[9JP!AN&6%S#P8N"933EV;&FC3(D@E9$@7Y9LE9>V.KL&KJ: MB(=C>Y/QN@6*/:N8>NY(,:JS^,NAX8+L*_#]Y"Y(=N'N!C/ZFF6"2UXH"^AL M(W3N>66O;&#:K',&#G3L2-`BP7=NG(;8WJR[?'XS>I*#>R1+?OHD6/Z5-13" MAC+I`NPY?]#0+[F>@L7V;/5]5X#O`N6T(,=*_>"GSY0=2@75#L"0]A7GSRF5 M&00*-)87:*:,5R``KJAF>F=`(.2I^S^Q7)4)]D,KB!S?!3C:4ZGNF:;$*#M* MQ>L_!N2>J0R)=R;Q0?WY.4Q=N7AQ7@S__6++6P9N$+XOP39VNG12HLAF+?@) MP8X#P;(E>O^Z,3!?8C$F^J#^E1,$I$GN-$N"(XP@`@FU?=SX_F)M/T)!LC-F M.\>X8\3N@M#I:]K43'09VJ"W%PVA#46_7L.+-@W6VBZL6S,!W+U8;R)DC@A6 M8T@ZAWA1#QF)A6)?+U:#86L-M/E^T/-VJ6P-!HK5ZY\@=N\BTK<0(_7PFJ%Z MO3]\.'QO1ZX7)1@BZA7Z?CAQ83#+;K/-.33=>IJ3C0':TJB3)^ MU/W6@^3ZV?Y3<.?I\SJ9W[HQ]`B8M_L'T*);?J,M`OZ+_NF[\```#__P,`4$L#!!0` M!@`(````(0`=(BKH(00``#01```9````>&PO=V]R:W-H965T4G>5KB&BWU=T3T;ZN_OBQ.N'TA!X2H!@HU6>H'2INY:9+L@*J4&+A! M-?QGA]LJI7#;[DW2M"C-NTY5:4XLRS.KM*AUKC!O']'`NUV1H0!GQPK5E(NT MJ$PIC)\VI9NK M16?0OP4ZD9OO&CG@4]P6^=]%C[ M]%C2G_B4H&)_H!!N%V;$)C;/WP-$,G`49(R)RY0R7,(`X%.K"I8:X$CZUEU/ M14X/2]WQ#->W'!MP;8L(C0HFJ6O9D5!<_<16SX^F!GY]P9 MKGUG8_+DVJ[WB2%,SRI^K^)8AF];,\=_?!ZP*#HSX/II,TQN;!>G(*7I:M'B MDP;)#]:1)F5+R9Z#\"5`W,X^9!]%#$+%1)Z9RE*'V4$P"*39Z\KQO(7Y"JF1 MG9GUD)F(Q.8.X8M(P!'X[!\DB81#PIV)(M$0D43B(2&+)$/$\9[Z!YE@;^\Q M9-NMQ_>3_V(E@YF5;#$P;]=RPT9N"'@##*@WQ?$DX\('F.@!)GZ`2>XQUQ@( MUL"R>MP:!L,.<#M/W^HMYVYQ!M9;[X4K$ALE$2B)4$E$2B)6$LD8(;@(T[UU MD2WBZ8>[["716*>E#K'JG7)\6_1JS9DQ-Y5$H"1")1$IB5A)))QXZG:GB6W! M7S]9P4PP[O-FLDZRF=*FLN8,#*,W7$Y-)1$HB5!)1$HB5A+)D'!\Y[Z?WO_Q MDW62_9SV^GRI\+CG=CW,3WK"WN3G^)F&P[*&4 M<6O.C'FH)`(E$2J)2$G$2B+AA.=V)EJ&=#G;.BG`X7"N)^LD^SG]?3$US=G^)J8 MV-[MAMT!FUM@.H72[KJC=T#`@9&(A$HB4A*QDDC&",%+J,6$Y!PWL:-E%Z\' M+>[B&1HQ8:-&@C/"WY[.;#;P.A0)1]C#NI%$`N'9[!4L[NBQ0$PM)B(2K%AE MB7-_-MQ*7HSR(J="[1YM4%D2+<-'5F@ZL#OTK7T1_#QAYVVI?6W/X?`];-_8 ML_@```/__`P!02P,$%``&``@````A`/,^VL6Y M`P``[@P``!D```!X;"]W;W)K&ULG%==;^(X%'T? M:?]#E/?FDT",@%&[57[-?VSW^?[F+;4IH6*,(>17+,6:&11+*,:M"O#KQ4#5N>W$*74_ER M+.\2D9=`L>49U^\5J6WER?)Y7PA)MQGX?O-G-&FXJXLS^IPG4BBQTP[0N2CT MW#-QB0M,FU7*P8%)NR79;FW?^\L'G]CN9E4EZ!=G)]7[;JF#./TE>?J-%PRR M#74R%=@*\6*@SZFY!8O=L]5/505^2"ME.WK,]#_B]#?C^X.&E1?X?@OR:"DF"F@0^:Y(@=&9!M(AO8'%1467PD6JZ64EQLJ!K(*8JJ>E! M?PG,C3/4T7J]9!4\&I)[P[*V%[8%+A34YW43QM[*?86<)C7F`3'PWF+\%N&" MFE82R.A+FDYR$]F`3623="/E`6_TPP338<)A&.-\=K&F33BS"*K7,Q'&G0U4 M@)A9#Q--*P!(WZA1$$)O7C=L%JUM<-FF,8P[AZ@`,?.J$`&TQXS$TPK`;U_! M]<@&/(X>X1;S[OLC,H\OPCD0UX''DVBHR86>6Y:[U!3.C/V]T: M\#AF5T=TBYBK,S[RBQC,=$Q@E$2D10QO(>-;5H";_T8(,7MVV&99C-/EN+,?$""3C$6@.!K!W M&D$7&V(T`6]4,#$*2;?MZHHTL[#WC""7^G(T%&^4,3$=29?J6D8S'OLRNB$R MK,>GYJ0_,2A[C[I:!H*P/V,_FO4VT%##IR8EG#O/1B4Y&Q((FMXC>.S$4UG. MY)[]R;),68DXFB.E#]NZO=L>=^^#ZL#:_@"GS9+NV7*%%69WYMD+#.;/Z>H#_%0Q.3IX#X)T0NKDP)^+VG\KF?P```/__`P!0 M2P,$%``&``@````A`+_`_&`&ULE%=-;Z-($+V/M/\!<8^A^;"-97L4D\WN2+O2:#2S>\;0ME&` M1G0[3O[]5%,8Z,;!)(?8F->/5Z^JNNCUU[<\,UYIQ5-6;$PRLTV#%C%+TN*X M,7_]?'Y8F@8749%$&2OHQGRGW/RZ_>/+^L*J%WZB5!C`4/"->1*B7%D6CT\T MC_B,E;2`.P=6Y9&`R^IH\;*B45(ORC/+L>VYE4=I82+#JIK"P0Z'-*9/+#[G MM!!(4M$L$J"?G]*27]GR>`I='E4OY_(A9GD)%/LT2\5[36H:>;SZ=BQ8%>TS MB/N->%%\Y:XO!O1Y&E>,LX.8`9V%0H M&0D]1.=,_&"7OVEZ/`E(MP\1R(YE92F$9^Y8/G_""(-%9(X#0E\-B2.._,< M?['\#(O;L,!GPT*Z"&@5.2Y%&R;,R%:8`7'++\NO5L>VV]0F;B!K-##/QO,41%A%>$3"C( M:S6";WV-MW-WE2+!4HK,I=2VPQ_ZSW6TY]Y`+%J(H@0\0X_4P?JN@#B,<0R@:@:2O<=PM"=Z88$";%,_6M2$FJ--J0_$' MRM]4SK>)P0G@*I0:]%=`_)PLU8[/&QO=AO01\H@Q$\HDVB]`+6YL",( MZGO7/1Q[>!2B.J?-CVE=+%_\[K9Q`QK5B3RW(:I.;9;-D8F-?&N>#!IY."Z&HY@,09W9:IJU MH7(GS3@'[C0R@L;&,9R;9#F/.8GG(GSASVEUI"'-,F[$["S//`1VB?;7]CSV MZ-0GJO8&'(?*Z$C_C:IC6G`CHP=8:L\6T`05'JCP0K"R/D[LF8"#4/WU!`=? M"N_@\-9H&@?&Q/5"ON&W1^GM;P```/__`P!02P,$%``&``@````A`-.`4@Q> M!```21```!@```!X;"]W;W)K;/+*]ZPM?O. MA/ME\^LOJQ/OGL61L=Z!"(U8N\>^;Y>>)XHCJW.QX"UKX,Z>=W7>PV5W\$3; ML7PW#*HK+_!]ZM5YV;@JPK*[)0;?[\N"/?+BI69-KX)TK,I[T"^.92L^HM7% M+>'JO'M^:1\*7K<08EM69?\^!'6=NEA^.S2\R[<5S/L-D;SXB#U<7(2ORZ+C M@N_[!83SE-#+.2=>XD&DS6I7P@RD[4[']FOW*UIF`7*]S6HPZ-^2G<3DNR.. M_/1;5^[^*!L&;D.>9`:VG#]+]-M._@L&>Q>CGX8,_-DY.[;/7ZK^+W[ZG96' M8P_I#F%&!3QT$P=<;!V,]&#[/@Q=!'**0 M_EB"IZ8SN/.8]_EFU?&3`TL.!(LVEPL8+2&RM`6#N==M`3_DF*]RT#`4:`&Y M?-T$=.6]@OV%1M(KB$ED5XCHC'@@[ZP1/)IJG-Y26F`].%1(/GL9Q@G%@`MD4".(X&N=FZ(+)W:Y+ MPJ8N[)N/315"!UT(A[YO`9D"R`",]PQ-L$]NUR1A2Q.R-"E$:0J3D!+S?C:] M3S'&GZPN>H\L"5NRK`RE"M%6^3&.$VMO9%,B"0(TKC[#K^@>81*VA&'3CU0A M2E@0AJ,=PZ[(U.W9#,IF."D6\QM1PI8B*T.I0LY641):FK,I,6-5W&"BM'6>Y9RR@=(J]=95_D4[L&9P:` M$*5D+#>FQI_K`JJ"3^O99(\I(Y%B]*)#U+>MS@R"$!1-2HLI4A;EFU>?;*RV M@6.MU.(4H\61B,:39ZM-H<-H!)K]A##5W=4)T&4KP&-NM#K%Z$='%!-J5I'/TQR](EWV"V'T"*<8NN-JYZS=-:5:#D-(B\&>^+*/+ M3D&LJIMJYF/5!\0J/9D!((+"L3R:$N_J&.BR91"[96A&22,^B?S(;F0&@H,@ M"8/1>U/>77T#J9IO;(=QWGH[*$;)>P@C$F%LK<],Q]$,3@CRT<@8`@.K>5`'0;5<:?-#^Q[WAW*1C@5V\-6\1=RLW3J**@N>MX.QYHM[^$(-WP] MPI&=P9G'7P"\Y[S_N)"'S?./`)O_`0``__\#`%!+`P04``8`"````"$`.A[' M(M("``#7"```&````'AL+W=OTK@M<2-:6J!7JM#- M[/.GZ4;()U53JCUP:%6!:JV[21`H4E..E2\ZVL),)23'&H9R%:A.4ESV0;P) MXC#,`HY9BZS#1%[B(:J*$7HGR)K35EL321NL@5_5K%-O;IQ<8L>Q?%IW5T3P M#BR6K&'ZM3=%'B>3AU4K)%XVD/=+E&#RYMT/#NPY(U(H46D?[`(+>IAS'N0! M.,VF)8,,3-D]2:L"W4:318Z"V;2OSQ]&-VKOV5.UV'R5K'QD+85BPS*9!5@* M\62D#Z7Y"H*#@^C[?@%^2*^D%5XW^J?8?*-L56M8[102,GE-RM<[J@@4%&S\ M.#5.1#0``%>/,],94!#\TM\WK-1U@4:9GX[#401R;TF5OF?&$GEDK;3@?ZTH MVEI9DWAK`O>M202/%P:/ML%PWP7[\74:I=G_$0*;3E^=.ZSQ;"K%QH..`V#5 M8=._T02<35E&4-SC98%ZF)A;$]2'@EK!4C[/DNMI\`SE)UO)_%`2NXK%$<5X M)PD`;\<(-?HXHPDJ$%S?&?.=?9_&W$KR/H'HR]7(G5ZXOSZTDZ>$&X(OC`"5#);. M2FQ?P=%SM+'.:QP\*DS2/!V5=[$NB)$K3.'MO M"`<@+-GD]U].[RBW[%3 M'6C1];OL4F@X4?K'&EX@*&S!H0_B2@C]-C!GW^Z59/8/``#__P,`4$L#!!0` M!@`(````(0`Y\O._,SL``'&[```4````>&PO:,>V'$G.(!CDHD6V)&8HDF&3 M]BA7>8=]%>`O!>/3;>SO;C^X5U:@W[@]&E[^]]^'L]=;S>T4]*T?]5;^] M=U/5]_[S=__S?WQ7U[."=T?U;^]=S6:3;[_YINY=5==EO3V>5".^N1A/K\L9 M?TXOOZDGTZKLUU=5-;L>?K/[Z-'3;Z[+P>A>T1O/1S/FW=G;NU?,1X._S:L# M_^CQ[MZ]WWU7#W[WW>QWK\:]^74UFA7[HWYQ.)H-9C?%T<@G@.[OOIG][KMO M]*@__K1X.Q[-KFH>[5?]]K?_-1]M%WN/-HO=1SN/VU_NSR^WBYTGR[],9&1S M%S^^&8RJXFA67==_:8_VH/U!&N'L9E*UOWRP\VCKC^T/]UEWW];^>EA>MK]] M<%$.Z\Y`:9;WU70P%L?ZQ:MRMOJYUX.Z5PZ+/U?EM'@-K^O./,MXE:8)KX?9 ME@_PQ]WVF&$?3ZK+03V;ENSNN_*Z0^.#@\,W;XK3XP\G!X>;Q=&[@^T5XQP@ M'U,6<<2>_US\H;II/_?@T:-'.T^>OMA[_*C]U<%\.I5XY7Q8Q;0'6UL[NUM[ M.^TQPG)>#X;5M#B`VY?C:9>&T^MRJ`=.JLEX.D/)BH/Q]:0<=9X\FY;2P>+T MYOI\/&Q/]N#@S<%I^\-``0->CT?%Z6S<^VFS.+TJIU5=',]GIL4,V7[MX/C= MJ\-WIX>O"OYU>OSFZ-7^&7^\W'^S_^[@L#C]_>'AV6FQ\>'T57'_8?OE5U4/ M9=HQ?=EK?QG9NE_7U:S^MO-U65^U/WL_K2;EH%]4/V-$ZJHCB,>S*[C7"_M5 MVL#M,<[&,^1@# M\GPP',P&57>9^STSK5[GG5XJMHII-434^HS-8MK4 MO4+]/Y:SP<>J$MI]:9%>VDO:#$JS!3'RJ;0T]C"SRA+M@V<7&N_&L*IYW M),3D\&H\[.-C'A2OJHL!CX]Z-QUQ8.LO*O2PC[\QT;W_:!N-U=**C^5P7OVF MV'FTB1+K_XO:Y;JSMN!+\H9P7&OTK&WQY` M@JOK=@1@O]]')LS23^^Q[;AZ*O9`/?UEU4VJB-82:**'^%(?SPJX\68`HS\9U?TD?.W5KWKCR`3SKD^O,]H+0OFU"PHN(HAT1Y7:]"U]W'7L M3H]F.MAY?KGS.3W#![T]?(?C.7Y='+\_/-D_.\([K=KBO3LCOHZ3.JD^5J/Y M$D^#/&`[<<&'*WS1254#F'I7)ME]AAF.S8NTU[CJN=O,]VDU'#+_9H&)A9:A MS5/VKPOI^+H(SXY'*USM1EC]0X!5;]S%9T>C M684)FD6/W:;HX*K$113HV44Y"(:\&%\4N(,[^R9W^CY_D0AJS_2NFA5:UZK/ MB_:7'2V*FDH7!$Z&MH$.9 MI&\6YVF.?C:'/]D9>(7%2XH@/3CX_?Z[[P]/0<'%Z=GQP1]^?_SFU>')Z8/B M\(\?CL[^O$HY3"C:7`DZ;0:M^/&MN<".XEL-RU`,9S0`(:P!EYP5M6F#HK2_+]MHL2%_<-0$-DX)/Y50A2%T0 M5.(CZZNE4/#'G0Z+?L&H)FHKQ."DZ@U!M0-0$L8'P3)5F96]*X..B1V_.;8C(_'R+\\&!"X.%H*P`TZ:F]@=%C2C2W+3?_[GCK%F_" MN(7:0*>H(P(P)K1ID*8/EV@Z(5M+FM;&^JW'6[*T]E51P,[OSG^ M8:4'/D!GBM?#\:=%O\+T^P*G%AJUI][O_W5>AX`"@9Y61!0]XF=%8;;!!9_J MWU+(8BZQ0#X5N+EC+M/(G6`"/(O()P4ZGQ5]%5-F'BP5-`.B'"F M@_-Y'*BNIA\'/8(=M&A\@8X2T[3'.S"UJ5N46J!JEB:+Q#I4NZ-;'M5*Y(S) M'P(?&B^_FL/M73D:?<172RA6O_-^#J9!!R75$PN36U%R>\4=RNXR2YNR1ES7 M4#8=]ZJJCY$66[\6BK M)ZT9I!U7-'R1C((R;K44".37D<-E7NCK7<^R480S^N*9[YBRSBBT42%EOQLJ MO,V8MDW6'0WG\?2R'`W^;I9@,P/&IK8"C+54@M"N)NA<:B\61\!ZU./AH&^/ MVB#YNQHK2`W0_I0!*T^M_+A_KGQH;];!&K_*\*^P@SC/.3!8$G$ZN!P9VE!V MW3-5,@_O(=S2.C^>53_/BI=#@%*'GG?*^.P4__K'?Q>+I#5!Q=UY=R<&GUU! M-50:%8 M-/"T;T[\TV!&6->P8S(=X)DF0TQ_",:&&,5>KYIH:MXE"5%\&!DAMI4F*N3N MI^"X8N-?__A?'[9/MXOO]_??_^L?__NAH; M&OZ&1(5L&[/UAO,^?!@.)4.:.7O1&'XQ'L]X%&JGRFUJ?=BH1(*#7)@XK-C` M91S:EE'2R.,)"-UAZ'4Y(N#Q-&D])^S-&)K35&9>?0,U1V_,XXQ'\`R"1ZH+ M#:%,65SM(5R[KA\6GZX&#*KPS%["%$#VB.Q<79?3&Z.Y]""234LJ&%G`.^NW M?S*N+1>F%PZ(K(O3,8ZNHJ8P(N+0%AV<'K$Y!0&`5JX/7,ZT8YN:G^UD"3^- MQI\0EKHX&_1^PJ2?C8O3*HUS[^SL].@>S_,`,W7SC1I[!;$L:SXD!N&]@?[C M0`<.VJ::.;\PA*4@1>/,KJ:5JW$]^+D@#E71JU+1:\G$E'#VMHLS7LOFR>;X M^D'9*@EDW*,!S!D`P16YH%^L0C2&&=CG.&V;1]R"2E M>#,@_0UID7Z1'KC=22(':?Z$$$>%378BB=4_ZU2E\'I0@::]1LZ*YUM_@-0A MDR7*3Z4O!J--&F)\IOK1-5!(2BHA/CT\,`O#G_\U9T.\-/.X$Y#D!ML&;&SV M=ZURJD0FT*Q=*HMWU<>R7[(O4XI8[MW@R374VJQDV)]:06@7\XP:FQB,J.T5 MTHUM/.A`\CNVSRV>3-%FL8':*/]LH2H)M4]HDO8MSM^G-B29,PMNT6OFOQPX M2X$;L>XLO+4:#2X/@/OKN;JW#$3<]LVXI5!X02`A(<7P']73LAKJ7^C7COZ+ M#]&:QQH/BT%H,:0^`=MJXC)3"V$R2B=2;!,[&4$]#X(M&:`G%\0("+('1]NY MP8KT_.L?B,^LG%YB@J+6:<1HBM/K6L_PYGIR-;XN-PN2_#,YLN+Z!O9>E[;W M+P^HL6ZX`;8=%NGLI7;57J_F/U77@U)FL"1"HX)@)MU`Y(3?>(YD&) MIA%6?-1-<4[C0'%-@F7\B44!._,W4+UZ?E[CIF`)#X\%PMJ//30J13D=!=0Y MG#=B6TEI:#JHB'=9Y0C0BVM!(E1-1I.%M.O5W!O*4A#BQ`**_MV?]^`G;,0` M3Y@,)]TO_E3-QEMF"@;7UZH@U3U6@\'%_>1$$1(T=%>&$V MINIKC#D?X)CCL\@V9JX:*;G#;B*+=37T:DYQ+LRE-5O60D2=5"8R`;>W;=?QJ'A;WA3/O*'#;OR[]2342:K#3B23$]*<-5E'TB%:2!71B3,S;] M+2?(S$>31,1?ODL`J=C08/?`?_[WO8<:1)\%._:@+O8)5WO:=;X!@F2V%.ZB MQ!XFZIW1W.J3/-=4.T/6LV5,TX2^T,[C+2K@N:$S&>Z+XMF3=AF3#X,A,'9L M%NV*K,.)-&OQ2;:QX[:4>P3`,9I!XTA$^B.X$T106[4;.G.2&@56^`8UO*@] ML=FBT14JX[1YK%2GDYE5W@`@H!1"=\E\WZWG^C+#UH&[ZW&^$]VB-#1-VL7L MID3G3#1`B:NK9:W,>,IU8%KP7M=C4`.Y)A01+B@4,;R=/5N,+`[G7)1;/N(EU!I+BUODOU0]<7E`8[$*V(\A^5P,[ MFH[B&G:F?&Z-6B[1OY9^LD.+%*W51M)AJF'I#8,QX>U<9XT!(2"`!4U`P!^9 MJ0S1QADC_7I:T^*3NW&G.2A-R<;\NT1O%M7%17!-/J.#O,<6*V))"`-,CA-B M-5XY';Y[.'\%M'A/]31%BH)>&9[)S8U9D[@,Y^_9Z:$$3,U/JP4FV7KB.5=V M90$^5EN&U_,TUB1F.G%#Y>7EM+K$X8NLW5LLH6I-)1J(/]3C:/2S)TW_@&$Y M+"MXQ4I**'85JBD6.\CJ"LN($S&AC#9_'(SG-=C&'(K0I52I<1DK%QQ;&=WI M*&PE?M'@KUB-QZ[BA)",)SH85P9#80ZSE*V"3[$/(RS,3P.>6M$T11SI`0LT M;+LS$8_XU.;8>?3H/^(^UQHEUIG@VK)WS&]:*/[&R0K/^TRR.MB292^>5ST) MN?CUB7>&-UN&6PQ;#OJ#X'_$!W?-BTNR>!V6?`HS&-M/%TE`A(5=0XO2XMY8 M+F;G>6KTR

_GG`#C+-RSH5D9A M0]0"K0PQ46B7#X7_0464]:F+9\^WGR2IRMJK5G!]V6@7B,CXDY3$V)$IC%FS M,O1-X?FR]C$9D6+CR4/+66"=0L58ZM2S+%OQ>//YDQ>;>[N/BP.DI[5_9C1D M"A03DM98:3Y<0C7"#V$.\*-E$J(9\1S$`M-R5S!9>GRZZ*<^#<@O`D,M$R)/AQ1B1T('9`@8HW<*M/A` MV0R!LU,!VEXY1V\S`^K"E7P::6%]F4"JG)QRRO\DR,OL2,]MKL54`(+<$IF+ M\:J<;44R%@H38IF&;#_=L.J7&5/TM"F;)*L\>Y/DG,0R3N"XH(>7I.`'QI10 ME_0(7E&16VD)E&8HZ#0[C*&2=79OK]#BG(Z)^1U)I,; MNX1\VU#,9Y.=-V1%WS+K2Z7^2`M%$\QMB]!60XLADM&8/KER:.T#(2](LD/K MIV0K'$3^,K0RY4S'OP8KIM(`R4T0`1R6FRW.Y\`JJA$*BL\97&BW@\J^'TLN MF8<4WJ@MO?[E@7]9K"[TM9Z[K02W:R6XA9?:,Y\AEP=A/RGN6P[5*UG*:,C; M`D"M#W*3W*JEXD-U9D1^$?]H2E86G\93RTE%WGFO,,)(.SF MQA%&RYO\'--Y]W&P"$JYN94!=-W:"#0U2O;43[85*EQ M:\Q=M>9H&'OO/L<^[`]RFJ8R=ZR8+#98MUS6DB6[;#>L%G-EL=K=U4L(?K+Y M[+&MVTPVE@8I\OYM]J,49,@<+-7`.5TMY3F6Q=83IC1KXX<1B+J5A):E).$! MK65QF4MG1W81$B;YU4JJRBDB=@MS6E,D!B`4^TC%7(?$)_DN\N2>"M%FYATS MF(=^^B9KH%&Z75.$DB)N8#O+_SL"M=,9EH/2\W%[5PD[+2"EWAM9&R0)`1-01JG3C^>45XVG#1OUOD$"594DSDA6G MA%B')`_MM>1,4LO^!44BQKR=N+(*6W<&R!2O/`[55,B''"=$[`EU2HI&.6<-3IHW:V%I>%80J/&\&IPXJF&F78]WE#\4EY7QK!=S9"2% ML+QH*AR&J#E.NUE7OH%FJS&5AA]C#R+9>*,'(N(UH.HI"?D@UUA1M15[P'5IP MMK->HE9F-<@WDAXRCBZBVA2F-",N0]S(G,O/+UI>IS$";Y8W(>0U-JT,""C@ M%(WDHK'IMM_&S4JC*"? M.;=U[JV'Q#F?HH"9]K4,5+0J[UB+U0=T1',;#&PRG8\9!'MQ`\?GTBLS%;`D MEO!ILV@ZQ,9&::L589%<5Z"HZ2R008>ID,D&6Y-*[&/`:`G;>C-HM(1R4!6M M*,)[HKHN*4ZR)YG>#2CM)?Y^UZI.W]+`U'Y\OPD>FAZG_54=5[<,7MS:';5G MT.R68=HTOF^ZC6`$<+%I(VL_JGBH"[E0+8(PJG:9&)C9;"(#S&KLAI*U9Q>: MP$`X*_=I(1PRD*5@0=\O2<+1LX2I6(Q4\$.]`#LSF%U[_=XZL"I5&@#3C3EL M:%D&L#^XAS^,YK3-D3-DJ&4XEZX:(\9$<(HZQXT[X*9!*GBV.G/[4LGK\J>J M:`RY^"#3>1T;&&4[2\N2&^,`7#=X5OIHRJ(^6:@3J6@E41PI>JUY/H7L(XQ/`<:<`J&F[`3Z@&"M91 M5R_X(\2ZO<$4-*U$$_[(19PP@82Z\=>!I;;55@.%(#G^U-YI47^=]R\-L&30 MN>V[6^BSV2BS^5*7$5@!XCC7@ZN9``7,KLOQ+;@[=VK7M-TOJ$5B%B$-V5?` M(HQ75`*!K$@3F(=$1+-,A!:!.1U_LH7;FHB^_,0LVBKP."M_%DN2\*B#D_'` MEVIXX[^^P6IS%"^T(ZC*0B^=S"YC*2GL"0H]%(%9R.Q84MFHV"Z2'MIHN39H M&2Y"D@08I1)']4GJ$$32"TJN%OALH:.IE25Y4`U-"`EC=.#24C&/D,EDEG6Z M>K`[C-"GS1$U5T^1^]7&F]!F.:/RR20N0800(,+^`"6>AJKF%0FFU4K?48\3 M^+FB^6')Z8N%I[,SA.P!3QOU04EAF^V?+\E`M:4QX"7[K29+>4V\I_IAV/5S M#@U>F!/E"1L*!/FMLX9133%]DI0Q*2'U`B*G`DJ_+CV"8 MB+QR58AYOE#._M0^"MCT)L2W0M$ER_U)B:6$KABV2C7&O7)'F^LB/X M9_+K*4?<;'TP#28Z*)-$_MZ#Q9)=_,K>DCV8*/0;1Y%@6W%O_'9YDE#A.%0V\.,)+],:4';A< MHZDT!,.5#*H7C3/DI2@<"!?HHTB\#T\0W2A0W$4+ M8*+8FE8V.)-1I%4C8)E%F-XC6O9]?R@H^)%73[ M:S,/G2(?"+(C=RX9`+F1,.1E@,%[^(*0^U:&I/T-)"P-`."_((,@Y(;4810:3!: M/:%<9'L>6U;$5UC%UR!W9_$%RX7A2N0OY&5,C#`&S;B!/D^C4L`9,#[Z$[#H MI&DF35F_&.@N6[2D(,N+GY):ZP-[.\L_BCW9$.B:V^"09>^'/F_U,[[>/WV) M_WF(3-K5;$L?_S`Q-=?S^ZTS5+.DU`5_8A0%?W[A4; M9QQ6[14O=IX\_+8X#%GE$`?%C6OH/4D7,)X(X$VMXY74Q)&A%R%KP%+3H\T. M_2EBH"/KI$7NTM3?JSXM;(#5=RJ>B]X#@%\Z`+Y]CTHT&LG*V,AK9-4-LIUV M2R=32TQQLT*2G*R0[9$VIQ@/M!(0$)D(&RH&U8UW;=P%.D0FV1'8>37[I%// M*^9(N1CT71W_REYK:"-`7QH)WW.(N=4'(?N@=:5@UTS+PS>V'D8 MQ5[6TKWT%B>O3"KR,\ZP65/"GEC#P&0UM4325FH0L;.RGFPR_!/R-^#[@.DW MBXW=AP6Y'LRSQFO8EXV,H2'U@/8QQ>K=8:B]AW;'"%D![!0LKGO3@0.-X"RZ MJ[=8Q:67)3DV$R%AQV6_1Y>(0#A_M?$XFR+PX&(P11*MM7W%$)@'KNY5J]5J M\EFBL+_.P\NR:3CE];$O.`Y)3)BMLP29IB#4HC:=$)#5`ZIZ:C7*D1M,`N=X MI07%$KQ",-!!*,^Z99`M?2W;W#J*R_E:?96?K37OI&U+ M%#GP8>+`-E-2+#N"L&";0\CR,!J`( MM7FOV+@G"R/?R/V[J;,<>NS$G="`F:#P`-;+F!OI0$`2'>'0K(F\8ZLZY1^$ MXQR#12K!V&TJ;6RC4@&^#H$PO"Y:9E$+S:;YK/AZ[^PA3&C;5K7^VWS*;=Z` M9\QF7Q:7F5_)]@7'YPZ:;:1403+4(EWW/-I\=O(N&W_/4)0J64/+(DE-M(FA M'VDI];*&F(J`26/:1F]Z8=WPCO4:^5"ND)S-6+%/EDI99C:=]S$ MP`V/@FO"WE-XQ9$$F^W,C-ZX,63+/:1TQI?*D83%]?G2Q:#*UKIHG_MC0(4G M3,*)1?6`(%[&<9T>#/C-[#9.V<3>6Y+\!H`4)V40V$N8ZMRS7M$$PEC&,OH[ M!O8,0Q2C9_7"`JZ'!@^U8>RG%AFD7>@HDI5Q'=GT_337($$*`%VD+:/!GDO< M`(_(Y"16*/#1_Y-=\$+>>@J:0"2`;6.IMRJMYUI#6G-;BAW]C-7U!F-UN/9: MUWO^2?4JYK;-5:W/Z]ZX;8^Z,>XM^;=-AGYMJ;RBS8-O`5$5L"- M@"Q<4NK93N`%?AA,EO0`A"=S?DRUR2R;C\#L:&Z]8( M^G%_7N_2?0*HY7;Q^_$G!()#"$QK#>R6C(V]#$)`P=\9Y#!S"/KR`Q!+ M=8,8MIS/;X1B855-/T/%O3':4U(U`E9>LV>7,`EJJL6W-9TYO&-=M[[/,BH+ M#.:5&X^ER\:@!`WFV94B$E9C=$!%P\(D46J]@#%>(K"R*J:5?1&="_N?A,.M M=+>G"V"SQ]GNX;QN\'*\LMQXP@/`/5;*_X1LI]RCW`EQK=:PI,]%[BGD+TS\ MO"4?(Y7TH*/HXGEN'D$?^JT#WS_LF]*-^@_;M-#DM)!3S1@BRIH*9S,QB2F: M-+F+L'M5_!O%R-P\MD6X3IK=TG7%W^94&E0M`)`9'/1*4!`'#T!)F!-,*\D2 MJ,3-YD0FYY,O4`3&9E$'.J13.VQQFG87:>K;#1-``>;1)2UD<.R2$Z\,J:_) M4H">PV.S_"_^XU=\+2Y)<#P>JEO!9!Q/:]6(0FS^<=\1IG"()CX1@0!?R5TWP1"0 M_*#GU*\0TV;&!A9CHK8FBL!-9U>/%/K*PTNF?+I`7,P0AP)MIC'\$[6"(UA; M:R22LGNS+Y^:)G)L`_^^3-9IQDFJ%^O6'G3YJVHG0(0Q[MX(E&O?0B&21C%M MJ\W+M*I&&3_A4]ZB"9%BB;K6C:D+`,U*H>)278L&F5D]W+S?,]-+;A.EHNU` M0F[ZZ*-&DQA8Y,L(CJI.G7@F<]&OR?+T[$H6NZ."V$9.RXH0=]BMEXCX@J`B MS4M$S6BRTR[%_C!;7<9_UAN!4(;NL@)%"D2JPO5_#R/K/_U"F(XMU&M7VY#>!HKK--L"6W&`]M^Q:8W'V3K$ML",5P3`1D MA4?(!INX=+3N#"%K7((MD;+)-03@91RR)8&-0ADLMHELGW#<*^5PQAL,5FM< M5,U5CK=[?LWQW*)QALTMRRMSW?$W&RXF.QRF;K0(Q4*M.`W1=@M%>'R7QV69 M\U<66![4+CR^][!SH^L?S3E^^?S>O&,;&A^-OGS>EY7L8/?3YMQI^Z6W?G;I MRV<6VO[N6.MI?W@4G6_[B^.T[O8W'S(_T?[N3=-!W?[JR,2J_:ESY\OGG<[E M^_&;W97?['6^^<$[FAK?T9[N?ON#EZ%BO+78L;_ZL8[DM1]]G=I`@NF0LXRF M%"P4;1*.R_Q.NRC.T\GVZ6BEPA3A)_W7:J$`QUB#8[B456^AYPR7T.MQ9;_B MYL8-I,`E:[@A]7[FTNN55J@.S?,.D*QE`C27[7K7'\5%1:>MP@3I,[H<%IRK M6PUCAN:G%RYV_EG6A!K3JA83P\_R!QP#4C!GU.Z-(K]3%0BHM#:05\MPL)_18&9MV@NHT;RYY6/,"2Y_`$OY[Y/_:'_)3T]QQ\A6P7^?=[[X++3_CUJR5D/3*J=A^O_.I)YZTT:],;T'Y[Y^EC M6]'3IYT%I:^ZC(!Q4//B1>>=-&-?C=;D?CNUY"^?NR)QAHBE/@;CD(%LU$_" MAW!;EXAJ2GF!ORGH@X)DN22EJ@2=JHAHK^;8P$J!**PG'JVXY=V!2MAR015R M*\^MZSKC`5B^404M9OE1-+5'.*;+;81IBZ5ZU/38[<=(^%RP4&'KG)Y([HO0-DV7ZYCUSF0N)=6LE4-5PMMB2\R"^I7MN-69^I/4!/[W M:CK>HMMC0L*%&T/[/KDA:/U4J-AJ(A$-'FLW0[ZP>GM";(+$57+1%GTMIPTV M2<1);@7@'7>FH^,9'FY@=1Z[JM'"CKI=T"PO6PYP4^Z)3+PQ7K'A,M.9&GWQ MF@^ M6-;F!N?["7JO1D9'N!BK"-[Q^8P>7;ZZI+U<>[B@Y`ULS;*5C42`&,S_TG%+ MIP`.WXM7ZLN],4)]WM!#T1/W,BH2O`&^FL><X%]ZF^[,JW&8)^'TU7OR)C?MEQ:^+,YTYYP"2X9: MLY5K7OJ:S7MJF[><;&WKPC1MPH]'Q3&I&_LI3;NSDZO'M3_10^*MR-,IQR_= MP5!0;:+WA3Q8.BJ6FG#E@763L1\SMJ#"[E:V*-@O8+5S!63#-4`H%#9-O+PY M(BG-R2EJ*?0F9'<4Q,DTA5\VS;V/G)4+%YEGWJ/KVAWC6L"K(Y M!\V&FH4Z*;P'*?K]P)IMOS8YX)R,@NA';-D]4JY^G3AQ@UW++>[R@W1_I[UB M1":&4G$E$=76_-'N!C;GW9WH5WZ;9R)7V)#LWW MQ/-8S'7;]=X]G3UEMFDYN0D1A30B753MR>^".^5#"C+"'>,_Q`M(19P3=IK] MC?NH=:S?1VH3M/#C=]59,2%UBNEHR^JNL5BHD.6!&@T7\LLG0%J$^+2D6K#0Q_86ISFJXQ+PZ]W5G,SXL\"!K=%5K\HDC://%@G=9C9'I3 MA\HWG1CM@PF5GI1G"<4>!#WJSZ8+5.PXT(-1"YF9NEK0&VYS&O8_`702-T6R M'@_>2LP*E1WH%5$L#0;R[& M*G4O,&@-A6;:41>?+8YNJX@C!+H6+8NVS4ZO:CZ+QS'(Q@*Z,F@JO+_K=S1W MMWWG-]8"J.WP+I*3J"OGG!,'R4GI_#>/;;5[L34NI/&M=";:[C]_M'B]5(#L M2H8D+"[\ M8D#X*X944TC`EM)<-JHPP#JAB^N M(RW:5%IDQY4U(B1!"ZH"I5DA_9P03P=5/!'OJ6Z5C)`_]!6V]D);O7\EE.[U M-M2:6))-@[5M[G=LXNNPB+L?!+I"^#^WB2^WLO M7C27RSW=V5EV89V;,+@ORQ:08);S^^KSRWN+PO$+B"9V2C?B/>824/VX\S:9_;-=L6RK&W&T90AZ3 MBA2*+9+7V?93G00-G=T/Z(SP.\MZ'5B]^-PA"13DS[SWZCZDU>]\#:A^YN@@ MHU,=Z*LI10MU^X9-;AH2*PW'NI0"]-")!5_-T^TMZX/^1?%9!.0.]/SG.!LD MX3D6+@[D*.9$6N"_)\AO9BQ>_2E=2D;"ITE/>N9./Z,93&1C];)KU^4`$!;_ MF48FNH]PTM#R_/'38H/9==2^]>W39YLO7CREP,!WZG2SE()='R%"PV^SJL8H MQ./I"LGVX\U'+QYM/GVZ0U*?Q);R[E@G_=NR5YS8\`Q@I-(#"O7,6 M>UI)0YA>L\GXL6FUG4O6HT`*?K0%1XY)QURH49;7.O?0R\RD:PC6C(@'T#)N MN3K:;ZNS6K4Y MY%"UULCFAIIC+8Y;.A;E.'3W/\M_>*+[BQ6RFN-AN*O(&BT+;KLW\U9+*LQ( M+H@%E)-.C!WCGF&T:@]B1=><8:Z4TEPTKXPSX\N(35E!6&(J4`'(GLDA]=1MHLZ9$?VG3?BJ"O^)VY>*^G M3E!JDK18-HR;I.X6,66Q>AY\-,&31EY@K#58=_;1#6@PGAV;N=].[`8!\RJ^ MG,.=15OP:B)L;!VBY^K$Z*2B"-/M=^/;29-]$OP<\&E_?%*%G'?[BW=SQ:!? M/H\OVM\!H2>FBX>X!DK4BT+!#3%8Q0E?[R.5M!F^0HQ!1'?9=%?/NA M->^O>2M)VI?/RR3E((%Z+^@?H/M`$"YTHSS4IF#MPUGO]YI$YMV'N*T9_'G( M9<:@Y`[TOR$=R4_`8&6[2?J#$*-@J_T8C^X&#$=U9$:#6;4XV@T4.9J['4`@ MG:?V19V+C0940V-1"!D$7TJ[@+L5,'+#UQS$8C^::E[/VC'QY',`6N MSWY2*L37-,_:981VU1/?*2RV<$LN6YF'@AYFE@O*.LDX<\D=B$CZ&-`WLQ>7>2U MK2,;O@69/4D)2=IC`$2X.8C$K&JD+$I)B2Z-RV:';]0XLXOYE@VG:;Q!6X/# MAT%%[5;72<^TK?+1EM#%\K#UX0M>LH.2;?T,5S;XIL:&3OV.9]1ISJG`0G4P M!MZ`B6L1O#)#G`W@6^5\CX6OY$X5>>^L"];M4"X_HHBPQ49"`+4 M`HG]U(7QV+,KZ;/L<;^$BA=B@!AR`6%OK35&:GE'=4/<`@0RD3,^M)9-Q3V[ M>&UQN0O<\B8"Q,7XXRH)PU33MGLKK;I>ZV?IJ?V"]2R(<5Y*>YO;7-*Z,UYX MP3!:EC1OHWR>0)%6!4[&9W&J9#`0&&K[-KOME!H*Z%F*Y7G;46U57!_&)QYZ M5-.7#C)W;_]\HT@LT6+:R5_Q1Q5TT)5$HK31:RI*NH\X%9(&U'7D%K$A$A(W M,PT<=.1Z!."3D1A/0E.:]2Q:\^TR"M6/P'Q+;K-V_3:-9HW(K'H**$:(H+AH MZ!,/RCY`C%,E_&6'$4U^`;J_-".2)(VY_2(?1+7AB M6Q8@@$ M5]1'VE2PCVG!H1J$'0K>RDR/M=G9%85F9E+V^KQS%X\YQW.[(LJV$@;=U3YD M[CA>YFWI6^U'4Z1:]`OQ9XG5ZS0;7$BFY,";Z].F"!WW636?D+@./WJ[L$+7 MP'AXN;G%7-8CZ)!2Y,$"?L6JL#\L0,4=[`46.RDDEIB`I2,S>8\&4I@R4NU- MB]'R[HL\7(YRZZCF%P?&2LE",J@:5%:+K:O#50\"FQ#S&85V"P&S:Q^:I%N3 MDUMRE:"E0+,PU)/0W:,MAZH/QKK=85._?&_AKNROUX+_2?K=?M;X)*\TGZE5 MUJK:2WBZ/[^]FN,8J-&(6+8E26`_=]$V:1R\/LLT/(,-"J2$[@3D;%WX28,2 M$3[*OPF8@PZU,BX%XHHWV"O,E?V&J55A(DR.14HQ2ZE(]%(]%#9)SPO9[EW6 MKWBCCE7>KVJ.6/+3Q5E+$@TFNM9(ZTF7T&_$?W7:40Z@.UTCL^EOW!0_VO,W MQ9HXZ`/^$RX=!G2`^P_OW.'=HQ&_TTXV%F]_$FNB8N4K';T;3X2:OF:XPW@_ M+;KA=TI\S=N6[`HY*ID6M,["M,WBV(^(B[(CZO;PE':0]_IQEJ]8ZVME&RV9 M(78U3?5JJ0B7?7X-M2V(W0DV2CK9##C[:HIFT(9?UJ)CW;C^=;2%N236 M#-[,)L%Z-^;<5IA^T^3$)S`#/N`VP*_CPR8'P^R$[/_U]05!6M^%Q[U9MTO" MVI'R/;M=('*?G!?L;J7C^,*$COVO^KD1L`'=#M1VB(GDK8SBRR&)[3M(093X MM>.'#-S7C&LN/_RBE0Q5Z&OQ/)1)L13I/6$#0N<2M?'*RMVU*11][@^+C0^G MKXK['2U=\CN/Q8]OK3_I+VTT$^A0),>SURAR3&"!?1NQ5K/J`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`[I'=8R7!IMI;C2S+M=T+VI<^([;>FP#-HJTW.2'SW*D>[:I<80 M(I0J4@:HR)"U77?,@17W"L`@9?4LDVJ706`6#^PGK4C36)5PL_A>77UMZG^= MJ5YEM^\*O4C_.E,]^'_:\[]JHCZ?.2L*7DW1L M8-_.('1&]_[ZPWBSYFI8^H:.'U0F"5W&NO:@#Y1\_?_G!$Z;O(Y*:^>C2F=) M"B11$CB:M0<(,3H*[:*J]Z-%:3]K^'U)WW%2^)66QX#XDF1FKDR"J/ES'*-4 MH!'NV%UGE9H4783O"R'-'5JREHWP?[B[=N2&8A!X%75I,I,B32I7L5M?PG'K MPI[)^/99$$@8B8<\[E(;?4#H>5F0%)1IS40U)!LPVTP8+CTOYQ+A'OO@^V%B MCZ1P:S:4"6.3U@,85I5JE.DFXM,K\B;L!&`ZH[`RQV"#%N'0Z^HT>/:E\`S1 MS@P`MC+-FIQX1KVAZ?KTTB\;8H@("JI+UIWB;6Z9QQ.8+LB[!3%\4+M+C[_/<2BN8V)"9YB^'E'DKEA8H<\,"?.-V%+DSC>Z%D M$4L,T,:.7^QAEZU_]W]T#L+[!!(ZF@H'NNFEJ0"S6Q7P8-:IK0/Y\P#)QLJD%I#J#O)VP-,,2!Y(.8K_ MT?<7[^!>G[/G]Z:V0)?5J6_/:J8^@X_K];;[`P``__\#`%!+`P04``8`"``` M`"$`+_F6/_X+``"\;P``#0```'AL+W-T>6QE&>AO&>J%L M6LS=&;>Q97/FF6>&PR%%29??/?N>]L6)MFX8S/3!^[ZN.<$R7+G!PTS_ZYUU M-M&U;6P'*]L+`V>FOSA;_;NK7__J,[G1\>)-1`1;&?Z8QQO+GJ][?+1 M\>WM^W#C!/#-.HQ\.X:/T4-ONXD<>[7%1K[7,_K]\YYONX&>2+CPER)"?#MZ MVFW.EJ&_L6/WWO7<^(7)TC5_>?'Q(0@C^]X#J,\#TUYFLMF'/?&^NXS";;B. MWX.X7KA>NTMG'^6T-^V!I*O+8.=;?KS5EN$NB&>ZD1_2DF\^KF;ZN:XE)B_" M%8#XW7]V8?SM;Y(_[_[P[EW_7]]\^X\?G-4_?_S]_G<_?J/W,C5$)OB@7N;[ M?JU8^#J1W$LMN+I1BS];V[[KO22'#3S``B/]G>^"F_!@+]'0 MK9Y[1)/9-$$8G$U#/$)M\L$D&P_6VV3_N\0F3M>H6=QP>HROW%=$3/=S/=,N"'#+H]Y%6ZK`3*9LN^J"O,V7GH\XL&UI#:RS5,BX6 M]_V&"H>63"H;%%H?QM>=T2E?695U:1KNJ@=@AY/+H@M=MZ9_CRU\=1$G'0]H M4CT&!5S\P7,?@F2XW>XV4-$M(W<3(W-E])[46F8;-_2P!%!DZ#O7=[;:K?-5 M^R'T[0!!TJ&5_9JK#+CPER]^1UF2*9X9L07K7,_+Z\;A""LK.')U"25L[$2! M!1^T]/W=RP;JJ@"J;:2EE_RNX=GQ2[.OOKOQ]/I=#(XGTPF4W,X,$U&\GT:T6ZP3Z;D!0/KFA*GJ%,$0`(Q'H\EH,#5,^)^ESM,CD,WI2%?M58)`D5<)`D5> M91.`GH3,G_846`M1W%<)`D5>)0@4>74L.0./E7N5(%#D58)`D5?9LI7$O@IK MC(K[*D&@R*L$@2*O2BL^TPP\5>Y5@D"15PF"KKV:3:L6-S<66\38K\RDU<>I M+BSBV^MBLT:8I]Z'T0J6#K(S'(-SF",FQZXN/6<=PXPT\6\<;N#?^S". MX=3)U>7*M1_"P/;@;2]KD?VM:0DGE^`\TDR/']WE$RCC5@T2;A(5I]*09ST3 M9Q/FV.R/S9%QGDS8)*GVG96[\_>MRW67QB70B-PV&TXX#'(E:3@4ZV<]]$+J M/L$6S-7,TX(-(":RD!!L([@ MO.9K!UO6I-]/%LQ$]=0+),!+(J8[1;"/2"9OA0 M`^`HE54I5E6*(6Z'GE90`!]J*+!@U)4SY`VJCP]:/]6>UXT+J7!F.E\]>.WJK'DR>TIFCN`+-IB$;+V:2^<6$^#ZRR>75CA#2"P,4=U1B0 MZQ2#]!"0U$6PYZJF"09)Y1BHJQ!/NN8,A[D:XJ!LUABK1#F^%=)=F:>ZU79$ M)L*)DYBM%D0H)OF&4:.-Y09(4Z9\`"79+T=Y629JY8JJ.,!5M[H.-T_7/!L# MXUB$E?YZDPB'KZ?!=1Q:;.&Z%8.X/:=E_4/BO1MT15K*RL?&B"0%`_5W`U[^ MG'S&(Y^P#N"8;6AZNR0?"^_U(LG;BE`.'9X!$8=W4$I*.M0!(8N),ZLO:1?K MV@#1<*CJ8@UXV_>Q@]P@:H40ZZVBIK*6HP.7]"CAAHD!?'JK85X5-@T&O-VP MJ:Q\FY+-07$M/`*2P*Y&"$-<79RH1]C0\RK[6F.!0.D!%GXY!7P;R[G2B,O; M#;P?4`0=$KC5^)IJ=1Y@9W',`>8S6BM&#P(L6,J+)>`]N&\W`2LE76J=T4%4 M"P8)28\YA'8PYAX"N#ICR8\`T1Z/BVAE"VKT7B.A`)/;M3H`+%@Q M$O]SF8#K:IVM2K99`JD)AX83EEV&0U5%_G-)"DJ#0C3U5@4Q1S)NA^JD`)=X M!HGOA6#.6S6`#G[H#:&],^5#7^6@W)@Y2CX$:X24]F$0][O7`]N4X;;0W&'[W*W MA3ODS).#Z9[,.EEYLC0PVH@L"+>VLD!"$J$&[OHFLF`O5UM9>;0/P5HB"VY` MT%I6WO7A-L.<+-AWUQ87-$EL'/+3 MV\HJ_(@[YXDL,+FMK,*/@)#(,D%)6UF%'\$+5!:$6UM9N1]-GON1(/?GI7[D M8Q6WFHO@HK(*/_*Q.A2,52JK\",?JVAR6UR%'T$JY1Z^:"NK\".?)TS!/$%M M+/S(#^E7`:?(I*G/60W?TKKSUNX?5)&(E;:I.]@]2\" M_"^[F-"(K8@0W`HN(N3.C>&.?UDGYD0@+"$1(5S2E(MXE5$$9?S-C@+L+5S7 M?16C%185%XA!];]Z+NZMQ7B/\4EM[*Y;^7P`B%HY:WOGQ7?YES.]>/]G=B]- M"*;T5]^[7\*8B9CIQ?M/>)-2Z,5P*RY(-Y^V<.-+^*OM(G>F__=F/IY>WUC& MV:0_GYR90V=T-AW-K\]&YF)^?6U-^T9_\3^@#!]K=P'/13OBL7'L\79PB=C` MO-AZ\'"Y*#4V!?^Y.#;3R8<$/KLS(<"&6_9E1O2V^6/WKOX/``#__P,`4$L# M!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM M;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC M@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C M=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[ M[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYE MEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%T MS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/B MPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[] M_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N# MUO5D"53,+2L?VW9`X8NXS'"LY1 MZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ M2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6 MKZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[- M&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F M<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4. MEJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P M!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_ MS3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A M0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N M'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+ M&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<&ULE%7;CILP$'VOU'^P_+Z` MN20;%++:!&V[4BM552_/CC%@+6!D.YO=O^\8LRB754OS@.W)F>.9,\.POGMI M&_3,E1:RRS#Q`HQXQV0ANBK#/W\\W-QBI`WM"MK(CF?XE6M\M_GX87V4ZDG7 MG!L$#)W.<&U,G_J^9C5OJ?9DSSOXIY2JI0:.JO)UKS@M!J>V\<,@6/@M%1UV M#*F:PR'+4C">2W9H>6<(--1"_KD6OW]A:-H>NI>KIT-\PV?9`L1>-,*\# M*48M2Q^K3BJZ;R#O%Q)3]L8]'*[H6\&4U+(T'M#Y+M#KG%?^R@>FS;H0D(&5 M'2E>9OB>I'F,_7X$=]LD>ZEL=/2A1?1,=!;"B3+RB<+?2RL"9S] M*^^'H0#?%"IX20^-^2Z/G[FH:@/53B`AFU=:O.9<,Q`4:+PPL4Q,-A``/%$K M;&>`(/1E6(^B,'6&H\A+ED%$`([V7)L'82DQ8@=M9/O;@(W3N(Y3DD M=Q!XGERTFC`^Q#XE`$68GX`%VP1LC]B,MI>&W:4A=X:S4,+@_5"@NO-#L6!H MQ-,40S+QNN@A;8$+^Y:DT`_7]AU)H2W`[D\.,%UZ6O&O5%6BTZCA)5P5>$L8 M)\K-)WL;TT,%>&;0V?$0ZM%W@`+J4T;P=[P?1AVOP!``#__P,`4$L# M!!0`!@`(````(0`F'1:K;`,``.\*```9````>&PO=V]R:W-H965TZ$U+XM]_OIGQ8:8W3T4>/$ICE2YGC/;!;*5T`#J6=L:USU20,;;J5A;`]78E<(\["KKE)=5&"Q4KERS[4I"XIT\FU3:B-6.<3]Q&.1'KSK MAS/[0J5&6[UV/;`+"?0\YB1,0G":3S,%$6#:`R/7,W;+)TO>9^%\6B?HKY)[ M>_([L%N]_V)4]EV5$K(-=<(*K+1^0.FW#%_!Y/!L]GU=@9\FR.1:['+W2^^_ M2K79.BCW$"+"P";9\YVT*604;'K](3JE.@<`^!L4"I<&9$0\S5@?/JPRMYVQ MP:@W'$<##O)@):V[5VC)@G1GG2[^D8@W5F0R:$S@?V,"(;\S.220.JX[X<1\ M:O0^@,4"G[*5P*7')V!X"(@^WX;X6H00&IK*3,(:M1X<1)#YC M\BXC3O(9CSD@1M*<$L0\:AEJS?)<\PHE+'>?\OU,XB2/DGMY6I#FNLXDCY,D MBGS&4\5QK)/#49?N[?JBV*?REMB"-$E-%?7&QZ10VFCX-+5'10<,MMC'TX:3 M?,!!MW`+TKP*2,,7`.)-YYTG[]<5)_F`L0=(&MHA@V@T3I)15[$DQ06,29?Q M[>JBN,N6^+DC":$-AWQX7%1471J_`(S#/OUX]NI97<28'].2PP%##0@].5_7MO](.&HWZ MYQ8:2PE79M0#\5IK=WC`"[EM5>?_`0``__\#`%!+`P04``8`"````"$`#[0: MWX\#``!3#```&````'AL+W=O3 M=UZ//?QP1P)M6)FQ7)8\)J]< MDX^K]^^61ZF>])YS$X!"J6.R-Z9:A*%.][Q@>B`K7L*3K50%,W"I=J&N%&=9 M_5*1A]%P.`T+)DIB%1:JCX;<;D7*'V1Z*'AIK(CB.3/@7^]%I<]J1=I'KF#J MZ5!]2&51@<1&Y,*\UJ(D*-+%EUTI%=OD,.X7.F;I6;N^Z,@7(E52RZT9@%QH MC7;'/`_G(2BMEIF`$6#:`\6W,;FGBX2.2;A:U@GZ3_"C;IT'>B^/GY3(OHJ2 M0[9AG@S;_.0Y3PW/8.9(@#.RD?()7_T"MX801-<`!M&_SV'N(XP2-F':Y^>0 MC_6T?5=!QK?LD)L?\OB9B]W>0*0)I`&SL'[A.81H@UB":H&HJS%NA.9V<=D-!U,9L,1!3S8<&T>!4J2(#UH(XM?%J(G*2L2G43@>+3/ MH[>+C$XB<#R)T&@PCB:SNQY60CNL.F,/S+#54LEC`.L5C.N*X>JG"U"^GA;( M![+W",=D!A,7$PUS\[P:+L-GR'YZ(M:6@-^&H"Z1G`F<0/#0&('<]#>",!K! M^4)G:WNC'3?RXG:)44,X1B`+_8T@#$NB-=YQHVJ=66+<(B8ND?P?X3@#D?[. M$(X)C+J9B:D;=VV)MK.92R1=XN+=<0:ET-\9PJZS.S?NVA)M9W.72+K$#6?3 MMSA#V'5&_05ND4F]^,?T+O*>)_9YV_H-8U!%_5.&L&?,JZNU1=J!J5\"7>2& M-_QB]MX4$/:\72K+UH!%'&]>F21=Y(:W^5N\(>QYN\A:;Q9QO'F%DG21BXA3 M!A2^:?T35].>.Z\"UR?&L>=52W*%N>4/-]_>$TOM5MW>0JA7A^L3T_;7*8DK MS"U_N$GW]V>W]+:_R*\*:AG'GU\65YA;_G"K[N_/;NR./[\R:'?SC_S2N,+< M\@?C;/O#9F<$:_(O7W5\RUV'T26`K1+HZY!IY]%#L/5#9%IOC=%H-)[,H\MP M;9W8ELTV(`57.Y[P/-=!*@_8@E%XM;G;])2G9J]Y`-U9Q7;\&U,[4>H@YUMX M=3B8P2=!V?[.7AA9U>W-1AKHR^K3/33O'-J%X0#@K93F?('-2/-W8/4'``#_ M_P,`4$L#!!0`!@`(````(0#>1*?F&P8``'`@```9````>&PO=V]R:W-H965T M?,C9);!)79^:B2>#CQZ[?+ESQ/'U]+P_&#UHW175WJO[>["EM#5`X-BMS MW[:GI64U^9Z663.J3O0(5[95768M?*UW5G.J:;;I;BH/ECT>3ZTR*XXF5UC6 MG]&HMMLBIWZ5OY;TV'*1FAZR%MK?[(M3TZN5^6?DRJS^_GKZDE?E"21>BD/1 M?G2BIE'FRV1WK.KLY0#]?B>3+.^UNR\#^;+(ZZJIMNT(Y"S>T&&?%];"`J7G MITT!/6!A-VJZ79G?R#(E,]-Z?NH"]%]!WYJKST:SK]ZBNMC\41PI1!M\8@Z\ M5-5WAB8;=@INM@9WAYT#?]7&AFZSUT/[=_46TV*W;\%N%WK$.K;(KR(!/P%M/7B+ M4:(>W6(<62>^Q4QD)KG%N#*3WF(NXT2*+*3*060G=Y-^'UEV%Z1W*2ASN1%K MSD`:/0=.:::'$CY*!"@1HD2$$C%*)"B1Z@C)$@B99(E^D#-Z98+CYS`[9*%8 MP1F>5F!1Q?_)C'?-S-Q;B'^-W)$).`-_S\U17`]1(D*)&"42E$AUA.0'S`;) M#_:*P),/NTOQQ5;?")Q9=.F>!%^4=.#I+_OZRP&_#+V\ZX1>($(%8I1(](]( M=0*2![`$DCS0SPE&J[%7)S0SAH?50E0(D2)""5BE$A0(M41DAFP MS'G`#$;+9KCJ/.`(CS2YG9YPQ,>1@",:TT.4B%`B1HD$)5(=(9G!JF]U`8MG M)W:7;(IC*RN6-6?N9B?]95]_.>"7=4Z@1(02,4HD*)'J",D)J&\D)_0YBM&J M`\H+8,T939`\E/!1(D")<$@XMK(NC6XQRJL_'C(*D:!$.B0<^Z(B&<+JN0<< MZ7#5DDM!PDL(`>D\P1$?1P(<"072OZ$FSMRY1*)K;B0AD[F[&!@7XP]*<"25 M'B06A^<5INP*J_O4C(67'(27B])"U[X4-<(=#O&<-1[-E'!X0D3CGH\C`8Z$ M.!()Y%Y;8^1Z@C\BO2\A.\+JQ6M'])F+_2`W2%UJ]2<@3:0]'/%Q)!"(F`0P MO-V%K>31$)>)<"3&D41J#)G?:DRJE9%]827CM2^?JSP(KS3EF:*6A`+2^J.K M6+OYYN,J@4"F;E?EP)RJ,H6*2%?$P[=>[MZXKK6$EU!W.6_`%<)I88,?^2)<(D81Q(<2;6( M[`JLA]*6E_#QB6;,O/N+3!=P*:@J[R2/(%H+=&5Q<(2%`GQ!T4X M$N-(@B-L0Y?%Y7:GN2M\PY;O6I6TWE&/'@Z-D5>O;#-V`A$]GSUO%'^SV9:& MKVUEZJ%G9ZNX][V-FGL`LS'@&\K:JV_\(>VE(ON=.U=ER;7MF57E9FT(A:#ZB00^' MLB`A+5XK4G="I"'GO(/UMZ?RTDJUJOB(7)4W+Z^7+P6M+B#Q7)[+[@<7-8VJ M"+)C39O\^0QQOSO3O)#:_`>2K\JBH2T]=!.0L\1"<U^>0$F3,UK73-(TBM>VH]6_PLCII82( MVXO`M1=QW8F[\!U_]@F5::\"5ZDR$'EP>U@HCP&NO>-\XDQM?N\';O/>#:[J M?E/7GR]XZ`\<8>_P^\&U=US>2X\E4LTK%^9=OEDU]&K`=H!DMI><;2XG`$]9 M,G%'5<3_JR$4CXD\,96U"8N'\K30>&\;S_97UALT2]';;+&-,[;820O6&4PV MU$&D@U@'B0Y2'60#8$$25":@87Y!)I@*RX2,82O!+36N%K:TD"ZA#B(=Q#I( M=)#J(!N`4=@>#MN#G7]_S\IZ,R?8G8-ZN^YL'-96V#B0;M446DOLE(D*'9$( MD1B1!)$4D6Q(1@F`+?X+ZLY48`]!EE6TGJVGI#=ZE!)EHE*"2(1(C$B"2(I( M-B2CE,##:YB2Q[W`C'GD6X/7;*2+J%B$2(Q(@DB*2(9$,R M"G3VF4"9\3A002!0&<,.D1"1")$8D021%)%L2$91P7/XX^5CQN.H!/'$" MPSM$0D%\6((JL>-[XQ)'RDBF)^X)'R/X(SY1-C=JA'RD@N.1;$'X2-;%)$,D'N!.K`_3\>*;<>A]JC8:P8A1A% M&,48)1BE&&4C-.IH=H)^(CYFK<77(\C@H$[Z%,)OLS;=6UG"'CE#1V>I'6J1 M='1$XR\]3Y..I<5-.OF0="H=A;1C>W-]JLRD"=<>YXU-/#_[*&`'NIY.@5P8 M*`;IU';JKG=T;Y-@V"-_H8Z+2%K->.ZFCKO4GAJQM+CI)%@GE59"A\EH.IFT MX#KC/+')Z*?SU(]7KHIMZ_1HV#US?0+LC49=)_S\H=^=KA-6[I)G;@XO6%I? MQE@ZZ=%CZ50Z"FG'F&J@?9_$XOL#OO'D"#YS&\I:.V$XC/ M&J)^XCU&S`,8;S,-Y`%,%YLD\@"$!\W`1 MP+F+>;((X"S%/%P&<&!AGBP#.)*`6RHP^'!QR8_DC[PYEG5KG,D!DF[S2:,1 MGS[$CZXO^#/MX),%K_T)/E$1F*OL"8PE!TH[^8/=0'WTVOP'``#__P,`4$L# M!!0`!@`(````(0"EKTNU^@L``-I!```9````>&PO=V]R:W-H965TOW8Z2&!U; M@>T^S-MO421%%G]U8F?[9CSY6"RIJDCI%RGUS>\_-B^C;\UNOVZWM^/B['P\ M:K:K]F&]?;H=__M/^=OE>+0_++[8WRTCX_K55.WJZ^;9GMP3G;-R_)`Y[]_7K_N@[?-ZAAW MF^7NR]?7WU;MYI5SLC=Q)THQGPUN9J0I[N;AS5%8-,^VC6/M^-/Q;6IKL:3NYLN0?]9 M-]_WR?^/]L_M=[5;/_RQWC:4;:J3K<#GMOUB3/R MZ\OA7^UWW:R?G@]4[HHBLH%=/_Q5-_L5993%=.2>E=T*_ MP97%<3_+;G3C]^F,6E\?UG/N>%WW/8X])DZ8[ M)OV>>,PKWY-^?<]WCCEQ=>K*7B\/R[N;7?M]1'.)*K%_7=J965R3MU!OE^-^ M!/QL`%#EK9-/ULOMF#)`M=W3J/UV5TRO;B;?:*2MO,W]@`VW6`0+.ZRLVSH' M(@9SWSJ:@_/>CI.(FB]ZDSP40`40"44`T$),2 MEA&Z>/R"C%@O-*DH[7VTQ:S@\=Y[H[=2TIOT*0$B@$@@"H@&8E+"4D)7Q30E MPW>#<#&PQEWDX8SO'9GR7.33H#<*W6H@`H@$HH!H("8E+%"ZF!\?J#7F@3I" M@888%D!J(`*(!**`:"`F)2PJNC`?'Y4UYE$Y,J4)DPSE*1_*B]XHA%X#$4`D M$`5$`S$I88%:&9KI]:8!^K(=!;+!Z0&(H!((`J(!F)2PJ*B^_+Q45EC M'I4C%%5:OEE6OMZH+Q\0`40"44`T$),2%FA!>O7X2#MK'JI':041U8@$(HE( M(=*(#$,\/JL]CAZ?]DZ9E=*C;"KF=]%HU1<3D4`D$2E$&I%AB(=L=B,-V2%6;4"U[YA8 M"402D4*D$1F&>'Q6."3QV6I7-$U/K;73'S2J0LGN[4.V&^;I5?HBKW5O%3K6 ML6-``I%$I!!I1(8AG@LK-Y)TMXJU*\N``E$$I%"I!$9AGC(5H(<'[(3+"SD5,-T MS_"+`E"-2""2B!0BC<@PQ..SRB.)[^,7:R=A6.B]JDFKG2V"+(K>*E8;D$`K MB4@ATH@,0RP;Y4EJJ[/F:LNCY#*\0%0C$H@D(H5((S(,\?A.4ELEJBV/N-JJ MLF6-1;3J2XI(()*(%"*-R##$0SY);96HMCQB)46UA58"D42D$&E$AB$>WX#: M^L#]MT2MY1$%GDS?*ENO642K6&N07P*M)"*%2",R#/%<6%V47,S>OO^63D6E M5RR/6*U1:Z&50"01*40:D6&(QY=IK7?B0TEE]PI`4E7YLE.TBB7M.P8DT$HB M4H@T(L,0#_DD256BI/*(E10E%5H)1!*10J01&89X?%;8)$/6[3:<75"^#\_K MU9?[EO0T78<'2CVE706WUU`Z=<1&LD?S7D\O@E5$M4=3NNW%=:PJ6\<2T2H4 M7R)2B#0BXQ%I3/+%,Y$IK8]E`@58Z5$,>X&H]FA:=%LUY7F1K0:):!"3X#W' MK0T5K>R.#[G)`8&`0T<_I1X%03&P4>I;$#JDN/+ONQ M(A#)@*(O%5#LJ!&9@+#D=MP='U]GS>560!1`,GZSTBVB59+H285NT9,.B%1"^(YD%5)3!Q0?2T5`]CK5;W!668PR6$5?*J#H2P$G M0\N?0?;/]O5G-YOD.F/%?[8( MZU%ZDT54(Q*()"*%2",R#/$ALA5L1]\ZID[>I;<.C^@((9@%HAJ10"01*40:D6&(QY?I0COK/_#8 M,T7!Z)%-;7)ER]>HHE5(3XU(()*(%"*-R##$LULXJ035: M"402D4*D$1F&>'R9,GPG/I2`4X?L!2(I:;X0%:UB2?N.`0FTDH@4(HW(,,1# MMI+L^.GK!5RR>#YU**G?`E&-2""2B!0BC<@PQ.*;9,1G\#Q?I(I6H;8U(H%((E*(-"+#$$]'IOC>'N$SI^/2J[5':;D1U8@$ M(HE((=*(#$,\/BM)DN'\?Y3;RZ1DJ,\FCG$R@VH1BN!2")2B#0BPQ"/+]-;MMP?V@&>H13S**MVOH05 MK4)I:T0"D42D$&E$AB&>C9.DV`REF$>LVLXJ035:"402D4*D$1F&>'R9%'MG M-*/BFCF4E31;.5E$JUC2OF-``JTD(H5((S(,\9!/4EPS5%P>)?5;(*H1"402 MD4*D$1F&>'PG*:X9*BZ/N.*:9\LIBV@5ZE ML9*""*O12B"2B!0BC<@PQ.*K,L7U]BSMK+FJ\BB;I?F"2+3J2XI(()*(%"*- MR##$0SY)5=FGQ^RQWZ.TI(AJ1`*11*00:42&(1Y?IJK>*2DJI\H+()(.\;EH MGB\(1JM8TKYC0`*M)"*%2",R#/&0K!\%2M:A=K6B`0BB4@ATH@,0SP=)TFG"J63 M1VP&HW1"*X%((E*(-"+#$(\ODTY6*'^PW"BKJEX=I;,[7\B*5K'`!%I) M1`J11F08XNDX2595**L\8N5V5@FJT4H@DH@4(HW(,,3CRV35AY^+*E1<'F63 M.U_CBE:AM#4B@4@B4H@T(L,0S\9)BHL^\83;LT/="K7S[#[B=%_S;9K=4[-H M7E[VHU7[U7Z@286YN^FQ^WKTOIK1YZ.="VBIJ*7[HA-:YM32;6="RP6U='M4 MT'))+=U.3MXRHQ;2I500:+FBEFY#*&^ISLE;M\$#+?9SV.[C46@IJ:5;-X&6 M*;5TNQ9YRXSZT#K&T+E1'UH!&&JAC-+3\%`+992>(X=:**/TN#740AFE!Y6! MEBGUH47QH1;J0\O)0RV4:UIU'6JA7--ZY4#+C')-2W=#+91K6O0::"DI!_0> MSU`+Y8"6.8=:*!YZ462@94JY=KM*>7VF=!QW:8,6.@YMGPQX*R@']$+H4`OE M@/8[!UI*RH';+,^/4U(.Z.V[H3XT=NB]M:$6BL?M+^?>"NKCY!JT4!]ZRW[` M6T$YH/?3AUHH!_2V]E`+Y=J]<`''H;%#KP,/]*$N@]6A#H/VE.;!+%.2!W-< M4([I0YF!(Q>48_J>!%OH!9YK^Y;-4,OEM7UG!5OH'17J,]1"7])_&JR7/?R` MIWM;X"%NA^L`_S2[_N2^U,^3;J\8`QWNJ7Y=^29]!_JR_G7YU/QCN7M:;_>C ME^:1+NSGW1;VSGV;[_XX^*WLS^V!OJGO=K6?Z=]0:.@;ZG/[*R%`+@T*J=*M MNEMI*ZU6>WEVP`2K@)'M-.W?[XQ-"#3MEKZ0,#D^9\Z,/<[JZJDJR2-76L@Z MH8$WH837J4:,/JC)6RY@E]YII>K3]_6AVD>M`%YX8`0ZT3 M6AC3Q+ZOTX)73'NRX37\DDM5,0.O:N?K1G&6V455Z8>3R=ROF*BI8XC5&`Z9 MYR+E-S+=5[PVCD3QDAG(7Q>BT4>V*AU#5S'UL&\N4EDU0+$5I3#/EI22*HWO M=K54;%N"[Z=@RM(CMWTYHZ]$JJ26N?&`SG>)GGM>^DL?F-:K3(`#+#M1/$_H M)HBO@Y#ZZY4MT!_!#[KWG>A"'KXJD7T7-8=J0Y^P`ULI'Q!ZEV$(%OMGJV]M M!WXHDO&<[4OS4QZ^<;$K#+1[!H[06)P]WW"=0D6!Q@MGR)3*$A*`)ZD$;@VH M"'NRGP>1F2*AX[/% M)`K>)_%=/M;>#3-LO5+R0&#/@*1N&.[`(`;BU_V`$<1N$)S0!260JX8F/*Z# M*%SYCU"XM,5<.PP\3Y@.X8-HIPQJXY41C,I864SEV@7Z,J=$!C+11V00G%!X MGI*/HBY]I^PPTQYFUB$&R@`9;Q#!T`.PU9.>=L1.VH%&2,.F&B^-8"O=%;>- M#.OPALOY1Z00/)1J(Y$]??WM`;NL;\$>N#GL]_?V**X;2K016-DK[;PK[:!G M.*]''P<$#Z7:B)T``][ED!?=A$MHY/_/&ZX:"K21H9?%ZUX"F'+CS5CT4.P8 M.K<3X"GOUE'`-C0][30ACKHMV=\W&7C4OX]-X`_1XC72_P!W0L!V_9VHG:DU*G@/G MQ%N`6>5N$?=B9`-5@:M`&AC_]FL!MSV'43?!JN92FN,+"G3_'];_````__\# M`%!+`P04``8`"````"$`?/O)<0($``#M#@``&````'AL+W=O?/O(4N^=2Y6(?.N32>A[/(]$G.2' MK?_O/R]?E[ZG-,MCEHJ<;_U/KOQON]^^;,Y"OJDCY]H#A%QM_:/6Q3H(5'3D M&5,34?`A7A#UQ\QFF!QT%G]8CKPE_1B MOF>G5/\MSM]YE1?:_=2(F*8ME4GMFFNTV4IP] MZ#=XJX+A])`U`%424K;_P/8BOH++O.T(6F^`=JA&5/D_6 M!WXO/K5'`-G4*4$:S93ZRU-%1F>,C.7"5)ZLH1F&]H>9NF&0^6RP&U4X7`1U M;Y(@RQK?9F!]9@V?A]K#(0HNXXFB,S0)Z%WJ1U8UL`UMG4:$!J+-T$B>SG'L M!J:QXH_K3!9UO4N+4Q(:UGDYA.=NU.N=163FE6+JZ9QG`Y6=SL""YT8Y066'F9%#JP M"0BHV'@^QML-5IFZC`AN^-&E,MXMZ%(QW+Y,^_N"&^..:*5*T(MN&`!(H(<( M;N@&$>S-?#:YV1EBA0"`Z\U2F=S>S`8HX6YNQ+T^:P2]6P4L33V4(($FM-G_ M*W"_$0.7M6*4)I?1@."1NP3`>+>BE1+0P^@N#2!=$:A,4(3&MID/M.8N&2!= M':A,/41ZE(`NR0AM)ETIJ$QN=RY?9D>"Z%U:8+S=[E2F+BG:T@*<-S*'T\NM MB3,+6U%*67`Y73["+J>[9(%V9:$R]7#JD87%8D2?:%<7*I/+Z?)U=SGAMAZM M"[04@88*5:8>3I!`$]I^AE83V';7E0%/#BUEJ$P.I^G`R8#>I0S&NS45@\I` M6\I@M"Z:.$794P`'`LO1QX[.7"GN`S+@_\ M=YZFRHO$"2\.%([>M;6^U#R:UK?ML_6CO>P$]1NX;!3LP/]D\I#DRDOY'C!# M4RAIKROV08L"J@)7#J'AFF'^'N%:R>'X'>*6W@NAJP?X]`7U177W"P``__\# M`%!+`P04``8`"````"$`4Y#6ED4"``#4!```&````'AL+W=OQDG1-QEJ0A[4(72NGA6I''MHAE M&4DYO7U'5N(&LH7TQK:DF6_F'_UX_G)2-3F`L5(W&4VBF!)HA,YE4V;TYX_- MTX02ZWB3\UHWD-$S6/JR^/AA?M1F9RL`1Y#0V(Q6SK4SQJRH0'$;Z18:/"FT M4=SATI3,M@9XWB6IF@WB>,04EPT-A)EYA*&+0@I8:[%7T+@`,5!SA_W;2K;V M2E/B$9SB9K=OGX16+2*VLI;NW$$I46+V6C;:\&V-ND_),Q=7=K>XPRLIC+:Z MPU7KG0U]SOX7)["Y[TUW`-T-R*/B^=M_U\0O(LG)XVRD*\KIF M^7D-5N!`$1,-4D\2NL8&\$F4],[`@?!3]S[*W%49'8ZB=!P/$PPG6[!N(SV2 M$K&W3JO?(2BYH`)D<('@^P))TNAYD(XG#U!8Z*@3N.:.+^9&'PF:!FO:EGL+ M)C,D>V5#G$_HH]?Z+ZFHT4.6GI+1,268;O%Z#HLD&K:$J'WWCD)YO6[O:F7@\Z7_0&:JN4EO'%3 MRL:2&@I,C:,QNL@$6X:%TVUWM5OMT$[=9X5_#\`!Q1$&%UJ[Z\(;O_\?+?X` M``#__P,`4$L#!!0`!@`(````(0`KH&PO=V]R:W-H M965T&ULG%A=CZI($'W?9/\#X5VA&T0PZLW(9'9OLC?9;/;C MF<%6R0AM@/GZ]UM-M4@7RN!]F5'Z4)P^55T':_GM(S]:;Z*L,EFL;#9U;4L4 MJ=QFQ7YE__/WTR2TK:I.BFURE(58V9^BLK^M?_UE^2[+E^H@1&U!A*):V8>Z M/BTZ[;N#D25;8&&%1CHDA M=[LL%8\R?5*^O)XFJ^#Q+2UG)73V%<`X2[>\Y=3Y;U4&^_U9FVS^R0H#:D">5@6>154_92JD;:6O52WS M_Q#$="@,PG40#]CK=;@T?+.#1)I]/29ULEZ6\MV"8H%'5:=$E1Y;0,#SAO#Q M[19O[1"VIH(\J"@K>VY;0+Z"M+RM(W_IO(&2J89L^A!F(N(S0B4`V+4487-= MBM>U/C-18,5$::^H;?`"Q&ZI`AA4(,@XZDI\,J&?;>:A"&AAI"PR>6$A6[@<=>$Q";$G0'D(JU!#FJ[ M2TX5F0=G;SB3ZB:B7V`RV"`$>+3[H/H-(0R*@4EQF)H"F_I%N;,.<%-CD%-"<(N0Z)UQ#3M",W`MG@Y(R,M(NOLZD MNHE0NQPP/`D(T8\/_,[CF_6XNSX)_)O\(I/?L&0*;/**J&0(0,7M+`S=_M%1!/81%S9 M]*F8/;V(G.=!%-U22[7B#JUQC8)A`^]V6D95V6C04*\8A)CRJ;;?.Y9S:Z MV%CG@<\N1\BD]E,FH%ZNR!GUJ`MHC-:.SUE`W2PV(#QTYST_XT&G>ON"J\1!L'O,H@& M;;X4,9>>!PT:RN<@Q,@G)TXQKB4W=YE&QESJ9!I$TX:6H1=17`[]O-,/38(_ MY1D#Z,W*V8P,!OG>[\:D?R'?0Z_L&8]3:FI`K M6]=8&,Y)`<0&@`7,XY?>::;X+MO@5VR#D::VT2"M71AY'D'$!@(F"-XMM@ER?H$S+D"_H@#T%,$8EUC.1YQ4(8*;,-[UH(.'#4;2>:YP@3@=&2 M48.*H0^5-FQRS5VD&3)J)AJ$/[CIZX&QZ+$93/W:MS"4$"=6.-G)1;D7L3@> M*RN5KVH:Q>&G9GNUG90]<#4E(=P\1)'8/BEEJ=FGO0L:QA=-1\/,*H4,(5QIP#>25F?OZ@93SO\7/\/``#_ M_P,`4$L#!!0`!@`(````(0!]W>:*1@(``-,$```8````>&PO=V]R:W-H965T M&ULE)3;BMLP$(;O"WT'H?NU["3>'(BS)`UI%[I02@_7BCRV M12S+2,KI[3NR$COYL?M=G9"L`1)#0VHY5S[8PQ*RI0W$:ZA09/ M"FT4=[@T);.M`9YWEU3-!G'\S!27#0V$F7F$H8M""EAKL5?0N``Q4'.'_FTE M6WNE*?$(3G&SV[=/0JL6$5M92W?NH)0H,7LM&VWXML:\3\F(BRN[6]SAE11& M6UVX"'$L&+W/>2XQ`U]V8J#(Z#*9K8:4+>9=?7Y(.-J;;V(K??QH M9/Y9-H#%QC;Y!FRUWGGI:^ZW\#*[N[WI&O#%D!P*OJ_=5WW\!+*L''8[Q81\ M7K/\O`8KL*"(B0:I)PE=HP%\$B7]9&!!^*E['V7NJHP.GZ-T'`\3E),M6+>1 M'DF)V%NGU<\@2BZH`!E<(/B^0)(T&@W2\>0!"@N.N@37W/'%W.@CP:'!F+;E M?@23&9)]9B/T%'STN?XK5DM$Q)7C=8GL.B^E@S@Y84G&1K(($G[TD MZ14,S?2.T,6MH[_7^!K8BWU@7W/O9!4V;L/\-O)'F.'_A/'BC"*[-S\=]NY# MX""9=,FG:9+&_7D(&X8KU%Z!*>$#U+4E0N_]X"1XK]_M9WHYZ,:R/\"9:GD) M;]R4LK&DA@*OQM$8&V;"5(:%TVW7V:UV.$W=9X4_#\`"Q1&*"ZW==>'GOO\= M+7X!``#__P,`4$L#!!0`!@`(````(0`@;V!Q+@4``/T2```8````>&PO=V]R M:W-H965T&ULG%A;CZI($'[?9/\#X5VA`4&,>C**LBWEFL%4R0AM@+N??;W57-Y?&06=?1*J_K^CZNJIORV\?^<5XHV65L6)EDJEM M&K1(V2$K3BOS[[_VD[EI5'52')(+*^C*_$DK\]OZUU^6[ZQ\J:[KZ\*RJO1,\Z2:LBLMH.7(RCRIX;4\6=6UI,E!D/*+Y=BV;^5)5ICH85$^ MXH,=CUE*(Y:^YK2HT4E)+TD-_:_.V;52WO+T$7=Y4KZ\7BGG( M(`(NNU'2X\I$HN8>*:U7@J!_LGH>]7Y;U1G]AZ7V>%'5E!0&\:)C\`S8R\< M^OW`34"V!NR]&($_2N-`C\GKI?Z3O?]&L].YAN&>040\L,7A9T2K%!0%-U-G MQCVE[`(=@%\CSWAJ@"+)AWB^9X?ZO#)=?SH+;)<`W'BF5;W/N$O32%^KFN7_ M(HA(5^C$D4[@*9TXK8\1GBMY$0\0EKB@Q_WI!-X*B?AE'BVSP,8^3BTBLCA M*7G>-"!VZ`;C/%_RX"EY+GSZPV0+ATQD0)34R7I9LG<#R@H& MI;HFO$C)`ASRH?>:OC?)\%DN0!)P)T_`MK3?(N51"-@K" MTX=SMFB`WY8SZW,BQ>E`_#YDIR#*[?Z&VZ#/B6]`Y@W$`F$:=2`9=75(P(O@ MD]I0>G#>RH3?-K:P^8((?X,0(BH3!4'+7,@W\&2FZ;7#=C%3 M")?[+L%UG'#F./UNQ%W$Q`T]8A/20'I:0('I6K@PU=R>))00G-078FXW[E$( MA'2%0(LOA!!A.K[6[>@^9(>0CAC*T`Z*IE\\ANAI`<7Z=2TX2=.BE1JU0`AH MT?9QKH6^10RJX]K$F7M:341=A&>'VD=VV-P1IHMW;7L>Z(D5*PJO[';\>I)` M37Q=$D[2)'&U]$!(-SW0@@)`>+;O:Q%&=Q&[QNOG0N\1`Z$W1:SGRQBB)P[, M\U\7AY,T<;0)88.0KCAH07$FQ`M#VVX'3"19A!!/E)?6ME-MS71ZWU^L."/) M`2O#U^/G)"U^;0`V".G&CQ89?^#:L)7L)U3414\30QM7=\@I"L&6N14`5.;G@O8?KL45%LCPAUGL2*,I`'T[?]% M+XA:^.V>!1G&+TUJ.IC;ONOH&DC,;1&:QD:%QM(/4W0A'O]>+P$WX5I M)?%0(@BB)H6^N9(8Z([J]U::Y/:*^$$`*YTV-?0PCNOH*^M.`CJS0X_BV5Y@ M!UI:QCW(9!9XL+-K5ZR^*'P[IHER?Y-%AZ9A.*&U/:YG=S[FO!=64>3\3F3X!X.-%GS$,7=:-FM[0`W"4/$FP,\-^:T/-$MO5PJ(V6O_%:`SQR-M;FQ@`,??%BS1V0! M)[:A_8FX"Z[ML`6"A1:16U;C#"X?KLF)_IZ4IZRHC`L]0C?L*3]TEWA]@2\U MNXH3[C.KX=I!_#W#-1.%XZ<]!?"1L5J]P*>MYN)J_1\```#__P,`4$L#!!0` M!@`(````(0![(-1D;0P``$LY```9````>&PO=V]R:W-H965TJK>S%#E6K]LSU/_TLG\_H=IA=XW<87O\\O7] MCUU]>`>)S_O7_?E'(]KO'79^^OQ6'[>?7Z'=WYW)=H?:S1],_K#?'>M3_70> M@-Q05I2W>3%<#$'IX>YQ#RT08>\=JZ?[_B?'WXS'_>'#71.@_^ZKCY/V>^_T M4G_$Q_UCL7^K(-K03Z('/M?U%V&:/@H$SD/F'34]\*]C[[%ZVGY]/?^[_DBJ M_?/+&;K;@Q:)AOF//X+JM(.(@LS`]832KGZ%"L#_O<->#`V(R/9[\_-C_WA^ MN>^/IP-O-AH[8-[[7)W.T5Y(]GN[KZ=S??B?-'*4E!1QE0C\5"+N]&KGL7*& MG\K9&[ASS_&F-]0`ZMHT`XI5(K/!W/,FT_GL^F;,E`C\Q&8,)JXWFS>QN-!^ MF$Q-Z?!3.LC@MA/F9_,%)HI0^21D[OLP+F`JG&"2?WL8CV9WPV\P,7?*9LEM M'--BA19B%@K9P`:A#2(;Q#9(;)#:(+-!;H/"!J4-UC;8:&`(L6X##D/I=P1< MR(B`8ZB6"*@'7"NZ:($N@0U"&T0VB&V0V""U06:#W`:%#4H;K&VPT8`179AA MOR.Z0@86>FTXNY.Q&$7,K`@02>WH1V/YF9PE\KH4OQ;DS;^C(2,1(S$C"2, MI(QDC.2,%(R4C*P9V>C$B#\LX$;\NSB,S\*O6 M"-T"1D)&(D9B1A)&4D8R1G)&"D9*1M:,;'1B1!7V3#=$55B;494$HHH!6S$2 M,!(R$C$2,Y(PDC*2,9(S4C!2,K)F9*,3(X2P,[@AA,+:#*$D8[E!%UN#%2.! M)-ZT#7/(2*1(DS(T6XR8V22,I,PK:VWTB6)M9_+6"/N]8$(ELUDSLM&]C*B* M'%7?O%V>[L+:C*HD>E09"231H\I(I(@6U=;F0GR2U@CCDS*AK+71A:R=3=X: MH5#!A$IFLV9DHWL9@88$Y(9`"VLST)+H@68DD$0/-".1(EJ@6YL+\4E:(XQ/ MRH2RUD87LO8\>6N$0@43*IG-FI&-[F4$VH'\_H9(-^9FJ!728\U1H!!$6V_N MQ'S3A62%[8T0:5V`R-2R]H()6:%6BHBT,D2FUM2L5TY6J%4@(JT2D:EE965K MLD*M#:)&R^P>D=7H*XY,%P?B#.'\LM]]6=:P<0"CCI5H#&FA2A:%BM5K$AF] MQE`@-MO@Z,&"V.Y/'(_U6FN%+8K0D:(3(]*U7,_:9"9DA5HI(M+*$)E:"[O7 M6+T*="2M$I&A-;7V8&NRPGIM$'7TFLB6]%[KZ!TX2FJ[1R97L/U&[:78BD/@ MC>YA*%!6'CF&'$6(J,TQ(G),.$H1D6.&B!QSC@I$Y%@B(L1K#@FHM+RGTR1%2AG&2PV@6W*A%1^6ONN$&K1M[L M!)%)W=`),O&"R8:56HJ32#XYK-W(BJS0,5#(F!Q2RX7UJNU0Q[/B%W''F,LG M:'51*^6.&3K24,\14;,+1&15];^ABX2*U44*F:\8:^2OG-:*ND@BE\(:*BMWT2Q` M\P5\_N59&YP(;6CXQ@IY>A4Z7C&RO"F^8KS9POAGO9)27N6,EYTKI%2]PM[-IFZ M&FNH1#!!L5]7#D.!0E.R"A6:T!"/T)%0C%9TW)(@(JL4'4D^0T16.71$JUCQ32!_D[M0:M"NQTY/O-.R/0*&IOA1* MJ\FDF6?3N;<8N]:B&BDW[247*S31=RT=\TR)B[U^]RZ"U3'CA>58F)29#*R4 MLN`N);I&2ML$NT`N/6RE[/R:8=9QR%'$4-9:H$CHI!; M11S%B&@?F"""C5Z[<+E3:WE+R0I+S#C*.2HX*A'Q+9>X-77+X)7YH[ZU:A3N M^U-JX(JC0"'].(Q;11S%Z$CR"5EI\?/LDQBRHOC)VFN5R+E5P5&ID-<1/Y&' MW3#Y9=IFQ$\B[;..E;@/!Y-?0P$B"D.("(QI&,VLW79$5AB&&!%I)8@,+<\Z MZ$G)"K4R1*25(S*T9E;W%&2%6B6BCBB+G.B&*,L4RHBR1-9G'&R[T%IAI0)7 M(6I@B,AHH'WR'I$5:L6(2"M!9&C-6.!9O3)T)*T8)&:33S1"'AM'@M3]Q6)$5UC5`1.T.$>E:[).0B*Q0*T9$6@DB7S`GY$SOES;A6CHZD52"ZJ%6B%1^QX^Z<\,9/21L5JV]DDB@VD9?Z1EK]]+." M0"F##/6-4J:3B`BMIC\_B8C1AI021+1K3!52%6+G!1FZD$J.B.I3(+I0GQ)M MFL+-B2&2,WT5^:7M]5BF>/I;%M&B#>9*(9@<&-^`6X5H18>L$:(+AZPQ5TK0 MC89PBDC.SXZ0JX90K7-TH?H4B&1].@^C2K3IF`8BG\.00WEVQ*\[C('OAHC% MVPBY1-IAC/SVA[S8?JB.S]6J>GT]]7;U5_'-#MC#/MRU6'WMQ'7\3_)[)]83 M.&3QQ0$#]!U[XL*3IE?9DS$\:<:O]02^WO*ITP,*Z2X#A+K*A@(Z]2>@W\3> M*G@Y\>&>:$XS]*=0SG-X+-:`IL=**?K"6Q=H)RN)[`1@7*ZGBQ=#\KIBD`(3T0ZQNL& MZ1>4T_4$DBDHI^O)TIU".5T1A2P&RNEZ`CD)E-/U!#(,**?K"5R*\4.X^\%K M#5=.\7/APB8QSN,8%;>\:_3$\$5>NN`]JW!Z?]V^GWFOU!`NBN#_0[QWEE^'D'V?U,=/G^@Q? M8H/U%M9K^-)B!5=M1P,P?JKK,_XA"FB_!OGP-P```/__`P!02P,$%``&``@` M```A`$Y;.MJ%$@``;&8``!D```!X;"]W;W)K&UL MK)W;S#1F M>GX8%IR]6:Z_Z>X!_CDV3GKSCS^>'L^^;0_'W?[Y[7EP<75^MGV^WS_LGC^] M/?_W[\EO-^=GQ]/F^6'SN'_>OCW_[O__MS??]XW MYY]/IY?UY>7Q_O/V:7.\V+]LGZGDX_[PM#G1/P^?+H\OA^WFH7-Z>KR<75VM M+I\VN^=S'6%]>$V,_<>/N_MMM+__^K1]/ND@A^WCYD3'?_R\>SERM*?[UX1[ MVAR^?'WY[7[_]$(A/NP>=Z<_NZ#G9T_WZ_S3\_ZP^?!(Y_U'L-C<<^SN'Q#^ M:7=_V!_W'T\7%.Y2'RB>\^WE[25%>O?F84=GH&0_.VP_OCU_'ZS;U>K\\MV; M3J#_[+;?C\[_GQT_[[^GA]U#M7O>DMK43JH%/NSW7Y1I_J`0.5^"=]*UP#\/ M9P_;CYNOCZ=_[;]GV]VGSR=J[B6=D3JQ]<.?T?9X3XI2F(O94D6ZWS_2`=!_ MSYYVJFN0(IL_NM_ONX?3Y[?G\^#B9KEQF&2Q7/VF[@+N)^I]7'BAWD,#V MD)^<&O>0P':1V2M;6@T<+0O]S^@!7NIAU(W*:'/:O'MSV'\_HZF.1#F^;-3$ M&:Q5.!Z/NF?V(_1'`Y1&IHKR7H5Y>TX=AX;>D6:5;^^"ZZLWE]]H)K@W-G<# M-M(B9`LU[%78R`>Q#Q(?I#[(?)#[H/!!Z8/*![4/&A^T#K@DK7O!J2O]%8*K M,$IPENJ.@6V!F:JJ,+2RB.X<2#GOM(V:7OH^OY0F86_22PXD!I(`28%D0'(@!9`22`6D!M(` M:5TBY*5?&DK:P[F5F>.TWF4OBYUZM[(W:+@,1`$B`ID`Q( M#J0`4@*I@-1`&B"M2X2JM)&:H*JREJIJ0JJR8"&0"$@,)`&2`LF`Y$`*("60 M"D@-I`'2ND1(2#L#(:':9LR6%R3YQ(V&"B35U61.8\*9+!9>G^V-N`DB(#&0 M!$@*)`.2`RF`E$`J(#60!DCK$B&XRI?=?=WX3*"LI:J:D*HL6`@D`A(#28"D M0#(@.9`"2`FD`E(#:8"T+A$24G8R04)E+274Q.N8_A:A-V*=(R`QD`1("B0# MD@,I@)1`*B`UD`9(ZQ*AJDKE)LC:F4M=#7+[)J((48PH090BRA#EB`I$):(* M48VH0=0*)"55N<;K![O:LGI=U2"OKZZ\2=1:]9T548PH090BRA#EB`I$):(* M48VH0=0*)%56.<<$E76*0IM8%NM.;6A)>-%Q`45H%2-*$*6(,D0YH@)1B:A" M5"-J$+4"24E5(C%!4I-WN))JY'7<:[_C]E;<%I&Z/B/;(D:4($H198AR1`6B M$E&%J$;4(&H%DBJK=&&"RB:[<%762'1<0)&Z@.5+"BA!JQ11ABA'5"`J$56( M:D0-HE8@*:G*%29(JE,+&@C<_^[4M38MEKMMO?$[;F_%CI%U9!0C2A"EB#)$ M.:("48FH0E0C:A"U`DF553HQ066=?0B534+B;&,#0!&B&%&"*$64(/UIG+O,T@1[\0480H1I0@2A%EB')$!:(2486H M1M0@:@62DD[+VV:8MQDDM[\WWIV*T%KUDS&B&%&"*$64(($G1,K94[H7MWD#)KQ>,BQU@% M6I6(*G2LT:I!U`I'J;)*GB:HK',MH;))OUR5`44SC83*@!)CY;18:AU=E;W; M19FULBK#0136RHWE7<8OK17'J@QRCJM&JP91*QRE\-.R._44":5R0GB3M[G" M`XJ,HQ!>6SDH,5;.":;6T17+N[2<62L6*\=8A;5R8WF7_DIKQ;$JC%5;*S>6 MUXB-M>)8K8@EVV):#CC#'-`@1[\04620(WR,*$''U%JYY^Q=@J,%9MK49B-=:* M8[4BEFP+/\74#VY=J*<*3Y]W]U_N]G0[E':,`TOSG![0TH]MS3#S-,B1-404 M&;2@Q*F_ZWKM34"Q->(32C!4:JULJ.`6UFI]I%0AQ\HQ5C$K,9*KN``(4L57W'&_7TC&BA)&- ME3*RCAFBG)%U+!A9QQ)1Q<@ZUHRL8X.H9=0Y"DGG?EKZ2^.@BR*7<$:D;M_# M@UNOBX?&BG(\[DJ107.:L1Q';T&-V>JF>UARMKA>W5QY$U6"P5-V&PV>L94X M]J5W[#F&+]AQ-'S)5J/A*PQ?L^-H^(:M1J1I17#9(:8EU7-,J@VBC3FW:4K:QCQL@ZYNA8L)5U+!E9QPH=:[:RC@TCZ]@* M1RFIGT'_VAC#Q%H]:$8[YP7].$/%VSN%QDJ,,>-(B:7C"&/,6"W&QIBV<8*G M?%2CP3.V4NMM_\PSCC$(7[#C:/B2K4;#5\;*.?J:'4?#-VPU(DTK@LL.0<'% M1M#O$+_O7WZT^7#6M[D*X\VZ&HFQ9Y`[]C1:V$4C-K$6UBHQB/90/(Y3MK*. M&2-KE:-CP5;6L61D'2MTK-G*.C:,K&,K'*74*E5V]]R^U*_:YZD+A+[2!HE) M'-5TL,C$^MGZIAWG9A*G%VMP>8/8Z:MB9VPE#AV''H0OV'%T_2G9:C1\ M9:P<96IV'`W?L-6/E6E%;-D=U/4!MSN,[R!I%P_MKI$880;9#AD91[&Z::N% M73(28R5&F+&R:TW&L:QCCHX%6UG'DI%UK-"Q9BOKV#"RCJUPE)+Z5QA^;83A MA8>Y1M[JYF7SH;%R^E'$CC3+V:7E%E8W$]Y,X8,C3)LXL=-7Q<[8BAK3'@&. M,`A?L./HH9=L-1J^,E;.T=?L.!J^8:L?*].*V+([T.@5(\SO#J]AFD3)RD$1HAA1@BA%E"'*$16(2D05HAI1@Z@52$H]=`WCEYX*IV4& MU-9(3:6V"]]ZU[]"XR@:H'?D9HK1*D&4(LH0Y8@*1"6B"E&-J$'4"B0;@)8X MT==_LIHHVF$*$:4($H198AR1`6B$E&%J$;4(&H%DBI/2_)IS^)W M7(.<@1\BBA#%B!)$*:(,48ZH0%0BJA#5B!I$K4!24I6IOGYGJ78UWEQ@$.VT MN$N&B"*#EK1WZ.?EV95W73VV5APK090RLEN_C)$,[UU-SJT5AR\0E0;I$Y)B MJ034%-X M^)P=;=90("H-&M)0Y6?_OX8ZRW-O,BTT$AH"BHS5,M`7AZX"[\I^S`;VH=V$ M4>_C29ZR@2NFKOJ']>3L8^LI&/VHGM(8#*FJ\B]7U?$E?:'3-2&?1D(^0)%Q MI'TT=ZZ8D1W_"2-KE3*R5ADC:Y4SLE8%(VM5,NJLY`!5J5?O46-&#>NR8#3MZ^6*. MCL6PHW?]M12.4F65ODQ066<[0F6-U$,PCEA^CDQ7]3J5[503&;24CM[V/F9' M>RD_&70,O%LO*3IF@XY77HTY.A:#CH&WXI7"4:KLITD_&=*8"]&=]&ZA$7TY M\!;%T%B)OJP=U9-@MGD";Q#$-CQWR<2@I4[!KRY6T(W[0V*?C.N7E7D#)\?* MBF%'K\92.$J!5<8RH1N;!,=.V'?J/KB:!D1O#+P1&+*5VXVUXU+=]/WVSNN% M,3NXW7?,(46'S*#A&G)T*$8=2N$@5%Q.RWPZ<[GY,4AF/H$W'876BGM.A"A& ME"!*$66(ZN4:.6*&Q M;K: M/-!%%&^O%%L#GJD31C9#31GU8;S]768-.$QNT$`"JB[L3.EF)@]R5R&-G#,- MNZ`TW#"5M8Q962M,G3,V:ISE">H M]N833E!OY<4,:Y#;"+.9ERJ&2VTE>D;OR"<8LY5NJF"U\)LJ80NW%T"\*C,PC)[/9+=Q02C!2 MRFXV4L9(1UK,%Q`H%X'$^%A-VSIWYIXH>NLL.H-!]B`CXTBWCZP"VHIN?S!* MC)7[\`HZ9HRL8RX#P(T\#)A@\9;?1X!E;Z>"+*WK.V5OJFQ_HK[W>K!7WFO0L!)4LJZ7:] M?LF"/@VO)U"_9'FU5I>LJ#VAA'SH6LI0R8Q*NKT=^,RII%N/H82.FK*Q@6@S MJH=>`1\JH7KH^O5`R?QZK1Y.&BJYH9+NI6/_".:W5-+=>O%+%J2!7G'\DH`4 MI8_<#-03K*BDRT/`AXZ-OB\RY$/'1I_)&"JA8].WA?QH,SHVO2KX)>0R>#8! M>=`'YX9J(:7I(VE#):2T7K3\6@)J4?H^U9`/M2A]9@E+Z.\0O!]L-57]@/V= M:N8A3E4/U?Q^L7Y/(P,KOJ,C&CJ@.VK%P4:D-AR,0RTXV(#4?D/-1P]&K-4S M#GA$]$S#6CV>@"7T(`#Y#)U>1B7J=OR`SW*Y5A<&L(0N!*Q5KH\E]$;F.M8; M):]IZ97+M7JA$GWH!CT22^AUR+5ZV1%+Z+5"JF=('7I+D.H9*J%W_JB> MH1)Z@X_J&2JA-Z^IGJ$SI5>KJ9ZA$GI1FNH9*J'7GJF>H1)ZJYCJ&>H=]-HP MU3-40B\!4SU#)?1*+]4S5$(?2J!ZAEJ;OH1`]0R5T'<-J)ZA$OIP`=4S5$*? M"J!ZAD8'?0N`ZADJH3?[J9ZA$GI/G^KI2B[[;D5_Z^-E\VE;;PZ?=L_'L\?M M1UK"KKITZJ#_6HC^Q\F\8?)A?Z(_\D%9`OWI`OJK+EMZZ>I*?5;XXWY_XG]0 M1[OL_T[,N_\)````__\#`%!+`P04``8`"````"$`M$=JB0`#```A"0``&0`` M`'AL+W=O/U4E>>1* M"UDG-!P,*>%U*C-1;Q/ZZ^?=U8P2;5B=L5+6/*'/7-/KU<N.W'"7TE4B6US,T`Z`*7Z*GG>3`/@&FUS`0XP+(3 MQ?.$KL/%33BBP6II"_1;\+WNO1-=R/UG);*OHN90;=@GW(&-E`\(O<\P!(N# MD]5W=@>^*Y+QG.U*\T/NOW"Q+0QL]Q@4@(R&`CZNHGBT#![!=-IB;AP& MGATF[!`!B';*H':Y,H)1&:N"J=RX0%\F.B\3OT<&P5#67O)1/.YXG;+#C'J8 M?PC/($`N-XA@V`.PU=4MBB='T@YT@33T0U\:.RV:8%>]L<&XSF;1U;F-^"69 M=GEYAB>^ZNN]A&!?JHW$ME_[G0(-=^IF-GC3#:[S)=H(K.Q5>7;>#8[=BT\& M@GVI-F(/LE>EN<]K]V8$]7V]7+C*%V@COI?Y>2\A#*O+S5BT+W8(G=H)\<#W MZN2F6CR8OKD]=N613#L]/%.CX0NFWC5!\&@=5?`0.F,*#_G_F7+C`:B[(Q2V M(=_4"U,1+B!/^?6NL.BC$AZ&!.B[OG,7DIOZ%5=;_HF7I2:IW.%E$\$<[Z+= M1;BV^1_'1XNUNR"#[A>XH!JVY=^8VHI:DY+GP#FTNZ_<%><^C&P@3[BFI(&K MR;X6\%>$PRP?XDG.I32'#\R\^W.S^@L``/__`P!02P,$%``&``@````A`%\U MQI)$#@``/$<``!D```!X;"]W;W)K&ULK)S;?O-4E6J*NM7R\8S M-TW[4^8O55;6(27!]>\_MR]GW]?[PV;W>M,)SGN=L_7K:O>P>7VZZ?SGC_BW M<>?L<%R^/BQ?=J_KF\Z?ZT/G]]M__N/ZQV[_]?"\7A_/2.'U<--Y/A[?)MWN M8?6\WBX/Y[NW]2L=>=SMM\LC_;E_ZA[>]NOE0^6T?>GV>[V+[G:Y>>UHAC%MFO7Y9'NO[#\^;MP&K;U4?DMLO]UV]OOZUVVS>2 M^+)YV1S_K$0[9]O5)'MZW>V77UZHW3^#X7+%VM4?(+_=K/:[P^[Q>$YR77VA MV.:K[E67E&ZO'S;4`A7VL_WZ\:9S%TP6PXM.]_:Z"M!_-^L?!^?_9X?GW8]D MOWF8;5[7%&WJ)]4#7W:[K\HT>U"(G+O@'5<]\*_]V$8;Y1DYVSU[7#<;?^GC0(CI47Z1H0^&T1:'`?&D3Z- M8^"H:Z?-C9[HR#O3)C?I8^`+*,]WM*N%TE[X3P*#.%/H/NYR/1Z/A MQ?BR/8(!YX?ZSXD7RAD2V!3Y8#0#SA'U'S[K!_M.J&J;A M\KB\O=[O?IS1W$?1.KPMU4P:3)0L#U"=^W@UYPW?U.4\/*V-RCC61#V(?)#Y(?9#Y(/=!X8.9#TH? MS'VP<$"78ET'G'+L[PBXDE$!YU#=,[`]T)?QG[(%NX0^B'P0^R#Q0>J#S`>Y M#PH?S'Q0^F#N@X4#1'1I&/X=T54RM-0XZ1Q<>LEZKVW4O%/G_,B+>&U2AQQ( M!"0&D@!)@61`A'?2\=+XW1FWQ MKTWJ^`.)@,1`$B`ID`Q(#J0`,@-2`ID#6;A$Q)\F<(A_?W1.^,3Y7`E5/<"1 MN]=D0*>N^R08>V-B6ANQ6P@D`A(#28"D0#(@.9`"R`Q("60.9.$2$7#:=8F` M-^]K>954UC*JFE!4.6!3("&0"$@,)`&2`LF`Y$`*(#,@)9`YD(5+1`AITW!" M")6U#*$F`UT]J%W#%$BHR7!]-0VEMQ#V8@5`.-@60&7B5 M8#,'LG"]1%15`>WNZ]H34UG+J&KB1A5(J(D;52`Q>"6UC1O5@5PYT]JHCBH( MY;6-*S240D5MQ$(S$"K!9@YDX7J)0%-QU4GGA#\ MREQ&WR`W_(A"@]P.0!2C8V*MW!9?RM"EUHJ;G*%6;JU[4EIUYS^F.**#1H2..VWBM> M>A-/9(U8/4:IQ%I9J>#*7X.M%6MEJ)5;*U?+6WD*:\5:,]0JK96KY4]EUHJU M%D)+=IJJJMQ.:^@T4CT#J!0W:I2?5C=]:UZ.D(4,[+;JH21 M=4P198RL8\[(.A:(9HRL8\G(.LX1+1A5CC*DJE!R0_JY<6#*+3?2!KD9'EQY M*3Y5=_8HTOWJ%KFYH:71@/9M]=`(KKRU-#*.@W%U)ZT_O+P8][R)*D;QA-U: MQ5.V$M<^\JX]0_F<'5OE"[9JE9^A?,F.K?)SMFH)S4*(RX10A9R;$.^,,5WW MT9CE\7NO[I&J/AW4:,K(WHP+#1K:GH\8Z4<3JDZ)T3%A*^N8,K*.&3KF;&4= M"T;6<8:.)5M9QSDCZ[@0CC*DJK!S0_JY,:;+0Q%IC8;N7:#@RML[30-M)<:8 M<:1YKFV,&:MAVQ@#\<2<;]@JGK*56F_YAGB`8PSDL MOS07;-4J/S-63F1*=FR5G[/5KR.S$-HR'>BB1#J\L[HI>,K.-".(J04@_* MD'YJ=:M49*0-\E8WKYJ?&BOZX`U(R(ZM4WC$5F8*;QIAJ)VP5ZMVRE:MJT^& M\CD[MLH7;-4J/T/YDAU;Y>=L]>O(+(2V3`=UIZ%MPOW8VJ;>9?!&GD'5@P!Y MRN9:_N0G.OVZFK?3VZ#G5;_W;$476$^"7FDPM38V*8VX'5,16L6($D0IH@Q1 MCJA`-$-4(IHC6@@D^X/22Z1`^R1+4RETM4;B41HL@%/CZ#P:"A%%B&)$":(4 M488H1U0@FB$J$=0JUO*FWGT1JB$%&$*$:4($H1 M98AR1`6B&:(2T1S10B`94II03PFI,O?6+(W<^TOJY32R1&%'"R*Y_*2,I[]T1S*P5R^>("H/TU1-UI&UXD;&B!)&;@SU1;3+9^QH-W`YHL*@IABJ$NNOQU"I M>'FHD8@AH)`VGLIQ%.@"OQ=X=V7B1O6=F5$7.B(%-1+A`Q3V#;*U:<3(WJ&-&5FKA)&U2AE9JXR1 MM>=,4/'O-$Q\)\& M"D<99;^J>"?*6#T,#!*Y''B+XM1847G#F14R$BD9>(,@LO+L&!LTTF54[_S" M3V/T29M/Y@V<#!WS9D?OC(5PE`%6YCAO)@2N\F M5)EGXQ$RLOOW"%',R#HFC*QCBBACA+7`0.VK3VB@V9G;>NR^4KCIB+OQ_;ZW M6D^-E=@_&2UWXX7O<["C*?>:[L:SB9L%']%.V5%K#\8#_U%:QA:5M,@,>H)S M2N`J<[DO,HCV19R(4T;.)HB1M8H,HNT].\9L91T31M8J1<>,K2I'V<#3=M9# MW%DS0&1FRENRJX&/I=%;.%DP6HD[*5UOGM8CCRA3(V M:>CST_;":DAX4Z%!HL_-]MAV78A6D4&BS\$Q0<<4'3.V:NAS?YOZJ25`O>#A MM]L@F0I^D64<12IH1YJA;2H89)[S]OM7\`0@1J7$($.CTU5B(9C",E0.V(*P;+M[R"$Z-XPFZMXBE;:?%A MCUXN]):Z3&C+B/J;5C^B'WL$2F_9P/C2R*D.]<\*Z.\K;]?[I_5T_?)R.%OM MOJF?#"")V^L:F]\SZ/J[0OX7-"1:OOC':'?9[AKO&;ZW89J`'CV]ZJ1 MC>>F$S3P.VH&/7INN%AJ16,CJ`V-3:`6-#6`'@=-U),=/`,]R9FHAS)XA!Y_ MD$^36DI'U$.(!I_!Y43MKO$([:8G:L.,1^B[!).(WJ+'(_1E@8GZ*@`>H5?_ M)^K%?CQ"+_)/U&OZ>(1>B*?S-'4+O=].YVDZ0F^KTWF:CM"[YW2>IB/AU22J M[AI[29%<3>A[/GA=^=6D:.+EU82^A8/V]#T8:D7$_K*'/)P/(FJKP+ZK1A/Z(MG M:)^/)_0],N3E>$+?%"/>K87HMTO>ED_KSE[6CS11]:HO7NSUKY_H M/X[F'<@ONR/]:@GMJ>F7%^A7:M;T6G!/?5WW<;<[\A_J!/7OWMS^'P``__\# M`%!+`P04``8`"````"$`O/0?S/,$```'$@``&0```'AL+W=O.;M4]U-0]/EG?Z[ZH?[JXZR_OI:%\4+J)J?5QG0FMFF0*J/' MO#IOS#^_AU^6IM&T:75,"UJ1C?E&&O/K]M=?UC=:/S470EH#%*IF8U[:]NI; M5I-=2)DV$WHE%?QRHG69MO"U/EO-M2;ID2>5A>7:]MPJT[PRA8)??T2#GDYY M1@*:/9>D:H5(38JTA?=O+OFUD6IE]A&Y,JV?GJ]?,EI>0>(Q+_+VC8N:1IGY MR;FB=?I80-VOSC3-I#;_@N3+/*MI0T_M!.0L\:*XYI6ULD!INS[F4`&SW:C) M:6,^.'[B>*:U77.#_LK)K5'^;S07>HOJ_/@MKPBX#7UB'7BD](F%)D>&(-E" MV2'OP.^U<22G]+EH_Z"WF.3G2POMGD%%K##_^!:0)@-'06;BSIA21@MX`?C7 M*',V-,"1])5_WO)C>]F8WGPR6]B>`^'&(VG:,&>2II$]-RTM_Q9!3B\_TA+-X;T.TC;=KFMZ,V`"@?W--673T?%! M3399^-2W_4==AW8SD0>FLC'!`&AH`T/U9>NN5FOK!897UL7L<(PSCMC+"#:6 MF&R@@X,.0AU$.HAUD"C``A-Z)V"(?8(33(4Y(6O82:!8HY4M(V1*H(.##D(= M1#J(=9`H8%0V3)A/*)NIP`17!H`SM<=U[D2,`_[WHV0V#MGW(;T7B!P0"1&) M$(D1250R<@26CD]PA*G`I`+;^VH]6[>D"WK/DCZDMP21`R(A(A$B,2*)2D:6 MP)JH6G)_"Y"+`0OFE*>M'BSF8HEG&N-B.S(?BD4D$,2#PX?2>6_<^4,?)%T+$8D0B1%)!''X M"XWJ9T=2M,G]9/U,8UQ_1Y3Z$0D$\1RQ)]K.5"N]_[TOO=,8=I"HC^'[JNUH M]L7][U(CZ32P$;##JT;<:3B:N%M/E8OQ6B8SATVL\ MB-@!Z?\N$FR[U^:,1.K86FA-W`]!@UE"RE4F4A?EKGB!/QA:W1NL>MLCF38H MQ1())?>^5=T+W!E8[.CTCE7?Z15&S-W]1%E>X.Z*O!*(]U0T1]Q.Q8VE)/69 M[$E1-$9&G]G-$[JY7?=87(MW]D3F)(G M2EOYA3V@_Q/.]A\```#__P,`4$L#!!0`!@`(````(0#.QMKAE@4``$05```9 M````>&PO=V]R:W-H965TE[9[FAL6^15>Z3O:5/M M?JO.!+(-=6(5>*;TA9GF.X;`V4'>25^!/QIK1_;%ZZG[D[YGI#H<.RAW`!&Q MP,+=9T3:$C(*,B,O8$HE/<$#P%^KKEAK0$:*C_[Z7NVZX\KVIZ-@-O9=,+>> M2=LE%9.TK?*U[6C]#S=RA107\80(7(6(YXV\>>`&TQ]0F0@5N$H51>3.[>%! M^QC@*AQG(WUIX7 M+)TW:)92V&RPC:M;;*4%ZPPF&YD@-D%B@M0$F0ER!3B0A"$3T#`_(1-,A65" MQK"10$F-$;:TD"Z1"6(3)"9(39"9(%>`%K:/P_9AY=]>L[+>S`E6IU;OJ1[6 MAMNXD.ZA*8R6V`XF0^B(Q(@DB*2(9(CD*M$2`$O\)]2=J<`:@BP/T7K>S$B) M,+J7DL%D2`DB,2()(BDB&2*Y2K24P(^7FI+[O<",^\CE$V\X\?5)%B@;')7-ZWZ?,F,] M4$X@4!G#%I$(D1B1!)$4D0R17"5:5+`-/QX5,]:CXL3G`Q;;1K>(1)P$T$%# MB=W`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`XK%[6V^7A:O>^ M?J.6I]U^NSS2/_?/@\/[?KU\;#IM7P?E]?5XL%UNWOK.PW3_&1^[IZ?-:EWO M5M^VZ[>C<[)?ORZ/=/Z'E\W[(7C;KC[C;KO65XOY9C):KX+OY![C?;E;[W6'W=+PB=P-WHACS9#`9D*>' MN\<-16#3WMNOG^[[LV)JQJ/^X.&N2=!_-^L?A^3_>X>7W0^UWSS^8_.VIFQ3 MG6P%ONQV7ZVI>;2(.@^@MVPJ\*]][W']M/SV>OSW[H=>;YY?CE3NBB*R@4T? M_ZS7AQ5EE-Q6^/QQ?53?7PX+, M>U_6AZ/<6)?]WNK;X;C;_L\9%=Z5__IC%[>=ZCGW/F[;G9X])%TUS3/I[YC$GOB?]]3T_..;`U:DI M>[T\+A_N]KL?/;J6J!*']Z6],HLI>0OU=CEN1\!?#0"JO'4RLU[N^Y0!JNV! M1NWWAW)R?3?X3B-MY6WF:%-PBT6PL,/*NJUS('(@OR`CU@M=5)3V-MIRDHWX MN3-M+HK1 M,*M]:Q2ZU4`$$`E$`=%`3$I8H#29?SY0:\P#=638+-#-%+8`4@,10"00!40# M,2EA4='$_/FHK#&/RA&**BW?*"M?:]26#X@`(H$H(!J(20D+U,K09#4[/4ZM M,0_4D:9ZS"TMC*G;"Q=)ZZ4Y7DQC.2EY&N?>Z-2,T)JTF08B@$@@"H@&8E+" M4E*0M$QS'Q6(B3QV6%>5EK$XM'M$FG'R- M2""2B!0BC<@PQ--NU_$D.1^DW:WZ+.U>"-`UE`C+VWRDM58Q9$"B`"01*40: MD6&(AWR60BE0HGC$9A5GE:`:K00BB4@ATH@,0SP^*QB2DEZ^AGCED5YD#F7S MRB2O=FL5JPU(%(`D(H5((S(,L6R49XFDQIJ+)(]P7BDS+7+AO-*X@7DED_;S M8'5J7HDV;=H1"402D4*D$1F&>-HS(7-Z7BE1K7C$M6F5[67::8/QK+;]6`E;3="TI)F=]J+LK6*ER\@@582D4*D M$1F&>,A6?"3#^X.0G51A(7OUDNP\E8!J1`*11*00:42&(1Y?)GO<)[B'#"6JH8#&[7R[0%1[-*35.,K$*E//(EJ%\2`1 M*40:D?&(I"_YXIFPPB.I]&69<.J%#0"/TDP`JDN'AH5[1G-=9$N]B`8Q"=Y- M?*:AHE7SJ.>ZR'*IHT%P8SSJ2(FM2YJ2CD%`DT48!8TU5TD!);$CJ@.Z;<>* M0"0#BKY40+&C1F0"PI)3ML^)SUIG\7E$A4C&;U:Z17,8ZCAIXZL](A49RB`" M"98N*@.P\%9YL%E46HPQ6T9<**/K2`8W=M5=.;D:W MV::("3;-M<;F#:M%TXODLFRA[FO\-J,F1GB3!;B(1C%9SA5-=`$);T47NIT5 M_F)H^3.(@U2%;M&3#LAY*KM3Y4^@8V!U:,6BBHO-'[MW"KASL4GG&92*]LZS MI0H=48U(()*(%"*-R##$X^N0"ZL//K\\/9B*MG6&CJ$>SRC3!==.*LT;F!6R=;#>;`Z-:M$ MFS;MB`0BB4@ATH@,0RSM(ZN)/IWVQKK)03CSN4=VJ4E&6KZ;&*U"QQJ10"01 M*40:D6&(AYP)IM,3Z01*[<70/$NI$8K@4@B4H@T(L,0CR_31/;JONCM@A'*)8^R M:N<;?M$J5MOY2G(FT$HB4H@T(L,0ST:FH#ZXN%$HC1Q*SGR!J$8D$$E$"I%& M9!CB\9VEBD:HBCS*2IKM,RVB52RI\Y4D1J"51*00:42&(19RE)1-'ODF2;0*6:@1"402D4*D$1F&>,A6=B3: M]X.2.I&2ZMO*H8[)(],5%]Y%5JW@B+=+Y22[,9\'JY.3A_?DOOEIOO.(W4(E M!"*)2"'2B`Q#/.V9*/D@[:@\*B\@Z(**=Y'C[.9Z$:U"?#4B@4@B4H@T(L,0 M#_DLY5&A\O`H66`7B&I$`I%$I!!I1(8A'E^F/.QXOYU<:JQ*.TW(AJ1`*11*00:42&(1Y?AS:Z MK-QCZRF+W:&LW-FDM_`=DPS5B`0BB4@ATH@,0SP=9ZFA,:HACY)@%HAJ1`*1 M1*00:42&(1Y?)GTNOHL&@94DLCZO.6$9T!W0!B/+.JF,Y(@F$+W4_167>>045G0"*_JP^=`T9=?6B$T/Y)5PN-$-IYZ&@IZ3BT7=S50L>AUZ^Z6N@X M].(2MLR&U71&#V>PA1[!3NT#SZX6.@X]%^QJH>/0$[6N%HJ'GB]ARZR@*\N] MO)%5FU[UG]H7Z['/O*#CT/OG72UT''ISNZN%QK5[;R0[SJRD<>W6@JR%7@JF MO'6.G9+&#KVIVG&^,"O-'8H3<>._I0H)UQ4IA=4&PO=V]R:W-H965TCBSLUPNO;IYJDKRR)46LDYHZ`64\#J5F:AW"?W]Z_[JFA)M6)VQ M4M8\H<]$#GNT3//2_\A0],ZU4FP`&6G2B>)W03+F_#*?77*UN@/X(?=.^=Z$(>/BN1 M?1,UAVK#/N$.;*5\0.C7#$.PV#];?6]WX($+%[O"P';/P!$: M6V;/=URG4%&@\:(9,J6RA`3@22J!K0$584\)C4!89*9(Z&3NS>)@$@*<;+DV M]P(I*4GWVLCJKP.%-BG'95.[8X:M5TH>".PWH'7#L'O")1!?S@620.P&P0F- M*0$9#05\7$?Q9.4_@NFTQ=PZ##P[3-@A?!#ME$%MO#*"41FK@JG-M*O M513'ERW@H!U]%A`\E&HC]N@.&F`QY,46C,+8@^J^WH6X;BC11F!EKSNN+[L) MHJY2=9',81F\YL@M/5-J!,?2T>,'3NX8&GJ*3`AY# M%SSA>3[U-(7D7M^CT(T!X.U.S3$T<'0=O.`(SW)/]@TU=_(':BYD[RW7=>X" M[Q<(IC;7;2[^#8V_]/X=+EQ%Z+?_0(74L-V_#M3.U%K M4O(<.`,O!K/*76GNP\@&]AFN)6G@*K*O!?SUX#"[`^R37$IS_(#*^=V?F?4_ M````__\#`%!+`P04``8`"````"$`Y;J94]$.``"[2@``&0```'AL+W=OCN^'CZ?3Z^+Z^KAYW#ZOCU?[U^T+E3SL#\_K$_WU M\/GZ^'K8KN];I^>GZ]'-S>SZ>;U[&>H(B\-;8NP?'G:;;;C??'W>OIQTD,/V M:7VB]A\?=Z]'CO:\>4NXY_7AR]?77S;[YU<*\6GWM#O]V08=#IXWB^SSR_ZP M_O1$S_U',%EO.';[%PC_O-L<]L?]P^F*PEWKAN(SSZ_GUQ3IP[O['3V!DGUP MV#Z\'WX,%LUD,KS^\*X5Z+^[[;>C]>?!\7'_+3GL[LO=RY;4IGY2/?!IO_^B M3+-[A[SX\GZNXI/9%ZL,7]G^'VN"%% M*GP_',^NIK&LI\?8JF-S,E$QGZJ-YUM9'/XU;<'LU MNIL&TQ]YSHTG_63/\=7==#J9W?W@&0,:1;I3U7`RO?HV>8)N/-`?+JV6AT%@ MC8.WB1OP0%!_,-6^2=Z`!X+Z@W$2BHZ?(FE:[UW&FG8K@^K3^\.^R_ M#6A](ZV.KVNU6@8+%8TGH1X7W;3\WJRDZ:BB?%1AW@]I@-&$.])2\ON'T63T M[OIWFOX;8[-$F\"U6+&%FNLJ;.B#R`>Q#Q(?I#[(?)#[H/!!Z8/*![4/&@M< MD]:=X#3`_@[!51@E.$NU9&#U@*AUX@SGL2OG4MNH5:<;\U/79-69=)(#B8#$0!(@*9`, M2`ZD`%("J8#40!J;./+32O9WR*_"T()$G=Q).YI,7'&7QNB<_IU)IS^0"$@, M)`&2`LF`Y$`*("60"D@-I+&)HS\MX([^_5LI7K25=2LSR[/49.P*[X_JSHC= M0B`1D!A(`B0%D@')@11`2B`5D!I(8Q-'5=IP7:"JLG95U8149<%60$(@$9`8 M2`(D!9(!R8$40$H@%9`:2&,31T+:&5P@H;)V)=1D3`N/M2+,W!5AU1FQSB&0 M"$@,)`&2`LF`Y$`*("60"D@-I+&)HZK*A.W-V_GIKJQ=5349MSE>N^%:`0F! M1$!B(`F0%$@&)`=2`"F!5$!J((U-'`DI17$D5/M?VH736G#A#E@%,@5U*52UP@J4X]'$E- M-D*370;N],8?N)V5#%Q`40`H1I0@2A%EB')$!:(2486H1M0XR%59I1L7J*RS M$T=E.V'1J5D`*$04(8H1)8A21!FB'%&!J$14(:H1-0YR)54)Q062ZOS#D=2D M)/I3HOJ\L`H`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`U.E[^\ M-F82AAN4LX]45C`2Q4M&8E5AK)JMQ+%AU#HZ^](1+7:7](LR]W9,&JG99/6+ MMPU9M?70IPE)^T-&LNQ$!LUTO\QNYCAO-=+ MACXY(VE0(6&XJTJTJAA)_34Z-FS5AG<[@=:N2SI!F7N=8)`[.;PMR6K46?'3 MA`8YDT-;J9=:UZ'!U-,O1L<$PZ=L=396AHXY.\I0+QC)N"X9B56%L6JV$L>& M4<^$\'/?GWMC8TH\TLB;)]Z[>"56TD7&40Z!(K:BQ>Y<%QE'&<^)<9S>=6MA M^J98&5O)$,\92?B"D;SV2D9B51ED-:)F*W%L&/5,%Y70VN^2G^LBG18[KQB# MW%GDC?S5J+.2+M*(FLPH,E;T0RU`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`2C)2RFT3*&)T]` M00QRSC9[^D8[?O=,/I0PTC?:ASXL,8K9:O;]C#]A&SE&21G)T4=FD&D0Y.4Y MNTB4@I&TIV1TICT5V[25NQ/#SPM_:E6?8+K(2(Y/5@;1Y&`Q0[2*V$H.,V-& M9PXS$XR4LIL,X8R1GI\]DIL'D587["+M*1GI]O0>^E1LTS,-_"31E_QM1XAT MY.2G-`:U@T/WLO[M$?J?K#]O#Y^WJ^W3TW&PV7]5OQFB_=#58?UK*Y;!=*$N ME5(70+10YQ4]]8S'5-(.>M]GOJ!_&=/C M$=Q0+:W2OD=`OX6#_E%"GP_5KQ<1\*'ZZ3YXG\^$2EIY/1_Z91\?>Y]%5=\7 MB2KOM5>/WF/_<;+XJ'^9B%?QDEK4UZ`E]6)O)U(?]G8A]6!O!U+_]7??W6)% MFT44B?;$"[7CQ1+:X2ZRWA+:KR[4;A1]EN,YU=/7Z;37HWKZ2FCG1O7TE=`^ MC.KI*UF.9U1/GS(1E:AL%-M&V2?5TU="N235TU=".1[5TZ>A>S$+=>L%2^B6RT+=8<&2Y7A* MK>X;:72V06WK*UF.:=#2B0]&HPMVU.J^"4,WZ*C5?25T'XY:W5="M]NHU7TE M=)^,ZNF;@'0[C.KI*Z&[7E1/7PG=W*)Z^DKH/NPBTJ?S?B]0B;KABAK0C=:% MNJ^*)70_=:$NI&()W0BEY^E;`.G*)SU/7PE=X*3GZ2NAZYCT/&W)===L^M5! MK^O/VVI]^+Q[.0Z>M@_T`E$7&X:#@_[E0_HO)_/]Z]/^1+\TB#;,]$M1Z)=$ M;>G",/V"G^'@8;\_\5_H0:Z[7SOUX?\```#__P,`4$L#!!0`!@`(````(0!5 MV@X#*@,``"0*```9````>&PO=V]R:W-H965T'3#!6L#(=C:[?]\9F["0BT)>DC`Y M/L=GQN-A>?]6Y-XK5UK(,B*!/R`>+V.9B'(;D3^_G^YFQ-.&E0G+95JF`&'M66ZDIQEMA% M14[#P6!""R9*XA@6J@^'3%,1\T<9[PI>&D>B>,X,[%]GHM('MB+N0U$6\>-Z64K%-#K[?@A&+#]SVX82^$+&26J;&!SKJ-GKJ M>4[G%)A6RT2``TR[IW@:D76P>`@FA*Z6-D%_!=_KUF]/9W+_58GDNR@Y9!OJ MA!782/F"T.<$0["8GJQ^LA7XJ;R$IVR7FU]R_XV+;6:@W&-PA,86R?LCUS%D M%&C\<(Q,LS<3">`-[;<&V>!'(2+]YI M(XM_#A747(XEK%G@NV893OSQ=#`,KI-0MR-K\)$9MEHJN??@U("DKAB>P6`! MQ.<=@17$KA$GF8=1LII/?R2U2".Y*U9&A[;_V\8!3UK9@ M6RZ<87]=.:2XL*M11V!E*[<7BH97=N]^0'!7JH[82Z"3IODMO`CN\M:1=NG# MV>1\10*XW_I[L.BNV"%TZB+`[FZE!ZLRG?8HBEUXI%+?%-VR3"]XNNFVP#8Z M2N`A=,83-O21IW#2QY.["8"Y:9R@#G7K-+O@"=NY)7SE[D7T40;KT!E/V,$M M:ML](TCX%0U<=J11A[I5FE]P=--E`!/[1,V%1A^W@9O);F057&WY%Y[GVHOE M#N=M"$.HB3;O`FM;D>/X:+%V[PBT^0=F=,6V_`=36U%J+^H_D#(!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($ M`2B@``$````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````G)%!3\,@&(;O M)OZ'AGL+;--,TK)$S4XN,7%FQAO"MXU8*`&TV[^7=5V=T9-'\KX\/-]'.=N9 M.OL$'W1C*T0+@C*PLE':;BKTO)SG4Y2%**P2=6.A0GL(:,8O+TKIF&P\//K& M@8\:0I9(-C#I*K2-T3&,@]R"$:%(#9O"=>.-B.GH-]@)^2XV@$>$7&,#42@1 M!3X`IVSW=O MOLY"V);X=U8JV=DQZ4%$4%EZCQWM3LEJ?'>_G",^(G22DVE.;Y8CPB:479'7 M$I]:_7T^`$TO\&_B"<`[[Y]_SK\```#__P,`4$L#!!0`!@`(````(0`:IO") MWP(``(4)```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!```````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````)Q6VT[C,!!]7VG_HVYGSLS8CJ[?EJ*S`FVXDOW@ M[+0;=$`RE7,Y[P=/V>W)SZ!C+)4Y%4I"/UB#":[C[]^BJ58%:,O!=-"%-/U@ M86UQ%8:&+6!)S2F*)4IF2B^IQ:V>AVHVXPR&BI5+D#8\[W9_A/!F0>:0GQ0[ MAT'M\6IECW6:*^;PF>=L72#@.$J*0G!&+689/W*FE5$SVQF],1!1V!1&B"X% M5FINUW$W"IO;*&54P``=QS,J#$3A_B"Z`^I(FU*N31RM[-4*F%6Z8_@[TG8> M=%ZH`0>G'ZRHYE1:A.74ZDVU%H6Q.OZC]*M9`%@3A:A0'U;+IFYSS2_BWF6E M@:M#3>>A1H*"0XP9MP+,9#:EVGH@]RZ;F"L4->(:T+:*))$Y&4F+?)%[65>; MJR;R70Z#R7@X&J>C(<%5.GFX'R89;FZ2AV0\&!UAD?87'AM)GI.)7^O^IU,<$ZKE2$XQ^2&>DU^*>Q>PI1DH*57(^5SR7&` ML75)PI@JL>AH,E4X61R'85=GU]9UD]SB-)!G*DJ_>./%D"E=TQQUH42.MQP9`F;`\8I;>W4':KGD MMG;JR,)P+A;JXT7GM4C+%P-_2X1!1BL'QJ_5RIV_P=KY]C?8GG"2.4;]:-IY M_P2-G\6V,.U=Z`]3MR'2[MH0JV4I%X9D^$J4%*_J76?M>ZR=)O],M=OX9ZI! M[0:6%\Y'->+/M%)FO:7NU_#;M8^('],F<;-!YDVTW.2:,/YT/0[:C MS'5&$]K!>_??"_?`Y:MY*C(UQ,MB^X0?'D;I@FK(\7';RO<'T1V^WEHX)X,% MQ4LAW^I\%+@/QW/]JXK/+DZ[O2[^)1IG4;C_/\7_````__\#`%!+`0(M`!0` M!@`(````(0`=?[]DX`$``+H6```3``````````````````````!;0V]N=&5N M=%]4>7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````` M````````````&00``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`.C!R>?? M`0``JQ4``!H`````````````````/P<``'AL+U]R96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'.[[2%Z!```-Q(``!D````````` M````````UQ@``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`)12,"BW`@``"P<``!D`````````````````#B0``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`/,^VL6Y`P``[@P``!D`````````````````@BX``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A`#GR\[\S.P``<;L``!0`````````````````83X``'AL M+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`"_YEC_^"P``O&\` M``T`````````````````QGD``'AL+W-T>6QE&PO=&AE;64O=&AE M;64Q+GAM;%!+`0(M`!0`!@`(````(0"09T*TKP(``-T&```9```````````` M`````+2,``!X;"]W;W)K&UL4$L!`BT`%``&``@` M```A`"8=%JML`P``[PH``!D`````````````````FH\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`%.0UI9%`@``U`0``!@`````````````````2K8``'AL+W=O&UL4$L!`BT`%``&``@````A`$Y;.MJ% M$@``;&8``!D`````````````````N=(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+ST'\SS!```!Q(``!D````` M````````````)_<``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`-#I5"T#`P``$0D``!D`````````````````!0\! M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`)WJ/Y`R`0``0`(``!$`````````````````J"0!`&1O8U!R;W!S+V-O M&UL4$L!`BT`%``&``@````A`!JF\(G?`@``A0D``!`````````````` M````$2

XML 13 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Deficiency (Details 1) (USD $)
6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 0.58 $ 0.21

Outstanding Number of Warrants 8,903,159 2,812,498

Weighted Average Remaining Life In Years 4 years 8 months 12 days

Exercisable Number of Warrants 6,859,324

Exercise Price One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 0.001

Outstanding Number of Warrants 2,043,835

Weighted Average Remaining Life In Years 0 years

Exercisable Number of Warrants 0

Exercise Pirce Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 0.750

Outstanding Number of Warrants 6,859,324

Weighted Average Remaining Life In Years 4 years 8 months 12 days

Exercisable Number of Warrants 6,859,324

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are exercisable as of the balance sheet date.

+ References

No definition available.

+ Details

Name: clcs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber

Namespace Prefix: clcs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Significant Accounting Policies (Details)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Schedule Of Significant Accounting Policies [Line Items]

Warrants 6,859,324 0

Convertible notes 0 2,297,487

Total 6,859,324 2,297,487

X

- Details

Name: clcs_ScheduleOfSignificantAccountingPoliciesLineItems

Namespace Prefix: clcs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 23

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1757-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Treasury Stock Method

-URI http://asc.fasb.org/extlink&oid=6527216

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Call Option

-URI http://asc.fasb.org/extlink&oid=6506649

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of outstanding written put options using the reverse treasury stock method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e2366-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToWrittenPutOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization, Operations and Basis of Presentation
6 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

Note 1 – Organization, Operations and Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial position of Cell Source, Inc. (“CSI” or the “Company”), formerly known as Ticket To See, Inc. ("TTSI"), as of June 30, 2014 and the condensed consolidated results of its operations and cash flows for the three and six months ended June 30, 2014 and 2013. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the operating results for the full year. It is recommended that these condensed consolidated financial statements be read in conjunction with the financial statements and related disclosures of Cell Source Limited for the year ended December 31, 2013 which were included in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on July 1, 2014.

Organization and Operations

The Company is a Nevada corporation formed on June 6, 2012 under the name TTSI. Prior to the Share Exchange (as defined below), the Company did not have any significant assets or operations.

The Company is the parent company of Cell Source Limited, which was founded in Israel in 2011 in order to commercialize a suite of inventions relating to certain cancer treatments. Cell Source Limited’s target indications include treatment of lymphoma, multiple myeloma and BCLL (which is a common form of leukemia), facilitating transplantation acceptance (initially bone marrow transplantation and subsequently organ transplantation) and ultimately treating a variety of non-malignant diseases. Cell Source Limited’s lead prospective product is its patented Veto-Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Cell Source Limited’s Veto-Cell immune system management technology is based on technologies patented, owned, and licensed to Cell Source Limited by Yeda Research and Development Company Limited, an Israeli corporation ("Yeda").

Share Exchange and Reorganization

On May 7, 2014, the Board of Directors and the majority stockholder of TTSI adopted resolutions approving an amendment (the "Amendment") of the Company's Articles of Incorporation to increase the number of authorized shares. Prior to the Amendment, the authorized shares of the Company consisted of 75,000,000 shares of common stock, $0.001 par value. The Amendment was filed with the Secretary of State of the State of Nevada on May 20, 2014, which increased the number of shares of common stock that the Company is authorized to issue from 75,000,000 shares to 200,000,000 shares. The Company also authorized 10,000,000 shares of preferred stock, par value $0.001, for designation in one or more series, with such designations, preferences and relative, participating, optional, or other special rights and qualifications, limitations, or restrictions thereof, as may, from time to time, be adopted by the Company's Board of Directors.

On June 23, 2014, the majority stockholder of TTSI adopted resolutions approving an amendment of the Company's Articles of Incorporation to change the name of the corporation from Ticket to See, Inc. to Cell Source, Inc. The Amendment was filed with the Secretary of State of the State of Nevada on June 23, 2014, which changed the name of the corporation from Ticket to See, Inc. to Cell Source, Inc., effective June 26, 2014. In connection with the name change, the trading symbol of the Company’s common stock was changed from TTSE to CLCS.

On June 27, 2014, CSI issued five-year warrants to purchase an aggregate of 2,000,000 shares of common stock at a price of $0.75 per share to consultants in exchange for consulting services previously provided to the Company.

On June 30, 2014 (the “Closing Date”), CSI entered into and closed a Share Exchange Agreement (the “Share Exchange Agreement”) with Cell Source Limited and 100% of the shareholders of Cell Source Limited (the “CSL Shareholders”) whereby Cell Source Limited became the wholly-owned subsidiary of CSI (the "Share Exchange"), and whereby the CSL Shareholders, transferred to the Company all 18,245,923 outstanding shares of Cell Source Limited’s ordinary shares (“CSL Ordinary Shares”) in exchange for an aggregate of 18,245,923 newly issued shares of the Company's Common Stock, par value $0.001 per share (the “Company Common Stock” or the "Common Stock"). The aggregate of 18,245,923 shares of newly issued Company Common Stock represents 78.5% of the 23,245,923 outstanding shares of Company Common Stock following the Closing Date. In addition, outstanding five (5) year warrants to acquire 4,859,324 CSL Ordinary Shares at an exercise price of $0.75 per share (the "CSL Warrants") were exchanged for newly issued warrants to purchase shares of Company Common Stock at $0.75 per share (the “Company Warrants”), which Company Warrants contain substantially similar terms as the CSL Warrants. In addition, outstanding seven-year warrants to acquire 2,043,835 CSL Ordinary Shares at $0.001 per share were exchanged for warrants to purchase shares of Company Common Stock at $0.001 per share (the “Researcher Company Warrants”), which Researcher Company Warrants contain substantially similar terms as their warrants to acquire CSL Ordinary Shares. The aggregate of 6,903,159 Company Warrants and Researcher Company Warrants represents 77.5% of the outstanding warrants to purchase Common Stock of the Company following the Closing Date.

For accounting purposes, the Share Exchange will be treated as a recapitalization of the Company, the accounting acquirer, because the Company shareholders own the majority of CSI’s outstanding common stock following the transaction and exercise significant influence over the operating and financial policies of the consolidated entity. CSI was a non-operating company prior to the share exchange. Pursuant to Securities and Exchange Commission rules, the merger or acquisition of a private operating company into a non-operating public company with nominal net assets is considered a capital transaction in substance, rather than a business combination.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y M,S0R-3(P-3@B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-130\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-U;'1I;F=?06=R965M96YT#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K:&]L9&5R#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I93$\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I7 M;W)K#I%>&-E;%=O M#I%>&-E;%=OF%T:6]N7T]P97)A=&EO M;G-?86YD7T)A,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D=O:6YG7T-O;F-E#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I930\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?=F%L=65?1&5T86EL#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D-O;G-U;'1I;F=?06=R965M96YT#I7;W)K5]$971A:6P\+W@Z3F%M93X-"B`@("`\>#I7;W)K5]$971A:6PQ/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;'-?5&5X M=#PO>#I.86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X- M"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7V4S,C0Y9#AF7V(Y-&5?-#@U9E]B-C@R M7V$R,CDS-#(U,C`U.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E M,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@O5V]R:W-H965T M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA2!296=I2!#96YT3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)S`P,#$U-CDS-#`\2!&:6QE3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)U-M86QL97(@4F5P;W)T:6YG M($-O;7!A;GD\'0^)T-,0U,\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT95\T M.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E M;G-E2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO3H\+W-T3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P M-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT M95\T.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%RF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT95\T M.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E M'!E;G-E M*2!);F-O;64\+W-T'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2!P=6)L:6,@ M8V]M<&%N>2!S=&]C:VAO;&1E'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@86YD(&%C8W)U960@97AP M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6EN9R!U;F%U9&ET960@8V]N M9&5N2!F;W(@82!F86ER M('!R97-E;G1A=&EO;B!O9B!T:&4@8V]N9&5N28C.#(R,3LI+"!F M;W)M97)L>2!K;F]W;B!A"!M;VYT:',@96YD960@2G5N92`S M,"P@,C`Q-"!A;F0@,C`Q,RX@5&AE(')E28C.#(Q-SMS($-U#L@1D].5#H@,3!P="!4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!D:60@;F]T(&AA=F4@86YY('-I9VYI9FEC86YT(&%S6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E2!I6UP:&]M82P@;75L=&EP;&4@;7EE;&]M82!A;F0@0D-,3"`H=VAI8V@@ M:7,@82!C;VUM;VX@9F]R;2!O9B!L975K96UI82DL(&9A8VEL:71A=&EN9R!T M2P@=VAI8V@@:7,@86X@:6UM=6YE('1O;&5R86YC92!B:6]T M96-H;F]L;V=Y('1H870@96YA8FQE2!,:6UI=&5D+"!A M;B!)6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&-H86YG92!A;F0@4F5O#L@1D].5#H@,3!P="!4:6UE2`W+"`R,#$T+"!T:&4@0F]AF5D('-H87)E M2!C;VYS:7-T960@;V8@/&9O;G0@2!I MF5D('1O(&ES6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!O9B!3=&%T92!O M9B!T:&4@4W1A=&4@;V8@3F5V861A(&]N($IU;F4@,C,L(#(P,30L('=H:6-H M(&-H86YG960@=&AE(&YA;64@;V8@=&AE(&-O28C M.#(Q-SMS(&-O;6UO;B!S=&]C:R!W87,@8VAA;F=E9"!F#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!#96QL M(%-O=7)C92!,:6UI=&5D(&)E8V%M92!T:&4@=VAO;&QY+6]W;F5D('-U8G-I M9&EA2!A;&P@/&9O;G0@2!I2!#;VUM;VX@4W1O8VL@&-H86YG960@9F]R(&YE=VQY(&ES2!#;VUM M;VX@4W1O8VL@870@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!#;VUM;VX@4W1O8VL@870@)#QF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!787)R86YT2!3:&%R97,N(%1H92!A9V=R96=A=&4@;V8@/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E3Y&;W(@86-C;W5N=&EN M9R!P=7)P;W-E&5R8VES92!S:6=N:69I8V%N="!I;F9L=65N8V4@;W9E&-H86YG92!#;VUM:7-S:6]N(')U;&5S+"!T:&4@ M;65R9V5R(&]R(&%C<75I2!I;G1O(&$@;F]N+6]P97)A=&EN9R!P=6)L:6,@8V]M<&%N>2!W M:71H(&YO;6EN86P@;F5T(&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E M,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT95\T.#5F7V(V.#)? M83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2`D,2PV M.#`L,#`P(&%N9"`D-CDW+#`P,"P@2`D,BPQ-3`L,#`P M(&%N9"`D,S0P+#`P,"!F;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S M,"P@,C`Q-"!A;F0@,C`Q,RP@2`D-2PW-#2!T;R!C;VYT:6YU92!A#L@1D].5#H@,3!P="!4:6UE2!O9B!T:&4@0V]M<&%N>2!T;R!C M;VYT:6YU92!I=',@;W!E2!O M<&5R871I;VYS(&%R92!S=69F:6-I96YT('1O(&9U;F0@=V]R:VEN9R!C87!I M=&%L(')E<75I&ES M=&5N8V4N($EF('1H92!#;VUP86YY('=EF4@:71S(&%S6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!O2X@0F%S960@;VX@=&AE($-O;7!A M;GDF(S@R,3<[2!E>'!E8W1S('1O(&)E(&%B;&4@=&\@9G5N9"!I=',@;W!E2!N;W0@ M8F4@2!F:6YA M;F-I;F<@=&\@9G5N9"!I=',@;W!E3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R M-3(P-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9? M8CDT95\T.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@8F]L9"`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@ M,3!P="!4:6UE28C.#(Q-SMS(&9I M;F%N8VEA;"!S=&%T96UE;G1S(&%R92!C;VYS;VQI9&%T960@86YD(&EN8VQU M9&4@=&AE(&%C8V]U;G1S(&]F($-322!A;F0@0V5L;"!3;W5R8V4@3&EM:71E M9"X@06QL('-I9VYI9FEC86YT(&EN=&5R8V]M<&%N>2!T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'!E;G-E#L@1D].5#H@,3!P="!4:6UE&5S+"!C;VYT:6YG96YC:65S+"!A2!M871E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!T:&4@=V5I9VAT960@879E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG&5R8VES92!P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)TU!4D=)3CH@,&EN.R!724142#H@-C`E.R!"3U)$15(M0T],3$%04T4Z(&-O M;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z M('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M M0T],3U(Z('1R86YS<&%R96YT)SXR,#$T/"]F;VYT/CPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R M96YT)SXR,#$S/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^/&9O;G0@6QE/3-$)T)! M0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^/&9O;G0@6QE/3-$)T)!0TM'4D]5 M3D0M0T],3U(Z('1R86YS<&%R96YT)SX\9F]N="!S='EL93TS1"="04-+1U)/ M54Y$+4-/3$]2.B!T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,BPR.36QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@1D].5#H@,3!P="!4:6UE65E2!R92UM96%S M=7)E9"!O;B!F:6YA;F-I86P@&-H86YG92!F;W(@=&AE(&%W87)D+"!U28C.#(Q-SMS M(&-O;6UO;B!S=&]C:R!H:7-T;W)I8V%L;'D@=V%S(&YO="!A8W1I=F5L>2!T M28C.#(Q-SMS(')E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE2!C:&%N9V4@:6X@9F%I#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!A9F9E8W0@=&AE(&9A:7(@ M=F%L=64@97-T:6UA=&5S+B!4:&4@97AP96-T960@=F]L871I;&ET>2!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@ M,3!P="!4:6UE2P@*#(I(&QA8F5L('1H92!F:6YA;F-I86P@2P@*#,I(&1I2!I65A2!E;&5C=&5D('1O(&%D;W!T('1H:7,@05-5(&5F9F5C=&EV92!W:71H(&ET M6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6UE;G1S(%=H96X@=&AE(%1E2!A9&]P=&EO;B!I2!A<'!L>2!T:&4@86UE;F1M96YT2!D;V5S M(&YO="!A;G1I8VEP871E('1H870@=&AE(&%D;W!T:6]N(&]F('1H:7,@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y4:&4@0V]M<&%N>2!H87,@:6UP;&5M96YT M960@86QL(&YE=R!A8V-O=6YT:6YG('-T86YD87)D2!I;7!A8W0@:71S(&9I;F%N8VEA;"!S=&%T96UE;G1S M(&%N9"!D;V5S(&YO="!B96QI979E('1H870@=&AE2!O=&AE M3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69? M8C8X,E]A,C(Y,S0R-3(P-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO93,R-#ED.&9?8CDT95\T.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@ M8VAA'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF5D(&EN(&$@8W5R&-H86YG92!B M971W965N(&)U>65R(&%N9"!S96QL97(N(%1H92!U#L@1D].5#H@,3!P="!4 M:6UE3H\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!T;R!A8V-E#L@1D].5#H@,3!P="!4:6UE M2!Q=6]T960@:6YT97)V86QS+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2X\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2X@07,@82!R97-U;'0L('1H92!U;G)E86QI M>F5D(&=A:6YS(&%N9"!L;W-S97,@9F]R(&%S6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR M+#0W-BPX,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)#PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR,S$L,C`P/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4 M:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO M9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXR,S$L,C`P/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D M/B`\=&0@"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D M/B`\=&0@#L@1D].5#H@,3!P="!4:6UE28C.#(Q-SMS($QE M=F5L(#,@;&EA8FEL:71I97,@F5D M(&-O;6UO;B!S=&]C:R!T;R!S971T;&4@#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"8C,38P.TUO;G1H6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXQ+C8R)2`M(#$N-C4E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`R)2`M(#`N,#@E/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXP+C`P("T@,"XR-#PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXV-24\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-C0E("T@,38X M)3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!D:79I9&5N M9',\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`P)3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF5R;RUC;W5P;VX@ M8F]N9',@=VET:"!A(')E;6%I;FEN9R!T97)M(&-O;G-I#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`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`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E&EM871E(&9A:7(@=F%L=64@9'5E('1O('1H M96ER('-H;W)T('1E3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A M,C(Y,S0R-3(P-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R M-#ED.&9?8CDT95\T.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA6%B;&4@86YD($%C8W)U960@17AP96YS97,\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@ M1&ES8VQO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B!B M;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6%B;&4@86YD($%C8W)U960@17AP96YS M97,\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6%B;&4@86YD(&%C8W)U960@97AP96YS97,@ M8V]N#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^ M(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#8P)3L@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,#,L-S`U/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S`L-C(V/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!4'0^)SQS<&%N/CPO2!46QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE3PO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEFUA;FX@26YS=&ET=71E(&]F(%-C:65N8V4@9F]R(&%N(&EN=F5N M=&EO;B!C;VUP'1E;F1E9"!T;R!397!T96UB97(@,2P@,C`Q-#PO9F]N=#XN(%-E92!. M;W1E(#D@)B,Q-3`[(%-U8G-E<75E;G0@179E;G1S(&9O'1E;G-I;VX@;V8@=&AE(&5X M<&ER871I;VX@9&%T92X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!A;B!E>&-L M=7-I=F4@=V]R;&1W:61E(&QI8V5N2!9961A.B`H,2D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A2!A9G1E'!I'1E;F1E9"DL("@T*2!A(')O>6%L='D@;V8@/&9O;G0@2!S=6(@;&EC M96YS965S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E2!F86EL2!O9B!T:&4@;6EL97-T;VYE2!T:&4@9&%T97,@2!T97)M:6YA=&4@=&AE(&%G6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`D/&9O;G0@2`D/&9O;G0@2`D/&9O;G0@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!.;W1E($1I M'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@8F]L M9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D]. M5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M"!M;VYT:',@96YD960@2G5N M92`S,"P@,C`Q-"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&EN=F5S M=&UE;G0@86=R965M96YT('=I=&@@82!G&-H86YG92!F;W(@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG65A M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE M2!R96-O9VYI>F5D('1H M92`D/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E&5R8VES93PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R M8VES960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^."PY,#,L,34Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^.#$U+#0Y,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!D;W5B;&4[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXV+#@U.2PS,C0\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E&5R8VES93PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXP+C"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@ M/&1I=CXT+C<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R M)3X@/&1I=CXV+#@U.2PS,C0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXT+C<\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^-BPX-3DL,S(T/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!R97-U;'0@:6X@2!L96=A;"!P M#L@1D].5#H@,3!P="!4:6UE2!C86X@8F4@97-T:6UA=&5D+"!T:&5N('1H92!E2!P;W-S:6)L92P@;W(@:7,@<')O8F%B;&4@ M8G5T(&-A;FYO="!B92!E#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;6]U;G1S(&9O M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT95\T M.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO M'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@ M8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@ M1D].5#H@,3!P="!4:6UE2!D:60@;F]T(&ED96YT:69Y(&%N>2!R96-O9VYI>F5D(&]R(&YO;BUR M96-O9VYI>F5D('-U8G-E<75E;G0@979E;G1S('1H870@=V]U;&0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE2!A('-T;V-K+6)A M2`F(S$U,#L@4W1O8VLM0F%S960@0V]M M<&5N#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE&-L=7-I=F4@;W!T:6]N(&%G M2!W:&EC:"!E>'1E;F1S('1H92!E=F%L=6%T M:6]N('!E2!H87,@8F5E;B!I;F9O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT95\T.#5F7V(V M.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!497AT($)L;V-K73PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!A<'!A2!R979I97=E9"!A;F0@=&AE(&5F9F5C=',@;V8@86YY(&UA=&5R M:6%L(')E=FES:6]N2!A6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQD:78@#L@1D].5#H@,3!P="!4:6UE M#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E;G-E9"!A2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E#L@1D]. M5#H@,3!P="!4:6UE2!D M:79I9&EN9R!N970@;&]S2!P;W1E;G1I86QL>2!D M:6QU=&EV92!S96-U2!S=&]C M:R8C.#(R,3L@86YD+V]R("8C.#(R,#MI9B!C;VYV97)T960F(S@R,C$[(&UE M=&AO9',@87,@87!P;&EC86)L92X@1F]R('1H92!T:')E92!A;F0@#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5. M5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ M(#!I;CL@5TE$5$@Z(#8P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@ M3U9%4D9,3U6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M0T], M3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\ M=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT M)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z M('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z M('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('1R86YS M<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV M+#@U.2PS,C0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR M+#(Y-RPT.#<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-BPX-3DL,S(T/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@2!;4&]L:6-Y(%1E>'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@ M,3!P="!4:6UE65E2!R92UM96%S=7)E9"!O;B!F:6YA;F-I86P@&-H86YG92!F;W(@=&AE(&%W M87)D+"!U28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!H:7-T;W)I8V%L;'D@=V%S M(&YO="!A8W1I=F5L>2!T28C.#(Q-SMS(')E6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E&-E<'1I;VX@9F]R('1R96%T;65N="!A&-E M<'1I;VX@87,@;W5T;&EN960@=6YD97(@05-#(#@Q-2X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E;G-E(&9O6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'!E8W1E9"!V;VQA M=&EL:71Y(&ES(&5S=&EM871E9"!B87-E9"!O;B!T:&4@;6]S="!R96-E;G0@ M:&ES=&]R:6-A;"!P97)I;V0@;V8@=&EM92!E<75A;"!T;R!T:&4@=V5I9VAT M960@879E#L@1D].5#H@,3!P="!4:6UE2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!497AT($)L;V-K M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L M92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#8P)3L@0D]21$52+4-/ M3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$ M)T)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)!0TM' M4D]53D0M0T],3U(Z('1R86YS<&%R96YT)SX@)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXV+#@U.2PS,C0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXR+#(Y-RPT.#<\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M-BPX-3DL,S(T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF5S('1H92!V86QU871I;VX@;V8@ M=&AE($-O;7!A;GDF(S@R,3<[2!T:&4@86)O=F4@ M9F%I#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@ M,3`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`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#0W M-BPX,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#0W-BPX,#`\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE M"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV M/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE"!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M)B,Q-C`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXR,S$L,C`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXR,S$L,C`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@.#`E.R!" M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^ M(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI M9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+C0V)2`M(#$N-S,E/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!T97)M("AY96%R M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT+C,S("T@-2XP,#PO M9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXV-24@+2`Y.24\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`P M)3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`P)3PO M9&EV/B`\+W1D/B`\=&0@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q M-C`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`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV M/B`\+W1D/B`\=&0@3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y M,S0R-3(P-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED M.&9?8CDT95\T.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6%B;&4@86YD($%C8W)U960@17AP96YS97,@*%1A8FQE M6%B;&4@86YD($%C M8W)U960@3&EA8FEL:71I97,@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXT,2PR.30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXQ,BPY-#0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,3$V+#8T.3PO9&EV/B`\+W1D/B`\=&0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT95\T.#5F M7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2`H5&%B;&5S*3QB'0^)SQS<&%N/CPO51E>'1";&]C:R!;5&%B;&4@5&5X="!" M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!O9B!T:&4@=V%R2!D=7)I;F<@=&AE('-I>"!M;VYT M:',@96YD960@2G5N92`S,"P@,C`Q-"!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E&5R8VES93PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXP+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES960\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^."PY,#,L,34Y/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.#$U+#0Y,#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXV+#@U.2PS,C0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXP+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)#PO9&EV/B`\+W1D/B`\=&0@'1";&]C:R!;5&%B;&4@5&5X="!" M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!7 M24142#H@-34E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/ M5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A M;&EG;CTS1&QE9G0^(#QT6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M&5R8VES86)L93PO9&EV/B`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXV+#@U M.2PS,C0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D M;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,S(T M.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT95\T.#5F7V(V.#)?83(R M.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAAF%T:6]N+"!/<&5R M871I;VYS(&%N9"!"87-I2`P-RP@,C`Q-#QB2!787)R M86YT&-H86YG M92!!9W)E96UE;G0@6TUE;6)E'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPOF5D/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&-EF5D/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO MF5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)S4@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!-971H;V0@26YV97-T;65N="P@3W=N97)S:&EP(%!E'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@("`\=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'!E M8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO&EM=6T@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)S4@>65A'0^)S8@;6]N=&AS/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG-"!Y96%R'0^)S`@>65A'0^)S`@>65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,S(T.60X9E]B M.31E7S0X-69?8C8X,E]A,C(Y,S0R-3(P-3@-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO93,R-#ED.&9?8CDT95\T.#5F7V(V.#)?83(R.3,T,C4R M,#4X+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO7)O;&P\+W1D/@T*("`@("`@("`\=&0@ M8VQA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%L='E%9F9E M8W1I=F5097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!O'1E;F1E9"!T;R!397!T96UB97(@,2P@,C`Q-#QS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]E,S(T.60X9E]B.31E7S0X-69?8C8X,E]A,C(Y M,S0R-3(P-3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93,R-#ED M.&9?8CDT95\T.#5F7V(V.#)?83(R.3,T,C4R,#4X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6UE;G0@07=A&5R8VES M960\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES92!0&5R8VES92!0&5R8VES86)L92P@ M2G5N92`S,"P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S4@>65A7,\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M2`H1&5T86EL&5R8VES92!0 M'0^)S0@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!0'0^)SQS M<&%N/CPO'0^)S`@>65A&5R8VES M86)L92!.=6UB97(@;V8@5V%R&5R8VES92!0:7)C92!4=V\@6TUE;6)E2!3:&%R92UB87-E M9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO7,\&5R8VES86)L92!. M=6UB97(@;V8@5V%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)T5A8V@@=6YI="!W87,@2!V97-T960@9FEV92UY M96%R('=A&5R8VES92!P'0^ M)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!0'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C M:&5M87,M;6EC'1087)T7V4S,C0Y9#AF7V(Y =-&5?-#@U9E]B-C@R7V$R,CDS-#(U,C`U."TM#0H` ` end XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair value (Details 2) (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Balance - January 1, $ 231,200 $ 38,300

Change in fair value of derivative liability 16,400 (64,500)

Issuance of derivative liability 2,229,200 434,200

Balance - June 30, $ 2,476,800 $ 408,000

X

- Definition

Represents the value of Issuance of derivative liability.

+ References

No definition available.

+ Details

Name: clcs_IssuanceOfDerivativeLiability

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those assets still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value (Details 1)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Fair Value Assumptions, Expected Volatility Rate 65.00%

Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00% 0.00% 0.00%

Maximum [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Fair Value Assumptions, Risk Free Interest Rate 1.65% 0.08% 1.73% 0.08%

Fair Value Assumptions, Expected Term 5 years 2 months 26 days 5 years 6 months

Fair Value Assumptions, Expected Volatility Rate 166.00% 168.00% 99.00%

Minimum [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Fair Value Assumptions, Risk Free Interest Rate 1.62% 0.05% 1.46% 0.02%

Fair Value Assumptions, Expected Term 4 years 3 months 29 days 0 years 4 years 3 months 29 days 0 years

Fair Value Assumptions, Expected Volatility Rate 164.00% 164.00% 65.00%

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accounts Payable and Accrued Expenses (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Accounts Payable And Accrued Expenses [Line Items]

Accrued fees and expenses $ 29,332 $ 103,705

Accrued payroll 41,294 12,944

Total $ 70,626 $ 116,649

X

- Details

Name: clcs_AccountsPayableAndAccruedExpensesLineItems

Namespace Prefix: clcs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(1),(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 1, 5

-Article 9

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

+ Details

Name: us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consulting Agreements - Related Party (Details Textual) (USD $)
3 Months Ended 6 Months Ended 0 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

ConsultingAgreement [Member]

Jun. 30, 2013

ConsultingAgreement [Member]

Jun. 30, 2014

ConsultingAgreement [Member]

Jun. 30, 2013

ConsultingAgreement [Member]

Oct. 03, 2011

Yeda [Member]

Related Party Transaction [Line Items]

Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross $ 210,000

Research and Development Arrangement, Contract to Perform for Others, Description and Terms annual Research budget commitment for 3 years in the amount of $800,000 for the period until October 3, 2014;

ResearchAndDevelopmentArrangementContractToPerfromForOthersNonRefundableAmount 50,000

RoyaltyEffectivePercentage 4.00%

LicenseAgreementDescription the option to license the organ regeneration technology originally expired on October 3, 2012 and has since been extended to September 1, 2014

Accounts Payable and Accrued Liabilities, Current 216,000 442,000

Operating Costs and Expenses $ 399,000 $ 330,000 $ 611,000 $ 403,000

X

- Definition

A description of the commitments for license agreements

+ References

No definition available.

+ Details

Name: clcs_Licenseagreementdescription

Namespace Prefix: clcs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The value represent research and development arrangement contract to perform for others non refundable amount.

+ References

No definition available.

+ Details

Name: clcs_Researchanddevelopmentarrangementcontracttoperfromforothersnonrefundableamount

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Disclosure of percentage of royalty on annual sales of the company.

+ References

No definition available.

+ Details

Name: clcs_Royaltyeffectivepercentage

Namespace Prefix: clcs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingCostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] (USD $)
6 Months Ended

Jun. 30, 2014

Equity Financing Issuance Costs $ 55,150

X

- Definition

Represents the equity sales issuance costs.

+ References

No definition available.

+ Details

Name: clcs_EquityFinancingIssuanceCosts

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Deficiency (Details) (USD $)
6 Months Ended

Jun. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of Warrants, Outstanding, December 31, 2013 2,812,498

Number of Warrants, Granted 6,090,661

Number of Warrants, Exercised 0

Number of Warrants, Forfeited 0

Number Of Warrants, Outstanding, June 30, 2014 8,903,159

Number of Warrants, Exercisable, June 30, 2014 6,859,324

Weighted Average Exercise Price, Outstanding, December 31, 2013 $ 0.21

Weighted Average Exercise Price, Granted $ 0.75

Weighted Average Exercise Price, Exercised $ 0

Weighted Average Exercise Price, Forfeited $ 0

Weighted Average Exercise Price, Outstanding, June 30, 2014 $ 0.58

Weighted Average Exercise Price, Exercisable, June 30, 2014 $ 0.75

Weighted Average Remaining Life In Years, Outstanding, June 30, 2014 5 years 1 month 6 days

Weighted Average Remaining Life In Years, Exercisable, June 30, 2014 4 years 8 months 12 days

Intrinsic Value, Outstanding, June 30, 2014 $ 815,490

Intrinsic Value, Exercisable, June 30, 2014 $ 0

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are exercisable as of the balance sheet date.

+ References

No definition available.

+ Details

Name: clcs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber

Namespace Prefix: clcs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average fair value of exercisable awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References

No definition available.

+ Details

Name: clcs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue

Namespace Prefix: clcs_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.

+ References

No definition available.

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)

Jun. 30, 2014

Dec. 31, 2013

Current Assets:

Cash $ 889,332 $ 28,878

Prepaid expenses 135,000 0

Other current assets 59,564 63,337

Total Current Assets 1,083,896 92,215

Property and equipment, net 2,557 0

Total Assets 1,086,453 92,215

Current Liabilities:

Accounts payable and accrued expenses 70,626 116,649

Accounts payable and accrued expenses - related party 216,035 441,700

Derivative liabilities 2,476,800 231,200

Total Current Liabilities 2,763,461 789,549

Commitments and contingencies (Note 8) 0 0

Stockholders' Deficiency:

Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2014 and December 31, 2013 0 0

Common stock, $0.001 par value; 200,000,000 shares authorized; 23,245,923 and 14,155,262 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively 23,246 14,155

Additional paid-in capital 4,047,077 3,229,522

Accumulated deficit (5,747,331) (3,941,011)

Total Stockholders' Deficiency (1,677,008) (697,334)

Total Liabilities and Stockholders' Deficiency $ 1,086,453 $ 92,215

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY [Parenthetical] (USD $)
6 Months Ended

Jun. 30, 2014

Equity Financing Issuance Costs $ 55,150

X

- Definition

Represents the equity sales issuance costs.

+ References

No definition available.

+ Details

Name: clcs_EquityFinancingIssuanceCosts

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 26 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events (Details Textual)

Jun. 30, 2014

Dec. 31, 2013

Jul. 29, 2014

Subsequent Event [Member]

Subsequent Event [Line Items]

Common Stock, Shares, Issued 23,245,923 14,155,262 100,000

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Deficiency (Tables)
6 Months Ended

Jun. 30, 2014

Stockholders' Equity Note [Abstract]

ScheduleOfShareBasedCompensationStockOptionsActivityTextBlock [Table Text Block]

A summary of the warrant activity during the six months ended June 30, 2014 is presented below:

Weighted

Weighted

Average

Average

Remaining

Number of

Exercise

Life

Intrinsic

Warrants

Price

In Years

Value

Outstanding, December 31, 2013

2,812,498

$

0.21

Granted

6,090,661

0.75

Exercised

-

-

Forfeited

-

-

Outstanding, June 30, 2014

8,903,159

$

0.58

5.1

$

815,490

Exercisable, June 30, 2014

6,859,324

$

0.75

4.7

$

-

ScheduleOfShareBasedCompensationStockWarrantTextBlock [Table Text Block]

The following table presents information related to stock warrants at June 30, 2014:

Warrants Outstanding

Warrants Exercisable

Weighted

Outstanding

Average

Exercisable

Exercise

Number of

Remaining Life

Number of

Price

Warrants

In Years

Warrants

$

0.001

2,043,835

-

-

$

0.750

6,859,324

4.7

6,859,324

8,903,159

4.7

6,859,324

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: clcs_ScheduleofsharebasedcompensationstockoptionsactivitytabletextblockTableTextBlock

Namespace Prefix: clcs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: clcs_ScheduleofsharebasedcompensationstockwarranttabletextblockTableTextBlock

Namespace Prefix: clcs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going Concern (Details Textual) (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Going Concern [Line Items]

Retained Earnings (Accumulated Deficit) $ (5,747,331) $ (3,941,011)

Net Cash Provided by (Used in) Operating Activities 2,150,000 340,000

Working Capital $ 1,680,000 $ 697,000

X

- Details

Name: clcs_GoingConcernLineItems

Namespace Prefix: clcs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of total working capital as defined in the regulations.

+ References

No definition available.

+ Details

Name: clcs_WorkingCapital

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 29 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 30 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Cash Flows From Operating Activities

Net loss $ (1,806,320) $ (1,056,322)

Adjustments to reconcile net loss to net cash used in operating activities:

Accretion of debt discount 0 384,034

Interest expense 0 12,500

Change in fair value of derivative liabilities 16,400 (64,500)

Depreciation 25 0

Stock-based compensation 43,000 0

Contribution of services by officers 0 76,990

Changes in operating assets and liabilities:

Prepaid expenses (135,000) 0

Other assets 3,773 26,418

Accounts payable and accrued expenses (271,688) 280,790

Net Cash Used in Operating Activities (2,149,810) (340,090)

Cash Flows From Investing Activities

Purchase of propery and equipment (2,582) 0

Net Cash Used in Investing Activities (2,582) 0

Cash Flows From Financing Activities

Proceeds from issuance of convertible note 0 210,000

Proceeds from issuance of common stock and warrants, net [1] 3,012,846 0

Net Cash Provided by Financing Activities 3,012,846 210,000

Net Increase (Decrease) In Cash 860,454 (130,090)

Cash - Beginning 28,878 161,323

Cash - Ending 889,332 31,233

Non-cash investing and financing transactions:

Reclassification of warrants to derivative liabilities 1,499,000 0

Reclassification of embedded conversion options to derivative liabilities $ 0 $ 315,200

X

- Definition

Amount of the cost of borrowed funds accounted for as coupon interest expense.

+ References

No definition available.

+ Details

Name: clcs_CouponInterestExpense

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

It represent the issuance of rights to purchase of common stock and warrants at predetermined price.

+ References

No definition available.

+ Details

Name: clcs_ProceedsFromIssuanceOfCommonStockAndWarrantsNet

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the value of reclassification of embedded conversion options to derivative liabilities.

+ References

No definition available.

+ Details

Name: clcs_ReclassificationOfEmbeddedConversionOptionsToDerivativeLiabilities

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The value represents the reclassification of detachable warrantee to derivative liability

+ References

No definition available.

+ Details

Name: clcs_ReclassificationOfWarrantsToDerivativeLiability

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of increase (decrease) in standardized measure of discounted future net cash flow as a result of passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 932

-SubTopic 235

-Section 50

-Paragraph 35

-Subparagraph (h)

-URI http://asc.fasb.org/extlink&oid=8451039&loc=d3e62500-109447

+ Details

Name: us-gaap_AccretionOfDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)

Jun. 30, 2014

Dec. 31, 2013

Preferred stock, par value [in dollars per share] $ 0.001 $ 0.001

Preferred Stock, Shares Authorized 10,000,000 10,000,000

Preferred Stock, Shares Issued 0 0

Preferred Stock, Shares Outstanding 0 0

Common stock, par value [in dollars per share] $ 0.001 $ 0.001

Common stock, shares authorized 200,000,000 200,000,000

Common stock, shares issued 23,245,923 14,155,262

Common stock, shares outstanding 23,245,923 14,155,262

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 32 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
6 Months Ended

Jun. 30, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Note 9 – Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would require adjustment or disclosure in the condensed consolidated financial statements, other than as disclosed below.

Issuance of Common Stock

On July 29, 2014, the Company issued 100,000 shares of common stock to a service provider in order to satisfy a stock-based compensation award. See Note 7 - Stockholders’ Deficiency – Stock-Based Compensation for additional details.

Extension of Evaluation Period of Yeda’s Organ Regeneration Technology

On August 15, 2014, the Company and Yeda executed an amendment to the exclusive option agreement to negotiate a license for organ regeneration technology which extends the evaluation period through December 31, 2015. The Company has been informed that Yeda is currently investigating the scope of its rights and title to the patents and inventions that comprise the organ regeneration technology (see Note 6 – Consulting Agreements – Related Party).

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document And Entity Information
6 Months Ended

Jun. 30, 2014

Aug. 15, 2014

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q2

Entity Registrant Name CELL SOURCE, INC.

Entity Central Index Key 0001569340

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol CLCS

Entity Common Stock, Shares Outstanding 23,345,923

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 34 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

For June 30, 2014 and forward, the Company’s financial statements are consolidated and include the accounts of CSI and Cell Source Limited. All significant intercompany transactions have been eliminated in the consolidation.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates, among other things, are used in accounting for allowances for deferred income taxes, contingencies, as well as the recording and presentation of its common stock and related warrant issuances. Estimates and assumptions are periodically reviewed and the effects of any material revisions are reflected in the financial statements in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions.

In Process Research and Development, Policy [Policy Text Block]

Research and Development Costs

Research and development costs are expensed as they are incurred and consist of salaries, benefits and other personnel related costs, fees paid to consultants, clinical trials and related clinical manufacturing costs, license and milestone fees, and facilities and overhead costs.

Earnings Per Share, Policy [Policy Text Block]

Loss Per Share

The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. For the three and six months ended June 30, 2014, warrants to purchase 2,043,835 shares of common stock were included in the loss per share denominator because their exercise price was determined to be nominal.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

June 30,

2014

2013

Warrants

6,859,324

-

Convertible notes

-

2,297,487

Total

6,859,324

2,297,487

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For non-employees, the fair value of the award is generally re-measured on financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period the services are required to be provided in exchange for the award, usually the vesting period. Because the Company’s common stock historically was not actively traded on a public market, the fair value of the Company’s restricted equity instruments are estimated based on the historical observations of cash prices paid for the Company's common stock.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Derivative Financial Instruments

The fair value of an embedded conversion option that is convertible into a variable amount of shares and warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815 “Derivatives and Hedging”, since “down-round protection” is not an input into the calculation of the fair value of the conversion option and warrants and cannot be considered “indexed to the Company’s own stock” which is a requirement for the scope exception as outlined under ASC 815.

The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option and warrants at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification.

The Black-Scholes option valuation model was used to estimate the fair value of the warrants and conversion options. The model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or conversion options.

Conversion options are recorded as debt discount and are amortized as interest expense over the life of the underlying debt instrument.

Reclassification, Policy [Policy Text Block]

Reclassifications

Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Standards

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation." This ASU removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company elected to adopt this ASU effective with its Current Report on Form 8-K filed with SEC on July 1, 2014 and the adoption resulted in the removal of previously required development stage disclosures.

In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its condensed consolidated financial statements.

The Company has implemented all new accounting standards that are in effect and may impact its financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.15)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 15

-Article 5

+ Details

Name: us-gaap_InProcessResearchAndDevelopmentPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Revenues $ 0 $ 0 $ 0 $ 0

Operating Expenses

Research and development 220,995 87,436 545,412 193,806

Research and development - related party 398,845 329,753 611,203 402,629

Selling, general and administrative 397,338 79,100 633,305 127,853

Total Operating Expenses 1,017,178 496,289 1,789,920 724,288

Loss From Operations (1,017,178) (496,289) (1,789,920) (724,288)

Other (Expense) Income

Interest expense 0 (362,001) 0 (396,534)

Change in fair value of derivative liabilities 31,100 54,300 (16,400) 64,500

Total Other Income (Expense) 31,100 (307,701) (16,400) (332,034)

Net Loss $ (986,078) $ (803,990) $ (1,806,320) $ (1,056,322)

Net Loss Per Share - Basic and Diluted (in dollars per share) $ (0.05) $ (0.06) $ (0.10) $ (0.08)

Weighted average common shares outstanding, basic and diluted (in shares) 20,228,764 12,763,818 18,774,759 12,763,818

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34747878&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 36 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value
6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

Note 4 - Fair Value

The Company determines the estimated fair value of amounts presented in these condensed consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of June 30, 2014 and 2013, plus December 31, 2013 and 2012, and, as of those dates, the carrying value of all amounts approximates fair value.

The Company has categorized its assets and liabilities at fair value based upon the following fair value hierarchy:

Level 1 - Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

Level 2 - Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 - Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability.

In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair measurements requires judgment and considers factors specific to each asset or liability.

Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category presented in the tables below may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs.

The following table summarizes the valuation of the Company’s derivatives by the above fair value hierarchy levels as of June 30, 2014 and December 31, 2013 using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):

Quoted Prices

In Active

Significant

Markets for

Other

Significant

Identical

Observable

Unobservable

Liabilities

Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Warrant liability

$

2,476,800

$

-

$

-

$

2,476,800

Balance - June 30, 2014

$

2,476,800

$

-

$

-

$

2,476,800

Warrant liability

$

231,200

$

-

$

-

$

231,200

Balance - December 31, 2013

$

231,200

$

-

$

-

$

231,200

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The Company’s Level 3 liabilities shown in the above table consist of warrants with “down-round protection”, as the Company is unable to determine if it will have sufficient authorized common stock to settle such arrangements. Earlier in 2013, the Company’s Level 3 liabilities consisted of conversion options with “down-round protection”.

Assumptions utilized in the valuation of Level 3 liabilities are described as follows:

For the Three Months Ended

For the Six Months Ended

June 30,

June 30,

2014

2013

2014

2013

Risk-free interest rate

1.62% - 1.65%

0.05% - 0.08%

1.46% - 1.73%

0.02% - 0.08%

Expected term (years)

4.33 - 5.00

0.00 - 0.24

4.33 - 5.00

0.00 - 0.50

Expected volatility

164% - 166%

65%

164% - 168%

65% - 99%

Expected dividends

0.00%

0.00%

0.00%

0.00%

The expected term used is the contractual life of the instrument being valued. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the six months ended June 30, 2014 and 2013:

2014

2013

Balance - January 1,

$

231,200

$

38,300

Change in fair value of derivative liability

16,400

(64,500)

Issuance of derivative liability

2,229,200

434,200

Balance - June 30,

$

2,476,800

$

408,000

The Company’s significant financial instruments such as cash, accounts payable and accrued expenses were deemed to approximate fair value due to their short term nature.

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Significant Accounting Policies
6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 3 – Significant Accounting Policies

Principles of Consolidation

For June 30, 2014 and forward, the Company’s financial statements are consolidated and include the accounts of CSI and Cell Source Limited. All significant intercompany transactions have been eliminated in the consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates, among other things, are used in accounting for allowances for deferred income taxes, contingencies, as well as the recording and presentation of its common stock and related warrant issuances. Estimates and assumptions are periodically reviewed and the effects of any material revisions are reflected in the financial statements in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions.

Research and Development Costs

Research and development costs are expensed as they are incurred and consist of salaries, benefits and other personnel related costs, fees paid to consultants, clinical trials and related clinical manufacturing costs, license and milestone fees, and facilities and overhead costs.

Loss Per Share

The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. For the three and six months ended June 30, 2014, warrants to purchase 2,043,835 shares of common stock were included in the loss per share denominator because their exercise price was determined to be nominal.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

June 30,

2014

2013

Warrants

6,859,324

-

Convertible notes

-

2,297,487

Total

6,859,324

2,297,487

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For non-employees, the fair value of the award is generally re-measured on financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period the services are required to be provided in exchange for the award, usually the vesting period. Because the Company’s common stock historically was not actively traded on a public market, the fair value of the Company’s restricted equity instruments are estimated based on the historical observations of cash prices paid for the Company's common stock.

Derivative Financial Instruments

The fair value of an embedded conversion option that is convertible into a variable amount of shares and warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815 “Derivatives and Hedging”, since “down-round protection” is not an input into the calculation of the fair value of the conversion option and warrants and cannot be considered “indexed to the Company’s own stock” which is a requirement for the scope exception as outlined under ASC 815.

The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option and warrants at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification.

The Black-Scholes option valuation model was used to estimate the fair value of the warrants and conversion options. The model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or conversion options.

Conversion options are recorded as debt discount and are amortized as interest expense over the life of the underlying debt instrument.

Reclassifications

Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.

Recent Accounting Standards

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation." This ASU removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company elected to adopt this ASU effective with its Current Report on Form 8-K filed with SEC on July 1, 2014 and the adoption resulted in the removal of previously required development stage disclosures.

In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its condensed consolidated financial statements.

The Company has implemented all new accounting standards that are in effect and may impact its financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization, Operations and Basis of Presentation (Details Textual) (USD $)
1 Months Ended 1 Months Ended

Jun. 30, 2014

May 07, 2014

Dec. 31, 2013

Jun. 30, 2014

CSL Ordinary Shares [Member]

Jun. 30, 2014

Researcher Company Warrants [Member]

Jun. 30, 2014

CSL Warrants [Member]

Jun. 30, 2014

Company Warrants [Member]

Jun. 30, 2014

Share Exchange Agreement [Member]

Jun. 27, 2014

Consultants [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Common Stock, Shares Authorized 200,000,000 75,000,000 200,000,000

Common stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001 $ 0.001 $ 0.001

Excess Stock, Shares Authorized 200,000,000

Preferred Stock, Shares Authorized 10,000,000 10,000,000 10,000,000

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001

Warrants Exercisable Term 7 years 5 years 5 years

Warrants To Purchase Common Stock 2,043,835 4,859,324 2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75 $ 0.75 $ 0.75 $ 0.75

Shares, Outstanding 23,245,923 18,245,923

Equity Method Investment, Ownership Percentage 78.50% 100.00%

Conversion of Stock, Shares Issued 18,245,923

Class Of Warrant Or Right To Purchase Common Stock Percentage 77.50%

Share price (in dollars per share) $ 0.75 $ 0.001

Warrants and Rights Outstanding $ 6,903,159

X

- Definition

Represents the percentage of outstanding warrants to purchase common stock of the company following the closing date.

+ References

No definition available.

+ Details

Name: clcs_ClassOfWarrantOrRightToPurchaseCommonStockPercentage

Namespace Prefix: clcs_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents warrants exercisable term.

+ References

No definition available.

+ Details

Name: clcs_WarrantsExercisableTerm

Namespace Prefix: clcs_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the number of warrants issued to purchase the common stock of the company during the period.

+ References

No definition available.

+ Details

Name: clcs_WarrantsToPurchaseCommonStock

Namespace Prefix: clcs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Maximum number of excess stock shares permitted to be issued.

+ References

No definition available.

+ Details

Name: us-gaap_ExcessStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 39 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Significant Accounting Policies (Tables)
6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Schedule of Weighted Average Number of Shares [Table Text Block]

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

June 30,

2014

2013

Warrants

6,859,324

-

Convertible notes

-

2,297,487

Total

6,859,324

2,297,487

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Deficiency
6 Months Ended

Jun. 30, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 7 – Stockholders’ Deficiency

Common Stock and Warrant Offerings

During the six months ended June 30, 2014, the Company entered into an investment agreement with a group of investors. Pursuant to the agreement, the investors contributed to the Company aggregate net proceeds of $3,012,846 (gross proceeds of $3,067,996 less issuance costs of $55,150) in exchange for 4,090,661 units. Each unit was sold for $0.75 per unit and consisted of one share of common stock and an immediately vested five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share. The warrants carried provisions that were deemed to be “down round” price protection features. As a result, during the six months ended June 30, 2014, the Company reclassified $1,499,000 for the fair value of the warrants to derivative liabilities and will be marked to market for each reporting period.

Stock-Based Compensation

On July 7, 2014, the Board of Directors resolved to issue 100,000 shares of common stock to a service provider in connection with the June 30, 2014 completion of the Share Exchange. The Company recognized the $43,000 value of the award as stock-based compensation expense during the three months ended June 30, 2014, which was the service period. See Note 9 – Subsequent Events for additional information regarding the common stock award.

Stock Warrants

A summary of the warrant activity during the six months ended June 30, 2014 is presented below:

Weighted

Weighted

Average

Average

Remaining

Number of

Exercise

Life

Intrinsic

Warrants

Price

In Years

Value

Outstanding, December 31, 2013

2,812,498

$

0.21

Granted

6,090,661

0.75

Exercised

-

-

Forfeited

-

-

Outstanding, June 30, 2014

8,903,159

$

0.58

5.1

$

815,490

Exercisable, June 30, 2014

6,859,324

$

0.75

4.7

$

-

The following table presents information related to stock warrants at June 30, 2014:

Warrants Outstanding

Warrants Exercisable

Weighted

Outstanding

Average

Exercisable

Exercise

Number of

Remaining Life

Number of

Price

Warrants

In Years

Warrants

$

0.001

2,043,835

-

-

$

0.750

6,859,324

4.7

6,859,324

8,903,159

4.7

6,859,324

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accounts Payable and Accrued Expenses
6 Months Ended

Jun. 30, 2014

Accounts Payable and Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 5 – Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

June 30,

December 31,

2014

2013

(unaudited)

Accrued fees and expenses

$

29,332

$

103,705

Accrued payroll

41,294

12,944

Total

$

70,626

$

116,649

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consulting Agreements - Related Party
6 Months Ended

Jun. 30, 2014

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

Note 6 – Consulting Agreements – Related Party

On October 3, 2011, the Company entered into a definitive license agreement for Veto Cell technology and also an exclusive option agreement to negotiate an additional license for organ regeneration technology with Yeda Research and Development Company Limited (“Yeda”), a founder and shareholder of the Company. Yeda is the technology transfer and commercial arm of the Weizmann Institute of Science, for research conducted at the Weizmann Institute of Science for an invention comprising methods of bone marrow transplantation and cell therapy utilizing Veto-Cells. The evaluation period with respect to the option to license the organ regeneration technology originally expired on October 3, 2012 and has since been extended to September 1, 2014. See Note 9 – Subsequent Events for information regarding an additional extension of the expiration date.

Under the terms of the agreement, Yeda granted the Company an exclusive worldwide license for the licensed information and the patents for the development, manufacture and sale of the products derived therefrom. In consideration for the grant of the license, the Company has paid and will pay Yeda: (1) $210,000 on October 3, 2011; (2) an annual Research budget commitment for 3 years in the amount of $800,000 for the period until October 3, 2014; (3) a non-refundable and non-creditable license fee of $50,000 per year during the terms of the agreement, commencing on the first day after the date of termination or expiry of the research period (which period has not expired and will be extended), (4) a royalty of 4% of net future sales by or on behalf of the Company or any sub licensees.

If the Company fails to achieve any of the milestones by the dates set forth in the agreement, Yeda is entitled to terminate the license upon written notice to the Company. To date, the Company has met all of the milestones and the next milestone in the agreement is October 3, 2016. Either Yeda or the Company may terminate the agreement and the license after the commitment of a material breach by the other party and in certain other instances as detailed in the agreement.

For the three and six months ended June 30, 2014, the Company recorded a charge to operations of approximately $399,000 and $611,000, respectively, for this consulting arrangement. For the three and six months ended June 30, 2013, the Company recorded a charge to operations of approximately $330,000 and $403,000, respectively, for this consulting arrangement. As of June 30, 2014 and December 31, 2013, approximately $216,000 and $442,000 has been accrued and is payable, respectively.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
6 Months Ended

Jun. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 8 – Commitments and Contingencies

Litigation

Certain conditions may exist as of the date the condensed consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company, or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed, unless they involve guarantees, in which case the guarantees would be disclosed. There can be no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. As of June 30, 2014 and December 31, 2013, the Company has not accrued any amounts for contingencies.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Deficiency (Details Textual) (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Stock Issued During Period, Shares, New Issues 4,090,661

Stockholders Equity Note Description Each unit was sold for $0.75 per unit and consisted of one share of common stock and an immediately vested five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share.

Reclassification Of Warrants To Derivative Liability $ 1,499,000 $ 0

Share Price $ 0.75

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.75

Proceeds from Issuance of Common Stock 3,067,996

Equity Financing Issuance Costs 55,150

Stock Issued During Period, Shares, Issued for Services 100,000

Stock Issued During Period, Value, Issued for Services 43,000

Proceeds From Issuance Of Common Stock And Warrants, Net $ 3,012,846 $ 0

X

- Definition

Represents the equity sales issuance costs.

+ References

No definition available.

+ Details

Name: clcs_EquityFinancingIssuanceCosts

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

It represent the issuance of rights to purchase of common stock and warrants at predetermined price.

+ References

No definition available.

+ Details

Name: clcs_ProceedsFromIssuanceOfCommonStockAndWarrantsNet

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The value represents the reclassification of detachable warrantee to derivative liability

+ References

No definition available.

+ Details

Name: clcs_ReclassificationOfWarrantsToDerivativeLiability

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Description of the common stock available to holders for each share of warrant and common stock.

+ References

No definition available.

+ Details

Name: clcs_StockholdersEquityNoteDescription

Namespace Prefix: clcs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 45 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accounts Payable and Accrued Expenses (Tables)
6 Months Ended

Jun. 30, 2014

Accounts Payable and Accrued Liabilities [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

Accounts payable and accrued expenses consisted of the following:

June 30,

December 31,

2014

2013

(unaudited)

Accrued fees and expenses

$

29,332

$

103,705

Accrued payroll

41,294

12,944

Total

$

70,626

$

116,649

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Significant Accounting Policies (Details Textual)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2014

Schedule Of Significant Accounting Policies [Line Items]

Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation 2,043,835 2,043,835

X

- Details

Name: clcs_ScheduleOfSignificantAccountingPoliciesLineItems

Namespace Prefix: clcs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e2646-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 47 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Begining Balance at Dec. 31, 2013 $ (697,334) $ 14,155 $ 3,229,522 $ (3,941,011)

Begining Balance (in shares) at Dec. 31, 2013 14,155,262 14,155,262

Issuance of common stock and warrants for cash, net ^[1] 3,012,846 4,091 3,008,755 0

Issuance of common stock and warrants for cash, net (in shares) 4,090,661 4,090,661 ^[1]

Reclassification of detachable warrants to derivative liabilities (1,499,000) 0 (1,499,000) 0

Shares retained by public company stockholders in Share Exchange (730,200) 5,000 (735,200) 0

Shares retained by public company stockholders in Share Exchange (in shares) 5,000,000

Stock-based compensation 43,000 0 43,000 0

Net loss (1,806,320) 0 0 (1,806,320)

Ending Balance at Jun. 30, 2014 $ (1,677,008) $ 23,246 $ 4,047,077 $ (5,747,331)

Ending Balance (in shares) at Jun. 30, 2014 23,245,923 23,245,923

[1] Net of $55,150 of issuance costs.

X

- Definition

Represents this element stockholders shares in share exchange by public company

+ References

No definition available.

+ Details

Name: clcs_SharesRetainedByPublicCompanyStockholdersSharesInShareExchange

Namespace Prefix: clcs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents this element stockholders value in share exchange by public company.

+ References

No definition available.

+ Details

Name: clcs_SharesRetainedByPublicCompanyStockholdersValueInShareExchange

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 48 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going concern
6 Months Ended

Jun. 30, 2014

Going Concern [Abstract]

Going Concern [Text Block]

Note 2 – Going Concern

The Company has not generated any revenues, has recurring net losses, a working capital deficiency as of June 30, 2014 and December 31, 2013 of approximately $1,680,000 and $697,000, respectively, and used cash in operations of approximately $2,150,000 and $340,000 for the six months ended June 30, 2014 and 2013, respectively. In addition, as of June 30, 2014, the Company had an accumulated deficit of approximately $5,747,000. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

These unaudited condensed consolidated financial statements have been prepared on the going concern basis, which assumes the realization of assets and liquidation of liabilities in the normal course of operations. The ability of the Company to continue its operations is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to incur additional liabilities with certain related parties to sustain the Company’s existence. If the Company were not to continue as a going concern, it would likely not be able to realize its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the preparation of the unaudited condensed consolidated financial statements.

There can be no assurances that the Company will be successful in generating additional cash from equity or other sources to be used for operations. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary. Based on the Company’s current funding levels, the Company expects to be able to fund its operations through November 2014. Should the Company not be successful in obtaining the necessary financing to fund its operations, the Company would need to curtail certain or all operational activities and/or contemplate the sale of its assets if necessary.

X

- Details

Name: clcs_GoingConcernAbstract

Namespace Prefix: clcs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for going concern.

+ References

No definition available.

+ Details

Name: clcs_GoingConcernTextBlock

Namespace Prefix: clcs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value (Details) (USD $)
6 Months Ended 12 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Warrant liability $ 2,476,800 $ 231,200

Balance 2,476,800 231,200

Fair Value, Inputs, Level 1 [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Warrant liability 0 0

Balance 0 0

Fair Value, Inputs, Level 2 [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Warrant liability 0 0

Balance 0 0

Fair Value, Inputs, Level 3 [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Warrant liability 2,476,800 231,200

Balance $ 2,476,800 $ 231,200

X

- Definition

Represent the value of Active Markets For Identical Assetsor Liabilities At Fairvalue.

+ References

No definition available.

+ Details

Name: clcs_ActiveMarketsForidenticalAssetsOrLiabilitiesAtFairvalue

Namespace Prefix: clcs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 60 149 1 true 19 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://tickettosee.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://tickettosee.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://tickettosee.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://tickettosee.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://tickettosee.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY [Parenthetical] Sheet http://tickettosee.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityParenthetical CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY [Parenthetical] false false R7.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://tickettosee.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R8.htm 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] Sheet http://tickettosee.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] false false R9.htm 109 - Disclosure - Organization, Operations and Basis of Presentation Sheet http://tickettosee.com/role/OrganizationOperationsAndBasisOfPresentation Organization, Operations and Basis of Presentation false false R10.htm 110 - Disclosure - Going concern Sheet http://tickettosee.com/role/GoingConcern Going concern false false R11.htm 111 - Disclosure - Significant Accounting Policies Sheet http://tickettosee.com/role/SignificantAccountingPolicies Significant Accounting Policies false false R12.htm 112 - Disclosure - Fair Value Sheet http://tickettosee.com/role/FairValue Fair Value false false R13.htm 113 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://tickettosee.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses false false R14.htm 114 - Disclosure - Consulting Agreements - Related Party Sheet http://tickettosee.com/role/ConsultingAgreementsRelatedParty Consulting Agreements - Related Party false false R15.htm 115 - Disclosure - Stockholders' Deficiency Sheet http://tickettosee.com/role/StockholdersDeficiency Stockholders' Deficiency false false R16.htm 116 - Disclosure - Commitments and Contingencies Sheet http://tickettosee.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R17.htm 117 - Disclosure - Subsequent Events Sheet http://tickettosee.com/role/SubsequentEvents Subsequent Events false false R18.htm 118 - Disclosure - Significant Accounting Policies (Policies) Sheet http://tickettosee.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) false false R19.htm 119 - Disclosure - Significant Accounting Policies (Tables) Sheet http://tickettosee.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) false false R20.htm 120 - Disclosure - Fair Value (Tables) Sheet http://tickettosee.com/role/FairValueTables Fair Value (Tables) false false R21.htm 121 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://tickettosee.com/role/AccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) false false R22.htm 122 - Disclosure - Stockholders' Deficiency (Tables) Sheet http://tickettosee.com/role/StockholdersDeficiencyTables Stockholders' Deficiency (Tables) false false R23.htm 123 - Disclosure - Organization, Operations and Basis of Presentation (Details Textual) Sheet http://tickettosee.com/role/OrganizationOperationsAndBasisOfPresentationDetailsTextual Organization, Operations and Basis of Presentation (Details Textual) false false R24.htm 124 - Disclosure - Going Concern (Details Textual) Sheet http://tickettosee.com/role/GoingConcernDetailsTextual Going Concern (Details Textual) false false R25.htm 125 - Disclosure - Significant Accounting Policies (Details) Sheet http://tickettosee.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) false false R26.htm 126 - Disclosure - Significant Accounting Policies (Details Textual) Sheet http://tickettosee.com/role/SignificantAccountingPoliciesDetailsTextual Significant Accounting Policies (Details Textual) false false R27.htm 127 - Disclosure - Fair Value (Details) Sheet http://tickettosee.com/role/FairValueDetails Fair Value (Details) false false R28.htm 128 - Disclosure - Fair Value (Details 1) Sheet http://tickettosee.com/role/FairValueDetails1 Fair Value (Details 1) false false R29.htm 129 - Disclosure - Fair value (Details 2) Sheet http://tickettosee.com/role/FairValueDetails2 Fair value (Details 2) false false R30.htm 130 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://tickettosee.com/role/AccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) false false R31.htm 131 - Disclosure - Consulting Agreements - Related Party (Details Textual) Sheet http://tickettosee.com/role/ConsultingAgreementsRelatedPartyDetailsTextual Consulting Agreements - Related Party (Details Textual) false false R32.htm 132 - Disclosure - Stockholders' Deficiency (Details) Sheet http://tickettosee.com/role/StockholdersDeficiencyDetails Stockholders' Deficiency (Details) false false R33.htm 133 - Disclosure - Stockholders' Deficiency (Details 1) Sheet http://tickettosee.com/role/StockholdersDeficiencyDetails1 Stockholders' Deficiency (Details 1) false false R34.htm 134 - Disclosure - Stockholders' Deficiency (Details Textual) Sheet http://tickettosee.com/role/StockholdersDeficiencyDetailsTextual Stockholders' Deficiency (Details Textual) false false R35.htm 135 - Disclosure - Subsequent Events (Details Textual) Sheet http://tickettosee.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) false false All Reports Book All Reports Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue had a mix of decimals attribute values: 2 3. Element us-gaap_SharePrice had a mix of decimals attribute values: 2 3. Process Flow-Through: 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Process Flow-Through: Removing column 'May 07, 2014' Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY [Parenthetical] Process Flow-Through: 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] clcs-20140630.xml clcs-20140630.xsd clcs-20140630_cal.xml clcs-20140630_def.xml clcs-20140630_lab.xml clcs-20140630_pre.xml true true ZIP 51 0001144204-14-051396-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-051396-xbrl.zip M4$L#!!0````(`/B$$T5Y^E15FAF26-(Y.GIT7F7[W5]OQCZY8D+R,'A?L[>M&F&!&WH\&+ZO?3L_JG=K MY*\?_O5?WOU;O4Y^8@$3-&(>N9R23S2BYX*ZWV7:G]C;]G:;X(=>?3\>UAW+ M;I+_MAJ[3F>WV?P?\K]?/_\?.>R?DSJYOK[>]F"$2(VP[89C4J^G=#Y2"31@ MG%\^GIT09]M.KMU<"I_OXO\)L!W(7==WY?O:*(HFNSL[$7>_LR@*)6,XW@Y2 MM]H-F)%N[//@>]88Z>-`VZ$80DNKL8.7+X%PVARO>CSK8#9N[^B+6=,[0U\W M5%N[U^OMJ*M94\EG-81![9U?/I_TW1$;TSH/9$0#-\<++^&]V)[+L.G8G;(> MND7:P6,3P5QCM4N"+TV[PR MHP,/KIB,9G?1UV;,)J#Q\%\G=V1W@PJSFT43,:0]79G2(97U( MZ23K,Z#R4JULU^3?#SQ$;_JMY%@@_O=3K%S2FJG0"O'P80)'GI%#F!?BPA4+?N0 MPLRRTW%NKZ5#&=/QC$[M>L.Z)>XE74R6#.+I3XD,D['O$ZSM7#3L/YM@;0>V MRU,*MFD@MKF)@FT^1+#-IT-L\Q6I@N8ZJ8+F*T+L\H)].L3NR]/`:EU8G4T2 MJ'9'HT0RK;K5R89/KJQ*,IL&M;QD3,RL6C+="[NUN9+IUNW6$TEFXSP50S(% ME^.I).-LGF2<)Y7,QOD*.DH#7?3C2\E^ MCV$"AU?PO\]L?,E$+#'N+%PZAV!P_X;+9Q9ST2%@0YAKE-%++GC`R,W$YRY/ MID"\5";O:TD[^YM8_`2<+I'/X>`__0:A(&\%5N.`+*IY4VNR.4%\'`,UF4QL6^YW'4&M3_ M2KEW'!S0"8^H7^$A;58JH%>.#=>-Q[&/Z>=/;(#3^Q0+'@P_L2OFAQ.<$0AQ MR"JP9&!92F*O##VSTV.5E5DS*[/6B<#9$*J,U&88J4V$5F7C7HF-6V?PY9.B ME4E<,Y/X?.G?RJ9MFDU[$6Q41NF5&*5G0<_L`Q\71Y2+?U`_9L?!)([D"8K" M-B&3-?@XS3[^)ZP@%>YHJIIO-G86G=^=]G<%]D)NS+H>@+D?:$X%M.6`YE1` M>Q#0&A70E@-:HP+:O5F!RG1NO.E``8)@&R>FD-9!`QGY4A,4Y MCWQV.C@./'[%O9ANN-69,QT%@SL2>#F[TGZ877$Z3^'`M&J51(VBPG MD(V#SM/XOK.A4]FC#;%'ZXRMQ,>IS-<:F*^BW^(\_8ULE?U9$_OS$@%-939F MF8T_0_!2!(+T3X4'8;^8JO"^@D("A=ER>65@F.->5IFOM"!I*J M9^_*CU/SRH;#9HDYJKI_450OA"N[;EM+XTIW:CQ]K?_PA@F72_95<)>=!OEG MN.#!"?66+3QE`^M!4>#Z1,U^'(U"P?]@WK?`8T(])^ET@M>_^A07)3?P*]!: M3R(,A=/92_`*BWRS8,>%R\ZOPPIV+P>[W!*\,MC-2=)46F]]X/="6F^M\TCW MH+92FB^.VA=2FAN!VGRJ*[DQAP=#FIZ]G17`Z'N^]H&=VV?D[>-1_J'J@B]R M%.#QGX=?F1B$8GP4BM-HQ`2LV.:_#F1%TS=OA)HG[ZJ>5_IP^`JK%5;73:_. M+B%46*VPNBFUC0JK%5;7(<,>!UP#5:I8H`"6,:,R%NQ#PIYJD@Z77C-)X&AS MQO_6_S1G<"[#IF-W=J'%P\>^@`GK&_T*5-2-\:RX"MCU2SQF@D:A*()S8=9, M@1='G$'P$PO",0_*2=XGZB+-NX.F5XV9+R##27Q'='F6L,%"ZX,O/3STU18K MOO(P>Y4`E2.2X/$,7UE??"NM8ND(ZQG>A5TC.+9JAR@B'G/YF/KR?AV M>XV&\V[''#J=8CDYXX6F)CFGE)S3[7:ZY=2^A!&37^F47OK,*,1P)@]\*B4J M2N\@%@+ELZ@,&N5,V6VKT;KE:@D.5LK\'(DV2YEO-NV.9:V$^7W7%3'S3CB] MY#Y779:4RU3.O>S8KSI1!WY7U@HO7*A-)RF`9\BE>6YF",.VRI' M2]-NM19G8\YK/HQNBVORM)H=J],Q<'POZ54P.T^*Y8:@X3B]EN,\AMDS M%E$>,.^0B@`<4WGW'1F+2[;<0-1;G6:GT3#VX_VT5\'M/-&66X1ZH]>T+?M1 MW"J!CT+?@V!`/Q=C<5F6&X&ZW>Z`P3*<@+NT'L+-/%F5J_YZNP<+VUR&&4/_ M063U&$&5VP#;ZK:;K<9,Q3N3\.,9G2?#<@/1R8=B@) M?`T^C[\<@;&VDG]F78NCZ6,EY%C8P$.P>EI]9Q&"8.:ZH.9 MFR>^YOW,*5?(:3N/9^XTCO"(A@?6:7'QM58B/H/TX]B<)\CV2@19PF:?^DR> ML2L6Q*S/Q!5WF?S""O[$[&)JGM-R@V1LDCD4'\=8+L.;9ZS<`#T58S/+)'G& MRB.6IV9LOL0:Y3',\HR=3C`U!^`[O,'S#TPNC:Y&>?32<9I.U_`*[Q!\*$[5J/76R4K M)6(IU];U7K=MF8@I924-65-_]B.5W,6*%O?CJ.C.+(*?A2($!]@$7]M@\AX^ M5L/V?)DV%XH0--NV]4QLWX_*IKV$M-O/S':)M)TEV&X]F.U_,CX
_[5Z`R MA^Q+C#73TX'J:KA[CX5\M57&#;+1`I.9;C=#OMYJJG"!9(,"K9)Z;_'@=WJT#+[[Q[JCQ= MJV/:Y$5X6"'?)0MQCP5W.G;;]-4?PCA8?:S^?A4AEMF]C]-ODGG'0>8^[@,G M5[K*!-SS((;?DHMA\("E*(_4ZHVF917\HT>P]RR3G;]^K?+HK^[8S5[7?N[9 M'@=73.9'6WH96^5!Y/U3FL'$RMDO69CRB+/NM+K.*J:`W4#7X1],NE]!C!]$ MZ);PT"MNUN77X)YBF=W(;Z5EF'F"B92L1GEH"V%*L]5\RGGLP_H*,86EO*]" M[>09+P^"[;;=R*4\%R&^:HX+F"D/E6<<"WHNAN>!O-QT-VRG\4(2G@?F$5-C\'QC[Z=TX%+++U>K4//_C1GL>OB(RF/GM?^[Q_ M]M/QEUUB32+X[V:/')U^.=\E-GX_YV/0ME_8-3D+QS38TC]LD3YLO@&I_3", M]DAAN(.3P_VSWD<-%F3L?,9*\E84P M@&Q,(^C"E$!)-*(1&=$K1D+7Q8-)'J&#B`FXP,@E]6G@,B)'C$7$@W[D,H[( M)1N$@JD6@&`/\Y4J;)&AS[&11P;IFR!@ZLE[0B3!VBY7A:UMHNX*)/$D#-0P M"5O@%FVI[RF['O=($.)94778>TKP1\'<GL- M\;#68$4N8OR$)5`%OG!`=%F/J+J>XEFU6$?NUUFTIP'Y6^Q/B=/;(FA:\EM- M[TS%Z@#,4LJKR1_YL4#EQZT?)8[_8S*/6UXU1=NRMBS+4K+`0=6/.D6!R^KJ M997JA%P4$DJD+J61B7;>!6[(4.`'N(RW#TO4`;I'_9+J'7I[:S&AUU2`=NDS MIJU)A]2)>99&KT_7L3M[1)_A8H$[S9D<-;163^9=RP14'NB-]+0=N`D1Y;ZL M]O=#]_?A3:1OO4$D'&;ZG^C(`'_$!P<9"R;)J1B"DCUC0Q8D030Y9^XH"/UP M.*WTPB/TPGX\!(-([-8LS4`#3ZT%83?,52E*-'5@_3QE06%G*A-^X_JQY.A( M3/1>3&]YPA8!&X811P>"$A]V.!A7M:-"M:3"7-(H6U)R/>+N"$8&I'BRX"@0 M?;,1_"K">#B"[>SJ>[H:MII$:SOG^(S`-E\R%H!&P7NVF*?]`C4O+HFKSV2# M=N0Z3S!4&1Q%4[KA1)DA#MZ$P+2I5#*)\#68Z?0G,+<@N8!#!#H'I8B@BA)< M:H^I?,9O9*JZVJ96NKV1C&1OSI)F@^2>!:(>OO7VKE9*O^#G"&]R`/\6]2I& M.2G\KKD7C79!9_]ECZ@V=9].PSC:'?`;YNW5B,M\7TZH"VRH?OA]@CI1?\_& M%]DG+]N/YD=Q^Q')X#?C9,6\:"D-JSS&=S^%KGJ]&-YOMW04U58%^/K?W^T4 MAS))[*<`/_+I<'D:=NW#`*)(IHGD!ILU$:WU#O5==_3FCCR+]!%X MK-3_E5%Q!+\LGYUK-S3Q/-G"J/,):_X>2+I9^_!W9Q9A8U23]*&Z9Q(L")<1 MOI[R"ZBQY:FV:A\.#D].2/_TV]G!X18Y_G*PK9F8-?Y=^@<,[R#UCR'(N/F9 M39=GH)V_(7;NR";IY*Z3VW5Y,-@ZM0_U]#T092/?G?@1]YDX@$O#4#Q@VMW: MA_Z8^C`&Z+M)*)0^3!2\*84<&9.+AK4KFQ9JSQ M=T![Q/Y0E.LBB7?BR'WA?H2NLK/IZ M.LA>[YB]^U-^RD)G/+3.(08'GQIPO^^Z88PEC^'7$.]L9H](>G7L#4MZ+>!W M$>J#L-[7P!&*F*@]L]>Z7&IKE0%A+A)4;HYM>C$F%K>(4DD@8Z!YT\&I@TAJTP#YS"O MS5U\.L+`#Z^EDA6.`Y$\!+]X4?(;`@Y,-)($XB88ZRYA+#WJ"-^@8]!8?E!8 M2@1LNH9 M"*:82FDD:+]FJD2B-D^F5PKP4HFZ]%9Z[:7#7B)'@#?2K?\,+/O0-YM!'_>5 M/A6"?*>O!U<9?RY5>M`$>__P(*>9PB2EK?EL5MG8AWH"IN>E5N+6^:K\@544 M7D$A4&A]13T*>UG`OLC*"IB,5$`&==160';`<_"2&FR`*0I4P]O@I?%0I`E' M?:]LMF'>8.V1#?!^=5UY?#N[DJJ<"_Q!WD9KH-TE0PTJ#`U:[:7'K;9."B=/ M%-&_SM;`6ZEVI6A,XB#1K<=24(9>%@+"SA7"E%T1J/?Y'YA0ES&,H^SL;>)9 M60"5P8;V3."3#,#F@O<((X!-B1+':08_.4T>43%D468(<>34>\J&0P3FF0#TZ53^O=#LK6J' MG(-?RJ"5FAQR0,D5^`(L2IS!H#Y6H3ON&C"N>&AM`2GZ:,0G(I03?#+5E:IO M>K&KW`3TC73Q`-;]'RP*ZVHT/AZC/I!3"7;=\&:-8D$*'!1HD':(0A]V,`KH MDH=&84%Y("S`?+O&IF1^PLPEIF64SSM(1P%_81(&"\UM*9:15UVV-:/U3 M$6P1\$?Q#RY(4BGR$,2S?!<($U0!)WUFG^ID/+4OVX_95J/IQN(Y+?RFAN/4 M9A1.7EZOK+72RQR(@CG"A3ACH>%55&[$(^JSG^F4=,S:[,>0"E4D_P3QLAN% M0F;AV)C^%@I\4(F\/?B`+=&'@'`WG"3!6>C'23@V4<66?4F"5&)5D]K[!\\T[O)`%NSM^]73J$ M`YXO(@,1C@W!IL/!]94NG:.'G[=V^:,!U)>AR>R*CT#=!Z*)8`.F#EXF.,K6 M^:D1I=)`$#5@**"W+7J9`9Y1(&,\X8G#H3)2L%)9-*,Q_*Y99^!M&&D'<"G4 M'$`U\(ERHK:2(R'4WU(QACHPB;X09BZ,`Q6_Q^!;#5)'O*;:3Q!AFR,%2!JR0051D-1]Z]2)=U@8O7M7(\XN0<_QS^A_EDTY' MLWS>/U0\GASTJXWUT(V5^7P'L'>2$[H#6-VZRM9>4WPJ>:3,YP10,$)O"_?0 M<"C8,,'@:NWJ,AX1`9>`8G%*'^)>L3'KM`K>$=H4%82H#(DZ+T=UM0?/)FKU MH$M)V5FZY+BQ1$-VQ<-80N2?'#WV4G\T@?Z38%CW(]AQ@U"9E4S>%"M-?BA1 MK'CX)U]N^O_VWG2Y;21I%_X_$7,/.#K3T78$)9,$5[O;$;26;KVO+.E(ZO8W MOQP@4!1K&@0X6"2KK_[+S,+*!=Q)`*R)F;%(`E6Y559F+4^B^=)1!UK;PJ/> MN`4D[DEHDTN9T0G'J0[F/9C:$R#?-FNU`/O<]O'VE`W^%+I+LL/@R/F\?9"$%,'%47/&&P`R',S$40IJ,3Q^9>X5WS[9164&C5BQL\F*!0`R*C2PN1 M-O=`,&$/9/(3I%3$JG4J]T:QTZVIZ@-N)`U2QPUFT/$6[ MTBB#X)5W$R*_"W\7!Z524I_T'#MUK?/8MMBK&=W.F)D"0VB4O""SQP0BX72G MS#DPC]35G>E]ZI/D[R?O1=B5$G(LEP3W*:',Z@H"S&#?W=WRHD#GK#E[T&]W MHE57&@2S)#``7V"_AH?8D[Z9HL'P+DLEU28&%S!&MLA*6EKOE:G(1=/%I;RM MRJ]1Z32[%;7>2(MOQHBG*`4'NJ@H>(!X1;AE).U;():3]V*O/?0^8I<^9?0S M8[\%%@&<[I>I&?X@9#$='XA\:/(9.BJ*&UH9II4/:UIA>@EW?."!92PK MX_$5C(S/-IH9"ITQCVW5M%J5;E6MU)K="=.:Y$ULP\SG?6>S9'O>+)D%S//C(!V]$[!6&MXD3I;XSAN3,K3N M!P<`,*_"#7T'LA`J/1$>(DJK+MC,B7L(!H]3H?S%#[:)0D6G$ZA7*[VP*-*9 M=)B?NEV16(-(FPSE,9H>G0R(9OWD:1AN#2!VIJOG+\$AG/C8'QU831S3%+<; M$NKR0D/#\0-Q4>"QDGM[^$NPN]\YER[SMX#SY8_%MX6,[Q MS5!K(^8\X\JK(V0=GR>E-9D7:0"7Y'<]Y6= M*4";'5WTJ1?LHL_JZ#9J"FH@X7-B.2JA(.75EDW.H^SNVM)]?-N"0N/$^)-G M7-8E#N./Z4/^D)H@H$=E[A[47)RAU$0L[N0'IQ;C,,0-UT7Q]QGKB&=*#[Y+ M1P:0#H338&):2][98;AK;6F)FS=ZTD2F`]6=S&XY46NN;6X/ON(/EW*_2U<< M+)5GZ3H(W(' M$-+ZHW$"PT.CC74:SP[=:D&_,HK()9'-R.C09, M,,Q1Y_R%LB&&&)H"2;"%;YP]AJ$ M(81A1*Y$N`V(([`9AT["P8-NU(;#!GA`/PXCYKD[NF@28B$)]_%&+1@,%R_I M1I"PJ^AZ*M[7]7SJ4EB03O"(!@?*G.`@W=!V,YRB#&/R0]SNPYB,^Q6N)X.: MM8E+R=5(R%5'N2IB)7`LKL`(-R9&-OB]`*K5,L(#\'0X6S,U<6*WSRPVX($O M%WX6?(2+)P#-R*]1+Q5EP.C^#30!XE8 M(V@SQ'C#-T8<DZ'7I7/)#W.Z="U7+N@<# MI6T&Z4RV@C`R\0'5D$C=%PK>"7>3D(9/@\$\0M8B-&%J><6<%2&,;KP:* M;5D#Z]#@&14WV@LY4\+*.2PH)!7S45'X((SUZ*8MQ3G)M2#1(,%01S#1A(2= M`*<.-XG$X5%@-(0MQ;-O"Z@3.RJIT-)WPZ0LL:&-FVF0)@:GYI,GI4`\'Z#G MQ+-\$-"1..R&3XX81&T&[59#=`XN&!5X1FMKJT!A5&9OS.[C;,2<@\0S@2_W7Z\80.<=O"+Z]N+2Z2QRJU/RK?KBZ??\?'J3[%>Q8[JY+9>XO$6 M[JE^N7NXN'PX/;^[N>G=/T*?.EB`-G;9)^7NS\N'JYN[;Q\5S)*AL86;K>$Y M!Q/H3!#BA%3\?GG]V^\HV/KX1^)W(_P]P:HB@/I"NWWZ]PW0)J"ATN*;5-"4 MI7]2@(^GZ_/>3=@TZ,"S1\&#WP*:&E6@GW:;?SU1FPDY)C:ID^/N2^_\?W][ MN/OC]@*%=_?P,4`XH"6:F78Q?Q]<[$/G5!BU',@BL-(O=T]/=U\_*O^W2O]1 M:N,?"FWT!(/B0-)J)Z155W\ZP3$$S,-`:&Y#=!@JQ.*#F$%:TSK6%!SQD"Y) MNJ12NJ2`H*>[^YG4S/58M5K28]6W(%E,:0I@7FL+3%I?SJU/+8#UY="YR1E2 MSI#%E<4J'DB*:CU158]/5M)NY!"30ZS`0VR--S*$MZ=`RJ25WM5E'C,'9J?K MC`T&NXJMHMN?J]M4SKB;96;SE_3SQMZ(&X;)]L@>XQ?I3/<:"N%4)!GE4J+E1:+?Y\>LRIS,HD.Z#^[FD3/Q:D2W%W%L]XS M[B#N2>/;8W,;@W>UYS.OVW1+/+DWZ2U2VO?N[77*_5NN]+H MM'-O]>6?U7>;&C_9GF;F/G8[I&]386@;MM]'*SM\]+K-=5LGB+&;E*EW=H9I):_*E?>J'($BGGZALCQXU8M9[AYP MA](G_,^:>&B_S(I,7J0;T:VLX%X:7DZE:[9AV0"'Z8R_B"M)4TCAKT%]&<0< M\1!9S_4W'U M;X>=!J13/S%V0(P#8D3W^E^8F_@&<1?,H$0@\1G>TR-\/U&&6R`\)"@1Z"-! MW4N+P!:>+:JF%&$H1A@%+!:@`#H(BGZ+FUA1_85)F4:<5A3?]8E+_"HD/H`U M4;Y,PTG.+UL20W9`:W@QS+(]1:,"*E0$4C.$_+00`W&D.7\Q;YXB9O47%BW" M^XG3ED"7F0*0!2-M%PDX$;N/$M,$P`1>CL/BV72;+;BX'' MN-U/$A>,T#WQKEL$_ZA\U^P)ATG=#ICF MT60E[L.R4>14$Y>'#?O5.G6PSG"BJ8G[QA5170V\"JM`!D-><<28@`UR=7M, M-S#9.*Q@G:@%3#BW1FR"`L"H]WBN=&K-)!VQF0J>?V?&,_CQ!"45Q>6(H+0* M\3QPX8@T._8](>X9]T-G^^]I%::T06@;FH4=]%D2ZS9Y-QOX_3%5)26-5?QJ M3=_R3M1&#B9$$F?HV">%KM&->I-N,*=$+&\PKS&H$W!3J:K6"3N.(ZCD]!T! MRDW5OQ1P4P(_8+Z'2)N7%UQ#C@V3[O('QHEC0;R5!(?3HF))A-#DI8(R@0:G MZ<-$"6P(,DRJ#^T.<40;5`^DAY@1(M2"L"O1!'<#3@0"30H7ND(?*18)@+AL M)\2K(<.EGB>!YY!&^F$6'4\I"2(<&?Y7C$T3/D;5(4/,KH2&4F%51A_7@UGM M">[=$,P<,7!(>"_47@)(3W!1"?T%Q(BBCC>(*6A1B"K03U)7U)@P%8I10P2_ M-"ER!*\Q@K^8&F3&C_K0)EQ>,4[0A(5V1[;!3`KP_:"<>!ATSYD)TCY_$=P;0NC%F)()"B+,-=$)#BC*'EYLG+Y, MRB#<>4D#@>YA6@J&ED@@@J&'S('X,!%!4"=[-H2+R0?324WXW>>##Q/SBTP`UQ^^D,5AJ2!1L2.,9P+@W1@L)A4*B)*C(P%< M#$^$I54"L#T!V6H'")\N.FN"/T\"E-)$X$Y'"D&?EJUP:!]FDF`22%0SC>"! M0XPO.?;S0]Q>QCY+5Y=X1!`VS3&D%UB;N.NP.G-4\CQ>9YLEZ:#4?++RZ%7O M\4NZU*BHZC?S]3_&E$0DW^\]_I%Z_=8^(W).:]5*>I$EQA2%!B&XN\2B1`BC M]>[)'G-=Z=::[S\JET'1@B"S"OUETL'A_9G MN,)U'48K4=>_^=R@M`RZ$%1TD.Y4*8VS$W!Z$.<"I^#$1O9+D`8:##+Q1"FC M)&JJ2QR*LDLQ,ECO\3Q8S^J_B:;"5&[FK@C'[02QOM9GWBOZ\SE]1."E!*\: M-Q']2"0@\/Q$04)!U1]QJ8@0H3J6;(!S/;=?$/"[VOMPEHC7!DX]^Y2LA=/, MHH5%EV@-*8:-!M$%:3S(O"+V$P:F_1J@LR:1'A-+5\$&1D5Y5W^OF%J?F1GX M]&X`(9VI)6A*?1^"Y#-ZT-4=/DXNTTV_2QLT(;IBL')&^;70/&9'UC,\:`AN MWC42741@V@Y8)-6!G-,$S*JF;6$%K0PC"]9G@X``FT-<>)B6#1$)!+U-O7\6 M&S=22WD@K3+1WJ'EITQ2Q!F(5??,+8O&V@"&E'(!SIW`-FO-$+A15#K!!',4 MO4:FSR&(N-0<3#J-(#OFA)XXXAZ5.DFNO+``>!Q7JO%IA&@7Q,:44F4%7($Y M1R1BX$MX"`Q!KC"DZ9S^+PC91/1T?/+Q\AQ_^A\?**@E*KS0$E9(D5AVB1$> M:;#B]M<@'=($^X736DE46Y"IZ>:S&DQ2T<0$RH\GF7J%"C='YP^4TZ!>8^K+ M8(9IUSHPP_32B/Z$]1N<9+C7WH3/^(9;Q]CS$Q7=%/LK/=K[PD$I`H0+ M)O>&D\B3YCPSA")'Q,8^>%9]*(HIB%&"[=&3>"`TOI".<8(.3]"1J!;B1IO3PM1Q!2BD4INFTHFHG-AXGZRU MF.P54@@QK9PIOY;<0KHT*+J'S0Y#** M/Z$U"B]`"A>E4E^I77(%,ZE/5UD)Q49%5L5""!J-ZR-4.C6U2$^TKS[+K89> M<9:G1/+(]=!\02(<0[^4,&-`YLS2%C1F!%T6.*X4?X).FMF(U_3\9=@LW`;TN,[' M8IDWV*")]$,T@I+<68L2(98AX/A3!<9FT2\GH.6)FU61 M-JG0(3H4/'DT$F83VD1BW\Z-G%=DI'B`2/@3JD(`XRY0)FIRKLE%QA,4Y8DL M!U=A\7]`CXCXLRF(EX."*92^'>%:^P(C2Y:7#:NV.LEB/W'HOL_5G.+41UVO MJJDH/$W3F2CB?2WTEBICVG/OK&K[>[U+Y4N_/T;;JI>XM_>5I@3?Q?8F?GIZ M&[,>3,#IBJ?JB>)#-DMMB_,?)Q#6ZGRDF>ZO)]>W5R>?:W0H.V9N#IG3W"22 M:>+];8/*K(TR5V;-ER],+PW*8J,[(.Z(BXT6QXEG.;!)9_>'R^X&<4FVE=U; MLV#NK0R>399&E:5196G44AC@5UD:599&E:51YY9&+4[0E0ZD)L.L:^O>L5%. M8=W*GF4D=IA%D+9Z]-62T=?>HR]9T74WQ,F*KN&AB`4578OC$Y?R>I.N\C(H M17G/'%JEVW@%KBV=Y-Z=I*Q,N_T+];(RK:Q,*RO3*K(RK:Q,*RO3;A^F1E:F ME46NBEP>I&R%^%+2DI5IBV!-LNZ>=$EE=DFYJ@TJ*]-*ZY.5:0OFW.0,*6?( MXLI"ELWL?I,3]J3%YKUR M8QY4F9-)5%:FS4]E+EFKLURU.F5E6FGMQV/M!Z\CEP>EYV16EY5I98U-66,S M/S4V96XN1XT<-;(R[881159EVN+GVDYNSS+.DU?B+R(LB@VN MZ'4*=D5O)9"L6]MC2B?<+VM6L99))$X!:I04Z)15Y82-?-^/,,.+A]SCSUI< MVRZB5UX_W*!J1P)L%L$@"0YWLE)7`*&U+,BGN+M-`'R5`&@$FP[JAR%:A[@, MEJX&6%'ZOA<\3J"CMF6^"703Z`[!3EX1"1GO5Q/J*?0Q\+&R8UB.3%P#M*E2 M'-5QHB_2(*A1\31"S4V@ZR3@2P*T=X+5I<='`DP>P2XMS\12M2](D$N%+J/+ MAH,(,T4`V].K>!>*>$UAC427RX%(DSTCIB5>IF8&W8:,T%/&+,"2?=:P3%%: M6,"G;V$GCKBEKO%1\&I:UL1'HOD4DAN(CJJ!!1B+(.J@]^",':!+J.%=?K M"YYUJ%@E5@8(>B?2T2KX(+I$*RKL$OBOX*\22SRL""'AOE8E[F;:RR=JX6+1 M!D]`)_3Z-0QHARZNB4(::GL>&495ZX3%HK@\`[D2M ML81BBHR[LEJZ-IGL44)(]262I0GN"*(+FKNV\+P>S-CWIF:YZR)7=0N6\94! ME(60KX/*(4G5[C8_2M\E/VOB]?`R^_AD)C$B_(\@<$8X)P*F$B5*J.ZQB'P1 M;O]'4$1:%-P0=1H(=I,*1Z5*-*?*UDX7X*57!4((5IEFH[%IO[$0WG'.\QA] MQ)..PTX#TJF?F=6^(@"_L.2(^`8!%D5QJXE2+)RP$,P,HBC&4)^$#'Z??"3,&\Z?S%OGB)F]8?EWZ`' M0L*9M@2"S9A=SCB!&VKW46+A5#H04RGAI@109Z%\`@)^3K-9Y)EPC;EL\C^LS)G0I%PHWF?32#@T33XC% M#8/-J`(?K".X(>059:$$JJ41IK'(/J.%@@#7!R>;&,5*U`\4H%\"!`I\O\?T ML!X>\\1D0-T.&*7+;@!A"[E^.&$D(+@,^]4Z=:!3(]'4!&I74`\3/"8D[88M MLB'&1,KCZI"SX+0C*DH*OXKEQT8"FYOJ(48F*%"8>X_G2J?63)<>#9\1//_. MC&?PB@E**HJ+=2M7(IZ'A9U`:F/?$^*>@;(T>VZ:5F%*&X2]&:U7)'+:),(9 M\/M#R'W>;`<\3&.EB7R6H_02=3ZC26M2Z!KATIF$`Y82L5RM6&-0)S"S8TNV M!TD[CJ/#9&@2H>)'Y(FU>7@#F%1NFF]A_B&JXIA#NM6>' M"5.A-0HO%7`*2'L-#,N-J@U!`&72RH<[Q!&-;9TI/41>%&$DA)2))F@E#SD1 M>+08:@Z&J"53G42.\]@!=/46*',%KC.`OI@99_Z,^M*D4DA@G8D<'_QK9!C,I M>1%BM^/UXMDS0=KG3X[;"*8?6PVF9]Q(Z_\G**8H)I^I@@6X`)E<58S7$1,4 M1,#QHI-H'^C%QNG+#"L8STZ(J'*`(ZJZ)Y*C8.@AA^[6(/UQ5HXQ87DU!T*$\&)_BT>X6'%]-#9 M1NL'2=516&!2E0IJ,_:/1RR_+4KZ/DQXVYZ!127QW8M$:?&5 M$]V:3'0/4*,@K4J9V6Y\!$;4J0\#M6#7*,:23<4X8C-I),I*P1-CWQG;%*W9 M81VI<(H9@#N#"8>VL)+E8VB&O*YIC93!49G=K8F M1;7Z=Y5Q52UA1(*]M8JAVUTVW%=&Q"PCQ!M#-)Z-;KM>:2!-P[F,UZ;[@R[O4L MXQ+2>:K:<C;IZTNLN/I>5)@TR+&;X)4=BW('WH MB>SAEJHHW`U$[>$G]'7K'YGNROV#_2YN2]3ZO`5V$K5>`F`6'CJL;""]*6E) MU/HB6)/$Y)4NJXX1*U7EJ?1*TOF'.3,Z2<(8LK"PFIO7M124AM:3=R MB,DA5J0AML8;$K5>HM9+#/"R88!+9+R*S]X!BS>5!Z3F9UB5HO\;08O'G"1Y_KOSLXN'NGZ?XBO83HFV`5#R+;/5&N]5) MWJW+ZG0S`N=)*OM^6UVMU=>E+P.?4EE7XI+7YF<[&4M0N9))OLVW&J$7%NZ`$+2S'.Z1R0\5,_S M'-[WR<4]V>>::0JP.Y1PN#$YY[*9FKAL-D%X\J*$X1..'8_:;PSV/6?>^%S2XLC9KU=IB/NL00$'\M"*?4\3M ME,4L5=:W;[$+F9L9.ES@33T8R-3@G>^YGD8%&^+;ZVLH4%U#@6M2MULFLU38 M6&,T[I+),`@,+`0]\Z/`-7JR']C8=_2AYK([YQQQM7T&VUH7;4 MY@*VUZ%W7X)H+"&(5IX$\K7;;:Y) MZB/8,'BWWP2:-[S2,T;W:"?=JN-^J=3BJ&7$##UJC.$G=V]GU::W>ZW7IUKV0O8^'9\^%I MH]NJ=[H'H3I+V-E3XRED6FT0^"9D/X@B:X[T]X7%LC8"=@W%`S22^=K]Q M;YA\90VSSYY#&]5ZJ]Y-SDP;T;B%LP<535@K"[Q#BK9\_A*B2- MS:*QFZ7=[%E?[78ZC>;.V*5,8VB;!G/<2U&$V.I\'LB/?E*9:Q\%YMY#&O3 MB280`]JV:,WT!WXT;U]:Y-N:>9J[+ MS(+`H5[O-NOU7;*CZ_[()_5>L`'7N7=!6->)"!S8>6;K\K<@OE"[#9@_:JLP M"!0[C`J<#"Y"F-R5)X!Z=@2A=AI5-;'B,J//]%F#!BK,L^FMDGD$SS3S:ZJL*PQ6P&?2+L(M>Z5?UH@LZ]F!@5H%UAJM M"7-=1,;.:-^"IM3LT*!1[4X.SL-QNUW7JRZ($JK53GMJ)CD@\[MUU&IV$%'= MC1S$,-^[S2^QLP"&7VVU%MO^!`U+Z6Y[(*)?Z^MF<<,UA#<@F6"5J-9G=P?6TS'=LG/ MDO&"Y?-68PO47["Q`ZUF[>-D27CIS?YD/VO0D"6F["F[WER.B-E%]%8722-[ M0DTZTID];D17AI@:V=-=0TV!?"]'V\:NK;$H=6TUU=0QA`6.9$.OUE@:=WPC M2I98PF@LR`M;]6JUMF5RL@2S]#FL!93<#2!T@=1NPS&6[=C;K6XW0=*L/C>@ M*TM,2Z=OR]`T[='3:/=KR&UI=[VH[RW1FB7+;+<^695@58+7=ZM;"$";N9DC MMIQ3-7M).D,B'!`>Y9A^R7F56:"]*L>JM1ZV1YZFDBMDAXQA33 M7+`?J[;;ZF9T+[,8O]WAO*`6B5J?6KW<>#=A=X-ZT2YMHUUMMW?)SFX'=RL[ M##AMMAMM55UIQ1/=D^GNKMS*]:L M[L1:2\_ERU.Q=?HS?%EKP4VC9J>^#1;BT\3X\NS1'IS\%VNE:W"2/96?0F;0 M3861*].T%Z:V,:*6SKIS*H+M3@>M1:>^"F(8NYY5EM]#7E<^M+8OW/4#P\*1 MS/CR=N_W3:X'U;N3,Y5X\%I<-[G\$=09W],06F(CNBGN80=;%INQM9Z$:.]L M#0%-$H=+IVVU6I]=39GT;9?+K=@!NWL2*NYAOIS()?MNM=V]MH-F$^SF.:S M8W_;7A@Y;D]BB2S_7'.'$+:]<`-;^\-E8`!!16SKN8=EZ,7E[*T<$V\OB"YK MU=3$NQEY>V$VPX^V%^R]3)X!VC*WMF6+'ZUGL9*S]G)_>]'A.[6>.N4VM^M- M:)JVZR,XR]K%=&N=6L&JZ?9A M0ERZ#.NM[3&EH9PJ*#6%Q#8%`I034G-=SA;K``=1"1BUQYP1Q"LNU?QEK@*-L+CQZXR!OO$>A&&PBU\03@R`QT+9<8$%W.C9@*S M0:#E*KZ+BY3:B\9-@E$::B_@6(/,?A0@4,`['VPGY`D%GA(PO/(F:C1K"O+L(&\,VM,] MQ;;FFTC`#=$!5"1^B:7W"D0I?=PA5?#(H(++D=PBK27U'QF'1MK`XJB*6JTH MZ.V(99QJ*LK8]%T%O"U%](I:HP?4\(%Z!?^J!&T`@T`4VB4,!%':VG'>T"9B M`S?-2"5D?C\"JA/6D,.A7!@_,P1-P`!@S[8C[!OE+#;U4&5F8JJ&\9"PGX3! M>*GZY8EGAAS\@*,/WS[F4`JY5M$-.D&E!G/JM37VR4,SY;^^C<,;'#`X,/)$ M.GDNX4Y@2(`#`=<+B8X.WB'0(GR75"*Y-6_"`,COT2-OZ($U'1VD'%9KZ:R> MUID!4Y[NP4R#NK'B3WV7.2_D3CD]''IH\0G^T4W?F%0Y*MCE(_##SKQ!.FT5 M&GIX]*)@"[AK'G;A^OH0O^3!L4'%(;^*#;YQ!M,>S'(OH<7@W)F@F:9&7!D$ M5@(2J1D8]M)NUK,;-;8;%+9O39E();`*=+*!#B/=Q+,S&(#+/3]8@7D=XN3N MT?]##`9&XID,&H*)U7JK1(&(6"9Y(P-#9^"(6Z?"R)(NY$UJ=T7BKC':Q6UU M',!"'3QR#P:ZVQ'DI9!?)B?.`88],*+L1-!HHIFX882K]>T7-G.NK22_#=H6 M`;!X%7[#*0*"[S3L+R;U8$J'^1S=`O4K:!;V!G;D\F>+#V":`;J`2'P: M^R.C.TO&%T(UG7JM_4G$%:Y+^4`0;,?MZ!3MC34(/74?_5MHX7:0SA!3*7:" MA,*-LPST76'^@1&B[MGPKSMF.G:";3&-G)ZTZ@V)^P(=IB8$D/P,ET5I2Y]% MIAYEM2)F3*6R8]OEPFE%7DTW056@.GCYE7O#P/1#?QD8[MN9T@/;`G-P?=,3 M>81O10G;L\:M8)JTT?[(QP639T:CTSDEH?2YP`V,"^(KG*-%#DC#*\$1,4&I ME99`^4,A]"=D]XZ=/9]5DLU$Z7=R9GX_+>3I-X?;P+DICWE=1\(8+0:5<1/%Y_7Q$+*(E79GF6X''U_?'EE@DT M^1L"DZ3X/6!D4VL/R<>;S=_BG#RS^]N;GKW MC]"G#E:JC5WV2;G[\_+AZN;NVT?EA;M8.FTA>KH"7OC9^O4$0>\3A.RYQOV. M:@W56ULNEY@[#K==#S)_#`*':.!@PF"E];)S>^SJ_'\TC\4\W].$5@K.CUVU M)>-6JK-4W!ZP;%_NA"'#IN(S*$=OJ1A(FE M%.P>NSY+QJV,F63,5"8&Y>@M%8,+U/E5;(W$3`]LIQ1\'[MB"7JD%(P>NR9E M_"L#IF-4=U$8E`%3J1A^HU,8_%$(@":XJY%8$"\;VD^W)Y8DCT;6X7Q1+I?9>*OXH%5^7BC]. MQ:M'KG@9Q1V5NO/%8.!KGN[N9SH:R?\\_JLE$8#4L.1?6GBA&906+BU<:ECR M+RU\OVF72:`P&XI"UQG;7=(5U#:*$=C6T/E^V1QQPS!9KE98'JE4:[5>E4J]+8I;&7W=A/I9%+ M(Y=&+HU<&GG!C5R&+?G)RG*\%;9?_O;BUPZOOKPL,&7XKERRO^WU)6G<>=*N M-.X":U\:MS1N:=S%9$\:MS3N,J=7FR72[07IU1?-I$)'I^G*&\><5B]<2U%A M6!FVW\?^!C.7P4M^01BZ-7!JY-/*B&[D,6O*2D-/6G8PPR%:MLIJO(Z9);B#1EWE($&__>BF3X33QO,8\Z(6_"T[W+K61D[ M7,=_1[;!3.C.X*YN^Y8'#^B:.U0&IOVJC)@WM`W;M)\YM&-#_LY'W-0"99XL/N(Y'0*EUI-H?C3UN6]@&QR+*"G<5W[+[ M8"?V:*Q9;T(9G7JM_9 M^+`^5(C"9S:"5]PSY5)S3,Y0/K1R4$G2L%`B`>/0(;`.'UZ8XY*\2>RK"^$L MA\,`J>@['V8[IWR0MRT7J:1\9"\:/V")'J@<#2NP?ASCFAA:@YF6(4:_JSN\ M#V^!:0]L$\:V^W&W+H]FRNO;BTL48?6LR6'FR[6/3DSM-S2SISE`^K]=7SS] MCH\GXPCA>(+.(PX3CW>J/T4KR^=W-S>]^T?H4P MN,NAL1-%9R96,D4'_>M)57P>:X81?M9,\+&_GF`$DB"D'&4\U:8L'U1`!E-K MY*EBO.H4MU>V$S,,3BS^\#1T6.+C5W"`0S?^?&D9S"B#A*0)S#6!1_ZCI`:0 MEQVUW`E#NOR25FA?Q2,@;&:B/GNU4E2];]O/2[T70^_2O4OW7OIAOLH)J?:B MI??U\)$+Q[HTCO6,8YW#4[EP#5+[TC5(UR!=@PP299!8OC6_W!R2EQJ6&I8: MEAJ6&I8:+DC8E;/CH;."K@?N_G4ZA MYV@\-P]V<30/2LU)"+;;];`H!'NQ36[2>W>W*E:_#AUU[6OF"S]Q@EN'F/M(N4=2U^_0I3WXZ#[F4 MU+#4L-2PU'"9-5PP=4I!A+[97Z+F(D"2`O'63J:+KG:Z9B M\@%#J"3\GENNY_@(OZ7T&8*A$6":<:8\_);"\AIH+AHUO,DL9^WV3 MZ^:;`OT8T/'`=A0M@0@&OY@VHJX!R39A='G`0V4*9HS`G9`2S8KYB1<>E;Z& M;-D6-.ZP%PXB"5@9S:U$'6WA(0J M^'N`!0>LC6V7(P05O"P$@:AGP!/"3R'P&+<4[KG0F.%#06Y M)M#J!HX]$J2,QB:'+]XX,PU7?/_'V2,TYC#-]9TWY6_FV*>Z[8]!/GT;,@:! M>H:B&FG<0O+)-$*L-,L3#WA3QK/`/G(X`'(].K?I))64ET1#$GAFI%V"XAH[ M-F:,+@W`T4@#RPCTJ0\1;@\-,8&/6(&/NNDCMI9B,0]'L.4.F$./:9;Q`8:R M[7MD\IIISL18&Y$%,@)"C%L.QZGN.PZV#H,7QSC!+R:Q#P4B(EB]3X\AI2[_ MH8P(^T9A"'FC($J"HE:IJ$"#,!?Q%IS$<)M!L`@,MHOAUFI*#+<58JZ&O$10 MFIN[*1&DKN:F@%WJ1;_#/9]/J>HE5"UO9$LG7C0.C_ZNW['S+RV\(`Q*"Y<6 MGK\I.P*W%+5GC(<\I$E>7+!GC33 M;#-5.Q7UN*TT)S-HCE/>DA]`RYGZ2E*%?'_1O#1/:9[2/(]FHMQ>/#1KHCRG MW?7TYCINFAO,X2^:QU]8M&K!X&#R8)PYF5AE!EIH/R1#?!GB2_.4YGEH_95_HMQM!GKMNC[M=LJL M,X.]UJ5>[\I]5&GU1V7U#;5Q[#:?DZE>YL3'E73DY8CF M@7*2W)S0E,:=)^U*XRZP]LL_2>_M\'%P??F8X[*%H;@*(\JP_3[VGS--;^G8 MYXJ,%S4)J5<:[5:E<]QIB#3W8S'W1K53J1ZWL9<"*JIP_$GRT^ MX+H&NAIP"T(8KID),"!XPM>'BN8JNN8.*XJFZ[:/7X^U-P(207@6^-+QF4'` M0I:+0$C,88K!V`A!AFQ%&X\=^P11XKR<`?\3@$SPE3NT'4\@$EF:YSOL M+,L<0XLU0SR3ONT8S"&PD4#09.^U3OU$\2TNGOSC\>+[F#G?J8T3T(X. M"C'=7T_4D\\(?U>+B5Z.CFU17ZM_5VM(O3I!O7HXZND1M^=[8)7\;[#BY67> M2%#M4C-)YR3NSO=<#UPN8F:MG&3TQ:]W$ MV&:QCXY<=)K\:NU[E4AO/-GSI-VMGGR>F//7GKN5DSV$$'W;-):.(VYMF,.; M8:S3K'Y20L$J]XF(()"M6BN)"[$@CQ!2, MT`<_[D):A0O)=X?`5Y4(?!N65)#`'[EG;W$]?TP?NU8OF,Y& M?>8D-+L68DLN&,_+7EGNA"'=LT3-E`"I1Z5J"9`JG7C1."Q+-+;*^:55AO4[ MW])\@WO,6.<6;B[47<;@>U?J+J0PI"^7OKQ,@_N(&91@OI+!O#,H;;3<9[X7 M39KA+N>`804N*]XZ6T/WI3D>F`?V))SO@D/;W8JJUG.O1FFE1VVEM:I::5>; MN==C^:].[3;W#*?1L?;FV*9Y*'WGX:K<03$<\A`WY@_#8;?Y0J-6J7?7V1F3 M)B]-OI@F7ZM7NHVC-OFA]BM8)="MPC[4/X[H]L$B6A7 M*ZUZ2XX4.5+D2%D0.=1:E5:C>\Q#Y?"7KXMS]W;-*U^3-\=`5$%+0-V]8UOP MI\[H1=B$M2KGZYZCU^BC[5/ M[Q4N+N3.?/V/L8&@`LGW>X]_I%Z_M<^(G--:M:(DGKM@+\RTQSB.L<%GIEQ" MZ^@3E'=/]ICK2K?6?/]1N33Y"'CPN&WA/;ASYG@:MQ)\/;"Q[1!=#^R_/G>$ M:ZB`+'33IRNPFJ7TX$N#^O)LY4_-X>0YKW&_E[E>W/5O/C<(1PJZ$%1TD.YS MVZ()D\@X.U&>AMQ5@%,%>K-?X#T4M<$&W.(AH1I\CCETB4.&W;PI`\<>T1N] MQW/2DL/Z;Z(I))>N^D7L.1%[!G?A7YTZZ#/OE3%K7A\\V!"UL?%$$]&/1,)O MO=[]&=H,>GYLMA)0]8?"`JD'K#D)R2H#V\GJ%P3\KO9>&8-@\5>@F(VQ\5// M/B5KX=8`)W_B`\2,[;L($"!:!]'98^;0SZ!%A+U0!J;]"G\C1R[>-A[:)LQX M;@))0T$"O;>*\J[^7C&U/C,GQ)CH04.>;)=E:PF:4M^CS'%^8O2@JSM\'.I7 M:'SR79Q17H0<@+77(=>']&2@>;`:9CW#@X;@YETCT44@BP%WP"+?F.;,:\*R M%=.VGD&S&4;F#344/NB!@[ZP.2#)4X::`<;#(LE/O7\6&S=2.Q@PG9#-4>N: M9?DIDP1%<1O\0)\]<\NBL3:`(:6$-XN46K,2."-DE^-XXZ/H-3)];ITIEYIC MOH$9VD*\T#$\,N*>QXRS)'8*V"60$Z":X-/01$!L3.DK]X;`JJN<^XZ#?`D/ MH4##5V!X2N?T?T'()K1"3SY>GN-/_^.;6+":J"5B43H116#,OHD=!V*CP0JB M`$,`0W_AMN^:;^$P,69HQ8CQ1\YR.'$4;5:#22J:F$#Y\213KR@G:"S,1)\UY9AYT[9LXZJ"G(0?+,()1@NW1G.5R<(O` M\`N'E^YI<%1.E'6)R-,0/>DBE-DVE$U'I!E2*(8R/>PY#=!=TJ^E>(0X7T\J9TIN<@]X0<`C[ MT\9C&#CL!Q?4/"?FWYD1Q[EM$%X2J5%H$94/FEQ&\2=()7A!AYEB;@,W\DKM MDBN82;V;E%LD-GQ3T$=&(U":J*E%>D(0GIEN-?2*LSPEDD>NA^:B]/.+G&]S M@7^-@I^1]A;HP\OD@'%TW!^5=QI.\[8[%KS@>R`5TPQE^NQH%L$7.,J(U):R MJ5@&&!5\PJ?>]=^#:KR,)J?4)$P[U!&(UDY@GVAN.%/',@J^@/G0Y!CZI809 M1BVQHY\=05A&2)<%CBO%GZ"39C;B-3U_&3;#^1N[];C.QQ@/$>FIV89H!"6Y M@=D#V]#54'O!.`1AO!Q""8,F=9K6<+)#>\7#;P2=$P2K>#9N!OUR`EJ>N!"Y MX3\^C/O!&Q&;5.@0'"&_10T>6`RUBJTB/B/BS*2!#$D&@F$+IVQ$N6BXPLIBTL>T&J8X3!$<3 MH?NTD15GY6K5):?)):M'?<@,WV1W@V76P)[PETV6K^H%6[Y:#2(H5^Z`J)#P M/1*^9^VC`[F[9""OHQ6200G?<^Q:E?`].SC9E3MA2/HPJ^)7R/].72EY?4EQ\Q@Q(:13*8=P:EC1[W#44)WY-3]B0P MBH3OD59:="N5\#UYF49WFWM*^)Z--PERIF6)92+A>Z3)2Y.7\#UYGM4E?(\$ M)9&@)`<')9'P/7*DR)$BX7NV"M]3G*M*FUPUFE&C'9^_=^P!O*YWE75>@HS:%D2MDI]K?Y= MI7M6Z@3UC4SJ:U6U76UNE7RQBO.D_=A8\,U,TALUR)RG*5_0_=:HGBOP5K;` M@>BM4+UPJ&PH_'8F&^TJQ"RK(67MEZ^YZNEDJZ?6@AEF^XP])E!?+@GIY=;V MV`SPL#5N3W;+?'L2Q:2TPYM\S>HGY7$.@,X%&W"=,TM_FYH-<\)+7J^(1U00 M9-FY/1K95H`]@;O:WS0'<1"4N\$`'K>>);S9VL1=^$X(D.7R'PK(V1LBHI+! M#($0HU8K"928"#2(8+X(5,-&W!9N(8H'@?-HSPZCB]T"64)3GAW;'^.-7?&0 M[;AGRKWON+XFL,,(IR%\2703/4G.Q^%]/T`H2M*@/<-+SPCW8#$/43,@&C;H MROR_U$JU5J]T&BWE'?3NNNE?4?+;0I.$GEKM2K+B*BZ$/Z6WG5 M7$RG#*)@JSQ7S]K-=.=CYHA.T3&D+HC;8+WND`!,!O`+^1`W\B%HM*,1,S@8 MD/E&(#2$[?'"3@DH[#7P,6!T8]\!B2*ZV?P6L7^0/'-T#@^.'03TV;;"9S-/ M!`E(E(!FP!T*GC!%(R8T1=UX1U\+`D4:CJ<^2\(&&_6HI,%8M(X$V&+`" M#7E,X.0-F.81YI;20W@B@51148SU'(G#=%.#N)Z07K8JK5JET>U6(+M/BPQ- MDJ`#-.XH+YKILQ!,()(>2`:FFN3)W"G?BA%&#)(FH.$(R!&\O14X)0HUD)64J\%VQB9+ MXDL2%)UR&4R1:20IX-U^MOC?3"`5;M4;-=1I?E/>AU"N$%Z+F#[M:P)W*H&^ M%ISE3'I:;PAA4Z:O%6"7KYH`'4U#S9V!83"1SW13^8S?=]E_?0SA+E\B?-(0 MT101C!)PHQB".49(4'I21)9VX?P*,,[2+BS,6&2BLI%`=P(!WU-, M=[*E.J4Z\>]O#,]A,*,4O!Z[,DO&K01$D(%2P1F4H[>\#,J9]7B4V7MACO;, M2L'JL>NR9-S**$E&205G4([>\C(H)]:CT>4#&VD#ZV-5Z&9PG+@6OQZ[,&SZ0BBP$@PL4>8TW4BR7ZZ5@ M5D9*,E*2U6*2.SG)H[H%5+AY2PY)_:>%%8U!:N+1PJ6')O[3P_:9= M>0-6GR&+.]]S/C%;5&E^+7J;R=,YZ+7=1I[S6K'WK8&E(?I<+2I--EVME M^52J\L@&HK34TJBRY`-1KC`76W\E'WW2/(MBGCG)/7:[`7)E.P/&Y1;(6A?< M2I-FKRN`HBY*'RPJ++*RCWZX2VLOM++E8)9+X$>DX1*.8&GBY33QG&1:>[S] MDBH'F?LD^Y"#6X7!;=A^'TWO\,L,J]Q].["`&H MADFGUJPTNM5C'BHYR3AWN[=W^$DR7\M'AU\[F36*D\YG;^P?:&UL??[EVEF. MV=M*(@4BS]/\/ASY6>7.7SP\Q1?1"(U MC(TEZ0T;/K^Y[#U\!"4.TW*<%..DP+[V'GZ[!CG!W_"_P+;$;Y,JJ(@O*LHC M$AE(;;ZH#D_/H= M'T\Z+6$!0><17XG'F\V?HL6K\[N;F][](_2I@PEI8Q>!G`>CM9!K`Y MY6FCRJZ1"2?.;J\QM^1.`+(4Y$F]M:H-))8!C]L&BELB9(O9=$[W*8ESKA/B1J7:'YKY=$`%+#DG]IX85F4%KXFOR7 M10!2PY)_Z<./':!@@]M?A;O:-<.NJV?5:OXQ/N6EW+T!QN3:6NN5:D.M=%1Y MC5Q:;`XM=@;3^;\Z*RWU""UUAF_-OZ66'W=KIQ%^OL+:+;(Z,ZQM-P^&QYV' M/*T81.E=67_Y`.[_9 M\7:PG'>;*AY^-LZ7_G*-?R&EAR]"B)\'%[@L8&KX@41"F(U]VS&80X"*@8"(F(^([_A)('N>FMJ;[7L? M!_P',SXM!&:,VG>BOXSPKP_)/YWXSY#B7S[X[NFSIHT_/B):Z-`V@3CW\K\^ M]]YN;8]=<%D>-^`+ M8-"WN'CCC\>+$\5@.@<;<9'7SW6U!H_$9&?VOG52OTPC>N#+6_3G[YPYFJ,/W^CQW@_N3K!:XY]Y9U>;W:GO6B.LD*'2IF221U[=7)Y_; M31&OQ71F=)U!Y;WFW#F/'H*#$Y/WS*&W5Z"VFY;G]S%SOE,;2:)5L",\;SF3 MWGE$;(?NV)[HBF*NN^%0JM47#Z5Z MM3HYEC+ZGB3SWF$#YCC,V)12=3&EM2E"LWO/IG7SH5]KK&<-R]$14J^;NOOQ M-QO2FG/;TIEC13G'ZL%,K7GR.4CKIF#R5X7_5U)9XHZJ$/0A]5JZ%`&F9DH] M+)?0K'Y22&Q*(+>I-#0G9.>ZO`.6V`A\IS+47,6R/>6961!C8#T-_-:!.,/R M\37\W6&Z[S@H=8MY"B3)+OZB*:^V\Q=^JVMC[FDFC(\!USFS]#<%WK('Z2H< MT+"A7#"=O+2BUNA;%1_3QF/'_@%#RV/FF_*O6@6BE0HNW.`;_VIUV_BA`F2X M8P8V#R'06X5^\UUT1YH[5+BEV&-D@-N6.Z/->@5L)VY3;8@/`]M1/)"&RW\H MX,R]H:LPRX!&IRE'8M,TG"G7EH*+$]AI91;+%6H\%C4*5]%TW1_YHG:)D)@W M@^!FI=T@OL]072YY,-$3Z$/C\(7K]Q&%T^,H>=OO>XK6MWTOV:6PPDZ]UO[D MPJ_,3L:S'+%7[3J M2)H>A%$8D!N$)BY8Q`M3^HQ96.%F#/.#H=@6*3"E$Z6ON1QZ?1UR?0@Z00^!C1+R87ZN<,B^C0NV(]$OKP'6``GHD' M$-E<9##P4]*,D_;#H;?$N.,N6/081Y#E(2<@,NV9>$U9XMC4K(@=;NFF;S#! M#A@V\@T]AC[%&SJV_SR$=M'`+>,#C%A&,1VT[OR%[+YR;ZBX]HA%@Q'>&_B$ M3ZL,''ND@$V`R_$<+?Y9J`,><(%_'74J"*&B0\P9H5/$;WW@%'3F`Z4>Z![H MT3QJ'-AP[!>.SJ+_EA0"AANN/Q"NT$-QX>-3SM)!+AQA"&@4$L[(&[9N#)TCI^90ZC M:2';68#0/&#,-]'>_D*_A>_TT71,AN\*^Q1V$AJGI[Q@2(3I,G3FA(]B]SI$ M\F_8/CVA!,YY`-EJ\`US/?*0."<-3'#$P'#`8%\#JP)%*M"+@GXP^%Z,K&@@ MX%=K#5;I&%=WC!AXPXS71ULBO^4(%=$@2MD;-TU\#,899BD#WT3U!3$)&D1B M!-!\3\,Z\`-@)F*`!T,9K0G:HN``)_A)O[:>KS9L,N[072'56K1ZXHKA1\[# M#CRS;B.L7S0WGBQFC6V, MV-#]A'[0Q)4C-QV0L!\8RX3R"@:L)QQYZX5O@B<(WC&[.E,)D@O0I#! MS$')U6B,GE+$?9I)4U_"/T$2%,NY@+M<\U/+5/(9+IHD\**?<-I+IY^M5/I9 M%PGS=VC8]4UO6T61#[:C-5;B-%EUQYHSV*NZ!T6=B>'+1FY6B99;&DH++64O!N9 MB&7S1*&6?6PBU9M+K/=WZHUFMZXFCN-,DKH9+^>N>>?`4Q"^B1?7U5YK"4>F MKLR,Z/@K\X:V<6V]L&#W]14R'7?(Q_>@9OBL/>]EUZ^>W#<>^VG#K(*R$MM' MR]*]&X:WIM5.!L>TJ]/N-+?`-0`S.CMM3,O"T=+Q%: M30_*;/I3,I"A;7#2&(=2F8Z&_*R>]V$5M?KUTD*;YEWKKG#^V`9]G'Z/O=06T3WQ-E*-?LPFMI([SDO3\K6FK6Y[J>Y)*NRKV$RXLAV.NQ=< MAXB?%H3NG)MX0:[GX=$IL1:]O)R6/)VU"36[YF@W9Q+5SJ)3>H63R<8G%]5N MZ62R\?G&QH*3\OD=0?-\5R/[('QX6#K/#.U(U=D!1V$%L[%?:&1'-$64R<;S M1R,[0-J23*9.32<>_\HTO#)DW%D/X2&I+WA8XP_+[KL,VNF;@F/XV892T M.;7!<;]&T8[[+;V9G%C$H\,U]DOJ:,,PM/5@JW:%(W0^'9KYKV_3^0],!NF0#VU_LNB8 M#&Z%1Y8?[G:^HY&EU-Y7%)<_6[0GC6=W:#\]-F%H#D=M^'C]O3A_EWS%M^8^ MKK[_F$/E[O;P1.(NZ`U=!:4OKF\O+I'&*K<^*=^N+YY^Q\>KB_2/TJ8.5:F.7?5+N_KQ\N+JY^_91>>$NA\86[CR^+!8\"H%U\>NUL=XB:44[!Z[/DO& MK8R99,Q4)@;EZ"T5@PO4&6P)QDP/;*<4?!^[8N]P_ZH4C!Z[)F7\*P.F8U1W M41B4`5.I&%RTR!2>'RD%L\>NS;OHP$XIN#UV=2;/'):"7QDKR5BI3`S*6*E4 M#"Y09^*4>"G8/79]BHL+I>!4JE*J4L9(1Z7N=*OXH%5^7BC].Q:M'KG@9Q1V5NO/%X"$KU!::_VI)!"`U+/F7%EYH M!J6%2PN7&I;\2PO?;]IE$BC,AJ+0=<9VEW0%6*Y109JW-72^7S9'W#!,EJL5 MEISI>88`_K43OAU$_YW-^'WOXN+Z]K?3!T%>,X1NVK\P9GBX>J71;E4ZU:HT M=FGL93?V4VGDTLBED4LCET9><".784M^LK(<;X7ME[^]^+7#JR\O"TP9OBN7 M[&][?4D:=YZT*XV[P-J7QBV-6QIW,=F3QBV-N\SIU6:)='M!>O5%,S5+9\II MNO+&,:?5"]=25!A6ANWWL?^K2-+!Q!KO?ZG'G%K+(]1'K[PL^VI<-; MFL=MZXG]\+Z8MO[7YW_^XY__4)1?IOKHN2[SW)YE9'<&#]S:EI/J&]\/>M&' M%O^OS]PGI"/J5`%2//CPP`:_GMQ7:]_AOP@K\F176]_5*OU]HG#CUY,K3?>X M\;W>:)U\#DP@U,G7WL-OUV!"8%?POV#P"3N;M,Z*^**B/#*'#Y24187-G=]< M]AX^PF`;IBU]TM`G37IM,DYFF^/A20+-^Z,QZL]5?`]4_SX,R0(*0B^&WJ5[E^Z] M],-\E9,K[45+HNOAUA:.=6DI9M8F:AG\[4M-E MUG3MK-$28[JM2DV76=,PENN[&=,%4VM.@K'=KH!=_A@SW6.&`I'82'GWQC3' M?7\HK2_-:HE"L2VF'3,&<^-,56$L-\^V?#%D,Z>=AU2K7'H&9UTEGUW?;J%6 MJ>=\Z5F.Y^/0FP>[T)<'I>8D!-OM>E@4@KW8IN;).@.ERJ9JK0:ES:V6 MS)K+K&>YTEEN_4;C6*YSEEK/+5K/[G;ERM?APZX]K7S!9VXPRW!S'VF7*.K: M??J4)S^=AUQ*:EAJ6&I8:KC,&BZ8.DN,5[5++*D%`%:;XF.M`575EE!5^R+I M:<@"@"G0J[!T9>S8&,*[BJ:X_FBD.6^(587@5?I0LY[A!VXI`[`2`K-B%?BH MFSY:OF(Q3_$Z2W.5,B6"U%W)%-)&O>B7:N?S*56]A*KE M%5GIQ(O&X=%?OCIV_J6%%X1!:>'2PO,W9>=@B[>]8,*.:WC]CV;YN!926P?Q MKN3GR7*@R"V5MRC#J0M9NR(7[$DSS393M5-1C]M*O<7S4OSE.8IS?-H)LKMQ4.S)LISVEU/;Z[CIKG!'/ZB>?R%17OF\DI3WA5< MG%-IN[[I46D<=Y"?!_;R9*ZY,#)\C#\:9DXE59J"%]D,RQ)=*N-.X":[_\D_3>#A\' MUY>/.2Y;&(JK,*(,V^]C_SG3]):.?:[(>%&3D'JET6Y5.L>=ADAS/Q9S;U0[ ME>IQ&WOIL7LVA=')0NGQ1V-\UL52<%<.@W9$(;@'S6-SX'?4!/R.^OTKM_C( M'WUEHSYS?!<[>,"S:+T?W)W`YNF<*+[%17-C8.A$,9C.P>1<"&%./B,(5;4^ M6PI99.Z6/>W'LNQUEV"OL[Z$<3;SQM[RVE-S/?8:FXZ]QF+C;!W.<\YA;WGM-9=@;T?&&6(//V'1 MK>W.=\W6R>?[ZK^SZ4[VOQMZEU=#&^AM?=T[O6N/B@[0V_BW^K7>O3@TTO54_@!UOZK-;Z@[M^,^H M_,X.TI!6UF1:Q]EFT5PSF\Q=,[B\:K*F4V*PV\T%@VL/F%8V@[6S5B./#"ZO MP?9"!A<$LSMF<*:7GN`A*]O/PS#;V&UGY?MYL,)-77P[*^,7#"[(]Y=C$'! MK\RXUQSO[0D!@+%_>/N"N[IIX\K7!H#0[5K!`*'[MFDLC>A[:X/66R&P;[/Z M23D'P?FFAUC&O6?(AT;,\MSD`X&T%1+WU!II3OC:+5+QAC#*=Y9RIWLV#!]% M)4SH6H5PH\_MT5BSWA1"Z0()<\NS%0W&S`!\2G`86F>6RQ0MU(PRL!WE3P;/ MG3/35#R$6;=-^_F-4*9AH$$#EL)^Z*;O8@,VC:O$^_"FQ9YMC^/PAT=Q)1H? MTT/EW\S0P#ATS]A+S= M\!%'ZWDG--2IUZN?\,WH8^W3^PHP/;!]RP`!83ON4'/8$-0/GP,P\*"Y,]$K M=^G+!$4A#CB]K]NC$7-T#CQI$,<&37QC_&]0D*5<6Z['/=^CD^>/.F>6SBK$ MM1-R`U[#\*G"D.8M?IG>!7%QZP581UD!!6.'$W;XB'E#VW#Q\;YM,66D.8[] M*@@>FYKE">D2W:32(0A\_*;XZ/_^QA90W:>H;O>,(-392XBRKXS!R&Q#Z`.( M1^>)&D:S'X#C"^T^M3_S\X3%_ESYV45;_7EJ4X:L%[D/K`A:#FV$OLVT$=OA MSQS,R@3[_C'F:-_VY#BH$]M#S55`5"#'/F-HO)Y`48?N'MG8HWE'J0DP=1K= MR!J2=@:_,^'2NDF/]>CW7?9?'\WP\H7<&2J(6P/R,1?%3>U=XK_]KFR*W7JM%.;SADIL=@[9/RKOX>I;W-OL%5^C">HNFA[QO/ MS"//S+UH(E.5-_B9:C>058Q@$B`!_JM3)=HCT0:.#G[FY@0#C4]I#M^IP(UB MV=8I*`PF%=JX17GC5SKX(2[V,&00H]$+T,KX&K)%D%>Y+.B,AK1G!:(\-WKD,>?T"`M MVXM<=&27?18Y8IB?WS50IH[]IID>M;Q-8:6=^D_8/);V&/@T,G%4NDH?)Q24 M19\--7,P$18H-/^^*:[?#]7*7.FK5R3N.BW3@<9-%R=A31]R$LDX4#N(PY* M\2"<(9X M&OPK?N(0C^*Q36`/)ROXQ:2Y,$V('`LK$G<5*-D;@@1%=)!9Y"=MAP[3\:`0 MN%.L8N0\D_G:XR!>((>OC2'$^,%1[1`A;W7R4;O=Z=D'6=AJ+RW(8B=[J81) M"(1,YELEF+UA/.GQ(@.D/[AZ1%:YJIC57(E9G3');UW,C:JZN9A[)(OIJE07 M3!?9E5H+Y;M#@=5KK7T(K%&?[@4G!DHN-5UW_"#.X1B+OV$LF!;HM+,LSD'` M%99&IU=51:#8LXS$0DXOMJ-SD*8#[3W9]\S!7`M&[QU.0NZY[7KNM85'#9GQ MFV.[;GK=M58-UEUK3S;^K=+?WW$V'9$!IA:7Y[#PY2WYRXS5Y^2)I3\>+Y*+ MS]63SY`-P7^2DMHBNUN4Y05S=8?3@@N\_40)P@&$J9Y\WFL.MQ7%S)!=J!G= MU-VH:1C]B96`A*O4@Z8]G$4PVX?F*U.-9/E6JNQ'XYW:/'SM-VI M9;+>J':JY1O^<^U@083<:+8L4P&KID6TUR0 M4[52PV<%&K9*_KSYKM/*-@FTB.V0_XA'%L#PF8&+4Q`742R62%J^O,6/0/N4 MTKQJCG'Y7Q^4B:<*')^.WE`F\P3.]4X>9X[G"N[VA+#N-/LJO4PP=TC&P>83KXQ!#!@1N^%.=HS([=RH7DL"OJR M1/L]X(#=.QSB$XLE5SIF$T_?NCW?&]H.9@MT,NC1L_6_!&7WIH:+(:F&YYPS M[D[$L=_'S/E.[29>/%^N-;VR M3VPL]HF=;E6M-;NE#A%7$."!/5]SB9B^VE`[:E,J+!<.K+5"U)$/A?77$L>T M,!)!3M#[A,M\8".-6]QZ#C?T?,W$/;OZ&H%QFV[$=K[6ZA<3=/RIU>66&PZ5+.=340<85VI5KFULFO'. M6457JTNM-=`YD_K1+C6DUZ17E/X2\9U:76H=H"[6`?:_"I\C5:17MW>ABL8R MJJ@>9#$_1WH(5LA]<,6[4$(S3TI8A=?]3]X;+7].B+VUDAO*$8_+I2S35/57 MIJKW_(RWJST$UG.XY7*="+CS/;RH1'>NEY=W]MF]3JW9Z$Y:^(&8VIJ`IY6; M[K.V@OBRC_MM0W(+J9V2"P:X>+"%&1=T#U9X;A$,W[)7^FGU,VYJ=8GMY<;4 M+OU2Q*1=%KXBL"E<83:(/W`Q[XCP,J370!>7>.\20N0I_@L?E_H2.A MF\/TFP"W`.'BI(=G[/'^(C&+'_!@/O3O(H4"#L12^&C$#"XN\XBP41GP%W9* M%Y%?Z30X(4:,?3PJ[K*L%CUQ)5^D(\H8\Q$ZYQ_12.^=A7YOD:`F3N;KIN:Z M?,!U,KV[P3=!G/MD;^/@E5K+/@A8:W2[R;/S*U$S<^Q3OK;\6*TMGV=,1;C4 MU201Y\A!1/B=\X`S1'HY(>(J^-5=P;?4UHO(UZ*J&!GD7$DM%3"3I)K[/8FU MI:AAS96ZQ.2YZ_T!M=8D\,G:U]:NUAW7YV92R/>.K3-FN%>./3I'53D>AWGU M@O6].8S//Q2KUK)/0$Y>BLOH>W,RL_23'>BM1B&Y\.1S\3G:55 M9MKV&KQD7T=0JZUVM]N:[=AFDI#2CICDK[BE$4I0^`+=3%Z#U@772INU9BC[ MK(Y7RO7$]U>V\\B<%ZZO92Y+G(:A":ZZ9,HW1=.2'%&PM`V&%MQ74)=A938Q MDYS<"9@,#$=`<^"Z$7K5L&Z]K7^3^\O;T-IZQT57/CA,: MU;2$YC*YJ332>^H'DT9V"-*JU78KC=G0^P>3QH)@1JWN1QKYL`TU.R!2@^6. MI:4AUG3T(3-\D]D#-\J=]$3N1`M%XJ(Z76]_@:F"0$I03'T$'7G"3^NC,ZMJ MT="9ET;#RA\&UC91>904'L\V6^XIKC\::3'@8;BJ&1I@$F\Q&\2+$($0+Y&P M2/LP#E\_3M&=-R7E&45M%R0E*E+>4$%*^N+Z]N(2*:MRZY/R[?KBZ7=\/%G^ M4N`V3?J,Q.,=1&X*BH">W]W<].X?H4_=-DUM[+)/RMV?EP]7-W??/BHOW,4U MAX603HIF\F?KUQ,LG)D@9*T"T@A4PIS]%Q.?6WY3W7:U]-QQ6$H&DU7`:\`A M&CB8L(4KT"7G5JJS5-P>NSK#_852\'KLRBP9MULIS2T#I8)P6$H&Y>@M+X-R M9CT>90;'+TK!ZK'KLF3NS9+QJT, MDV285'`&5QF]`C4AYMD>E(+K8U=K>&6D%+P>NS)O^$`JLA`,+E!D=%NY%,S* M2$E&2JLQ&)QW^W+W]'3W%:BCVQ)5I3;^@9?0N1$CT+O=+WMN'4MH[6"J+N,ZUJ!>WFZNY_I M6TJ?:J[-?[4D`I`:EOQ+"R\T@]+"I85+#4O^I87O-^TRZ<+RAJ+0=<9VEW0E M<.PJR@73":5"46MT0UY=PP!RQO.V!_A^V1MQPS#9'MES\";$;/[N>Q<7U[>_ MG3X(*IHA/,#^53K#9]4KG5J]TNAVI$J+-R#_=42&BF5#2JG$`MEHGKQJ;@Q3 MZB\O[.U]]$GS+(IYYB0EV>T^$.&2KW4;-V?,Y=(-+GF;)#4.Z+:ITAFMJ M5:K=:J75.EA>8D]]CM!LB5[0P8EUL@:UUP*TV:O:X`BKHH?;"HL,C*/OKA+JV]T,J6 M@UDN@1^1ADLX@J6)E]/$:CD)./<[=[>X2?)?"T? M'7[M9-8H3CJ?O;%_H+6Q]?F7:V!3W"*,TWK_J5WEF: M=RG,.R=IU%ZN9VE@)'+CKFB+37E<;LO1LM)*/J]5Z32[%;6>?[O/H];S/_++ MOXJZXN;9X9`K\N7AY4`N@STWSMI2W])QE]_0\W_G=T\IV0L1A7=MO"G!S;X]>2^6OL._\7\\,FNMKZK5?K[1.'&KR=7 M2*/Q757K)Y\#W8;"_MI[^.T:;`,,!OX7C"=A0)-F5Q%?5)1'YO"!DC*5L+GS MF\O>PT<8/\.T"4]:\*2MKDW&R6P[.SQ)3T.F#&S3M%_!+(4=*V.'NW M%Y=(696#=_YV??'T.SZ>G"6$!4R.NL3CS>9/T6KA^=W-3>_^$?K4P82TL0M> M^P[<^=7-W;>/R@MW.32VT!$JFLF?K5]/<)9)$++TBEG!ZR[6V\FZB\VIJ2TJ MI1N9<.*P_!J3>>X$(&MOGM1;J]I`8MWUN&V@N#4YURX5I&87:BUDV2!9-TH: M@ZR2ME#;]6QM?V.X*K$67DGA1''LIB`'?LGC`ZGZ4@WTM=4IT[V",;A@DNZ] M,$=[/O*TK2@,+AB;,@T_WFDV1"8_;L47A<$%RKSUL=YNS+,]*`77I5?K@KGV M@8TT;F'D%+%]PP=RR!:"03ED]S`%%WSG9)&1W#M9(O9=$[W*8ESKA/B1,8*'YKY=$`%+#DG]IX85F4%KXFOR710!2 MPY)_Z<./'1%B@^MVA;M+-\.NJV?5:OY!5>4MZ+TA].3:6NN5:D.M=%1Y;U]: M;`XM=@;3^;^K+"WU""UUAF_-OZ66'^ALIQ%^OL+:+;(Z,ZQM-P\&@)Z'/*T8 M5>5R6%:OJ!9_.E=67_Y`.[_9\7;` MLW>;*AY^-LZ7_G(-."A+FQZD+M>,85.&E MAR]"B)\'%WB,"+5+@,B&R+2^>_JL:>./5QIW_M1,G_5\RX MX"_<8);QH'EL#OBLF@"?52?`9^&S;W'QQMAWV(EB,)V#+;EX&>$SGOGXY<.J M=&R9_BSPW$:.Z6\L(?]F`>C/DG]K9_3_\G].3Z]LV[NU@;!'>`9Q>:&?T].0 M/9-;?WTM[XXXV]C>![XANZ9JW?3K\.#FF<[X9>F MUF)'H%@L-7H(.1">#8HT@>XBMX;P'GP1,?!B#TTU@"D^*^++O-G;';W".[ZK+LMG;&;FLK[`)1:4>#SAN^_^4#-L$_XO\3 M_?\_4$L#!!0````(`/B$$T5D;./J``<``$)6```5`!P`8VQC&UL550)``,3MO-3$[;S4W5X"P`!!"4.```$.0$``.U<;6_B1A#^ M7JG_P:6?S4N2WEVBI"IJDZ+/<`JRR[=71-0U?_>78-S)E[; M"R2P?OIR/B38`+S.A%I5&M5SR@`0LQ'5Q4/M]?^^\J MWOM??_SA_"??]WX#"AQ)"+W>S&LAB>XY"AY$HN\UJHWJ&T]_./6;T<`_JC=. MO#_KQV=';\].3O[R_NE\_->[ZMY[OO?X^%@-E0496Z@&;.3YOKX/P?2AAP1X MRC$J+BI#*<=GM9J6G_8XJ3(^J!W5Z\>U1+`RESR;"KPD_7B>=[,"9G(WAHB+P:$RTX_&U(8?^124@@8C#7']S M7-?Z/U\R&@(5$*H/@A$<:KX^(*)!=X<`4E0\;?WS7?L)A,3!`TC)!(!FHJ:_ MK]D8JBEO7\/?KDH,&`&5XK9_.]8YIV*^D>-Y%K>!X!*)X35ACR\&(&7P!?QO M!@&+E-T.FJ$>@28-U14>07@U'6LW;-VVL+,-;UL@$28OYO23N2??`T2"B,0) M=*,\7<(`4PF*O#!!H>_Q8F3'I4$Y0%BP=%.BBQ+CRY%;W#.N/'TD>G'YB80_ M0&AY/4`]([-77]%4.%*IU^3+D4$\2'Q0'Y?R+CL"+21J(AJ-8FL^5OF6 MZ/@/5:9P.,Z>+/6C';OLM+.*AH(`_H_3!LFA$:^;RR`4NGQ>B M-NUP&".<#.4%Q):K'BS+Y=#-E!^G*/?7X#S;V>DK7R]9-&:T325P$#*?N2+A M@^.J"*R9G1,W'\B6ZA@F"N,$;C#J81)'8*7G,L?"P5&^<@3,>?"+"WG0@C&' M`,=`"\A>%CM81I=AFFE[XP)MW2'B\`'%4].1KC9E!.8I'"R5>8#-I+YU@=3; M?A\'P(4EI6;Q@R74#-=,YSL7Z,P.#[=R"/PRXES-T)M"Q,NT*XRO)O6#I=L. MOIG^TPW[W]?B?[%\N6Y_95+_CO@WP<];OG#A^<^)2YM.U!QA*2ZK+U`:C3B0 M"Z^X&&F$[/"21P?-XEV">]8,5"@X*$`JZ^6L0Y`J8#34`1IKD0+Z5S'B`/VK MI_QS\ED55HHB+0=(?YD'(E,NBE"_RMY&SMIHVI&V$)$^B7';5W.5 M$:-=R8('E?!?$.>JB`D5BKQ5TY7-'!RSZX7!N@]0<:H].R2PQ;,#RT=T=G!F MH'36:9A7;MV]Q1ROU,LG.0<>@N7`9K;KEOUU>--5/\DEAT4S3'D>]KFW M#D=[>3NO/.]SY/>%CQSW'9[$Q6M.ME7))+POU)A\=[M'-L\*S;V5G9HS7!5T MNP7N_]\#V>5.:@%1Q3!N)X>,J&`)'4\Y*\B?7Y M0V&"X_"0GUW%MFAW\W7<(JYDD"G`X3!CGYB$Y`SZ'1!=PSJ(Q]X3)`3N8U7@ M2CEL;H2,H=[/>/AG7)BB]7VBLEB*`ZW@RL-XB7#M@,TK33^F20=?LK4 M'+`/*J/F"']')"HZ_&N4=H`L>WJ,"!P>[5*+K&7D9$7WBIFL^PX_-LTPQ'._ M.@B';7J)QE@BDL)0U#]:*.\5=3:`'!ZN[O1[BQ3"*\0II@.A^N)H%,6=4POZ M.,!%_8:-\EZ1:0/(^B3];M1L MDI9J.)#YQM!GNK8\``ZW!M]0+;;;5SFW8J.\+^398'&XEW@ZF?GMY?_\/8VL MK`,LV6=B9I\CB\?E8V1W($`%1Q^7:JEB05B\W%_^TF2)G@,4YB9AMCTHA.)P MO4PMALWN.:("!=K-!+!.W=1E\07+85JED-X-+>]7`FP(UN%2W`6B;`[F/]Y$ M]"^P3X;:8')[A?6*4)7#G@U4YE04Z#K!GU1@50'"8 MK/(WVG,E72"F+-6RW:O5:^IN-$#?V7OJJW.YT2OH1P:.M[:"8OWS7KLX)YOG M6W9C3'VG:`ML-O'7-+G3@PH=SOH@1)PWU[`.:GLK#CR!FQ*?<^3!#K_#]U[_7Y$?W'Q?%P,3WNG_;.CO[[ M=/"^__;]V=G_'/WO^//_'7V\NS\Z/OKV[=OK$$8HRA%>!^G\Z/B8?B>.DM\? M_)P<`6%)_O.K65$\OC\YH>V_/V3QZS2;GO1/3P2Q_FV5D\O.K(`[R$I'3\\$I_=3?+M,D)$E.0OA' MGL912*']X,=4/GDB(KE33))LWDI(46*Q4,8H/%N\9"3/Q;PB8]/ M5`97I/"C.+\GWXN%\O26#6*"SFB:1!-8'""+($@7((QD.@8,@XBT)%IGQ#UQ M8)#T/:Q`6"\S/YF2_":Y*]+@]UD:AW!*?_QC`1/5R)*4?,$`A[^D(#KX=D"R MI-4T$@U@@+X5OG`^+/V'F,`^`+]D"Q)^_/Y(Y:8Y<]2',T#[M1]EO_GQ@NC1 MV.QF@)91-O63Z,]RXWP^IH#_#WX>P M5UNL5V1"]Z4D6&IN^=PFI%*![@E,=V!0!TKEJWF@>Z@%K#O MM\2^;Q][U6DI&\0VG9JJA-)0;L]C8]>65I_;ZVW`/*N"T3><^5FP9F[US_I' M-Y?K*"E.PFA^LFISXL?Q*ZDT.-?\]2V=WN_?E$(J1^M*$OP;1`'GU'%()CYL M9@8)9(QMD-QT[D>)'6I70W$[F#R0S2>GVN%W)G`%%6;!X(,<;$1@D MECEZ5Y*3M!@:74OK`3>$P8R-DH@J<)]@N*T/P1Y/8`,)UY^B%'6V9Y6V-_AN MG`9;'XNI@3#-F&R5+$W\_*'D:Y$?3WW_\81NI"GS:6UD$_[;Z MV=OL>,`AN8%_YNNOQ/X#B_S&7K]W_BPP1Z3?TYN-"MEE0R!YL$7R,\K# M;)MXF&GK85>33FM[GV3I7$V`JX^F[\RFHFT)$@$K M;)#>N0)I5,Q(ML6>`*%F8^#)IN)L"1X>'VQL+E`<)JJ'"'!B54^V@PB#!SPL&LYW8%29>. MUWO3.R`\"H\4:!UIG MQH$:\>H7''XGD)-[^+0`D6+*XI"#HCMK0>6YTZ1:M$OR^GA]!,JY!`#.'BID MB0.:,[/"E[0@:^^KFEL(I9K:JJ))1$(YC!JC>/W^@0*KRR0':F=6BBN214]^ M$3T1K24JZ@::`@*#4BLTY6QQ\'-F]=!"C;7](+A/MX**PPL''V<&C\MT/H^* MTCT'3OS+M/2")@GU@189!_F]8!HBN,094&2D/'*@=&8?:76[$(D&@>'$`(X2 M#CG/P@[M*F1"8+^HF"T]2\5&XMW6<%-&<).02)UK)V9SPP')F2&%[@UIHH30 M;E.OC^*=L04Z3$XXR#@SN`S#,*J(&?M1>)-<^H]1X<&%@X\STXI,X>I@J/8&"`S49BVG*^T5:W!B*_T.^ZUB\//B_.5OC@<7VE-L-#Z2F\;7$`9&&4EVV%YP1^3 M[&X&"H*R_8DW@-)KVD,Q\NBEF:17\^JX]2-'<[`J\( M+,)=4&1SA,POFT7R39XOM)&K.@&/*$Q675&KFT;,/N64E>V));\O#"S+_!T*&9?;;#0FGWO_)CDM^2))`MR M1[*G*""Y.&R3T\,;H'#'T#K=!)P@L^.N5+1DNLXKK.#/R^WCG2$(8=LP+ M,K/M+`(6V:3FZ0@&2\]<9@!UMR$N`L(WY. MKDCUWYN$&3HNWC)51O#Z&")HNJ"IP2:VY"5?TB1=GQ@5]_+5R.T#+")P%&J/ MI(0Q=#E,2/%\(`A[ M:X]\!Z;%N4ZP.$(\ERL]0#^(OLM(WI;A;U83W>F'OW'SWK/H_LL/HA$,8S4U M6J?P-WYR)@D[+\P/HF\W+:&)\+<^U[S%X^>%^4$`3X?B!Z$-%EH_"+B/T--_ MG*5/$2@5'Y:_PN9\DVRLL,.@B)ZJ0'^Y65)_,.\-@B<>O3.Q)9/('"O:W;W? M('@@:"E_E>OX&^X;@;/;^##\YR*O4O#=I[<$E*L@BLD6V?>IN15LXW/>&P2O M$49GC34I(?,'H2F1"25F-+F*\K+BNVCN-%M[O7<(]G=K<'%F!T\.QMPXFD6- MZ2_>9;IX3!/YJQ2_,=")P`"^)[QD8D#FF;&_]ZS>.P0F]CTO6BW98',,N2*/ M&0FBTM5!@'^]&3""P!J_9Y";`L#F$;)^6:"VVCG=BV28LCMXO0L$FOJ>T16) M`IOKR&@RB0*2Y8HHLYH#8S_.62T7!'[WDPW'J[RS"MT,61$ZE>X>?/K% M8LQC%YNS3)/R9ADI+9R;W3T,I7HLPEF^2)Y*8>V`2#>6\07/.-/+#)F,16BVCL+U>:\##X8Q%EA%LL5P"X M^B!P/B)`NB5V[(F@RSRV.D;JPC"RY+US!('21B>`)N_82B1QR+^.$A\NQF:V M?L%@L,'@ULO=+N<16@PD8"`@)U_&(3[!K10\Q:+X/DLKPO%[>&88RD&WA MX>SO,G;-56+BO)C6*:!9!VE5D-&DEMX.#IFO?I;!<8H#@]!?S&0Q*1%L5:,H0[1(*OR'JJ5/?DQ5US')HC3<-7R( M_&(UAO'.$3C7Z)WOVNR)BTAA@7D(\SG+EC!-I;4P5?I[YPC.>A/`LOCB(.K, MN'>W>'RL8E7\>!T(=9-,TFQ>;C"?SY?&)&0<--13+T[S1484`.\ZM'>.P*2O@RU_S7<6`V?:M##;<73\6Q+0 MD(QH$@5^Y96Y5D7OTZ:/%RN)69MA0,=%8)PW@A!#X6\E#$ZX4@OSG#+2'T$\ M85@&OL+MDD;]C,KO,\EDV^$,C0PB0&">W=]\:" M4-M*G<&"E6A>W:E>F3<_)N&57\CF_%9;X,'A);+KY&>P8B6^51>.:[C6^/$_ MB)]=PR\RI7JG-?#A\![7%1(F,U:RB[<#I9HRZK#4VGN]GL,D8V:`:;!C)015 M3TFZ)=,R<7E2?/'GO-V+U10X<.B?WA80/B=V@C[UP+@$;C(_ODE"\OT_"-U3Q\WI]N%L\Y.2/!:T4]41=**Y( MX4=Q?@\C+8`J%PE:MRD2O4;(NGB]-LZ;5MB0IFQE-`?RW16P%8IT>]++><#S M-F$.4/B>+(4KNP>(!$\A6RYD:A!OL80LB2N#5FF>4&X?X-#J?48]I:L(`670 MZDPAR^MJ'#8<3RFV\$.;ZG6'ZL];6I8TNF)%P$9/11/AED7;>:AQOT,;$V8T)GFZN/8;7LYI?FJFP=Y#R]E)H MR2T>U=ZNVU'/:C)J):6])4)-"P63MX/R1>K93?+IE"+/'%2G^Z!\D8!B M'`IT!Y&CU9%%I9[RNDZR>/@G"0J:Y>YQD04S/R>C[)+&O<:Q+)FCL6]XO;<. MM3MCYYPEN0AU>D1*XJ%KART>7-%HAU8#:(UJAPU;1$MN?QCM\-RF/F)+.SQ7 MTP[/^1E/D.HL=D-?VVF'YX+'PCK=AZ4=GI\CU@[51(Y6.RPS%*PB9BM]I-1- MAD6110^+@JYAFM\XCE>Q;K6T)P)]L,.H("V'?MK&SC)CDD!FQU7BYVL6%:!7 MCA?%BJNN4Z4Q(,C&H1NYFUG"$0*RZE[,*\^J?G##2>4YN[KNY5(^(DC'H5N[ M\2G220K"((4]71S%)9M'D\N9GTQ)?E/=B&=I##3F-/%*L3S(&LZG[EY%6]9P M[KVUN:=JUW!NQKB*Z,9S"S0`7#7M:460-*$>R:^(P#*.*EK$?A3?)JJ*&%"5A/^`409(Q;<04>$)VAX,K MRF*^B*F"?@4B#J+B:I'!M>**/)$X+=/3PRXS)7(XM08"62!(,*:/;PLFD55% M9ERY1-KF;F,X51#DZ=>]0["YL!(Z;M!O4ASSI-(-^$2:BY6/EIP?9*6-2U(K M!\]J-Z@"X% M>15E81AGYJC`.H88(@M`"]C%5GW87*5Y!'F--<]?`2?8"@EO%<\6H+/5#I@_ MN'.2P8"XV.^>7F)_26F-VS0)2)98".NJ#_])YIW+;.P-3LUI!?4O"/UL&PV! M#)N;.M^95B`4QE;.H1O/@ZCM7,TV52QUMU@.#-N`<1DX*-_7,ZLAB&VS-#=6 M!YON@_)]!8IQO"YV$#G:Y\.U]OO1SQ)8NWG3D"_03N2=8?T[3(2G=Y#H#EE=[HP]27+4LJ]I]CMEH3(7\72R[59`F4-[=PO5 MC$4^!E_,E0]J/O:75%,9)B'\`GI>^/$[O3R:#>23?DQZ25`?P3MK4W6O+>'" MZX1:;Z]_MG>GRU8R9TLI0HTE5!UC1-7.W#XC%II5)_=ZB M@R+O\4?((S(_S3J14I^_9F.O;[4V4`L/3;;4V5#Q^$'FFFD`(QS7)@M@H;U. MK;8-T#`G),]+HJX)R5>9M6%?H27ZJO\1NXRIC@+2PU'R2VA0H/K^`<_C_)?D_0A)]D3%?=- M\K@HX,\@5N@E+5!J\W/>H.?,U]0@/[+(0].?\OKG-E4!8>RBO6G`WBOLR.XE M7-`WDOFPW/SS/R*2`8RSY2?JCB^YK:L-``*SJ85H153:F0R2B:<@'627_@V] M*]F4SHM-)J1W3:UQ8!%;=212-A7H`">!7IUO9"8%9S,`ER'"P51`:[#8$%UN MAGG)?4\:TR;HY0VL%E-1=%)KL58E2/,X16:&8-';;X5G?\,E`J]>JWAN<8K, MT,"B=]`*S\&&2P3N^%;QW.(4693IAM[G`)+11"&;G+`?'%4(HAF=W0'Y(C$6 MR,I]'2^B)_+9SWXG,'W3+`J!B"CPXV&>PR^CK":*84$)?J($\Y_+6PT'0L*T MI"W#WUU2PC#9/9D*1]G43Z(_2W97_D=5YL-2/J/).",YS85'?W9?*_`RC6&N MII3*)S*D*VQ:;=DK0RSGS_?PK]P/2M94C(DF/^/U+]P%X6QRWAG@2)K`S/C' MO+[5!/1"0Z+Y*<#QU[`DM9=@0KR/"BJ8FR2,GJ(0MAR)Q9#9'L2!)^6:);#9 M4TL@#F06P0:E7Z-B=DNJ<@OY+'J\3R7.^BU'\OIVDS8H6P4%6"F"J\(H,C.@ M4]AQF0+W@;\%VQ_G.D*SRL*'Z/V':R)@-P0Z$>3;:+6X&+<##GO83'51XL.= MQX]ODAR.>WK.R)[FV#V`.^H1V!W-+W2&1B$7`[K<>S;2J/"Y8"ZQ(M8L5Z@KM;DA/J`D"R53ZV]<.N6/Z2;D`\WNSI'!R46,*6 MAFY%H]119:N=-\"0WTP9'0$/YM+-<2U]&HN"/6_.,/@!:6Y)?$;$2>40Y"P? M+HI9FD5_"E/G"GJ!=HH`KWT]STH%P<';F36F1O#8ST99J?14&;W')"MY4,.= MUQO8=ACVZ1!_L4`X\\!9_-C'[P')<]UU+^@%;"+P[=L7[E)!2*KB*!O"`T2`H$SCWFYE>F+AS`R'MCB@.:./ M5:M$DYSYU51Q"`R<2QS!56V%=I,^U>II$@P2Z(_%N+<[OOZ MM#<8./-K.N2<>H.^3?.K6DX]JU."O6O8D>-+"(Z]+3V`Q4ZTFS;`MDU#@=LL M>26D[.FS(P!D8:\E=5+7I%HK6"E6#<'*7K`[T M*>`^^]^C^6(N162K'7"$X";`:HHI!DW)D M`9IU?6LQ+\G*;Z/\]^N,P"%8D(SDQ:U?**F?DB%@VT!@8T"A8"I)"EGH)8MX MFNH^*$C(<1%0[0K\(C!.8)L930D9BY6T/R-^2VD"`Y#=LL7NP1X$Y(?`/0SK M+&')"EEXIHC\*YK\@B1AA]E2'\([LUID[<#G2E-2XCC./9E#RX>561K#M_.J MZ"Q)@J7#LB+E.P&@0$(:A`'W)+^:0!O#](?EA.)+.4CYS&BGN2OXS=`4'NOM6D:9LY+EED1X;%5JM95WRE-SIA-[`+F M"','&4%P>YIP>;=BG%3%3))GC5%*WFTX/E>*36$WZ;9BA[0H:1PVQPXB1VMR M;'T25)YHM;PMHV)&LON9GXPJO>Y+6OJGD?#+0F)*VQL-WN`=@K!FRX?O?H6) MS'IKC_M?2M^-FV1,LB@5A9/MBP20/X)PED.=S"Q9(K."VV/^MW(9.YW+VR2` M_!'$]QSJ7&;)$IF=WA[SUVDV(9'KZ=R@`E!`\")XJ#.:(\Z]I&6TPE`M$).K M#N^;!)`I@J=/.U/4C2R1/6WLX2KPE5!/9A(.GTCF3TFI55WY!=D8^MU>^Z3D M>0,,Z>`.=9O6E3.VQ)S[NE[@7"6:-`*$"$)M#W6IM!(VMK2H^[K"X%POFC0" MA"]6O4(J;',Y:+&OE]4%:9&1'.=BT2$0P$/@%W.H*T5?TM93!N_EXM5FWB.B MSCL[?;'F>W1BQI:4N63\85#J?3C$SA5+T!.41)'@7ET:J1 MLLT160#4C_$(YU2^V!+`MY9(4[W1T'(/\83A47IB7/3[RF29%4+ MEX;4K,O6Y65)7S--LSBR=PP_B2V&%:EH5&>1`0G$U' MN)9!(-K(LZ>2KABP):NI[]6RBH#-QM[@C=7W(/74-9HPR,&L,X@MQ4UWT'`$ MG^P#/0M1*IP7@G^0T*]43G'!M-UV<%(A/I8+]K'ZO+2#WZ9ADDS2;7Z=9>5V$:4=+.4O//P/C@XC19'"S<#0:DQ"R M*(8.G%&^%/9L`^/#JK1J*-(XFXW-`^,3;5=;4J9.FQB'A+UF:6]*" MFM\!90+!TT87PY(%<6#S+^_`XA7)@RPJ68'>]-G1TM1B?`B$B6*C%I271"$W1-%DE([QG^/%TD!>^0 M,OL5$`V"QZDV4\6:,,PY(?/F2;KTXV)))A,2T)H4C]("._P>0#*"H([V^$D8 ML^[I^BF"[\$<6BL[X?/NP0-#T`6(1A`RT!H-*6?8W#"'04#7;3[VEW05PWX/ MOV0+4L^(>$F5#.9VVF(4$-V!`MR:66P.A2/8(_RB].K*R^R7-/\DS%J1>L7M MXYT=ZO&GR)K8RMU?%)PI3#\)6_PQMD&:X85Y5)#W;\"PG+F MI6$%=_:J-RZQE^#J<1TE/C#GQ\\^D9)W+4X/$`D:)P[C2',FE$@2R/PXRB-R M`E2M[%_C8I98W-7TCZ-?0QD MB\"<[$*[,BQ"9%Y#BA*]G%%CZDWR:Y(1/Z8!6K\`7I_$;V6=QP:)(;B9XU/I M91(SYCW$,9C2*O6P!Y/1Y'EE;!8%SV0J[.0-SA$D==X#TJJB$/KE8*B:XJ2B M-/JR*>\0Q,<<1MD49W6@3<',WL$-B^@EF&38@E`*^/ZP;(9\2\PY%KX&4"!T M6C8ROSB3V)8,C1F1.(I)\]O<&[FP/:QPMX5AK"/!T$K$PC!FK]D#=+BL(E@P MW%]@T!85HX1?G5S0&BAV>/=36!`RZ>]P8NS>+Y-YE`7D_ENJ*/.MUD"I0T>B MCC)G<((LB@9##F<;]Q^C*:;?O9`LDH(K`AHY(PO^V8-@,)4QNT!@\3KXF5X7 M)K(BYD@2G![6`I81&TL=NNO$CS5YH/@:=3.]'4C2_PUXQWF M][HK0)&CTE1ZTV@T]LY.W2EX:VJD#PU;#8%DFPM,_%K`$2!GEV?0C<>$;[OR MN4U[C9Z1G`'#-F!E2CZ:?"W#GHO\/M7PS-(:CR0#`93F1:N'1A%EF1HG*4!(6%^#1)Y]N&\3.?S-"F/!`'< MTK[>V0!#[0\M:!69,I?2A_?X79[!J\B09+HFI0R'YCZ!"_H`V0@2,VD<<7)F MT)4A%6FVU>_7:5:%!+57_AL#@3`P&&O-70(X'**KHLGFH7R,-H`V>QP0!8+X M$2-@BQBTGB!'NLT/DW!]@G\AW*Q5FL,`GEY->(R&^(CO(TD74B90&Z3<; MPQRW:O)2CP<02UUX`6_P@RP%@P&,<+S16`!KC[[[QJ_2&'(^'%Y\@7GP`D'P?9EJ6D&`F\,M$`DAD_NE?'[<)N(=Y M$6?IGW\X?O7F!P#3,(OB].[//WRY^7CTSS^`?_V7__[?_O0_CH[`+S"%>5#" M"-P>P%E0!C=Y$'XK*GIP_.KXU1\`_N&GHY/]W=';-\<_@J]OWOW\]G_]_../ M_P'^Z^K7_PL^?+X!1^#AX>%5A'HH20^OPFP+CH[P=Y(X_78;%!`@QM+BSS]L MRG+W\^O7N/WC;9Z\RO*[UV_?O'GWNFKX`VWY\V,1=UH_O*O:'K_^/[]>?`XW M MYB+)\]>8_G4*[_!DX2_\A+]P_`?\A=^Q7U\$MS#Y`>"67Z[/A0+]U.F+$;U& M7-KB\PKF<19]2,VS_GG,LC+";RWZ6UR?Y.503**[S:E38X_P7'CW-!9 M'5]D-.&X\6U1SLUQR7-K/*C<:";XWQ>(APYW\+&$:02CBC],+;&KI'-BCXF) MQ-UF8:?#!!OG+!^4E_2U#HI;TN&^.+H+@MUKO$"]ADE95+\A2];1FV-FC7_' M?OTWI(0EW,*TO%Q_C%.T@,1!)M(2;OYF15^-5C5A' MN!P6V3X/H=%HT7GHLA7<&K*%%DI$C/T!F!Y]^?S#O]1D(%N#FA!4E.!K1?L? M?Z(L].0ZR;OS%N1AQ23Z42$8:_$ZS-`JOBN/.C*N\VP[9N09-]F8X6G/F@-` MW@2WC8K+H,<:N@-9Q:D83E])$Y]0TQE=(3X&AM8>$DZ*`I;%Z3[/$2<:MDC0 MWCHN1'SWX4';K0!KJ;0NDQE'NYG;K%Y@)_-?\4W;_^P>W%+`]#&N@19[4#\- MBHT$V?3/UH',N.+F'?W:+4*-&;.)PO9<]D''3Z1MO/F&'N3X![3_!$4/^!XI-@#@&P;[<9'G\#QC]$:19]=N8"$WT M*=N7.'X+AZ>!H`3_MD\A>/=F!4BD&6YP!D.XO84Y>'=,?OO.O:Y)4-K7,25$ M[2Y"6:JE6'Q3)\M-C]LATYRE'NJ3/N]"37K[1JI*;]^MWO[X^]5/;]\1'3G^ M<77\^]^OWO[A[2P:MD([Q6('0^Q$)8*-HNVU;0BY0PN:&+86SRNCB(24!,E5 M$$?GZ6FPB\L@:;$G.[C4(+9_@JDC$7][M-'6BM$3$SD(FI)(P`=0 M-8W_Z7?O?OHCH"3@I"SS^'9?DE.^,L.GF%;NR[1.]2:*>`;7,=I[I.'!@VLS M->#XV#$]M+G:3"&H7.8DP"TBB^,5S#]C7T%[?R7NP/&62R*9&:$&6`TI- M?4B`Z`'IP*4RS2`B?J#11A+<*^BLHU\E!X\?VIX=G=<4@)&XU8-)TD0-A7OMT,)77T<, MP&534^J8K<--'J0%6J?B+&5<%1^1Z*U?%[_%Y:9-(M6EB3T[T+:I8\$CN`GH M/(`6\:K2R`)@=+7_5(`'U'$G%G2I>$AMO9U_7(8U6R\.U*ZFSZ(?O"V843DL M>I(P07W>T-(P`)C77=DO'?!UO= MMED@?7EP-TT,]RJBA%%?*S0Q9/,DK(1H@C4V'00'/(/WO>3KX'$!^KJO7@XMS7DW9!LY] M"05X4=&^Q,%8`^]7%@C.-U61L4*>;M"_()9K'<3537"V1EL?_;+X0\6GWY/(1=[FVS&+@VX_7_'+P6,SM-Z]W:"WTJ0I4@GS]0BGW/P)F"14>-#[>O/8#M1?PCP M-@7]F:Q'U0=Q4O,7^)O(7WH)FO."YKO>''RX&J@KT/0-FLX=;T$7&A8V$H,#X5[1YU&,@1WP;%KAHY'0V!"/ MZO*:KMHW3H6VQ5=5P8%M;T_"O^_C'"*> M$9?EX0I-8'F21OA1,XD@E&BR22?V7UV92,CYG8P8'Y`P$[D!D@W+9K+XZ,X8K]PIM)%:=+[+GZ3TLYEIDI9WY MLLC*)39<9.O.GM`B:S8`_45V2&+W&CP>W9J+K#:TG6LT*T8VCT9+._-%H^42 M&VITW=D3TFBS`>AK])#$WFJT!KHU-5H;VG8K6.'LJ>@_V%^X#Q+L4]!"K_T3 M/HDNFW7CI"*6@92#\"5I@/$/K1Y6@/8!!DZK71YQ392774USY^_G*?"G5IHV#K&OM/$'&)<\/R(XH$Z'JT7NBC[QM1/C,G$TA/[K"K!>6YM2;(\&7?BF:V^\^07&!G5U M1$8D[HS(NAZ1LO5*V8.PJ[F49:`WKE(5(P,G^*J-$((6I1<6R7B^*C2-G"Q3&U7`\-5==O\Z M@C$U3^B'OE5"OZHY:3%P@Y_K#,!,WMP:LA1<"\'401!I[1`^.D-?(49_W)<" MR06\"Q(*U)/'>"C\;["554CP/')5J'&+RIY\Q8T<`T`PK.UYEX[ITC;A!G6K ML`.TB1/=9]P)]1W_W0\%;X_CD%+S@[C4S)Z@ST7XDQ^3X$XPM;TV5N>VSQ_W MA*+Z.\`-W,[NX%BVIUA;B@30%N"TAC/Y`A M&/4A;$B'W`XZ*#SU\=%I[Q`A7;Y5&&$FQ#N4#(R^&"?"H5\**=0'O89W))E? M6GX*MJ*%9;BI57P(N.U#@^T%FG8`-W0+"ME`M_&@'N5EH7"*L)@'R7D:P<=_ MAT,)C"5M'8"!YU>`!M80D)8`-?4!#X+1Y@$A'>JE$,$JKS=+F-SS%#>WB@L) MU]S5)FW:<3/\\$%50]]&B-ZX+VLV/L8)S$_11^^R7&XT>BT=F(P^KP*#09J! MJIT/UF)PD'E;(1GAI4!PDP@4+6>EO%J4/M@(G3D: M<"^T)\C9I;KH^DK>W/55NNCZJG^+[O[J2F?8%5?G,UQ=S0<7]#W!I9:2PCEH M&MZ5N,%MG=]Z:TO9](ZLZ%!I:& M)L(9FB[B%)Z7<&M@D%HDKK'4YEZ]E.'6@#3W#TGB:QW>V^<8Z%NO>F-JM?P;6S`HBK@3(_>IZ(:K6"V-/HK>;K[;&DDV1<0N0B>Z]8@H%+06JJ=C("VNUEQ8W%A,76N\72%& MV_6G98.G64Z_[1UWD'Q>%'L82=`HI+#_=E;(.W=O/'`1L`*TN>,WKJ8R%%2& M@EYFQ!(1K+Y3E<.(>WZJ@R%G1S^_PNTMS&4&>;B]ZT.?FF_UB0]MZH-ME0V] MXJAG:-QM6LZ6%TSL^4%G,9>3.;"A4BEX(]1JOJ(+]@%\9?_U:M76F1_>+NE. MCCV^#YD9*-NLP+' M59Z%L"BNT58YAD)*DJ'5X)=C3I'=3BT).++\@!&"&H*,GA3XO6 M;_`932A?[<)X-NWN.&):W0GG*")Y]N]@&AHG^S'KQ\GNQ$3.(7^?T=,L8NT> M3-+UV-X'&$_NT.Y@Y,S:@_&'(,?ISG`./K*%T?<`E936H:J6A0NP8Q3X%0_= M3_MM3C5GJX]$HZGRS(3J;4;,.O+3B,HW++I6U"N\CIOA48;4.9J)9KT/"H@X MW.)J7/0B:<=NE\[1@*6X!CDN%5`H/=E1O=D_N1DE,W>N@WLYNL7=@'8_*T![ M(HBO^R*%,PJOS?0$*'!G15-Q8$\!/@9Q3E)RMBY/SU/DWI"'IFK(:]);![FN M7'U88SJ:%K=[I]^B]=O;,)K0/G!'S*;%PD5YG.7TT?,U#).@*,C5%E&JNFKO M&2S"/"::)D&M>5?VBQB92]O'RY"E\4O5T7NH\Q6S*!!O3P279"N8T0? M=HL;&,HGM)&7:XVG89*<'Y.EC%AFR6#HX'1N:9'9+UK2!HVT.];%*\=%'<;@ MME/<83QHE\W*),Q1P3=QD&E)F('B`TO8[SSEA&@D^2Q);A-*7,3!;9R0`EKJ MXXFAQM97]D&.N?(-32,O3BNTF.X>6;1(W#L#8ICT'0,51IQ`&[_HQ>]X-ED2 MP;S`V\92=EFM)G4)>Y$T$B6H3S)*0ACG):Q,D[!T[.39NZ^--=AHD M"0TVQ?[&;T&.:T/(CG,G]>K@7=Z4,>!?Z]6]U3F;Z9U$W\B=QQ#)_6*]A M6.)C+/P5%N],'=CJ0VZ=A7E'2"Z3W8>)D]'//U><"?J>V8#?\K@L87JU+QGC M4]5_H$,_-7](\EF5GGT`H"]4NO\$U%UG6$ZS%'VRC+'L:5;Z<$(U#>RCM%V! M='N*/GA33``)(R[S?A/;+-'TT3U:5_7QLG/+ER#X@'4V4)H!-/VY5>SY!H'L M?-QK\T1$]]5Y%C@[UNFN]XJE!3(*6E8M/Q9/'Q MP0XQCN_"3#L?TY$V7;ZOO#D3XX)X= MR,%A=?^7;>%%5A0?D33T9?T>\<485.[UE,0N]G5JB0;V<(@(O,!D+P&>6-!0 M@H;4P\/J4?+BY@"W;\GF7GWTP3BP%S-"HLW;')8\'*USW,FO1G8H37H'=SYZ M$NB.R&?4D$9S2!_VF\\?0ZP2=G!^26RE"194=0OD].YPZ)`#N[R MB(*L:>=/'3.=&1%B3#T=$\*O3[,]ZO8\+2&:PI+Y+0,@D36V&U`MXI@_J<3M M0-6P\B?='-<8<5ZS#!=E62N@6Y?GDRV.6\;6O]Q`$&8%^?DVR_/L`6VIU_LT M*JHP;OQOM$T."M2.S%'<$]AU;+=4*3I!W!H:X3!9OKR>KAZ9^[3Y\EJZP[GS ME55T;<9K&$K4C]P`+^*4)=1?*L),.XK#N-!Q9%>0L64-M##6K6V0^5"HV43U ME54.?"C2C+FAU1;.]CE^!D.021).?8(/Y"]R'U:+WDTLG89<@^%UK!((H)2` MDJYH"C+\-/V!-G!\Q3Q61/P'8AV0OQ"V%(T$RSRP0`KB,(1!L?'D";L13@=C MQ=)UFV4`@(/,EV M/+00"!(:.S;YVNQC&\?8#Y7LNT^L++35&L"QA_M/69I5][[TPDI\BJI!8QW] M,O[["&JW!=7M*FN^U)9>Z[K41`@6:$!2'.K)8%,5E'#J:X,FEASV?6P]Q MK,*+\VPEZO'FC@T5@^W`T%S$*3Q'/VI9F%9C=Z:ES;$XEN(K;@9(.P\@(AYN MH341C+7%T,[U.@YA7FAN28:;VP_P'.::B_%DS6B,C3\;$DWV<3P7B;K#I6!P MPB^8WR.Z`MP>T#]I%^Y1+T,0%_^IA(_EC.K4'\3I4EE`JD9HFHK03:9UF23# MV:`=6B@;3,^N"3'+CV:#`IY!^M_SM([G M/@UV,=HT:FB/22=N'L?J2CCX(!:_<'E1D;\$<=H*V&==>*-DDZ0]W:!_(8N! M)&Q./&@A!&)2DB9AT\_NU=`3=5!`FA8(IC']P')BI'XE,UT-.*Y+.C3 MX#XE83H)2:@2W;T_7.UODSC$6\X@/;1?HY!XHG.:O^+#8T@HDC^\/@'8)6)^=%TVL].AG'HMK'%I14'._B0L`$WHVVQF!>P*)*AH*0-8=/W"N7S;, M8CRZ:>SGLQPN]Q(G89@C*]W*PVNTEQ@B]V`O,2B5YEZ"T:JSD;O;SVN)QTHJ M%&`7'(B?@K?O`1/.G]J=)I!4[S%4>+3A?]"&!;](A[Z_V&J,NY,GO[]"G'=+%B7%MW7YN+?F5_:B%WRES3P` MB7"H)>\JA\;9YO'NX+&4$B@*.@?'MG(Y^"/:SIGL47,FZQ&7$Y!K\:4*+$^#8G.59_=QA!WC+P5$1N0\O8<%ON@_"L$-+TX??(RBZQ,/`/I MK#Z&,48L]SIF)%S]*5:H$72FWX5WQ0LE(5C#10R]"2^;4;*G7=-0%5HV#IWV M%/`*]07S'$;&F;.4E-;532U+'XLU13>%ECJ#EDT(:DY1'WE&\V/QW=)^MTNJ M&B-HW**EO@FE!B]@;TS^3D&=Q M$299L2?9Q-;#,GL07&P(5^XQV!BLVK3^60AA5&68KHH;G<%;F0)*J1Q8?9D, MO,6GK>N$Z'5!)TS@5K.F2!)W,AAURU2YUR(-G/'+ER;(+%Y2L;JZ5S"OLG#$ M(?+J6$4=V765BM+^Q952%NX*JZK^C$BHG[0"A(IX\8S.K0*9"X6/`DCA@%HH M<,1+16[3HRQ)@KP`.]227"M[D"]#$Y'<+9X)'/VH_]3R7/75;FR'7E5VDDIN M7,:IO;6QI[\EVN^.J^8V:1`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` M+`7UATCP?K$"[6\!\C'0_9K\<,])4.?,@!/&@2Z"-@<*^OY0__B_8YBC8=\< M+G!Z'45E6=T.W"F32C*9BM0$WI2>-9LP(6P-9LL!&)OJ#Y=K5N5!"X/#=.Z@ M)Y!#$B[?4."[AHK&[9&2J3A579:J,HD'.5:TD"54%C6L)ETEXC(NOP;Y-U@6 M'[,\CM!WXC!(:.VBR[R=WZ7$/)&8:/'=XLCN;%\VCI6:/_XA97!85Z#=%ZO0 MA=\`M'V=DQ+4'3K,Z#W?$+P/$OPPW^W5ZES"U.FW0;F!+/Z?Q$'TIQF<]^99 M,LWN[V,G*7GO@G8<1(72*7W#<9CFI6W6"S>@=C6AB!WJ"/]^@GXH@Q.@3 MAE4L^3&'T40SCI@LI*'S&=#^#CE+1U\Z"D5-0/MC_NP#ET.=.!YI&G-MDXZ]GW(:0R\Q90UCR$L M"M/78E(J^ZEJI#)P:6I(:\/78E9SMJBGA,O7HCL?$W8ZOV2XVC$6(9Q@4-*L^W M(B`+F]N%LIAKP9%=`5I-`6[K$LOZ[+=*=M55DF%+DA*1N8:R`D(=,&OA9P8X MWV17:.8V00%;3ZQ5H!80N8&V2`(AP&\R4%&`]K-_'X"N*TRG0AT$:9V`K09_ M3&IBXTKANTI8W#)L)0?`[=GO2+4_5B<%_VH'\SB+?%$8*4@'U48#H1:S:>": M[O6]P65^C1.D,<6&5WDM M5]5B!0'IKGUA5C=R?'7FR2#XFT!GBG)P:4*F:X;%N^XX#=(P#I+S%&VYR!JA MBK004=B_WQ;RSMUL5RU!T]2;,S?%%'#7P3KC[_"T]K>XW%S#A'@:Q2;>W60? MT`:O/"@KG1KWY/Z$5RDK[S(UC;%;1)M[5"-UY'0JCX9-YG+"C@+MO(M]4F+3 M*JQ#*&IH=^A:O/4U*//C0V$?G5(^M,W*K](] MVL5ZO"G/0P/5?X7E)HMHG3@26?60PAP;J"ODK^$-\YWLGM^@#T<%N_7D$Q3Q MIL2@H4:@J^A!TX%[]!G/Y7"U;^.)M)D,$Q<&P8^R+]>MZ[%S!(&O$%R[C!_/[.$16^G(] ML.\H;A`OQ?"?U.[^K)^QOQ>8=Y1T=JR%3_N$!4#";2(60\B$'091T0^/X0;' M39W!T@ M=3,G]&5Y,SM.WN'CY/F2G1P+K\N47JB=F[.9Y.]=J.WJMMCQ:17S:2[8 MVC=KLENU=98DV4-UL8;C+/#/45`Z#TF?HBK=,X?)>F+3FY\ED#5EU2V2RQS9QR`_T(V4 MX@A8U-SRVBGDF@/LYPM0-:TVP)ZX88JA[QIJG7&?`(-KM(3BA\0P/Z6K7W79 M*H>#DLPN+-12\-Y#10$827,%[PE,-*>F`Q>C>;%\LT!N\U57"JR1F[N$BL/A M?1WYJ^,BZVHN=R2BQ-?8$1X(@U<>`RBP6&^6J0Q:G6F\B=Z-F)S,?NU8N13" M6$OLS;$`)*_NS'1FA2MLJCTEUM$E7%X%[5SA1[B`5J<.\L72EF%4<8N]08_6 M=RD8!"B>V?'KO+V0);X?:.CP<8_@973_88_SM/4Z3/=.L#J/>,".U`IQ?>`D M1(GX'8_+U]"?8'D:%)NK/+N/(QB]/WPI8'2>7B(7*,!%64@:!I)D06)Y33IQ M4*G'0$*^1D\),#6HR,'M`;S`/8`X?0GJ3D#3BWL;:3ZG?%V><1,ZY;%.EG_# M.A'LXC+@YK-^+=%K9?DY3I]';HFG#0!KX?2UC8I7_#8RV.)LQ.0T'^=;!@^, M_Y!2@:``$5S'*8$[,;DYO-NS,$O7EG88,=VG,A*X3+FDK9-A?([OTG@=A\C; M:!6RP@L1T@W9&?K(?BQ?YIK+*4S`XY*T9(\ M:"3?59*O`WQ_!IT_1AL+[.X5^"14/\VLO1I9J9?YW)/.WBMYN;]H!E^_RL:.G[#O.Z+CNNDORP M["NL$FJCY^SBO/[6"M0?`LV7_-9R&V@5YWBU!E5G=L#&$C[7EUSK]L(+-TM, M^YS7['DQI]#;)[]23_NL5NMZ.0-=;S]'UUAQ= M@Y/B%EWO1J'KG5?H>C<"7>\\1]<[OZZ[CX]C&'")$E1/-77@>E5J%)91=.#[$4 MTLEJD#7$*X#)`:8'50<`]^`>:Z8S*3M!TI]&MTC]\+B#80DC0>YI?5(OD-F3 M1A>1%9DD/[5K'`[-DP[^Q)/D!^[^DN$()US2;X2-%'7B%18Y"8U1V?3@L:&4 M3Z@)5&6S^>1OO(W.U!?[M.N[L"5&<\$K;C^/UQ<&IJ5[;>?'[F0#H=SY=UJY MV:^)7PO3'9LW)^`#(SJX:W.[1_\U>(RW^ZURYGOMK,]]G\_^[+._>W2&,SBR M?01(AM4B!N)4#P/==O8QT..3PP#]NT\8&!I9#@/B8;5H_W$J:QA=!7EY:"UOU*HI1E,9(ZV&82FEPW'@])SIO/$+35&D^0>=V=U\32=,#FC7KQ! MX[",!L!L.M"HD^<#2B6SJ@M8Y92ZJ,`M8O;]H?,7[2+;1OTYK*-M)K>L5+88 MY2O\`+;[9P^K88]`@+C@]>CI=V^WNRRJ+O\,.O'&:@]**#?:WEPC&D^:KE56 MS9A-8-+L6B=I=(;OP+,=*2C4I.P[S5+B\=QD5S!?9_GV8Y9?EAN8%Z=941;G M*3ZJ@=$O>5;(L3OK=QS`>]YQ$B5O(\>+K2^TDTZN0/41G/>5?884RZ4?PG]' MGP+5MU:`?,T'15H`9+RN+8:P)Z&.9[`(\YC3P2"VC MD:UOD8[(UYZT1DIP-J-**D$V0X)0-!]1PU;0L!4RMLILA]A"@X=8RPA;*;Z< M6._3"#N3-#G'@)(M\A4WZ4=G&R.1>FEB`WV@QL:G++VN/W!"/N`R&\7B0X43 MP=R3.\F\REH!\K9U:GT6M+X+PI9QVK6,$_TX0%\'S>=9KAG7&2Z64<[!C+)+ M:.84LY0=@J0\P/4:XNQ-<*D696-5FBQ@40*8"4 MQ*X&R+GOXX>UKNO/M-P=ESI@)L0):/V]!>]M7-(R"GBM26B7H.[3H?>K"[,. M\K4Q]N02*BC.UV?]BNO@L8EC9"N)@@>GG@N`:Z&L"2X/].<1X<(\L/,IYTF8 M;:PLJ..%Q^&;BR=&6`)J#G3S$T2.51[?TS)$6*8J^O0@D@W7J>?DTU+/&3_F M3D/G'#&9DN*TS+BOXAC7P3?(^,\[LW`K&=6.;9;8W0."]D:+SS MG4Y)B=;S]$N:PR")_P&C7X(XO9#?,\_0MZ_^D70\IGI$M'.<1+SI'N#^D55& M7Q#469H\-)JU4)88H4;B-1XK>L">K4'4+$M)I5<>V9FI.C/2Y]-5F"=Q5?[^ M<(.X4T9;S=+_4[H8[XS+,O?A^`,>!7C-"*$9+[]%^'$3KZC,'3?4V&G\H3`+ M7"_.T)_';\+AED44CDWD)KA_.2^*/?:O+]>->UE[EJ(;&`61W3L8E01].%3M M<>V+UF[T0K[L+^WT3!/%R(.Q`SSXT<"0DWJRV,#V16! M\,6,9T?]NA.E^=3`^6'\!#<8.\$:SN*?8+K<-41)SIKMY+,[E*NEH([CJLIZJ`H7Q9ZS2GIK/M&\V'/&K,J M;\55<"#!TVF$?I/O83LMSRE^!C,8USZJ%^N6U4Q&+JB-40-&3NPHZZ!=?@'9 M4-J'>^LX8E+[-G#TC+IX/OYY$^3P?5#`Z#3;[B!R=<@SD<9@%^\/31LD$K'G M#T$>Z3\IG_P-A\_,IX^/[.DYH3RZQ:2@W7_;P2CP(_1V0_810+[B3ZS;[)@2 M/U*?%5`6M6Z0;?+;XF1?;K( MSM.BS,EQ;$&V)S>;(*72XB=S][`H8?1IK\A:9I$'3Q1SF?'EEE"-95.Z:JX` MY0*TV*#[=5`B1L!EE0*XY@7]2+AQ'Q?GSN5[NRZ)$CCU) MWWH&0[(G`^^.5P!IYCO7P70>C-:E<+2JT#L\4C^ZC0IR.4ZM,0$\PGQ=@!=< M2O26Y<77D>>P6/]",'2>7AbM[K/PC)9J;G3=K=24%1R"2)EYKN94.>1# M:S0A@H(Q>1ZF=%C1[5E2F98_!T/Z%[),.#6D?1:>D2'E1M>=(:6L/']#JASR M(4-:G7$\:U,ZK.KV3*E,SY^`*=6)`YJC\Z=C_F2Q1),-FVEIGO"UG"\YMOS4Q1J M/R%PC;]*$\9N*MK;#563\*UWY>H\2E)K^#O1:7IC/Q<8+E-QJ31I:X=`:/.L M@`%JZDNDHGS8Q1`0C/D<`(C1%-T\9)H`Z+5V!(`^SV(`X)8`-?4.`(/#/@P` MR9@_!W>[OB[Z#<9W&_3?$^0D!7>0''Z>!26L7\"[C8K08.\9.>A&L^)%+$7% M*&"G)?0[PY0_BL7J+M@P27Q'BK\EA\ MX-"-T^*#Y-I^RXIZ*@5HV`-[S!\@##)W!!`65V#H%*+^+7FR5+LOG.VKN04M M=DE1&@\<%R_G3#*$%_$:IYX$?X5!OE3RR1+FW\/H=?#KYRKLQ?B*%V(?V)OI M[&@YQZ(EG/`AA'T6[)YRV1W=P240O)=OW=^SK3MKU[TZ%^[<;UH[]\YRN.@K M")UD3FZ'G!\*=:CZ\KM&#P9&$BREO0Q-'BBM#%INQPG7'TOKL4JS](CNS@`D MO3.'=L>T-&X^M@+P,4SVY)%$03S9%UF./-NX?`FRRD.B M)$_NL?K#%G*#NH#2+4L#76P@+$&$MH.N$W\Y6+`Z1_G.5JOG<#_0#8+V\Y+` MF,=G=%-@/C_^/.CXWF\-IL^=\O3VNWLFXN%Y[23S]!S6D&[TMY]KB#&/SV@- M,9\??]ZR?.]KR/2Y4ZXAW^$+&0]7D4D&ZCFL(BPV=X_4U,\EQ(S!9[1^&,Z, M\Y<&F-'O?=V8.&?*1>-[>K%@9)*L/V8888]\OYT:8_^]XNX9WFF-MOR6K[N< MFGV/[GV6W"I\C_=#8\837QT]5&,:L#'MUMOK7/)@G@IYAB MYG*PR[,U;AMN8O1+HI:T%$I:?^2),Y_V,3AAEQ/0<1(=D`*&A<`K=\X!3@B M2PX@NTWB.U*#HLS0'POT!2IE^\H,?[1$(UNL40\!+=R(FB-59_VB\=QD8!,4 M(,U*<("((21"L8Y1O[B$PX)PXS33/7DHBS,D9N2QP%(80B+`E>,15W>X>*. M95RB84?_0H*&$**QQ]X%D:,(:+Y?_#.5EHQX^\CLKV8D3C]QLZE9BN@<:DT>" MP=KTSAU-70+ MI75[:.>\!C>9;P5A%Q"X43*RQQPHJ1K#I>*#M:S/=)EOZOJQ>;>H;#XP&!$L MD04BEHF-"X2"@1$@P9H1&JGD'9,T2<-=[Q_YW?.M\>[YY.XNA_A$YASY-G%: MQ"'9*+><(N--HRVV/-DI6IL%=S>J-7N@YH\>H'=V,3YN"9U-CFR@GLAVSZYY MT=OCN;`M3\#,\T>A7=F.ES#B&A]].B9:9P07,,"UB>WG'Q%[YT6QQ_>NE^M3*@?EIO9A2:W*W'E=#9NGHJ@B7,MW&* MPT+P/8;KX^"1FM^Q39/4WIZ+CCY]&A0;Q.U]','H_>%+@>/U/\8I8AAM'4[" M,KZGI<))W,N>7"O!G(!,5EEB:L?67>W)(\&E(D#:CGL$59?8=WZ!>P5Q^A+4 M'8.FYQ5H^@9-YTOE(W% MSH(^250B0XS_V%K3UQ2(00*8FN#'[SA,D[Y@#$")/_0*W&Q0^Z8-ON+=%S02 M,HJ+,$%.&.XURTE[1$J"%\F!0E`4&0[31*T?XG(#(I*I'FR)`U^`"*Z),X!^ ME:4D]'&+-RK!(R2N!78Z*`^._01S%>JX"&/U9]:+Y`]HR*,(;\!3Y#D7^'=T M;SUT881LDO[=LGG/KJ^;1XR%S@UTU2UH^JV#_([HQUW+;W$P.`P\6I@ MPF9@6`ZAIW)Y/OL42/FVDS.9W04=]W3+(Z]39=R;RC95VG0 M6M\ZZ<@C/T`Y;YTAM$^-W.\!M.>J[^8;3M24NBSDAK#>/U0?.\V*4KA+"$C^4M^M*W M&_RO&_2O]\GPYFJA[UA^JS3_.'&6E'WBUK>(4=S`LD0<6XRO?-+H.2EFV/_TNK'LZ!M+UP=_D*0(MXA6H MR$%%#W`'[ETATXGL>T;C9M$4J`4,7]UE]Z\C&%.,HA_ZT$2_^ML9.[\Z;ZYA M91?\:A)KT-/@GGNNS)J#5GN-&WL;Z-*=BPI-9A,QP1WX):,I`4*82Y$A:VQW MH19QW$<#:0=80V\"-W2YO]G$!4BJ0(W^F]==EL3A`5^;W!$I0R;E.DB2[`%& MK@^.I:CJK/L22"&NJ13H]]_0O]&_T`_8,R!B_3]02P,$%`````@`^(0317\] MV?VW*0``F-2S<: MC9___OP0'CV1)`WBZ)?/[W=7;LS='?__W?_V7G__M M[=NC7TE$$COZ1[UWO7>G1_0?']^.%K.W_>/>\.B_ MCP<_]3_\-!S^S]'_3G[[OZ/++W=';X^^?__^SH<6LKR%=U[\_SI_7M:_OD^"=_%R>Q]__AX\'Y=\$U1\J?G--@J_7VP M+MM[_U^_??[BSW7$;<$_;^WZV)OZ4]O>_VW@]Z[Y]1_`QP<'?VSP/M&LBQ.":$R>$___E[IW'((9$M4_; M50STX4LPBX)IX+F`T_/B!0"-9I,X#+R`I(J=DK1AH)=7;I#\PPT71+%'I?(& MOKX"E4[ MH'7U,2%LP01SB_N4_+F`]B^?Z$=4.=NKUO0<8G(N,3JG"+]T1P>HD3ZO6S(S MLGTZ3U!U2J%YGP[&3VY(%_(O[4.,8-K]5"YM<9F2#WU M%#9AH(_C9.9&P5_YQFC\2+?&\`\Z[7URTR`=3R<)26&RR7^^()D;A.D=>R:FLDU3!^JS'LE:+9JP2BH->=U&&UN/-2=9 M<1M-]U)UYF\ZOPOB[,?4L-7C0 M_IL7E:#U`]MS#5AP)0R/I9\_0Y>WP,!<28`D?PV'?JB&1S\_<8!OAK&W]9F0 MGG7$B8PT^HLC^L#H/J6G/-FZH="])V'>O*-WLBI+\]"4EWKM9 M_/3>)\%[VG_ZCQS(V^/>ZNSE;_#3IC>E3N0>`T;O1<6AP\.M#I6./=/CU8EWC_FZO_6FP?A1A.F2?Q0B=E5;V)58(L4NA@_TE_IV(L3 MF#!_>0-[(X`Y)4E"_,\%3UP8.8:@?-2L1(BP#,4X1BVQ$#7W0O&-BB M.D$LJA$`\"F(J]"=<62U50:`?FBCL!@@V-(Z12RM-?`)28(8-F/^!1@TDA&V M51:`G[51>@(P;"E^:($4KX(43,Y_$C>Y@E]D"]Y.:0#_L(+9$/R*6:+&OOB6S@%JV47;C/O"F6%91@&W=@J@B M1SX6CI%^C%Z&YT!!XH;7D4^>_Y,LA4+<*0O(^^V5(A,,1XR8G2WGBR396BK$ M.QY><<`_:*,PQ7@X\L3OC+D*0I*<`XY9G(@'Y59)0&W5%5IO2#*@<`2(V5]S ME[CT2L>7Y<-]'')$MU4&D&+TR$B%Q@#!$1=F/\QJ-8@?'N+B2/++'-A*QXN, MWEZA`,5KHJ`B<-)*GXTJ,HZTZ[AR@*3WNP=R#1W4;5US,7$P5VY0=A#'*NOT M/WS4UWF%SM"(CT]0^9M*;S:%G?Z956-+PM.VVLI@F#]$.Z"FBN\^::EN>8:< MNNE]CF^1OIVY[F,Q39(P2]>_[,Z7JY^=_5X(]%U>R>GU/]2;[*M#$=^K$`P< MO08`HE6?HJH0MD=5%8RM'FDO=_HLC*J7T&0P9L(X721*XTI4S>D/>K9&%JM? M*@-*6`\`6?4YJ)/.'DD*X%H]@.373^TM5_N=^ARX]T$89#"+K?P(\+<;V$"L M_D=Y4:O<-(C\U-8`5>G[BYJJ#-V*+0()5H]IS`J3/?!K4=/J*4%ZR=O"C%#^ M_EWB1BE(+P\6E8]X655G,+"VF>7U36\4:[0"8%%L:]6$PAZ9VG!;/1HY"0TL MC,']^/^;.",*(U!F?V#,FF3W3&WW*;0!0%&-/11P1U-DM@C:7H+P@`BY["5NB!/)(P?\P#^7(D%,E:J M#W19C3ZI)WH-B'BN]%77B$LWB8"A=$*2/-A&?6*7U`2*4'@)JFF!$C@\=_]J M[(TIND]NGHOA@9Z4K;(8Y%**_.O(`XZ#)S()W2B5S@\56G-Z0ZO1/O7TI#)@ M/)<1#1RTCZ=70>2"+4[#VH&T//!/KBU*]8$NJU*D MN&9T2[S03=/<*LM%Y?^Q2'/_S05)O21X++*A<)5#MRD@$46`1C4]J886S^W* MZBIS0[Z7*$OB"/[ID=+H4-^1Z#;E]-N\]%1#:_X2)Q8WSRKG;Q> MG/B+$):KKR28S3/BCYY(XL[(S>+AGB3C:1&1GW.MY$:MTAX0@.+L0B8BSI:P M.N16^V`5\JY;.>S?)`#<;,`F<1J4TV,)#\7EU9V=6U0VT/'2E[$+.GV[=RZU MV>4=X^^#ZH++=8/KG&X$8<*@X0J>\PEC=P=`%U^@H38E2R,-V M00>9#']AH_C9OB3/U2]7L,H[/12!'PQ)B43*`F'(TXA! MLC11M&CIA#\[/1SG4%QQ<);)==<-.?DP2&N2D$#;F5P.*$*VR"KLC.1A3 M*=GPC%WIH'5Z=A.L5]SC%MTVE7+-_O@LW10L27*X%&*TX?12A5);70AETJ"YJ#A2%?; ML6;?)!#=XA>XO_FU0/U1&.P&-G]2E!PU:*47KI(U**(5A7O.@!9(,'*B1O2] M=]"\]4.4HK\YXB)II/`(9;>TTSM%8?=)),8]16'CX0BXE>ZZ4@9LF7QWBSI] M)-$'%63+Q,*1J[9;#X-<1[X?%$`F;N!?1^?N8P`[BQ)ND1$OK>ST46S5*\E> M$1U'&UKIS;LEF1M$Q%_?-1UYWN)AD5NL18(T<39`664'1^+G2MJ@B(ZC#:WT MZ^WSI+6A<_HHKDQ4DC8'#4>ZVBX\^]:;;'M;XR#'&:`XP#'KP^B$MK=N M5R=LI'JW=V&MB83O@YUK!C;@E%3H-^+2_OGCZ);0;,FPBGQRTR#]/8KO4Y(\ M4>ZOH\=%!G^.(P]J%:]!Z^2)-_@YH`^%(2X7,7OP-L=)%R[T;-A9!39$OIBF M(LEWLL4:K;_BQYM'P9\+C5N8!_D^B`N%Z5E;A9LGJ0M7F';H.L1\:^9+(`(4 M9K(A/35#A_G+5YC>_K">&@#G"R`["5,.:>QN[LBKH*B0;4"_6:`#Q0[,C%@Y MAG9M?EJ=H8#]!(&]R:&IAPB&5=[>XCSGN%:9>)K2M!7W--695TIUEM*N%`J1 MOU_Q!)W)**,9R.>>*HYT]#;R'6[`V2(==6ZJ.AGUW$_KN?6.: MI=`^4(C4H6Y.HY1I,&_!''`=&"H9:=_IGU9X0MCT9O(\#@%@G.0A M?R.JRC.RC@NB.R7.G\N/+TD3Z1C_F-/_@,*%;U`/9+M/L]1UP4-X%V24F.O( MAZ7%^#;)X'ME-VYL'C77P99;`+ MD.81TFS)Z9^A,(@%\E54"!6<=K,/<;;&JQ6_D9H\D#>'G>O((!"X8RO M)`O&[I4#L`MIAAAYH263/Z<&4((B@O^PT[^0C"YD6<_9@,[F41$D>0J$)JQ MTXG?05]2]I_DJX/!SSC]CR@V(D+=X"P>QFFPF]>=YW2A/H#+9V].Q]SF>63Q M(B.J`U!17!DT+SZ6*T5*1!<2LV^,N\+)1-^WB*-\\E;,1,JJ!_2@,'8/NT8I M4&(^+[N%MX2VT4F7'&9YH`.%V:$@,[:P!:@,98,R;&2DX3CQ819,ED5FK4N@+&E3&SG#,X1K'8*@M5@,)4=J=Z5SVX?AJ-D%1.`F/P.R>H5.(/,,FDH995E_-[+<6R`#%-&5>WCR]DE!A*LT4%C69N,DXR4T?/X\Q7K]_JJ8NO-K`%8H\ M8Q;41DR)J>13]K-27#[3-Y-UIQI!+2`(Q4)V*)V14F$J5975J68[?8>&IH@K M`D,HG$:'4A85-DPEOT*D+Q56)[4&@#$4WBL[^B-F!4?V+([EO38]+Y])X@5I M$:F://!L;TYQIW^&XKRR:?'+.3"5)LNLSW/=Y;MXLDB\N9L2<25`^RH, M&54F3&7/LFO'%"_+K>".DUOZ_.I*S$08"JY%X)#\-\(;,;]Z^B) MI'EFTO'W"$ST>?`(>RN/2G8FVK0JMP&\H;B3=#`C68\84_G!+'OG`&B2YC=9HNB"]E?8P`""ZE'DEH7HSD+7;EYP<5E;EFG_^&#L56W_`'> MI6!V06=P;-6;*.&'L>AQ(."Y6)L2[]TL?GKODZ"8T.`?N_,8_.1$C,WO,PO ME'&BU!FEG.&)55^@2`3;PN)V'L]%5U5)78KOK.X6`9A6]Z! MR.">?VZ5`CA6(V3TQ,4%8/YBY2'S#P:S*(!9A[XX7N1?!'B3.*2)"-.5/64Q M26FI,^KI1QF5G-YIA<2BDNQPXZF0/:&%IM,&=!Z%LU-&+V.\Z,-\+09>[]3^ MW*1UZ2>\S%)XMLQ4A=1=MK$'BU>LYI1\@XM%J+P*S5DU+C"E:+ M!T-6_KZ&(3/V+6:5-F[SG[39YK=[N*1*;VV;GW\8U4&;_\2^>UI?.@HV_PG7 M+=TIF__$JLN&R[S,YC_!FDO8HLUO-0F1D8%8`WD7;'[F9@YHR/=QY1P9B_L_ MB)?=Q;?D<14P.T[.W<@C89'Q67?C7.4;3L_N>PHU=$5C*UV=&?-GW38>3[9X M7-;$Z\G]TPI/=AF&8^#I7LGC*:8_!;2AN,4K%RU[9#?#!YX=O@&E_+3<_/,_ M`IC_8%Y;?B9/1/9`BEH#0!@*RZ\919`HG0(S>.P,`ZJT(C0/_-]'+LU6K-4. MK.Q74H/^AAH4J68:58,MK%V(K66!'%12@\&&&EP[UR;48`NKW4A:=*:2R,_6 MY.=`ABAN[%K9\1KGL0OOO&S8>3F%?NFE MD71Z^?4'\IN;?".P#,1)X`.`P'/#49H2FK^I1.,HHV"?*%C>64'%YH!@7(MC MP\I3GRM##\M8#9C8=>WVNN+;'?1/K,_M+?3M#OHH4K+*17L@WV[.1Q=\N[?Y MLWEB]^VF#,!&D1JO&7&R56<'?!>$!_ MQ>\EK\%D9KHRN4`/@J3355T^WWOE*>Q MV/:/(E^\X!09K)*M]8?6+U8:XLVCX,^%.*SK4)\&(>%R?1]@*3\,IYWRK0)3 MBX?BOLEMD'Z[2@@PGQ'0E>S6S91,$$D3(#!+ M+;L/;3>O9A M_RO.X`27.<85J))I59^*+OC6KX+(!7!N>!T!@PMZ_BP+E&;7`$I0^%^-2YFC M3"(6NN"`SW.90V?IHOH%B`H\H&X\9>!.[Z`O*?M/TB!IDY\!\E'XDH6ZP58G M\S1TX43!S%BNX,JL'[1A]S+YH2?#)MCKPKG*AI@;DEV0)'@J7HR@+*T-E26/ MK:]!-M]C3$F'C7T,!('1DV!&OR2J;)A$0T=-C]"EV/^2N4EF-0^2HD3.Y_1L M[CKZ'6QN-Z1/3?\*"]3G.#4P%_/;!L9Q10(=4&WK<88B4QJ"`W2#:_609YX9 M1^("Y=8!6E`$BK"$)1$K&TH7/)EE9%)_Y'YA(`+%0BR1%%N\/#A=\`YN"%%Q M\.T7=OHX\BM4&*L[&+K@*9NLNUH\E>PFXR2'Z^<;P@E)\NQE`@&K->#T<<0L M\T3)%KP.-D..IHPDENVW;="K=..+;!XGU&^AK`F[%8$E%#[-.AK`QM2%H%X6 M3NJVT!9X40F(P;7WKBSL,IXN!->R,*J]'RZI"13AVH)7%OD>J"[$PI;2CU98 MY!5J.SCND^F)7Q578]?VK2J"QMHNJ.6T<6&T\8=G`@+ M1\K:CC244E9;U475G`&*X]R:\MX%Q!&ZMF_-:@Z658;R=.(NJ?=B%/GP2P)Z M32/AHQ3#*[7[?2O=$3A?)%3TQ;T`;_4_RN_:5&[:Z0\_&#L8E\I`^.Z-6FWH M,(I=M1GB&6?C.C3\./;8\T#;O0ZD+4'MLQ#^%9Y7=A9R@LMGSI:4^EG("==] M;OGU':DVBPX]-%MPAG93)M4QG55F"\ M6+WC4TG2[,E`&W6'WLA=8W>7T*7PSGVNK#.2%H`YJ\ZX!O1%"3&*,%J[1E0# MQA-P:_^%1F/:5(,"0^<_69RYH;58QG01TH?-1K.$%$GD;TE(G=X3-\F6]I^[ M+?Q7]@9G*!P1>J* M3JX`97PHG1+_)+[[D.?/Y&8*999S!CB>7>21S?`GL"%TP6MP"]0#;7/86%[0 M1W?BQSQ!`7UQ8E;XU.(H7_[NX@E)IG'R[:[%19 MSB35`#"*>!2#TF,LB$HD="$RE3/1B\Y;5*L"23B"$P]DQNP`[T+\:HU!=AZG M67I=N/+\7Q-Q$@RCWP'1(5G`5-3$^-K$(Z0+25]KT')!4B\)1!M+$&M@WK9&ZD>^_('5?D'HKI%G\"$B!94`;YT@CFFYW MNHA\NH2X#_34@[?-,OL5X!-%U&@5#6N,#E.!QH;5*UZZ8;8DTRG)WS0$.!Z% M.N,&+?)K`$X4CH/J8I=`,Q4V;%:$GP./GGYN3`/_98+CR5!0!9!B=O'*A2C% MQI%BNR[@:YQBFPD'`+Y;JQ>5X7)4I5U.YS%,8RYU'N1[<0"]#I<0*`:WCC-L M[]*N"(XC]#K.W0.&=^0AMO,X]/.M[C3P`A)Y2XM70>_4B._'K1)S?/#/9`E6@U#C8;Q?33\J4,S#NYF?+=37SUZ(Z:WP"B M4$S<*N*4Q7L8H0)/#$A*O'>S^.F]3X)"^>`?NSH'/SF?R,JN< M9M1O'$8+CM1I30Y_TW1U(<:D,A?%HEQZTB+WE][-W6A[]"$_1T:Y(CM3(>MKL`\D,1W=W6 MXAF"[66Q\&CLF;(^/RF21> MD%(G!5?##]T%F)YP>/T;47`[;)H*$*NKX*V9[[^28#:'_XY@?7-G)+>N+MR, M;!X;LKL42+OG##ZB..QN_2JAR+2I$+G7YGG".;2M7RP(4$N=0T^D@"![',7Q+QYD^ MUZ9B=KL]R+ICHPU[/QS;!V3:5'1TF[U\5<8,HMXYP^,.1PF@(YHS8K0C"!"Y M#>]WF=U]0.?W"$#F$=\%;9/0W5!')DG@D5LJB=*['"MZ=SB])31H-+^J45RX M7+@AO;+;EZU*]GL(TR6*:]8'6)BPD,T9:>V-4#!%;&G20CK.JO<0)MG7[#_T"V;UGVAW6OO$T:S64)FL!NX!@:#*`V\?$N@]B*7S6Z!B%^+ M06658Y@F?@_4PLUZE[W;I/ M?6)M^FC9?6H.Y3FW:T*VVO/RWW-]BRQ_S,?PU$@2-ZPJQN MZ7C##?!G]]8XQZ6]WV'N)7%A>6=PAM@A94!Z##^PF`N4B?ZWNCR.B#@_,KLT MP+.Z1BEP+Q/6#A:[-[-EH@H2C]Q]CQ5%M54:X-E_`+*ZJ!A8NI`;O[[EU7!R MAS,-6<$NO0`X^=B9UBM5Q M4J:S:_>![9\XMN``>O"Q,ZDF)`,)"]F&;AK7&V8_[AD7TQYBIU)=Y;?#IJE[ MQG@/SBP^+MW4\=GPV-[#TB"T7!&E9V!;!:'+.(:N`K&<-8F!!\]I5-/9?9&< M0NZ+8%M8W,Z_AA2]5EV[7.;W!;3?[4ZDZ%TKIY)7=J\P:#..,U7I&)-AZ$1> M6[I,7*?I@O@7BP1,@^+J;6&!W)#O^9_$`E9I``C#<3&:(TJ>X-6QV3V?X5E- MS$W`A?PI(VE%`(W#'ZPD4!U,*-_YO25>Z*9I`#O^G.'Q]&O^;EJ6WL47H)1/ M+GU9:_W@SI(G5LUFG&$/AS-37_T MOPOO[YY3?=VHZ3BYI2Z[[:"-C0ZO_IJ*`K@KM0=TXO"V:JE##:A=>"EWDL0> M(7YZ!332K8@;4<#G\<-#'.6+G4!+I'6=X0!',(261BC"PODH;;$IN0HBZ#5L M-M?]S]]3XX8_">H`5AQWCM27;SDZ3],"/4=SI]7&X2H3T$)$4E,6=!E3)\X>MR%RKP8)RSN]`MF*%SFUV35`[S'NNG9$ MQG%>BR"9/X0\H)UR'D/Y*(_LC-(X#'PPZOR-:9>.I^-'DN0?2VT8+=<1])1L M^J-@LW!J.(,S>ZZA:L&)/1RW4T2$\AP\^S@Z89VL<:W.L@K7A<0^X=4!6G!L M;!C"DHB5#:4+UDD9F=0LV2\,1."P1\22$A[0[L'IA"E2,PRR]Q''[E1_K.Y@ MZ(39X88DO26P>5N0]3$!V[TNJ>$,L(;%Y;+B2%:`Q9"]@>'NY6K;&AU&#]2CE:H!>(6UG-Z'U#( M7"Q%MN05@'4HY<`M":G-.7&3;'F7N%$*Y`"L-5_TS+#T<_HUR.;E*D(%J=4R M,(WB=+V:"AF`WJ6K_"2$-F>_D@BX#&%@C?R'(`HHCS3&6#[9J#4`O*'8*%91 M&1V$*&Z?-[31T-E@.$,4,5I5Q,W&8BK8,HLS-[0JU\)M]3E.\\F.)E$(HD7^ MK,;&GRES(HHJPSA`$:]91?2JZ$R%;]I7ACSM0`$;)C8=DT)8$;;O*,:_IF&A M@*E+K^)>1QD!N2A8%#LE@0H<&T`%@?%&.@-0[6#*CX5LH_R-![MO<0$K"7%3 MTO^C?D.QEIR.2=;F<,VSY,-]'8^KU1?L2O703FA$MG9!D MG6\J\*B7+`@7F3`F15+3&:(X":@N=15\77H;<"=97I$[;)6#N?3.E+J"5&O0 M.4$1HE%=;VK`;NH)/#3!3^/I^9PFN$NOH_UT%'82MVUZMM\AI?QM"O7!]/]@ M_9A>-U+J`XI%6X-?R:E]"5:G`J<**F@2R3C*;[PH!D^QZCF],Y0!5!_D<7%\ M.%T(HMI!)XVC8I9W^EA2,TIEQMF1\5%U(:*J%!$MO=BQ5Q9H0.%8$\B(+50. MDBY$58U\/R@`3-S`OX[.W<<`[#VI<(7U@!X4WA)M02N@ZL+ECI'G+1X6^;E_ MD:$X*V[DE\).8`*<\5_@JM80$(ABPZ:O%A5@=BA2JVX8;1_)N]KZ.[8=#)U( M0K=OTXJ$N5L8]CXH`NQX(N()E(W#4*C38Y'M)G.3S.I`W;NO5O+EJ&W4]JH! M3[@&KY*\Y8@,A3)AD;PHN4Z-%,';]8$Y7,:9^MA7@];<^Q-H-,)XUNB>W0=7 MC>H$$YNI<"@,2C'R_UBD67[%]R[F&#NKC$S2^][:;3E]M*F*!:I2$2:.2"K1 M2TWI+7SUY^+L)0B?J-`FDMVE:: MPFLJOYU=)5FE1C"L)R@. MU33XE1RZE&!U*@K*2/JH80_7MK:K&D.&LG!TX7 M@IUJOZ*))!FU_EC=P6`WT.E@3_$,L9YT#O<32BO",1^MA&:["K/.N9O.K\+X MNY45]\[H?>OO0O6K.2=_Z7*>Y^^PCF^-XK"KM.?O\R>XU[SG[2-+M,X2E MN^?L\[/LOZX]9Q])XG6QI)3WG'U^WO77M>?L]W%M8M3'Z@Z&+@37WY",KD:3 M)'X*?'KX]SML9JZC3?*>D9<%3WGZ!86-@WYCS@FN,;XC8>YY2A68'+Q[C M2)Y,C5\8,**X#7@@:N=H3CD//"$H<5.ERXO7!#HLQ?(0@/+ MQ8`$%">C!U:1?0JZ=%_!7+`H"NOHP+HA(@/'_01#:7ZGT\`C2:JH(ZSB0,IK MVJ/(J70#7R7U MM+@J#$84&U]-Z:JJ"`ML[7L0B'(0,VBC.1O/%PDE?92FA!FKHE/=@4]W6$-X M@&O?L4"M)=13M(!>5;2A]ZL[)RBV-PTI"0=OES+?JCNY-=\\J=>P3)] M[%27$6-)<$A5/'R!&V#"9':5KI&9ZXRW7*!._/ M19`0(`.&2+:_.,`W8?(FEBQ!8[`RH`B+,+)F27%RU*:5 M?F0`[Q'BKY_'@RYEP7T(=L:]<)7BUW*&.*(QJPJ7LR[)`'-T`D=:FW+OUQ=F MQM/2%7!86%?YG#C/RU=I!HA!X10VHPG5&>"H1BO=ONIDAD*1Q'#7/2:Z%Z+1C'.*(F1/;U>C#9"C(BU\ M-(T-?02C*$F6,#CRK'3:NK%3WSE%L;\QH10L9!QMJ)COQWZ6X`/I1`O-'W5D M')TPD@K(0H#5XO$QS&ERP_7%V>MH&B"[O&>A-''OSSQ644^8P-%XUE#^-TD1`%=:G;M'.*XB!31S/X,TYM(C@W7@\< M\\NQM&^)1R_J!M/`CV-FY16LT@S8F2B.)(W(EV%V5Z*#HR<' MC@E6UI/+AWOB^WG>#_AB2G_+^\Z$R#X#,-0RT(?B8.EPVE2-(8Z"&7`#H\PW M@RD;HK'D,\/!1VO;T*JY#X>X,J=Q:>7L+QEH?J2?V)I#@[=PZ<'^EG*&VXO,3J8W4'PVM)>8C55Y<+@;%AE<-I=;J\"P```L``00E#@``!#D!``#M76UOXS82_EZ@_X'G`PX]X!S'R;XEMVGAQ,ZN M<=DX%WNO+8JBH"7:)B*37I)*XCOID9SLQ##F=( MB_O^N^=I@!Z)D)2SBUKSZ+B&"/.X3]GXHO9Y<%U_5T/???OU5^__5*^C#X01 M@17QT7".VECA@<#>@TSX4?.H>?0&Z8NS>BLGYR=OSU^]^AG] MY^[3?U&G/T!U]/3T=.2#!&4D''E\BNIUW8[T)F2*D<)B3-0MGA(YPQZYJ$V4 MFITW&HIZ#T0I+@G13`W=Q/&;4ZUV0*:$J6LNIFTRPF&@+FI?0AS0$25^#8&= M3)Y[@2<=9!GB!9W6]>GTB(LQD!PW&S]\NND;+1.I`64/*]3/0Q$D]*<-_7J( M)4G(]5M?+1C2Q*\;T&-'YA'%<_;M9/FPL_\Y`I,5^U41+O:,P?&_%+S7:ZQA8* M`=VOB"]^F].>3V@^#[S((2?/WB2?7K_)8:#LD4B5SQ*]R[&&89KJ;2L\YI5F M::ZR2.KE,\"+''(`0,UG1.9"8][DV"+53!0T`F]R6O')3!!/C_O"_G76P,(3 M/""@@:?JY'D68(85%_-KN%\XA#,63O.%^$HTM,8-(*H#%1'46_!M9HH9(((@ M]!XSQB&T0$@R]_K);$;9B,>W\$#W[W.M\`#8D;[X?-\MC`S&LC;W0AUA6LSO M,$75O`L2Q=2T4T,4G&.E6+2=M.Z3$674:-D\;D),3-C3ER`*1;)02MC[QKJ$ MK[]:%Q]*XO?8M^8:\),@S?#JH!'SQR1VWF4C93D]''AA4-AHS-98@2(E^_H00)2.D'.CL>)T`2'UP*(D!N^K=MCNW_4Y; M7_5[-]UV:P`WEZV;UNU5!_4_=CJ#?@7;UK#=80C]:D*`'0>N&*XRV0$]W090 M]--*$S]7`).%NV1OU9CJS!(UL`[2`P0[L*S=@^P/X\ZES"Z#VKE'OKG/? M&G2!H()T*TA[HZL)9F,BNZRON/N_K'Q]Y-NW/?_\N?3\_^CCK__-P=_%AUA?UW!=>XOHTT>R=Y M\^MTDFI*V->4<(7EY#K@3ZXSPI+>#OS;;2:$JU;_([J^Z7U?30B[`UIZT!0C/D+I%BI@"X#]P"D;PY#TB(B!6WEB!:9YO`Z,X45> MQ%SYO,#G?3IF=`0!AZF69]9*P6MW$!,]2N*YT$YB1Z6YCDI*&%I*0XFX"J<" MG*XQ%?_"04@B3):W=O^?K/M?,R+#6;FZP-5QMX2Y?XZ'`8%I`IZ(D/B=YYG. M&N)AL9G,#LWI.C2)0!1+-#-(+!,E0BO4BA-"&08ZF+3&@D2)W#T)=&8'>55J M&QS*1$5IA5C3YI&KJ-B@.,P#S8J0*WMGQ>9V9;E)2 MHL)Y*:N"I7`H3:=4F:X,40VZN.[?X+%%1F`CL`/T)CN`%J),O%L15B%4-'#" MH21?0K"U\ZA=%P^9]:=V+-YF!LN"'T4"*O]ODS67R)X=L^AW);-H]$UR]=<* MPFT@'.C\RP7`F-`.7V;-8"-\D=@*O(W54!JH]8=64$XRZP7+RJCR_\XE4AH7 M5V([7IF5!*=RJ8)RNQQ\)0#:*.R@998?;/EXA=4^5[[;1&$:R`%Y5F&R[[$# MOQWGS%I&^55Q]$W<(HJ;K+J!RSIY'LR6]W88,\L;T1IZ+*I":#_)9>Q%A^PR MH;2CEEWTV)1>QG(K_';!;V7(E6&PHYE9(7%%LQJ5SE7#R@C,/+7CDUDU2=<- MU<`J"4$S'X/F!A`R"R(Y(*!F!8,K#"?Y,)QL@"&SL&%@>%R%X:2"8>LR>B50 M.5-;03O-+'PX%M)5;-MQ!S(O;RC)8TIED!'I8U"UA(<+@6P0`H:]':F-FO7=%X2W_1#W?I+_[-(S"+"X58 MY@01V]$8T>$C-]PSHBPL^JZ>\-7UHWKSI'[:/'J6_M+[9918VEA.B81O"R7R M#QYQ;#YAT.V^=FW1>G)(0<.FT5S&!@F43)[4EZ)*V6\YQ<.F4`Y;?%U?BMA* MD;S345PT2?,E-SOKDG?BBI,R:<;%W:X890YG<5%EP62N=E4A>W"+BPY+KNBR MOA2PE1;KI\&XZ)#PZ(N=VU\_*,9)@83)7&VA0O;0&3/9,#+62R=ND2L08H5+ MAZ\S'3:;;W96PS%XIE10>VG>?O2.JTII*9VED"TTM![`Y-)3$AY]L<6`M1\1 MY.20=:Y=<(ZL8HOA,-J.0_7BDUE#JH^"@OT9I MJ3G.[!R>43;N*C+5554-X9CJHJ:$_NXJHH(TD7)_8/C\4,1?F3(:!'KM/*&5 M4)!"HZ%^^T'P<)8T0D%\5`'KO/<7-RT+3-3GPOEA0'JCS;]1?7%3?74^`4[A MA4/2736ZG-X%QE]!2YQUF2)0@*IXFV+5RBF'H(?%/,_.$0YD24,CVF%TY@\0 MDB%5[D@7Z%L$[00#V;U>PV#$OYS?A4-PRA6?SC";IY>IS'9=EQGZ#J0<^K2* ME_2")XA?Q@T[&K:KNR)"J[]D1+(?;^W=+04&%/C%[:>WAQ0;7#4N-%C11_() MBP>BY#47U(=W^CB%EI3PI"=N*![2@.I*OZ7T=O5C]%'MSB,FJL_5OL/&U@85 M."C]V\##F0;SM7(P0:_N7@8P/!(;HE,?SU7R_(7'<8%N!99\CX6`/B,[SS`6 MJ-0-#HB8KN*1*/7"EA3JML&6`;\+!80E2?2G?3PZ-^D`(NP&_0JS#+.#KAD_ MD>F0B+5^YO,I1.R7'2PY.MFFQ6226/P"X&`,L:M7A$B`I>R-8CA[XIZ.)RH7 MU#OHN'IG8CG!:T-GT=/]Q'9GR+92NL@#,N@)GS*8H:)LX&``+=2LP))[(@D& M%Q`19SK)(#T8BS9JZ#)''5J.E:-<45#GXD'3XAE5>N?VQ;*DLF7%NJ*[56SH/,Z,-4KOA(T$GXZXX`IZOH3Q M)\@H9+XV`$]UTP=<:._;T")_\CD.U)R,1L2DZ+.]S39[B%H6W0K,N:&>+J]P M,@O[1'J"SB(]W`;!KVB05;L"B[I2AKH#]49MT.41:T8.Z/ MQ(>_>E(ZF,DSJY(]RX9^M4#XP$S9J&&!97'U1.X$].!['8':1OL#,*E8-1=; M>HP<##A%BFVR@T)4'#SQP[-C33%;=7<)Y8.O[PW.PS M/&'A1\<7=R$5$V%TX*F>_08P8_9,2$W7_+=AVCE;U^\[5U`O:NQOZ?#OB:X- MB=]Z)`(F[`^ZVFAC15('`*ZD%Z;%/R`6#GXH@BES4O;RG M%Q-,):`)%ZL*W5`=7H979U'=@>N* M$CH30*\I`\TT\'&7N^)2O:A+2@X3N]H;5K#XR&1A^L>XOI>:A:4>7SSR(];% M/S2AM,YZ1VRH=Z,&T5;.8>V;[=^L7?SW%`6G/XK?G,QQ6,@^H'!;H)8VXGTC M^H69L>=_4$L!`AX#%`````@`^(0317GZ5%5R@0``40\(`!$`&````````0`` M`*2!`````&-L8W,M,C`Q-#`V,S`N>&UL550%``,3MO-3=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`^(03161LX^H`!P``0E8``!4`&````````0```*2! MO8$``&-L8W,M,C`Q-#`V,S!?8V%L+GAM;%54!0`#$[;S4W5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`/B$$T41-NMK42,``$4Y`@`5`!@```````$```"D M@0R)``!C;&-S+3(P,30P-C,P7V1E9BYX;6Q55`4``Q.V\U-U>`L``00E#@`` M!#D!``!02P$"'@,4````"`#XA!-%B2]%3=,W```M#P,`%0`8```````!```` MI(&LK```8VQC&UL550%``,3MO-3=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`^(0317\]V?VW*0``F`Q0````(`/B$$T7Q[7FZO`L``'-T```1`!@```````$` M``"D@=0.`0!C;&-S+3(P,30P-C,P+GAS9%54!0`#$[;S4W5X"P`!!"4.```$ :.0$``%!+!08`````!@`&`!H"``#;&@$````` ` end XML 52 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value (Tables)
6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table summarizes the valuation of the Company’s derivatives by the above fair value hierarchy levels as of June 30, 2014 and December 31, 2013 using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):

Quoted Prices

In Active

Significant

Markets for

Other

Significant

Identical

Observable

Unobservable

Liabilities

Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Warrant liability

$

2,476,800

$

-

$

-

$

2,476,800

Balance - June 30, 2014

$

2,476,800

$

-

$

-

$

2,476,800

Warrant liability

$

231,200

$

-

$

-

$

231,200

Balance - December 31, 2013

$

231,200

$

-

$

-

$

231,200

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

Assumptions utilized in the valuation of Level 3 liabilities are described as follows:

For the Three Months Ended

For the Six Months Ended

June 30,

June 30,

2014

2013

2014

2013

Risk-free interest rate

1.62% - 1.65%

0.05% - 0.08%

1.46% - 1.73%

0.02% - 0.08%

Expected term (years)

4.33 - 5.00

0.00 - 0.24

4.33 - 5.00

0.00 - 0.50

Expected volatility

164% - 166%

65%

164% - 168%

65% - 99%

Expected dividends

0.00%

0.00%

0.00%

0.00%

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the six months ended June 30, 2014 and 2013:

2014

2013

Balance - January 1,

$

231,200

$

38,300

Change in fair value of derivative liability

16,400

(64,500)

Issuance of derivative liability

2,229,200

434,200

Balance - June 30,

$

2,476,800

$

408,000

X

- Definition

Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Stockholders' Deficiency (Details 1) (USD $)	6 Months Ended
Stockholders' Deficiency (Details 1) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.58	$ 0.21
Outstanding Number of Warrants	8,903,159	2,812,498
Weighted Average Remaining Life In Years	4 years 8 months 12 days
Exercisable Number of Warrants	6,859,324
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.001
Outstanding Number of Warrants	2,043,835
Weighted Average Remaining Life In Years	0 years
Exercisable Number of Warrants	0
Exercise Pirce Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.750
Outstanding Number of Warrants	6,859,324
Weighted Average Remaining Life In Years	4 years 8 months 12 days
Exercisable Number of Warrants	6,859,324

Significant Accounting Policies (Details)	6 Months Ended
Significant Accounting Policies (Details)	Jun. 30, 2014	Jun. 30, 2013
Schedule Of Significant Accounting Policies [Line Items]
Warrants	6,859,324	0
Convertible notes	0	2,297,487
Total	6,859,324	2,297,487

Fair value (Details 2) (USD $)	6 Months Ended
Fair value (Details 2) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance - January 1,	$ 231,200	$ 38,300
Change in fair value of derivative liability	16,400	(64,500)
Issuance of derivative liability	2,229,200	434,200
Balance - June 30,	$ 2,476,800	$ 408,000

Fair Value (Details 1)	3 Months Ended		6 Months Ended
Fair Value (Details 1)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions, Expected Volatility Rate		65.00%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	1.65%	0.08%	1.73%	0.08%
Fair Value Assumptions, Expected Term	5 years	2 months 26 days	5 years	6 months
Fair Value Assumptions, Expected Volatility Rate	166.00%		168.00%	99.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	1.62%	0.05%	1.46%	0.02%
Fair Value Assumptions, Expected Term	4 years 3 months 29 days	0 years	4 years 3 months 29 days	0 years
Fair Value Assumptions, Expected Volatility Rate	164.00%		164.00%	65.00%

Accounts Payable and Accrued Expenses (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accounts Payable And Accrued Expenses [Line Items]
Accrued fees and expenses	$ 29,332	$ 103,705
Accrued payroll	41,294	12,944
Total	$ 70,626	$ 116,649

Consulting Agreements - Related Party (Details Textual) (USD $)			3 Months Ended		6 Months Ended		0 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014 ConsultingAgreement [Member]	Jun. 30, 2013 ConsultingAgreement [Member]	Jun. 30, 2014 ConsultingAgreement [Member]	Jun. 30, 2013 ConsultingAgreement [Member]	Oct. 03, 2011 Yeda [Member]
Related Party Transaction [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross							$ 210,000
Research and Development Arrangement, Contract to Perform for Others, Description and Terms							annual Research budget commitment for 3 years in the amount of $800,000 for the period until October 3, 2014;
ResearchAndDevelopmentArrangementContractToPerfromForOthersNonRefundableAmount							50,000
RoyaltyEffectivePercentage							4.00%
LicenseAgreementDescription							the option to license the organ regeneration technology originally expired on October 3, 2012 and has since been extended to September 1, 2014
Accounts Payable and Accrued Liabilities, Current	216,000	442,000
Operating Costs and Expenses			$ 399,000	$ 330,000	$ 611,000	$ 403,000

Stockholders' Deficiency (Details) (USD $)	6 Months Ended
Stockholders' Deficiency (Details) (USD $)	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants, Outstanding, December 31, 2013	2,812,498
Number of Warrants, Granted	6,090,661
Number of Warrants, Exercised	0
Number of Warrants, Forfeited	0
Number Of Warrants, Outstanding, June 30, 2014	8,903,159
Number of Warrants, Exercisable, June 30, 2014	6,859,324
Weighted Average Exercise Price, Outstanding, December 31, 2013	$ 0.21
Weighted Average Exercise Price, Granted	$ 0.75
Weighted Average Exercise Price, Exercised	$ 0
Weighted Average Exercise Price, Forfeited	$ 0
Weighted Average Exercise Price, Outstanding, June 30, 2014	$ 0.58
Weighted Average Exercise Price, Exercisable, June 30, 2014	$ 0.75
Weighted Average Remaining Life In Years, Outstanding, June 30, 2014	5 years 1 month 6 days
Weighted Average Remaining Life In Years, Exercisable, June 30, 2014	4 years 8 months 12 days
Intrinsic Value, Outstanding, June 30, 2014	$ 815,490
Intrinsic Value, Exercisable, June 30, 2014	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:
Cash	$ 889,332	$ 28,878
Prepaid expenses	135,000	0
Other current assets	59,564	63,337
Total Current Assets	1,083,896	92,215
Property and equipment, net	2,557	0
Total Assets	1,086,453	92,215
Current Liabilities:
Accounts payable and accrued expenses	70,626	116,649
Accounts payable and accrued expenses - related party	216,035	441,700
Derivative liabilities	2,476,800	231,200
Total Current Liabilities	2,763,461	789,549
Commitments and contingencies (Note 8)	0	0
Stockholders' Deficiency:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2014 and December 31, 2013	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized; 23,245,923 and 14,155,262 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	23,246	14,155
Additional paid-in capital	4,047,077	3,229,522
Accumulated deficit	(5,747,331)	(3,941,011)
Total Stockholders' Deficiency	(1,677,008)	(697,334)
Total Liabilities and Stockholders' Deficiency	$ 1,086,453	$ 92,215

Subsequent Events (Details Textual)	Jun. 30, 2014	Dec. 31, 2013	Jul. 29, 2014 Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued	23,245,923	14,155,262	100,000

Going Concern (Details Textual) (USD $)	6 Months Ended
Going Concern (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Going Concern [Line Items]
Retained Earnings (Accumulated Deficit)	$ (5,747,331)		$ (3,941,011)
Net Cash Provided by (Used in) Operating Activities	2,150,000	340,000
Working Capital	$ 1,680,000		$ 697,000

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock, par value [in dollars per share]	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value [in dollars per share]	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	23,245,923	14,155,262
Common stock, shares outstanding	23,245,923	14,155,262

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2014	Aug. 15, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Entity Registrant Name	CELL SOURCE, INC.
Entity Central Index Key	0001569340
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CLCS
Entity Common Stock, Shares Outstanding		23,345,923

Organization, Operations and Basis of Presentation (Details Textual) (USD $)					1 Months Ended			1 Months Ended
	Jun. 30, 2014	May 07, 2014	Dec. 31, 2013	Jun. 30, 2014 CSL Ordinary Shares [Member]	Jun. 30, 2014 Researcher Company Warrants [Member]	Jun. 30, 2014 CSL Warrants [Member]	Jun. 30, 2014 Company Warrants [Member]	Jun. 30, 2014 Share Exchange Agreement [Member]	Jun. 27, 2014 Consultants [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common Stock, Shares Authorized	200,000,000	75,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001		$ 0.001			$ 0.001
Excess Stock, Shares Authorized		200,000,000
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Warrants Exercisable Term					7 years	5 years			5 years
Warrants To Purchase Common Stock					2,043,835	4,859,324			2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.75					$ 0.75	$ 0.75		$ 0.75
Shares, Outstanding				23,245,923				18,245,923
Equity Method Investment, Ownership Percentage				78.50%				100.00%
Conversion of Stock, Shares Issued								18,245,923
Class Of Warrant Or Right To Purchase Common Stock Percentage	77.50%
Share price (in dollars per share)	$ 0.75				$ 0.001
Warrants and Rights Outstanding	$ 6,903,159

Stockholders' Deficiency (Details Textual) (USD $)	6 Months Ended
Stockholders' Deficiency (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Stock Issued During Period, Shares, New Issues	4,090,661
Stockholders Equity Note Description	Each unit was sold for $0.75 per unit and consisted of one share of common stock and an immediately vested five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share.
Reclassification Of Warrants To Derivative Liability	$ 1,499,000	$ 0
Share Price	$ 0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Proceeds from Issuance of Common Stock	3,067,996
Equity Financing Issuance Costs	55,150
Stock Issued During Period, Shares, Issued for Services	100,000
Stock Issued During Period, Value, Issued for Services	43,000
Proceeds From Issuance Of Common Stock And Warrants, Net	$ 3,012,846	$ 0

Fair Value (Details) (USD $)	6 Months Ended	12 Months Ended
Fair Value (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liability	$ 2,476,800	$ 231,200
Balance	2,476,800	231,200
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liability	0	0
Balance	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liability	0	0
Balance	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liability	2,476,800	231,200
Balance	$ 2,476,800	$ 231,200